



HOW SHOULD WE EVALUATE CLINICAL TRIALS?

Symposium

Chairperson(s): S. Dunbar (Atlanta, US); M. Tendera (Katowice, PL)

- | | | |
|-------|--|-------------|
| 08:30 | Considerations in choosing and analysing composite primary endpoints. | 1778 |
| | – S.J. Pocock (London, GB) | |
| 08:52 | What value in patient centred outcomes? | 1779 |
| | – T. Jaarsma (Groningen, NL) | |
| 09:14 | Common pitfalls in economic analysis. | 1780 |
| | – W.S. Weintraub (Newark, US) | |
| 09:36 | The optimal evaluation: a 21st century view. | 1781 |
| | – R.M. Califf (Durham, US) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



**MANAGEMENT OF TOTAL CARDIOVASCULAR RISK;
PUTTING THE PIECES TOGETHER**

Main Session

Webcast

Chairperson(s): I.M. Graham (Dublin, IE); S. Del Prato (Pisa, IT)

The European Society of Cardiology and the European Association for the Study of Diabetes

- | | | |
|-------|---|-------------|
| 11:00 | Total risk assessment: principles and practice. | 1782 |
| | – M.-R. Taskinen (Helsinki, FI) | |
| 11:18 | Which blood pressure to measure? | 1783 |
| | – S. Laurent (Paris, FR) | |
| 11:36 | Boomerang effect: from low-density lipoprotein to high-density lipoprotein and back. | 1784 |
| | – U. Landmesser (Zurich, CH) | |
| 11:54 | Modern diabetic management; it's not just glucose. | 1785 |
| | – C. Berne (Uppsala, SE) | |
| 12:12 | The final piece of the puzzle; comprehensive risk reduction. | 1786 |
| | – G. De Backer (Ghent, BE) | |

12:30 Lunch (Meet the Experts Sessions & Workshops)



BEHAVIOURAL CHANGE: THE CHALLENGE FOR PREVENTION

Symposium



Chairperson(s): B. Fletcher (Jacksonville Beach, US);
M.E. Leventhal (Basel, CH)

- | | | |
|-------|--|------|
| 08:30 | Behavioural skills training for health care providers. | 1787 |
| | – N. Houston-Miller (Palo Alto, US) | |
| 08:52 | Motivational interviewing - is it effective in cardiovascular prevention? | 1788 |
| | – P.M. Davidson (Sydney, AU) | |
| 09:14 | Behavioural change - it's all in the family. | 1789 |
| | – C.S. Jennings (London, GB) | |
| 09:36 | Can we change society? | 1790 |
| | – J. Tuomilehto (Helsinki, FI) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



TRAIN TO MAINTAIN: EXERCISE AND PREVENTION OF HEART FAILURE

Symposium



Chairperson(s): M. Mendes (Setubal, PT);
M.C. Deaton (Manchester, GB)

- | | | |
|-------|---|------|
| 11:00 | Impact of exercise on cardiac and vascular cell biology. | 1791 |
| | – V. Adams (Leipzig, DE) | |
| 11:22 | Exercise and heart failure prevention: epidemiological evidence. | 1792 |
| | – P. Giannuzzi (Veruno, IT) | |
| 11:44 | Exercise training in heart failure; which practical modality? | 1793 |
| | – V. Conraads (Edegem, BE) | |
| 12:06 | Lessons from HF-ACTION. | 1794 |
| | – C. O'Connor (Durham, US) | |

12:30 Lunch (Meet the Experts Sessions & Workshops)



IMPROVING PREVENTION AND MANAGEMENT OF CORONARY ARTERY DISEASE

Abstracts

Chairperson(s): A. Tonkin (Melbourne, AU); V. Gupta (New Delhi, IN)

- 08:30 **EUROASPIRE III: Risk factor and therapeutic management in people at high risk of developing cardiovascular disease from 12 European countries.** 1795
 – K. Kotseva, C. Jennings, G. De Backer, D. De Bacquer, P. Amouyel, D. Gaita, U. Keil, A. Pajak, Z. Reiner, D. Wood (London, GB; Ghent, BE; Lille, FR; Timisoara, RO; Munster, DE; Krakow, PL; Zagreb, HR)
- 08:45 **High prevalence of dyslipidemia in 18,574 patients treated with statins in Europe and Canada: Results of the dyslipidemia international study.** 1796
 – A.K. Gitt, J.P.P. Kastelein (Ludwigshafen am Rhein, DE; Amsterdam, NL)
- 09:00 **Trends in acute coronary syndrome management and early mortality: Myocardial Ischaemia National Audit Project (MINAP) 2004 to 2007.** 1797
 – C.P. Gale, B.A. Cattle, A.D. Simms, P.D. Baxter, T. Munyombe, T.H. West, D.C. Greenwood, K.A.A. Fox, R.M. West (Leeds and Edinburgh, GB)
- 09:15 **Persistence with beta-blockers in coronary heart disease patients in UK primary care.** 1798
 – E. Setakis, C. Morley, S. Cockle, T.P. Van Staa, G. Kassianos (London, Bradford, Slough and Bracknell, GB)
- 09:30 **Identification of patients with impaired outcome on ACE-inhibitor therapy.** 1799
 – J. Brugts, E. Boersma, A. Isaacs, W. Remme, M. Bertrand, K. Fox, R. Ferrari, M. De Maat, A. Danser, M.L. Simoons (Rotterdam and Rhoon, NL; Lille, FR; London, GB; Ferrara, IT)
- 09:45 **Impact of non steroidal anti-inflammatory drugs (NSAIDs) on CV outcomes in atherothrombotic patients: insights from the European REACH registry.** 1800
 – O. Barthelemy, J.P. Collet, G. Cayla, T. Chastre, U. Zeymer, P.G. Steg, D.L. Bhatt, G. Montalescot (Paris, FR; Ludwigshafen am Rhein, DE; Cleveland, US)

10:00 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)**

M
O
N
D
A
Y
A
M



HIGHLIGHTS FROM EUROPREVENT STOCKHOLM – NEW SCIENTIFIC ADVANCES

Association Track

Chairperson(s): H. Saner (Berne, CH); J. Perk (Oskarshamn, SE)

- 11:00 **New scientific advances in basic science.** 1801
 – O. Ellingsen (Trondheim, NO)
- 11:15 **New scientific advances in cardiac rehabilitation.** 1802
 – J. Niebauer (Salzburg, AT)
- 11:30 **New scientific advances in epidemiology & public health.** 1803
 – J.H.A.J. De Sutter (Ghent, BE)
- 11:45 **New scientific advances in exercise physiology.** 1804
 – A. Mezzani (Veruno, IT)
- 12:00 **New scientific advances in prevention and health policy.** 1805
 – S. Capewell (Liverpool, GB)
- 12:15 **New scientific advances in sports cardiology.** 1806
 – M. Borjesson (Gothenburg, SE)

12:30 **Lunch (Meet the Experts Sessions & Workshops)**

CARDIOVASCULAR DRUG THERAPY IN THE VERY ELDERLY **Clinical Seminar**

Chairperson(s): S. Taddei (Pisa, IT); J. Silva-Cardoso (Porto, PT)

- | | | |
|-------|--|-------------|
| 08:30 | Therapeutical challenges.
– F. Follath (Zurich, CH) | 1807 |
| 08:52 | Blood pressure-lowering drugs.
– N.S. Beckett (London, GB) | 1808 |
| 09:14 | Lipid-lowering drugs.
– P. Amarenco (Paris, FR) | 1809 |
| 09:36 | Antithrombotic drugs.
– D. Atar (Oslo, NO) | 1810 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

3D ECHO: IMAGING WITHOUT FRONTIERS **Read with the Experts**

Chairperson(s): A. Franke (Hannover, DE); R. Martin (Atlanta, US)

- | | | |
|-------|---|-------------|
| 10:05 | Transthoracic 3D Echo for follow-up in a heart failure patient.
– L. Perez De Isla (Madrid, ES) | 1811 |
| 10:11 | Panel discussion.
– L. Perez De Isla, H.P. Kuehl, M.J. Monaghan (Madrid, ES; Munich, DE; London, GB) | 1812 |
| 10:21 | 3D TEE for monitoring of mitral clipping.
– H.P. Kuehl (Munich, DE) | 1813 |
| 10:28 | Panel discussion.
– L. Perez De Isla, H.P. Kuehl, M.J. Monaghan (Madrid, ES; Munich, DE; London, GB) | 1814 |
| 10:38 | 3D TEE for monitoring of transcatheter aortic valve replacement (revalving).
– M.J. Monaghan (London, GB) | 1815 |
| 10:45 | Panel discussion.
– L. Perez De Isla, H.P. Kuehl, M.J. Monaghan (Madrid, ES; Munich, DE; London, GB) | 1816 |



CARDIOVASCULAR PREVENTION IN CHRONIC KIDNEY DISEASE: LESSONS LEARNED AND FUTURE DIRECTIONS **Symposium**

Chairperson(s): F. Zannad (Dommartin-Les-Toul, FR); V. Sansoy (Istanbul, TR)

- | | | |
|-------|--|-------------|
| 11:00 | Renal function in cardiovascular clinical trials.
– M. Metra (Brescia, IT) | 1817 |
| 11:22 | Unmet needs and challenges in chronic kidney disease and dialysis patients.
– A. Jardine (Glasgow, GB) | 1818 |
| 11:44 | Cardiovascular risk factors in chronic kidney disease: what are the treatment targets?
– R. Schmieder (Erlangen, DE) | 1819 |
| 12:06 | Cardiovascular morbidity and mortality trials in chronic kidney disease. Insight from AURORA.
– B. Fellstrom (Uppsala, SE) | 1820 |

12:30 Lunch (Meet the Experts Sessions & Workshops)



DIABETES PREVENTION, TREATMENT AND CONTROL

Abstracts

Chairperson(s): E. Amouyel (Lille, FR); To be announced

- 08:30 **Risk of death differs according to type of oral glucose-lowering therapy in patients with diabetes and a previous myocardial infarction: a nationwide study.** **1821**
 – T.K. Schramm, G.H. Gislason, M.L. Norgaard, J.N. Rasmussen, F. Folke, M.L. Hansen, C.H. Jørgensen, A. Vaag, L. Kober, C. Torp-Pedersen (Copenhagen, Hellerup and Gentofte, DK)
- 08:45 **Do angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent the incidence of diabetes? A meta-analysis of more than 100,000 patients.** **1822**
 – M. Al-Mallah, S. Siddiqui, M. Sinno, A. Abu Samra (Detroit, US)
- 09:00 **Does more intensive control of glucose reduce cardiovascular events in type 2 diabetes?** **1823**
 – K.K. Ray, S.R.K. Sheshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, D. Preiss, S. Erqou, N. Sattar (Cambridge, GB)
- 09:15 **Does tighter glycemic control improve macrovascular outcomes in people with type II diabetes mellitus? A meta-analysis of 27082 patients in randomised controlled trials.** **1824**
 – K.Y. Ooi, B. Billah, H. Krum (Melbourne, AU)
- 09:30 **Diabetes is the strongest independent predictor of mortality in acute cerebrovascular disease.** **1825**
 – R. Margato, H. Ribeiro, S. Carvalho, C. Ferreira, J. Gabriel, A. Velon, P. Guimaraes, P. Mateus, P. Fontes, I. Moreira (Vila Real, PT)
- 09:45 **Effect of multifactorial comprehensive cardiac rehabilitation on risk factor control and mortality in type 2 diabetes - three years results of the randomized DANSUK study.** **1826**
 – A.M.B. Soja, A.D.O. Zwisler, S. Rasmussen, T.M. Melchior, E. Hommel, J. Fischer Hansen, M. Madsen (Copenhagen, Roskilde and Gentofte, DK)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



FUTURE OF CARDIOLOGY AS A PROFESSIONAL SPECIALITY

Symposium

Chairperson(s): R. Ferrari (Ferrara, IT); H.V. Huikuri (Oulu, FI)

The European Society of Cardiology (ESC) and the Cardiology Section of the Union of European Medical Specialists (UEMS)

- 11:00 **Cardiology as a profession in 2020 and beyond.** **1827**
 – E. Braunwald (Boston, US)
- 11:22 **Training in cardiology in Europe now and in the future.** **1828**
 – H.S. Weber (Vienna, AT)
- 11:44 **Update of new European training modules.** **1829**
 – P.G. Mills (London, GB)
- 12:06 **Accreditation of cardiologists and visitation of training centres in Europe.** **1830**
 – P.E. Polak (Geldrop, NL)

12:30 Lunch (Meet the Experts Sessions & Workshops)



THE POLITICS OF PREVENTION

Symposium

Chairperson(s): W. Wijns (Aalst, BE); P. Hollins (London, GB)
The European Society of Cardiology and the European Heart Network

- | | | |
|-------|---|-------------|
| 08:30 | Strategies for cardiovascular disease prevention in Europe: an overview. | 1831 |
| | – S. Logstrup (Brussels, BE) | |
| 08:52 | European Heart Health Charter: a political opportunity. | 1832 |
| | – L. Ryden (Stockholm, SE) | |
| 09:14 | The art of political advocacy. | 1833 |
| | – J.F. Martin (London, GB) | |
| 09:36 | Role of the European Commission. | 1834 |
| | – To be announced | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



EUROPEAN NETWORKING AND COLLABORATION: HOW THE EUROPEAN COMMISSION SUPPORTS CARDIOVASCULAR RESEARCH

Symposium

Chairperson(s): P.G. Steg (Paris, FR); K.R. Sipido (Leuven, BE)
The European Society of Cardiology and the European Commission

- | | | |
|-------|---|-------------|
| 11:00 | Support of research on cardiovascular disease within the European Union 7th Framework programme. | 1835 |
| | – V. Dambrauskaite (Brussels, BE) | |
| 11:18 | Networking and exchange: the People programme. | 1836 |
| | – J. Albuquerque Silva (Brussels, BE) | |
| 11:36 | Refocusing towards early disease detection and promoting health. | 1837 |
| | – V. Fuster (New York, US) | |
| 11:54 | Integrating basic, clinical and industry research in the era of translation. | 1838 |
| | – M. Wehling (Mannheim, DE) | |
| 12:12 | Cardiogenics - the success of a European collaborative project. | 1839 |
| | – H. Schunkert (Lubeck, DE) | |

12:30 Lunch (Meet the Experts Sessions & Workshops)



CARDIOVASCULAR PREVENTION: FROM CELLS TO SOCIETY

Main Session

Webcast

Chairperson(s): R. Ferrari (Ferrara, IT); C. Yancy (Dallas, US)
The European Society of Cardiology and the American Heart Association

08:30	Cellular origins of atherosclerosis. – P. Libby (Boston, US)	1840
08:52	How to cool the burning plaque. – V. Fuster (New York, US)	1841
09:14	Risk factors have no boundaries. – D.A. Wood (London, GB)	1842
09:36	Approaches to prevention in society. – D.E. Grobbee (Utrecht, NL)	1843

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

HOT LINE II

Hot Line

Chairperson(s): C. Di Mario (London, GB); J.J. Bax (Leiden, NL)

Webcast

11:00	Immediate angioplasty versus ischemia-guided management after thrombolysis for ST-segment elevation myocardial infarction in areas with very long transfers: The NORDISTEMI study. – S. Halvorsen (Oslo, NO)	1844
11:13	Discussant. – F. Verheugt (Amsterdam, NL)	1845
11:18	Unprotected Left Main Revascularisation in Patients With Acute Coronary Syndromes. GRACE left main study. – G. Montalescot (Paris, FR)	1846
11:31	Discussant. – C.W. Hamm (Bad Nauheim, DE)	1847
11:36	Primary Angioplasty versus Fibrinolysis in the Very Elderly. The TRIANA Study. – H. Bueno (Madrid, ES)	1848
11:49	Discussant. – D. Dudek (Krakow, PL)	1849
11:54	Routine upfront abciximab versus standard peri-procedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock. The PRAGUE-7 Study. – P. Widimsky (Prague, CZ)	1850
12:07	Discussant. – A. Lafont (Paris, FR)	1851
12:12	Randomized Trial of 3-Limus Agent-Eluting Stents With Biodegradable or Permanent Polymer Coating. ISAR-TEST-4 study. – J. Mehilli (Munich, DE)	1852
12:25	Discussant. – A.D. Kugelmass (Detroit, US)	1853

12:30 Lunch (Meet the Experts Sessions & Workshops)

No session

MONDAY
AM

10:00–11:30

**CARDIOVASCULAR MAGNETIC
RESONANCE IN CORONARY ARTERY
DISEASE (LEVEL I)**

Hands-on Tutorial

Chairperson(s): G. von der Recke (Bonn, DE)
Hands-on Tutorial organised by Siemens AG, Healthcare Sector

11:45–13:15

**TECHNICAL PRINCIPLES, CLINICAL
INDICATIONS AND ANALYSIS OF
CORONARY COMPUTED TOMOGRAPHY
ANGIOGRAPHY**

Hands-on Tutorial

Chairperson(s): J. Rixe (Bad Nauheim, DE)
Hands-on Tutorial organised by Siemens AG, Healthcare Sector

12:30 Lunch (Meet the Experts Sessions & Workshops)

No session

MONDAY
AM

10:00–11:00

**REVASCULARISATION AND THE PATIENT
WITH DIABETES: KEY ISSUES? SILENT
ISCHEMIA AND DIABETIC PATIENTS: WHAT
SHOULD WE DO?**

Hands-on Tutorial

Chairperson(s): M. Valgimigli (Ferrara, IT)

Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company

11:00–12:30

**VASCULAR CLOSURE DEVICE WORKSHOP.
INFORMATION AND PRACTICE ON THE
DEPLOYMENT OF NEW CORDIS VASCULAR
CLOSURE DEVICE**

Hands-on Tutorial

Chairperson(s): To be announced

Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company

12:30 Lunch (Meet the Experts Sessions & Workshops)

No session

MONDAY
AM

10:00–12:30 **CARDIAC ANATOMY AND PATHOLOGY OF VALVE DISEASES
FOR ECHOCARDIOGRAPHERS AND INTERVENTIONAL
CARDIOLOGISTS**

Chairperson(s): P. Bruneval (Paris, FR); M. Galderisi (Naples, IT)
Discussants from WG17 and EAE

- 10:15 **Live-video demonstration.** **1854**
– A.C. Van Der Wal (Amsterdam, NL)
- 11:15 **Hands-on specimen demonstration.** **1855**

12:30 Lunch (Meet the Experts Sessions & Workshops)

AORTIC VALVE REPLACEMENT 2009

Main Session

Chairperson(s): C.M. Otto (Seattle, US); R. Dion (Genk, BE)

- | | | |
|-------|--|-------------|
| 08:30 | Surgically implanted valves - the right valve for the patient.
– S. Rahimtoola (Los Angeles, US) | 1856 |
| 08:52 | Other surgical options - repair and the rest.
– A.d.J.J.C. Bogers (Rotterdam, NL) | 1857 |
| 09:14 | Transfemoral implantation.
– A. Vahanian (Paris, FR) | 1858 |
| 09:36 | Transapical implantation.
– T. Walther (Leipzig, DE) | 1859 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



DISTILLING FROM HEART FAILURE GUIDELINES

Main Session

Chairperson(s): K. Dickstein (Stavanger, NO);
K. Swedberg (Gothenburg, SE)



- | | | |
|-------|--|-------------|
| 11:00 | Approach to diagnosis and classification.
– A. Cohen-Solal (Paris, FR) | 1860 |
| 11:22 | Pharmacological treatment for systolic dysfunction.
– G. Sinagra (Trieste, IT) | 1861 |
| 11:44 | Devices and surgery for low ejection fraction heart failure.
– D.J. van Veldhuisen (Groningen, NL) | 1862 |
| 12:06 | Treatment for preserved ejection fraction heart failure.
– P. Ponikowski (Wroclaw, PL) | 1863 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

08:30–10:00

COMPLICATIONS DURING PERCUTANEOUS CARDIOVASCULAR INTERVENTION. FOCUS Session

Chairperson(s): E. Eeckhout (Lausanne, CH); R.-L. Gao (Beijing, CN)
In collaboration with EuroPCR-EAPCI

Complications during percutaneous cardiovascular interventions: What would I do different today? 1864

Case 1. 1865

Case 2. 1866

Case 3. 1867

Panel. 1868

– A. Doganov (Sofia, BG), T. Lefevre (Massy, FR), S.T. Lim (Singapore, SG), T.A. Mabin (Somerset West, ZA), A. Pichard (Washington, US), G. Stankovic (Belgrade, RS)



10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

11:00–12:30

ASSESSING ISCHAEMIC HEART DISEASE: FROM ANATOMY TO FUNCTION FOCUS Session

Chairperson(s): J.M. Knuuti (Turku, FI); R. Gibbons (Rochester, US)

Introduction. 1869

Echocardiography. 1870

Cardiovascular MR. 1871

Nuclear and combined techniques (Recorded case). 1872

Panel. 1873

– P.T. Buser (Basel, CH), P. Nihoyannopoulos (London, GB)



12:30 Lunch (Meet the Experts Sessions & Workshops)

08:30–10:00

SAVING LIVES BY CHANGING LIFE

FOCUS Session

Chairperson(s): J. Perk (Oskarshamn, SE); G. De Backer (Ghent, BE)



- The high risk patient.** 1874
- The gender issue.** 1875
- Is it ever too late for prevention?** 1876
- Panel.** 1877
 - H. Gohlke (Ballrechten-Dottingen, DE), F.D.R. Hobbs (Birmingham, GB), E. Prescott (Copenhagen, DK)



10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

11:00–12:30

BIOMARKERS IN ACUTE CORONARY SYNDROME

FOCUS Session

Chairperson(s): To be announced; N. Danchin (Paris, FR)

- Interpreting elevated troponins.** 1878
- Role of novel biomarkers.** 1879
- Differential diagnosis of raised biomarkers.** 1880
- Panel.** 1881
 - C. Mueller (Basel, CH), M. Tubaro (Rome, IT), M. Weber (Bad Nauheim, DE)



12:30 Lunch (Meet the Experts Sessions & Workshops)

**THE ROLE OF IMAGING FOR RISK ASSESSMENT
BEFORE NON-CARDIAC SURGERY**

Symposium

Chairperson(s): P. Nihoyannopoulos (London, GB); D. Poldermans (Rotterdam, NL)

- | | | |
|-------|---|-------------|
| 08:30 | Nuclear techniques.
– M. Mazzanti (Torrette di Ancona, IT) | 1882 |
| 08:52 | Echocardiography.
– R. Sicari (Pisa, IT) | 1883 |
| 09:14 | Computed tomography.
– D. Ropers (Erlangen, DE) | 1884 |
| 09:36 | How imaging should be applied.
– E. Boersma (Rotterdam, NL) | 1885 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

**STRATIFYING RISK IN ASYMPTOMATIC PATIENT
WITH SEVERE VALVULAR HEART DISEASE**

Main Session

Chairperson(s): J.L. Monin (Creteil, FR); W.A. Zoghbi (Houston, US)

- | | | |
|-------|--|-------------|
| 11:00 | Aortic stenosis.
– R. Rosenhek (Vienna, AT) | 1886 |
| 11:22 | Aortic regurgitation.
– A. Evangelista Masip (Barcelona, ES) | 1887 |
| 11:44 | Mitral stenosis.
– J.-W. Ha (Seoul, KR) | 1888 |
| 12:06 | Mitral regurgitation.
– P. Lancellotti (Liège, BE) | 1889 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

HOT TOPICS IN RESUSCITATION

Symposium

Chairperson(s): L.L. Bossaert (Edegem-Antwerp, BE); F. Fedele (Rome, IT)
The European Society of Cardiology and the European Resuscitation Council

- 08:30 **Is compression, ventilation, defibrillation and cooling all we have?** 1890
– B.W. Boettiger (Cologne, DE)
- 08:48 **Is there a future for automated external defibrillators in the hands of lay people?** 1891
– K. Monsieurs (Ghent, BE)
- 09:06 **Role of revascularisation after successful resuscitation form out-of-hospital cardiac arrest.** 1892
– C. Spaulding (Paris, FR)
- 09:24 **How to improve response time for defibrillation in the community.** 1893
– A.P.M. Gorgels (Maastricht, NL)
- 09:42 **Cardiac arrest during major sports events.** 1894
– D. Zideman (London, GB)

10:00 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)**

ORGAN DYSFUNCTION IN ACUTE HEART FAILURE

Symposium

Chairperson(s): U. Janssens (Eschweiler, DE); H.N. Sabbah (Detroit, US)

- 11:00 **Lung.** 1895
– J. Masip (Barcelona, ES)
- 11:22 **Endothelium.** 1896
– T.F. Luescher (Zurich, CH)
- 11:44 **Kidney.** 1897
– M. White (Montreal, CA)
- 12:06 **Liver.** 1898
– A. Mebazaa (Paris, FR)

12:30 **Lunch (Meet the Experts Sessions & Workshops)**

**PREDICTORS OF OUTCOME IN CARDIAC
RESYNCHRONISATION THERAPY**

Abstracts

Chairperson(s): C. Linde (Stockholm, SE); P. Caso (Naples, IT)

- 08:30 **Cardiac resynchronisation therapy is effective in elderly patients. The results of the InSync registry.** **1899**
 – S. Furnagalli, M. Gasparini, M. Lunati, M. Santini, M. Landolina, A. Achilli, F. Tronconi, S. Valsecchi, N. Marchionni, L. Padeletti (Florence, Rozzano, Milan, Rome, Pavia and Viterbo, IT)
- 08:45 **Differences in dyssynchrony and response to cardiac resynchronization therapy between native LBBB and pacing-induced LBBB.** **1900**
 – T. Arita, K. Ando, Y. Soga, M. Goya, H. Yokoi, M. Iwabuchi, M. Nobuyoshi (Kitakyushu, JP)
- 09:00 **Outcome of chronic heart failure patients after device implantation is highly dependent on concomitant medical treatment regimen.** **1901**
 – C. Adlbrecht, M. Huelsmann, M. Gwechenberger, C. Khazen, F. Wiesbauer, M. Ehlenitzky, S. Neuhold, T. Binder, I.M. Lang, R. Pacher (Vienna, AT)
- 09:15 **Effect of heart failure history on CRT patient survival.** **1902**
 – D. Gras, C. Muto, T. Maounis, A. Schuchert, M.-G. Bongiorno, R. Frank, T. Vesterlund, E. Boulogne, L. Padeletti (Nantes and Paris, FR; Naples, Pisa and Florence, IT; Athens, GR; Neumuenster, DE; Aalborg, DK; Zaventem, BE)
- 09:30 **Old age does not influence cardiac resynchronization therapy effects.** **1903**
 – A. Vicentini, S. De Feo, C. Muto, T. Maounis, A. Schuchert, C. Gazzola, E. Boulogne, L. Pedeletti (Peschiera del Garda, Naples, Milan and Florence, IT; Athens, GR; Hamburg, DE; Zaventem, BE)
- 09:45 **Heart disease and QRS duration predict ‘hyperresponse’ to cardiac resynchronization therapy.** **1904**
 – L. Koutbi, F. Franceschi, J. Mancini, E. Bastard, G. Habib, J.C. Deharo (Marseille, FR)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



**HIGHLIGHTS FROM EUROPEAN HEART
RHYTHM ASSOCIATION SCIENTIFIC
DOCUMENTS**

Association Track

Chairperson(s): J. Brugada Terradellas (Barcelona, ES); P.E. Vardas (Heraklion, GR)

- 11:00 **Emerging therapeutic goals in atrial fibrillation patients.** **1905**
 – P. Kirchhof (Munster, DE)
- 11:22 **Revised recommendations on driving for implantable cardioverter-defibrillator patients.** **1906**
 – W. Jung (Villingen-Schwenningen, DE)
- 11:44 **Updated catheter ablation management of patients with ventricular tachycardia.** **1907**
 – E. Aliot (Vandoeuvre-les-Nancy, FR)
- 12:06 **Practical recommendation for use of loop recorder.** **1908**
 – M. Brignole (Lavagna, IT)

12:30 Lunch (Meet the Experts Sessions & Workshops)

IMPLANTABLE-CARDIOVERTER DEFIBRILLATOR THERAPY: PATIENT AND DEVICE MONITORING Abstracts

Chairperson(s): T. Meinertz (Hamburg, DE); J. Kautzner (Prague, CZ)

- 08:30 **Event notifications by remote monitoring systems performing automatic daily checks: load, characteristics and clinical utility.** 1909
 – N. Varma, A. Epstein, A. Irimpen, L. Gibson, C. Love (Cleveland, Birmingham, New Orleans, Lake Oswego and Columbus, US)
- 08:45 **Early detection of heart failure decompensation by Optivol fluid status monitoring.** 1910
 – R. Bover Freire, I. Fernandez Lozano, J. Fernandez De La Concha, X. Beiras Torrado, V. Monivas Palomero, J.J. Garcia Guerrero, E. Garcia Campo, J. Perez-Villacastin (Madrid, Badajoz and Vigo, ES)
- 09:00 **Implantable cardioverter defibrillator recipients: comparison of primary and secondary indicated patients during long-term follow-up.** 1911
 – C.J.W. Borleffs, G.H. Van Welsesens, L. Van Erven, R.J. Van Bommel, E.T. Van Der Velde, F.R. Rosendaal, E.E. Van Der Wall, J.J. Bax, M.J. Schalij (Leiden, NL)
- 09:15 **Hypertrophic Cardiomyopathy: Single-center experience with ICD implantation & follow-up.** 1912
 – L. Valtuille, N. Galizio, J.L. Gonzalez, M. Ramirez, A. Fernandez, J.H. Casabe, E. Guevara, F. Landeta, M. Diez, L. Favaloro (Buenos Aires, AR)
- 09:30 **Longevity of ICD pulse generators: 10-year multicenter experience.** 1913
 – L.M. Kallinen, R. Hauser (Minneapolis, US)
- 09:45 **Lead dislodgement and lead related cardiac perforation in ICD patients.** 1914
 – G.M. Nair, J.S. Healey, L. Long, J. Dean, S. Divakaramenon, S.C. Ribas, C.A. Morillo, S.J. Connolly (Hamilton, CA)

MEET THE EDITORS: INSIGHTS AND CHALLENGES

Chairperson(s): S.D. Kristensen (Aarhus, DK); E.E. Van der Wall (Leiden, NL)

- 10:05 **The Editors' Club initiative - an ESC task force.** 1915
 – P.E. Vardas (Heraklion, GR)
- 10:15 **National Society Cardiovascular Journals. Data and current status.** 1916
 – G. Ambrosio (Perugia, IT)
- 10:25 **Mission statement document. Summary and joint publication initiative.** 1917
 – F. Alfonso Manterola (Madrid, ES)
- 10:35 **Role of editors in CME. New proposals.** 1918
 – A.D. Timmis (London, GB)
- 10:45 **Discussion.** 1919



ANTIBRADYCARDIA PACING: FROM STIMULATION TO FUNCTION Abstracts

Chairperson(s): R. Sutton (London, GB); H. Haouala (Tunis Montfleury, TN)

- 11:00 **The relationship between left ventricular dyssynchrony and left atrial function in right ventricular pacing.** 1920
 – D. Leong, A. Mitchell, H. Lim, H. Dimitri, B. John, M. Stiles, M. Alasady, D. Lau, P. Sanders, G. Young (Adelaide, AU)
- 11:15 **Long term results of patients with AV-block randomized to biventricular pacing versus DDD(R)-pacing.** 1921
 – A.E. Albertsen, P.T. Mortensen, H. Egeblad, J.C. Nielsen (Aarhus, DK)
- 11:30 **LV apex and LV septal pacing for long term preservation of mechanical coordination and ventricular contractility.** 1922
 – F.W. Prinzen, R.W. Mills, L.M. Mulligan, N. Skadsberg, R.N. Cornelussen, F. Van Wijk (Maastricht, NL; Minneapolis, US)
- 11:45 **Adeno-associated virus-mediated HCN4 gene transfer increases spontaneous ventricular escape beats in canine model of AV block.** 1923
 – N. Murakoshi, R. Kamimura, K. Setoyama, D. Xu, M. Igarashi, K. Yoshida, K. Tanoue, Y. Sekiguchi, I. Yamaguchi, K. Aonuma (Tsukuba and Kagoshima, JP)
- 12:00 **Assessment of right ventricular function can predict the long term clinical evolution of patients with permanent conventional dual-chamber pace-maker.** 1924
 – E. Moro, C. Marcon, E. Marras, G. Allocca, N. Sitta, P. Delise (Conegliano, IT)
- 12:15 **Left ventricular electromechanical dyssynchrony after long-term ventricular pacing in patients with acquired atrioventricular block.** 1925
 – R. Costa, M.I.P. Leao, R.F. Mori, G. Giannini, K.R. Silva, R.T. Silva, C.E.B. Lima, S.P.L. Costa, I.M. Penteado (Sao Paulo, BR)

12:30 Lunch (Meet the Experts Sessions & Workshops)

DEVICES IN HEART FAILURE. UPDATE 2009

Symposium

Chairperson(s): D.J. van Veldhuisen (Groningen, NL); G.S. Filippatos (Athens, GR)

- | | | |
|-------|--|-------------|
| 08:30 | Open issues in implantable cardioverter-defibrillator and cardiac resynchronisation therapy.
– P.E. Vardas (Heraklion, GR) | 1926 |
| 08:52 | Implantable monitoring devices.
– L. Tavazzi (Cotignola, IT) | 1927 |
| 09:14 | Ultrafiltration.
– W.T. Abraham (Columbus, US) | 1928 |
| 09:36 | Non-invasive ventilation.
– D.E. Newby (Edinburgh, GB) | 1929 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

**CHALLENGING INDICATIONS FOR IMPLANTABLE
CARDIOVERTER-DEFIBRILLATOR/CARDIAC
RESYNCHRONISATION THERAPY IN HEART FAILURE**

Symposium

Chairperson(s): M. Santini (Rome, IT); J.G.F. Cleland (Kingston upon Hull, GB)

- | | | |
|-------|--|-------------|
| 11:00 | In asymptomatic left ventricular dysfunction.
– C. Linde (Stockholm, SE) | 1930 |
| 11:22 | In narrow QRS.
– F. Ruschitzka (Zurich, CH) | 1931 |
| 11:44 | In female and elderly patients.
– J.C. Daubert (Rennes, FR) | 1932 |
| 12:06 | In severe heart failure.
– J. Lindenfeld (Denver, US) | 1933 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

CARDIOGENIC SHOCK – AN UPDATE

Symposium

Chairperson(s): M. Pfeffer (Boston, US); R.J. Seabra-Gomes (Carnaxide, PT)

- | | | |
|-------|---|-------------|
| 08:30 | Initial and ongoing assessment in the intensive cardiac-care unit. | 1934 |
| | – S. Price (London, GB) | |
| 08:52 | Pharmacologic management. | 1935 |
| | – D. Zahger (Beer Sheva, IL) | |
| 09:14 | Role of revascularisation. | 1936 |
| | – C.J.M. Vrints (Edegem, BE) | |
| 09:36 | Ventricular assist devices and the role of the cardiac surgeon. | 1937 |
| | – J.R. Pepper (London, GB) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



AUTOANTIBODIES IN HEART FAILURE: BYSTANDERS, BIOMARKERS OR ACTORS?

Symposium

Chairperson(s): B. Maisch (Marburg, DE); G. Guardigli (Ferrara, IT)

- | | | |
|-------|---|-------------|
| 11:00 | Clinical presentation and autoimmune features in myocarditis and cardiomyopathy. | 1938 |
| | – A.L.P. Caforio (Padua, IT) | |
| 11:22 | Predictors of outcomes in patients with suspected myocarditis. | 1939 |
| | – M. Boehm (Homburg/Saar, DE) | |
| 11:44 | Novel immunomodulatory approaches in immune cardiomyopathy. | 1940 |
| | – H.P. Schultheiss (Berlin, DE) | |
| 12:06 | Immunoabsorption: a therapeutical option in dilated cardiomyopathy? | 1941 |
| | – N. Mahon (Dublin, IE) | |

12:30 Lunch (Meet the Experts Sessions & Workshops)

OPTIMISING THE CARE OF ATRIAL FIBRILLATION PATIENTS

Symposium

Chairperson(s): M. Freitas (Coimbra, PT); T.M. Norekval (Bergen, NO)

- | | | |
|-------|---|-------------|
| 08:30 | As the atrial fibrillation population increases, so does the need for care.
– P. Raatikainen (Oulu, FI) | 1942 |
| 08:52 | Can we improve patient management with nurse-managed atrial fibrillation clinics?
– S. Kikkenborg Berg (Copenhagen, DK) | 1943 |
| 09:14 | It's not just rate and rhythm: symptoms and quality of life in atrial fibrillation.
– M.C. Deaton (Manchester, GB) | 1944 |
| 09:36 | Organising the teams that will deal with the epidemic.
– J.-Y. Le Heuzey (Paris, FR) | 1945 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

ATRIAL FIBRILLATION IN PATIENTS AT HIGH RISK OF STROKE: CLINICAL DILEMMAS

Clinical Seminar

Chairperson(s): M. Glikson (Ramat Gan, IL); P. Alboni (Cento, IT)

- | | | |
|-------|--|-------------|
| 11:00 | Patients with an acute coronary syndrome or a drug-eluting stent.
– A. Rubboli (Bologna, IT) | 1946 |
| 11:22 | Patients undergoing catheter ablation.
– M.B. Ozin (Ankara, TR) | 1947 |
| 11:44 | Patients requiring elective surgery.
– D.C.L. Gulba (Dueren, DE) | 1948 |
| 12:06 | Patients with a history of major bleeding.
– G.Y.H. Lip (Birmingham, GB) | 1949 |

12:30 Lunch (Meet the Experts Sessions & Workshops)



PREDICTORS OF CARDIOVASCULAR EVENTS: LESSONS FROM LARGE DATABASES

Abstracts

Chairperson(s): W. Koenig (Ulm, DE); D. Vanuzzo (Udine, IT)

- 08:30 **The eight independent predictors of elevated resting heart rate among 8922 patients with stable coronary artery disease.** 1950
 – L. Lorgis, M. Zeller, P. Jourdain, J. Beaune, J.P. Cambou, B. Vaisse, B. Chamontin, Y. Cottin (Dijon, Pontoise, Lyon, Toulouse and Marseille, FR)
- 08:45 **Prognostic value of resting heart rate in a general population of patients with stable coronary artery disease: a prospective, single center, cohort study.** 1951
 – M. Ruiz Ortiz, E. Romo Penas, C. Ogayar Luque, D. Mesa Rubio, M. Delgado Ortega, J.C. Castillo Dominguez, M. Anguita Sanchez, A. Lopez Granados, J.M. Arizon Del Prado, J. Suarez De Lezo (Cordoba, ES)
- 09:00 **The CHADS2 score predicts adverse cardiovascular outcome in atherothrombotic patients without atrial fibrillation: Insights from the European REACH registry.** 1952
 – O. Barthelemy, F. Beygui, J. Silvain, A. Bellemain-Appaix, U. Zeymer, D.L. Bhatt, P.G. Steg, G. Montalescot (Paris, FR; Ludwigshafen am Rhein, DE; Cleveland, US)
- 09:15 **Pharmacogenetic of Acenocoumarol in patients with extreme requirements.** 1953
 – V. Perez-Andreu, V. Roldan-Schilling, M.F. Lopez, A.I. Anton, I. Alberca, J. Corral, J. Hermida, F. Espana, V. Vicente, R. Gonzalez-Conejero (Murcia, A Coruna, Salamanca, Pamplona and Valencia, ES)
- 09:30 **D-dimer testing, thrombophilia screening and recurrences in patients with venous thromboembolism: a 6-year follow-up.** 1954
 – J. Conard, E. Ombanda-Moussa, M.M. Samama, A.G. Turpie, M.H. Horellou, I. Elalamy (Paris, FR; Hamilton, CA)
- 09:45 **Evaluation of the TIMI and GRACE scores in developing countries: insights from the ACCESS registry.** 1955
 – J.C. Nicolau, G. Montalescot, C. Martinez-Sanchez, N. Antepará, A. Escobar, S. Alam, M. Sobhy, A. Leizorowicz (Sao Paulo, BR; Paris and Lyon, FR; Mexico City, MX; Caracas, VE; Medellin, CO; Beirut, LB; Alexandria, EG)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



UPDATE ON RISK ASSESSMENT IN ACUTE CORONARY SYNDROMES

Abstracts

Chairperson(s): D. Ardissino (Parma, IT); I.A. Paraskevaidis (Athens, GR)

- 11:00 **The HEART score for chest pain patients at the emergency room.** 1956
 – B.E. Backus, A.J. Six, J.C. Kelder, T.P. Mast, F. Van Den Akker, P.A. Doevendans (Nieuwegein, Woerden and Utrecht, NL)
- 11:15 **Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors and clinical implications (analysis from the ACUITY Trial).** 1957
 – E. Nikolovsky, R. Mehran, A.J. Kirtane, A.J. Lansky, A.M. Lincoff, A. Caixeta, M. Fahy, J.W. Moses, E.M. Ohman, G.W. Stone (New York, Cleveland and Durham, US)
- 11:30 **Four times higher hospital mortality due to major bleeding complications in NSTE-ACS in clinical practice: lessons from the Euro Heart Survey ACS registry.** 1958
 – A.K. Gitt, H. Bueno, W. Wojakowski, M. Tendra, H. Katus, M. Gierlotka, M. Tubaro, Y. Hasin, F. Schiele, J.P. Bassand (Ludwigshafen am Rhein and Heidelberg, DE; Madrid, ES; Katowice and Zabrze, PL; Rome, IT; Tiberias, IL; Besançon, FR)
- 11:45 **ST2 and IL33 have independent prognostic value in patients with acute coronary syndromes compared with GRACE score and N-terminal pro-B-type natriuretic peptide.** 1959
 – O.S. Dhillon, S.Q. Khan, H. Narayan, N.G. Kh, M. Noor, Q. Pa, I.B. Squire, J.E. Davies, L.L. Ng (Leicester, GB)
- 12:00 **Performance of the GRACE risk score in acute coronary syndromes: impact of patient-related variables and of variables associated with the acute event.** 1960
 – P. Carmo, J. Ferreira, C. Aguiar, P. Goncalves, R. Gomes, S. Lima, J. Brito (Carnaxide, PT)
- 12:15 **Serial assessment of MPO in patients with ACS provides independent prognostic information.** 1961
 – M. Weber, H. Nef, H. Moellmann, C. Liebetrau, M. Woelken, C. Hamm (Bad Nauheim, DE)

12:30 Lunch (Meet the Experts Sessions & Workshops)

CONTROVERSIAL ISSUES IN NON ST ELEVATION MYOCARDIAL INFARCTION

Main Session

Chairperson(s): Y. Hasin (Tiberias, IL); M. Tubaro (Rome, IT)

08:30	Time to coronary angiography. – K. Toutouzas (Athens, GR)	1962
08:52	Invasive strategy in the elderly. – M. Kelm (Dusseldorf, DE)	1963
09:14	Management of renal failure. – P.M. Clemmensen (Copenhagen, DK)	1964
09:36	Management of hyperglycemia and diabetes. – F. Cosentino (Rome, IT)	1965

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

CONTROVERSIES IN STABLE ANGINA

Debate

Chairperson(s): Z. Reiner (Zagreb, HR); W. Wijns (Aalst, BE)

Invasive coronary angiography for all.

11:00	Pro. – N.H.J. Pijls (Eindhoven, NL)	1966
11:15	Contra. – S. Yusuf (Hamilton, CA)	1967
	Rebuttal.	
11:30	Pro. – N.H.J. Pijls (Eindhoven, NL)	1968
11:35	Contra. – S. Yusuf (Hamilton, CA)	1969
11:40	Conclusion.	1970
	Non-invasive coronary angiography for all.	
11:45	Pro. – S. Achenbach (Erlangen, DE)	1971
12:00	Contra. – W.D. Weaver (Detroit, US)	1972
	Rebuttal.	
12:15	Pro. – S. Achenbach (Erlangen, DE)	1973
12:20	Contra. – W.D. Weaver (Detroit, US)	1974
12:25	Conclusion.	1975

12:30 Lunch (Meet the Experts Sessions & Workshops)



UNRAVELING THE LINK BETWEEN RYANODINE RECEPTOR MOLECULAR STRUCTURE AND CARDIAC ARRHYTHMIA

Symposium

Chairperson(s): A. Gomez (Montpellier, FR); K.R. Sipido (Leuven, BE)

- 08:30 **An overview of the ryanodine receptor mutations in arrhythmias.** 1976
– A. Lai (Cardiff, GB)
- 08:52 **A genetically modified mouse model to better understand catecholaminergic polymorphic ventricular tachycardia.** 1977
– M. Yano (Yamaguchi, JP)
- 09:14 **Genetics of cardiac arrhythmias and sudden death: insights into calsequestrin and its mutants.** 1978
– S.G. Priori (Pavia, IT)
- 09:36 **Towards fixing leaky ryanodine receptors.** 1979
– B. Gellen (Creteil, FR)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

- 10:15–10:45 **How to submit an abstract to the ESC** 1980
– E. Picano (Pisa, IT)



MOLECULAR CHARACTERISTICS OF ARRHYTHMOGENIC SUBSTRATES

Symposium

Chairperson(s): R.N.W. Hauer (Utrecht, NL); E. Cerbai (Florence, IT)

- 11:00 **Ion channel remodelling in atrial fibrillation.** 1981
– U. Ravens (Dresden, DE)
- 11:22 **Reverse excitation-contraction coupling: the role of the sarcomere.** 1982
– G. Iribe (Okayama, JP)
- 11:44 **Not so innocent: 'bystander' accessory subunits and arrhythmogenesis.** 1983
– H. Watanabe (Niigata, JP)
- 12:06 **Cell-cell coupling and arrhythmogenicity.** 1984
– B.K. Fleischmann (Bonn, DE)

12:30 Lunch (Meet the Experts Sessions & Workshops)

DIAGNOSIS AND MANAGEMENT PROBLEMS IN PATIENTS AND FAMILIES WITH CARDIOMYOPATHY **Clinical Seminar**

Chairperson(s): D. Brito (Lisbon, PT); A. Di Lenarda (Trieste, IT)

- | | | |
|-------|--|-------------|
| 08:30 | Genetic screening and prenatal diagnosis.
– P. Charron (Paris, FR) | 1985 |
| 08:52 | Clinical screening and management of family members.
– A. Keren (Jerusalem, IL) | 1986 |
| 09:14 | Ethical and psychological issues associated with family screening.
– T.M. Helio (Helsinki, FI) | 1987 |
| 09:36 | Clues (red flags) to the correct diagnosis.
– C. Rapezzi (Bologna, IT) | 1988 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



RISK STRATIFICATION AND PREVENTION OF SUDDEN DEATH IN CARDIOMYOPATHIES

Symposium

Webcast

Chairperson(s): H. Seggewiss (Schweinfurt, DE);
A. Anastasakis (Athens, GR)

- | | | |
|-------|---|-------------|
| 11:00 | Hypertrophic cardiomyopathy.
– L. Monserrat (A Coruna, ES) | 1989 |
| 11:22 | Dilated cardiomyopathy.
– E. Arbustini (Pavia, IT) | 1990 |
| 11:44 | Arrhythmogenic right ventricular cardiomyopathy.
– C. Basso (Padua, IT) | 1991 |
| 12:06 | The paediatric population.
– M.T. Tome Esteban (London, GB) | 1992 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

THE ACUTE CAROTID SYNDROME

Symposium

Chairperson(s): D.T. Kremastinos (Athens, GR); M. Hennerici (Mannheim, DE)
The European Society of Cardiology and the European Stroke Conference

- 08:30 **Pathophysiology and definition.** **1993**
– M. Roffi (Geneva, CH)
- 08:52 **Imaging and diagnostic work-up.** **1994**
– B. Reimers (Mirano, IT)
- 09:14 **Surgical and conservative treatment.** **1995**
– H. Sillesen (Copenhagen, DK)
- 09:36 **Interventional treatments.** **1996**
– H. Sievert (Frankfurt, DE)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

CAROTID ARTERY STENTING

How-to Session

Chairperson(s): E. Minar (Vienna, AT); C. Stefanadis (Athens, GR)

- 11:00 **Patient selection, equipment.** **1997**
– A. Mathur (New Delhi, IN)
- 11:45 **Technique.** **1998**
– F. Castriota (Cotignola, IT)

12:30 Lunch (Meet the Experts Sessions & Workshops)

LONGTERM PROBLEMS IN PATIENTS WITH COARCTATION OF THE AORTA Abstracts

Chairperson(s): E. Thaulow (Oslo, NO); F.M. Picchio (Bologna, IT)

- 08:30 **A novel approach to assess vascular function using aortic wall tissue Doppler imaging. Study of repaired aortic coarctations versus normal subjects.** 1999
 – M. Serban, M. Iancu, I. Ghiorghiu, I. Craciunescu, C. Ginghina (Bucharest, RO)
- 08:45 **Late expansion of an implanted stent in growing patients with coarctation of aorta.** 2000
 – J. Suarez De Lezo, M. Pan, M. Romero, J. Segura, D.J. Pavlovic, S. Ojeda, A. Gamez, I. Tejero, M. Lafuente, A. Medina (Cordoba and Las Palmas, ES)
- 09:00 **Aortic growth late after coarctation repair.** 2001
 – R.J. Franken, P. Luijendijk, B.J. Bouma, M. Groenink, A.M. Spijkerboer, B.J.M. Mulder (Leiden and Amsterdam, NL)
- 09:15 **Complications of aortic coarctation repair assessed using cardiovascular magnetic resonance.** 2002
 – S.S.M. Chen, R.H. Mohiaddin (London, GB)
- 09:30 **Comparison between a beta-adrenergic receptor blocker and angiotensin II receptor antagonist for the treatment of hypertension in repaired aortic coarctation.** 2003
 – E. Moltzer, F.U.S. Mattace Raso, Y. Karamermer, E. Boersma, G. Webb, M.L. Simoons, A.H.J. Danser, A.H. Van Den Meiracker, J.W. Roos-Hesselink (Rotterdam, NL; Philadelphia, US)
- 09:45 **Do we need to screen all patients with coarctation of the aorta for intracranial aneurysms?** 2004
 – S.L. Curtis, M. Bradley, P. Wilde, J. Aw, S. Chakrabarti, M. Hamilton, R.P. Martin, M.S. Turner, A.G. Stuart (Bristol, GB)

10:00 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)**

ATRIAL SEPTAL DEFECT CLOSURE – UNRESOLVED ISSUES Abstracts

Chairperson(s): J.E. Deanfield (London, GB); H. Baumgartner (Munster, DE)

- 11:00 **Closure of the atrial septal defect in the elderly patients.** 2005
 – M. Pieculewicz, P. Podolec, T. Przewlocki, L. Tomkiewicz-Pajak, M. Hlawaty, P. Wilkolek, W. Tracz (Krakow, PL)
- 11:15 **Real time three dimensional transoesophageal echocardiography improves anatomical analysis before and during device transcatheter closure of atrial septal defects.** 2006
 – E. Brochet, P. Aubry, J.M. Jularid, L. Lepage, D. Detaint, D. Messika Zeitoun, A. Vahanian (Paris, FR)
- 11:30 **Transient hypercoagulable state and neurological symptom after transcatheter occlusion of atrial septal defect using amplatzer septal occluder.** 2007
 – K. Suda, Y. Kudo, S. Itoh, Y. Tananari, H. Nishino, H. Ishii, M. Iemura, Y. Maeno, H. Yasunaga, T. Matsuishi (Kurume, JP)
- 11:45 **One year efficacy of patent foramen ovale closure using the new bioabsorbable septal repair implant.** 2008
 – B. Van Den Branden, M.C. Post, H.W.M. Plokker, J.M. Ten Berg, M.J. Suttorp (Nieuwegein, NL)
- 12:00 **Cardiac troponin I release after transcatheter closure of the atrial septal defect.** 2009
 – M. Pieculewicz, P. Podolec, T. Przewlocki, P. Wilkolek, L. Tomkiewicz-Pajak, E. Suchon, M. Hlawaty, M. Olszowska, W. Tracz (Krakow, PL)
- 12:15 **Symptomatic tachy- and bradyarrhythmias after transcatheter closure of interatrial communications with Amplatzer devices.** 2010
 – M. Szkutnik, J. Bialkowski (Zabrze, PL)

12:30 **Lunch (Meet the Experts Sessions & Workshops)**



MICRORNA: NEW SWITCHES IN CARDIOVASCULAR SYSTEMS (CARDIOVASCULAR RESEARCH SYMPOSIUM 2009)

Symposium

Chairperson(s): L.J. De Windt (Utrecht, NL); H.M. Piper (Dusseldorf, DE)

- | | | |
|-------|--|------|
| 08:30 | MicroRNA: basic mechanisms in transcriptional regulatory networks.
– C. Nervi (Rome, IT) | 2011 |
| 08:52 | Control of cardiac excitability by microRNAs.
– Z. Wang (Harbin, CN) | 2012 |
| 09:14 | MicroRNAs: novel regulators of cardiac hypertrophy and failure.
– T. Thum (Wurzburg, DE) | 2013 |
| 09:36 | Role of microRNAs in angiogenesis and vascular diseases.
– S. Dimmeler (Frankfurt, DE) | 2014 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



SCIENCE HOT LINE

Webcast

Chairperson(s): A.R. Pries (Berlin, DE); R. De Caterina (Chieti, IT)

- | | | |
|-------|---|------|
| 11:00 | Focal adhesion kinase regulates load-induced PGC-1α expression and mitochondrial biogenesis in mice left ventricle.
– T. Tornatore (Campinas, BR) | 2015 |
| 11:15 | Connexin 43 is fundamental for cytoprotective signal transduction on mitochondrial KATP channels.
– U.C. Hoppe (Cologne, DE) | 2016 |
| 11:30 | Myocardial ischemia/reperfusion injury is mediated by leukocytic TLR2 and reduced by systemic administration of a novel anti-TLR2 antibody.
– F. Arslan (Utrecht, NL) | 2017 |
| 11:45 | Exosomes are the active cardioprotective component in MSC secretion.
– D. De Kleijn (Utrecht, NL) | 2018 |
| 12:00 | C-reactive protein and all cause mortality.
– B.G. Nordestgaard (Copenhagen, DK) | 2019 |
| 12:15 | Chronic, low dose epoetin-β treatment following PCI significantly improves left ventricular ejection fraction in ischemic heart failure.
– M.W. Bergmann (Hamburg, DE) | 2020 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

ARRHYTHMIAS MANAGEMENT AND SUDDEN DEATH. THE VALUE OF IMAGING **Clinical Seminar**

Chairperson(s): J. Selvanayagam (Adelaide, AU); R. Brugada Terradellas (Girona, ES)

- | | | |
|-------|---|-------------|
| 08:30 | Impact of late enhancement in the risk evaluation of arrhythmia in hypertrophic cardiomyopathy.
– J.A.C. Lima (Baltimore, US) | 2021 |
| 08:52 | The value of nuclear techniques in predicting sudden death.
– I. Carrio (Barcelona, ES) | 2022 |
| 09:14 | The value of echocardiography.
– P.M. Elliott (London, GB) | 2023 |
| 09:36 | Implantable cardioverter-defibrillator and arrhythmogenic right-ventricular dysplasia. Is magnetic resonance imaging the link?
– S. Sen-Chowdhry (London, GB) | 2024 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

MULTIMODALITY CARDIAC IMAGING: FROM REDUNDANT INFORMATION TO CLINICAL NEEDS **Symposium**

Chairperson(s): F.E. Rademakers (Leuven, BE); L. Badano (Udine, IT)

- | | | |
|-------|---|-------------|
| 11:00 | Comparative value of different imaging modalities in coronary artery disease.
– R. Bonow (Chicago, US) | 2025 |
| 11:22 | How to combine imaging in coronary artery disease patients?
– J.-L. Vanoverschelde (Brussels, BE) | 2026 |
| 11:44 | Imaging in heart failure patients: is a multimodality approach always needed?
– P. Perrone-Filardi (Naples, IT) | 2027 |
| 12:06 | Cost-benefit and risks of multimodality imaging.
– L.J. Shaw (Atlanta, US) | 2028 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

HOW TO MANAGE PULMONARY EMBOLISM AND PULMONARY HYPERTENSION IN PREGNANCY? **How-to Session**

Chairperson(s): I.M. Lang (Vienna, AT); S. Gaine (Dublin, IE)

- 08:30 **How to prevent, diagnose and treat pulmonary embolism in pregnancy?** **2029**
– I. Greer (York, GB)
- 09:15 **How to diagnose and treat chronic pulmonary hypertension in pregnancy?** **2030**
– D.G. Kiely (Sheffield, GB)

10:00 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)**

ACUTE PULMONARY EMBOLISM – A NEW TARGET FOR INTERVENTIONAL CARDIOLOGY? **Symposium**

Chairperson(s): A. Torbicki (Warsaw, PL); J.S. Russell Gibbs (London, GB)

- 11:00 **Hybrid therapy - clot fragmentation and local thrombolysis.** **2031**
– O.M. Hess (Berne, CH)
- 11:22 **Percutaneous aspiration devices - safety and efficacy in acute pulmonary embolism.** **2032**
– J. Sandoval (Mexico City, MX)
- 11:44 **Percutaneous retrieval of mobile clots in the right heart.** **2033**
– A.J.B. Brady (Glasgow, GB)
- 12:06 **Retrievable venous filters - current indications and future perspectives.** **2034**
– P. Mismetti (St Etienne, FR)

12:30 **Lunch (Meet the Experts Sessions & Workshops)**



PROTECTING SIGNALS: WHAT'S NEW?

Symposium

Chairperson(s): M. Ovize (Lyon, FR); S.E. Harding (London, GB)

The European Society of Cardiology and the International Society for Heart Research

- | | | |
|-------|---|-------------|
| 08:30 | Survival kinases: do they protect?
– G. Heusch (Essen, DE) | 2035 |
| 08:52 | Does cell-cell communication count?
– D. Garcia-Dorado Garcia (Barcelona, ES) | 2036 |
| 09:14 | Cardiac protection needs mitochondria.
– E. Murphy (Bethesda, US) | 2037 |
| 09:36 | News and views on the mitochondrial permeability transition pore.
– P. Bernardi (Padua, IT) | 2038 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



BASIC MECHANISMS IN ACUTE CORONARY SYNDROMES

Symposium

Chairperson(s): P. Libby (Boston, US); G. Heusch (Essen, DE)

- | | | |
|-------|---|-------------|
| 11:00 | Potential triggers.
– P. Holvoet (Leuven, BE) | 2039 |
| 11:22 | Perturbation of T cells.
– G. Caligiuri (Paris, FR) | 2040 |
| 11:44 | Procoagulant effects.
– L. Badimon (Barcelona, ES) | 2041 |
| 12:06 | Therapeutic implications.
– F. Crea (Rome, IT) | 2042 |

12:30 Lunch (Meet the Experts Sessions & Workshops)



YOU WANT PROGNOSIS? DO ECHO

Abstracts

Chairperson(s): J.U. Voigt (Leuven, BE); M.J. Andrade (Lisbon, PT)

- 08:30 **Left atrial enlargement and dysfunction - a new marker of long-term poor prognosis in dilated cardiomyopathy.** **2043**
 – E. Michalak, Z.T. Bilinska, J.M. Michalak, J. Grzybowski, W. Ruzyllo, P. Hoffman (Warsaw, PL)
- 08:45 **Prediction of life-threatening ventricular tachyarrhythmias and death in patients with previous myocardial infarction by left ventricular longitudinal strain analysis.** **2044**
 – C.T.A. Ng, M. Bertini, J.W. Borleffs, V. Delgado, G. Nucifora, G. Boriani, D.Y. Leung, M.J. Schalij, J.J. Bax (Leiden, NL; Bologna, IT; Sydney, AU)
- 09:00 **Speckle tracking echocardiography for the prognosis of patients with systolic and diastolic heart failure.** **2045**
 – H. Dokainish, M. Alam, J. Nguyen, N. Lakkis, M. Stampehl (Houston, US)
- 09:15 **Global longitudinal strain is superior to ejection fraction and wall motion scoring for the prediction of mortality.** **2046**
 – T. Stanton, R. Leano, T.H. Marwick (Brisbane, AU)
- 09:30 **Prognostic value of peak treadmill exercise echocardiography in patients with normal post-exercise treadmill echocardiography.** **2047**
 – J. Peteiro, A. Bouzas-Mosquera, A. Campos, P. Pazos, P. Pinon, A. Castro-Beiras (A Coruna, ES)
- 09:45 **Prognostic implication of stress echocardiography result in hypertensives and normotensives. A study on 10,054 patients.** **2048**
 – L. Cortigiani, R. Sicari, R. Bigi, F. Bovenzi, E. Picano (Lucca, Pisa and Milan, IT)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)

DIASTOLOGY: JUMP INTO THE FUTURE?

Abstracts

Chairperson(s): J.K. Oh (Rochester, US); G. Maurer (Vienna, AT)

- 11:00 **Normal values for diastolic strain rate from combined speckle tracking and Doppler tissue imaging. Preliminary data from the HUNT3-study.** **2049**
 – H.D. Dalen, A. Thorstensen, C.B. Ingul, S.A. Aase, A. Stoylen (Trondheim, NO)
- 11:15 **Are E/Ea and E/(Ea x Sa) ratios reliable predictors of left ventricular diastolic pressures in an unselected population?** **2050**
 – E. Chieffo, M. Previtali, A. Repetto, M. Ferrario, C. Klersy (Pavia, IT)
- 11:30 **Long term endurance training does not prevent the age related decline in left and right ventricular diastolic function assessed by Doppler echocardiography.** **2051**
 – A.J. Teske, N.H. Prakken, B.W. De Boeck, B.K. Velthuis, P.A. Doevendans, M.J. Cramer (Utrecht, NL)
- 11:45 **A new global tissue Doppler index: correlation with left ventricular end-diastolic pressure in patients with severe mitral regurgitation.** **2052**
 – C. Mornos, D. Cozma, A. Ionac, L. Petrescu, D. Dragulescu, S. Pescariu, D. Maximov, D. Popa, S.I. Dragulescu (Timisoara, RO)
- 12:00 **Role of exercise E/E' and ischaemia in predicting outcome in patients undergoing exercise echocardiography.** **2053**
 – D.J. Holland, S.B. Prasad, T.H. Marwick (Brisbane, AU)
- 12:15 **Incremental prognostic value of the novel diastolic indices for prediction of clinical outcome in patients with ST elevation myocardial infarction.** **2054**
 – M. Shanks, A.C.T. Ng, N.R.L. Van Der Veire, L.M. Antoni, S.A. Mollema, M.J. Schalij, E.E. Van Der Wall, J.J. Bax (Leiden, NL)

12:30 Lunch (Meet the Experts Sessions & Workshops)



IMAGING THE VULNERABLE PATIENT – AN INTEGRATED APPROACH

Symposium



Chairperson(s): N. Danchin (Paris, FR); M. Vannan (Columbus, US)

- | | | |
|-------|---|------|
| 08:30 | Clinical, biomarker and gene profile: do they really help?
– G. Pasterkamp (Utrecht, NL) | 2055 |
| 08:46 | Vascular profile: carotid intima-media thickness, brachial reactivity, ABI index - what role?
– J. Fernandes E Fernandes (Lisbon, PT) | 2056 |
| 09:02 | Plaque profile: atheroma morphology and biology - clinically useful?
– J. Narula (Orange, US) | 2057 |
| 09:18 | Myocardial profile: morphology and function - good for prediction?
– M. Vannan (Columbus, US) | 2058 |
| 09:34 | Myocardial profile: molecular targets - where are we?
– L. Hofstra (Maastricht, NL) | 2059 |
| 09:50 | Panel discussion: how do we integrate imaging data in clinical practice? | 2060 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts, Meet the Editors & Hands-on Tutorials)



PREVENTION STRATEGY: THE ASIAN PACIFIC AND EUROPEAN EXPERIENCE

Symposium



Chairperson(s): A. Kumar (Mumbai, IN); D.A. Wood (London, GB)

The European Society of Cardiology and the Asian Pacific Society of Cardiology

- | | | |
|-------|---|------|
| 11:00 | Causes of cardiovascular disease in Asia and Europe: one and the same?
– M. Woodward (Sydney, AU) | 2061 |
| 11:22 | International guidelines for cardiovascular prevention: same treatment goals, different treatment goals or no treatment goals for all populations?
– S. Mendis (Geneva, CH) | 2062 |
| 11:44 | The differences in cardiovascular risk factors and treatment goal achievement between the Asian and the European: results of the Lipid Treatment Assessment Project 2 (L-TAP 2).
– F.T. Chiang (Taipei, TW) | 2063 |
| 12:06 | Global alert and prevention of infectious heart diseases.
– A. Matsumori (Kyoto, JP) | 2064 |

12:30 Lunch (Meet the Experts Sessions & Workshops)

POSTER SESSION 3

Posters must be set up between 08:00 and 08:30, removed between 12:30 and 13:00 and be on display between 08:30 and 12:30. The presenter should be present throughout the coffee break (10:00 and 11:00) in order to discuss the poster.

**MODERATED POSTER 1
CORONARY ARTERY SURGERY: MISCELLANEOUS**

Chairperson(s): A. Leite-Moreira (Porto, PT); E. Rodriguez (Madrid, ES)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 10:00 and 11:00.

- 10:00 **DNA enzyme targeting transcription factor c-Jun reduces intimal hyperplasia in human saphenous vein explants and inhibits Vein Graft stenosis in rabbits.** P2065
– J. Ni, A. Waldman, L. Khachigian (Sydney, AU)
- 10:05 **Appraise a Customized strategy for left main revascularisation. The Customize study.** P2066
– D. Capodanno, M.E. Di Salvo, A. Caggegi, D. Tomasello, G. Cincotta, M. Miano, S. Tolaro, L. Patane', A.M. Calafiore, C. Tamburino (Catania and Pedara, IT)
- 10:10 **Assessment of repolarization features after coronary artery bypass grafting:.** P2067
– A. Ben Halima, M. Ben Halima, A. Ben Youssef, S. Bouraoui, S. Ouerghi, K. Mzoughi, Z. Ibn El Hadj, T. Mestiri, T. Kilani, S. Kachboura (Ariana, TN)
- 10:15 **Randomized comparison of Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery versus sirolimus-eluting stenting in isolated proximal LAD-stenosis.** P2068
– H. Thiele, P. Neumann-Schniedewind, S. Jacobs, E. Boudriot, T. Walther, F.W. Mohr, G. Schuler, V. Falk (Leipzig, DE)
- 10:20 **Influence of on-pump versus off-pump cardiac surgery on completeness of revascularisation in patients with stable coronary artery disease - MASS III trial.** P2069
– N.H. Lopes, E.G. Lima, R.D. Vieira, C.L. Garzillo, L.A.M. Cezar, A. Hueb, L.A.O. Dallan, F.S. Paulitsch, J.A.F. Ramires, W.A. Hueb (Sao Paulo, BR)
- 10:25 **C-reactive protein is not predictive of atrial fibrillation following coronary artery bypass surgery.** P2070
– A. Kourliouros, O. Valencia, A. Tsiouris, M. Tavakkoli Hosseini, A. Kiotsekoglou, A.J. Camm, M. Jahangiri (London, GB)
- 10:30 **Impact of on-pump and off-pump coronary artery bypass surgery in incidence of early postoperative atrial fibrillation.** P2071
– E.G. Lima, R.D. Vieira, H.B. Ribeiro, C.L. Garzillo, F.S. Paulitsch, A. Hueb, L.A.O. Dallan, J.A.F. Ramires, N.H. Lopes, W.A. Hueb (Sao Paulo, BR)
- 10:35 **Low cardiopulmonary bypass perfusion temperature is an independent risk factor for acute kidney injury after coronary artery bypass surgery.** P2072
– A. Kourliouros, O. Valencia, S.D. Phillips, P.O. Collinson, J.P. Van Besouw, M. Jahangiri (London, GB)
- 10:40 **Discussion.** P2073

**MODERATED POSTER 2
CREATING ALTERNATIVE IMAGE**

Chairperson(s): J. Hartiala (Turku, FI); C. Bucciarelli (London, GB)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 10:00 and 11:00.

- 10:00 **Cardiac MSCT as an alternative to coronary angiography in the pre operative assessment of coronary disease before aortic valve surgery.** P2074
– J.-C. Cornily, M. Gilard, V. Jan, P.Y. Pennec, G. Le Gal, J. Boschat (Brest, FR)
- 10:05 **Predictive Value of Multi-Slice Computed Tomography (MSCT) for ischemia on myocardial perfusion imaging.** P2075
– J.E. Van Velzen, J.D. Schuijff, J.M. Van Werkhoven, E. Boersma, F.R. De Graaf, M.P. Stokkel, P. Kaufmann, J.W. Jukema, E.E. Van Der Wall, J.J. Bax (Leiden and Rotterdam, NL; Zurich, CH)
- 10:10 **Effect of glucose lowering on carotid intima-media thickness, coronary artery calcification and coronary circulatory function in type 2 diabetes mellitus.** P2076
– T.H. Schindler, A.D. Facta, J. Cadenas, J. Sayre, J. Goldin, H.R. Schelbert (Geneva, CH; Los Angeles, US)
- 10:15 **Evaluation of arterial healing after stent implantation by optical frequency domain (OFDI) imaging: An in vivo comparison with histology in a pig coronary artery model.** P2077
– C. Templin, M. Meyer, M. Mueller, P. Kronen, K. Weber, D. Paunovic, S. Hoerstrup, R. Corti, T.F. Luescher, U. Landmesser (Zurich and Itingen, CH; Leuven, BE)
- 10:20 **Optimal acquisition time for myocardial perfusion imaging using an ultrafast cardiac gamma camera with a novel detector technique.** P2078
– R. Buechel, B. Herzog, V. Treyer, R. Katz, L. Husmann, I. Burger, A. Pazhenkottil, I. Valenta, O. Gaemperli, P. Kaufmann (Zurich, CH)
- 10:25 **Can ventricular dyssynchrony during exercise predict response to resynchronization therapy? A radionuclide angiography study.** P2079
– C. Valzania, F. Fallani, G. Gavaruzzi, M. Biffi, C. Martignani, I. Diemberger, M. Bertini, G. Domenichini, C. Rapezzi, G. Boriani (Bologna, IT)
- 10:30 **Different patterns of myocardial iron overload by T2* Cardiovascular MR as markers of risk for cardiac complication in thalassemia major.** P2080
– A. Pepe, A. Meloni, V. Positano, G. Rossi, P. Pepe, M.C. Galati, A. Zuccarelli, G. Restaino, G. Valeri, M. Lombardi (Pisa, Catanzaro, Olbia, Campobasso and Ancona, IT)
- 10:35 **Aortic dilatation and reduced elasticity after surgical repair of tetralogy of fallot - assessment by magnetic resonance imaging.** P2081
– A. Silva Ferreira, E. Rizzo, M. Ladouceur, A. Redheuil, M. Bensalah, A. Azarine, Y. Boudjemline, E. Mousseaux (Lisbon, PT; Paris, FR)
- 10:40 **Discussion.** P2082

THROMBOSIS AND ANTI-THROMBOTIC THERAPY

- Slow response to clopidogrel predicts low response.** P2083
 – A. Bellemain, J. Silvain, J.-P. Collet, F. Beygui, O. Barthelemy, R. Choussat, N. Vignolles, D. Brugier, B. Bertin, G. Montalescot (Paris, FR)
- Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.** P2084
 – V.L. Serebruany, S. Rao, M. Siva, J.L. Donovan, A.O. Kannan, L.M. Makarov, S. Goto, D. Atar (Towson, Durham and Worcester, US; Kanagawa, JP; Oslo, NO)
- The clopidogrel patient information card significantly improves knowledge and adherence to anti-platelet therapy.** P2085
 – S. Bhattacharyya, H. Madani, S. Myers, R. Rakhit (London, GB)
- The effect of duration of Clopidogrel treatment on outcome in following coronary stent implantation.** P2086
 – D. Zahger, H. Gilutz, C. Cafri, R. Ilia, A. Porat (Beer Sheva, IL)
- The variable response of PCI subjects with apparent Clopidogrel resistance to re-loading with 600mg.** P2087
 – A.S.P. Sharp, R.T. Gerber, C. Godino, A. Latib, M. Ferraro, A. Colombo (Milan, IT)
- The frequency and intra-individual variation of clopidogrel non-responsiveness over time as measured by VerifyNow in patients with stable coronary heart disease.** P2088
 – A.A. Pettersen, H. Arnesen, I.U. Njerve, M.T. Kase, I. Seljeflot (Oslo, NO)
- The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the verifynow P2Y12 near-patient testing device in patients undergoing coronary angiography.** P2089
 – A. Worrall, A. Armesilla, M. Norell, S. Khogali, M. Cusack, A. Smallwood, J. Cotton (Wolverhampton, GB)
- The relative contribution of the CYP2C19*2 polymorphism in the low responsiveness to clopidogrel in the VASP-02 study.** P2090
 – B. Aleil, F. De Poli, M. Zaehringer, J.P. Collet, G. Montalescot, C. Leon, J.P. Cazenave, M.C. Dickele, J.P. Monassier, C. Gachet (Strasbourg, Haguenau, Paris and Mulhouse, FR)
- The significance of clopidogrel low-responsiveness assessed by a point-of-care assay in acute coronary syndrome patients undergoing coronary stenting.** P2091
 – K.H. Lee, S.H. Lee, J.W. Lee, J.K. Sung, H.S. Wang, Y.J. Youn, N.S. Lee, J.Y. Kim, J.H. Yoon, K.H. Choe (Wonju, KR)
- Adverse events associated with high clopidogrel loading doses after acute coronary syndrome.** P2092
 – C. Pizzi, M. Dorobantu, G. Tatu-Chitoui, L. Calmac, O. Manfrini, M. Udeanu, E. Craiu, C. Macarie, R. Bugiardini (Bologna, IT; Bucharest and Constanta, RO)
- Anti-thrombotic effects of an anti-von willebrand factor a1 domain aptamer in blood from patients under aspirin and clopidogrel therapy.** P2093
 – D. Arzamendi Aizpurua, F. Dandachli, G. Ducrocq, J.F. Theoret, W. Mourad, J. Gilbert, R. Schaub, Y. Merhi, J.F. Tanguay (Montreal, CA)
- Prevalence and predictors of bleeding in patients on prolonged dual oral antiplatelet therapy undergoing DES implantation.** P2094
 – R. Rossini, G. Musumeci, C. Lettieri, N. Lortkipanidze, M. Romano, T. Nijaradze, A. Izzo, G. Biondi Zoccai, A. Gavazzi, D.J. Jacksonlillo (Bergamo, Mantova and Turin, IT; Jacksonville, US)
- High-risk patients for GI bleeding on dual antiplatelet therapy in Spain are more like to receive PPI therapy than their American peers.** P2095
 – A. Lanas, L. Guastello, R. Casado, D. Saini, M. Polo-Tomas, J. Scheiman, A. Del Rio (Zaragoza, ES; Ann Arbor, US)
- Age-related differences in the antithrombotic therapy in patients with PCI. Results from the ALKK-PCI Registry.** P2096
 – A.K. Schwarz, R. Zahn, M. Hochadel, S. Kerber, K.E. Hauptmann, H. Mudra, H. Darius, J. Senges, U. Zeymer (Ludwigshafen am Rhein, Bad Neustadt, Trier, Munich and Berlin, DE)

- The in vitro effects of E5555, a PAR-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.** P2097
 – V.L. Serebruany, M. Kogushi, D. Dastros-Pitei, M. Flather, D.L. Bhatt (Towson and Boston, US; Tsukuba, JP; London, GB)
- Thrombin generation curve in patients submitted to angioplasty with a combination of antiplatelet agents, fondaparinux and unfractionated heparin.** P2098
 – F. Schiele, E. Racadot, N. Meneveau, M.F. Seronde, V. Descotes-Genon, R. Chopard, J. Duthell, J.P. Bassand (Besançon, FR)
- Elevated residual platelet reactivity to adenosine diphosphate and arachidonic acid in patients after myocardial infarction compared to patients after elective coronary stenting.** P2099
 – T.F. Althoff, M. Fischer, F. Knebel, E. Langer, S. Ziemer, G. Baumann (Berlin, DE)
- Incidence of late stent thrombosis up to 5 years after implantation of drug-eluting stent in routine practice.** P2100
 – Y. Onuma, P. Wenaweser, J. Daemen, G. Hellige, K. Tsuchida, P. Juni, R. Van Domburg, P.W. Serruys, S. Windecker (Rotterdam, NL; Berne, CH)
- Differential proteomic profiling of coronary stent thrombosis versus atherothrombosis.** P2101
 – K. Distelmaier, M. Kubicek, B. Redwan, C. Adlbrecht, O. Wagner, I.M. Lang (Vienna, AT)
- Fibrin clot structure/fibrinolysis and relationship to ischaemic heart disease and metabolic factors in older individuals with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.** P2102
 – R.A. Ajjan, K.A. Hess, A.M. Carter, A. Trehan, K.S. Standeven, P.J. Grant, R.M. Williamson, R.M. Reynolds, J.F. Price, M.W.J. Strachan (Leeds and Edinburgh, GB)
- The novel synthetic cyclic peptide (S,S) PSRCDCR-NH2, inhibits carotid artery thrombosis in rabbits.** P2103
 – V. Roussa, E.M. Stathopoulou, K. Egglezopoulos, N.D. Papamichael, V. Mousis, V. Tsiakaris, C.S. Katsouras, K.K. Naka, A.D. Tselepis, L.K. Michalis (Ioannina, GR)
- A proinflammatory and prothrombotic environment in young individuals with type 1 diabetes: the effects of glycaemic control.** P2104
 – K.A. Hess, M. Mathai, T. Koko, K.F. Standeven, P. Holland, A.M. Carter, F. Phoenix, P.J. Grant, R.A. Ajjan (Leeds, GB)
- Effect of edoxaban (DU-176b) on thrombin generation and platelet activation in shed and venous blood with fondaparinux as active comparator.** P2105
 – M.M. Samama, M. Wolzt, K. Ogata, J. Mendell, S. Kunitada (Paris, FR; Vienna, AT; Tokyo, JP; Edison, US)
- Concomitant administration of low-dose rivaroxaban - an oral, direct Factor Xa inhibitor - with clopidogrel and acetylsalicylic acid enhances antithrombotic efficacy in rats.** P2106
 – E. Perzborn, E. Fischer, U. Lange, M. Harwardt (Wuppertal, DE)
- High Density Lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells.** P2107
 – E.W. Holy, C. Besler, G.G. Camici, T.F. Luescher, U. Landmesser, F.C. Tanner (Zurich, CH)
- Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation.** P2108
 – J.-W. Suh, H.-S. Kim, J.-S. Park, H.-J. Kang, I.-H. Chae, D.-J. Choi (Seongnam and Seoul, KR)
- The impact of the genetic polymorphism G455A on the b-chain fibrinogen gene on thrombotic process in patients with coronary artery disease.** P2109
 – D. Tousoulis, N. Papageorgiou, C. Antoniadis, G. Hatzis, A. Miliou, A. Giolis, A. Antonopoulos, C. Tentolouris, C. Toutouzias, C. Stefanadis (Athens, GR)
- Effects of direct thrombin or factor Xa inhibition on clot thrombogenicity in vitro: Comparison of dabigatran with rivaroxaban and apixaban.** P2110
 – J. Van Ryn, M. Kink-Eiband, I. Kuritsch, W. Wienen (Biberach, DE)
- Heparin induced thrombocytopenia after cardiac surgery and the tale of complications.** P2111
 – A. Neykova, B.T. Tzvetkov, M.K. Kirsch (Creteil, FR)

Patient's clinical characteristics according to clopidogrel and aspirin response tested in the cath lab during coronary stenting: data from the Verifynow french registry (Verifrenchy). P2112

- C. Thuair, G. Range, M. Kerkeni, R. Berthier, E. Teiger, J.P. Claudel, N. Delarche, P. Brunel, F. Albert, J.P. Collet (Chartres, Rouen, Corbeil, Creteil, Lyon, Pau, Nantes and Paris, FR)

CONTROVERSIAL ISSUES IN THE MANAGEMENT OF ACUTE CORONARY SYNDROMES

Metoprolol administration pre-reperfusion reduces infarct size by diminishing myocardial reperfusion injury. P2113

- B. Ibanez, G. Cimmino, S. Prat-Gonzalez, G. Vilahur, R. Hutter, M.J. Garcia, V. Fuster, J. Sanz, L. Badimon, J.J. Badimon (New York, US; Barcelona, ES)

Lower rate of invasive revascularisation in acute coronary syndrome patients with significant stenosis on coronary angiography when angiography is performed on a diagnostics only hospital. P2114

- A. Hvelplund, S. Galatius, M. Madsen, J.N. Rasmussen, S. Rasmussen, J.K. Madsen, S.Z. Abildstrom (Copenhagen, Hellerup and Glostrup, DK)

Primary PCI with a new drug eluting stent: mid term results of multicentre NOBORI STEMI study. P2115

- F. Fath-Ordoubadi, A. Serra, Z. Xu-Ming, P. Laanmets, N. Jagic, J. Monsegu, D. Hildick-Smith, J. Guarinos, S. Hoffmann, G.B. Dnazi (Manchester and Brighton, GB; Barcelona and Taragona, ES; Macau, MO; Tallinn, EE; Kragujevac, RS; Paris, FR; Berlin, DE; Milan, IT)

Procedural characteristics of radial versus femoral arterial access during primary percutaneous coronary intervention in STEMI patients. P2116

- W. Dorniak, G.D. Pinna, J. Klauzel, Z. Lajkowski, K. Pawlowski, W. Krasowski, G. Raczak (Gdansk, PL; Montescano, IT)

Longer distance from home to invasive centre is associated with lower rate of coronary angiographies following acute coronary syndrome. P2117

- A. Hvelplund, S. Galatius, M. Madsen, J.N. Rasmussen, S. Rasmussen, J.K. Madsen, S.Z. Abildstrom (Copenhagen, Hellerup and Glostrup, DK)

In-hospital management and outcome of Acute Coronary Syndromes (ACS) in developing countries: results of the ACCESS registry. P2118

- G. Montalescot, M. Sobhy, S. Alam, C. Martinez-Sanchez, A. Escobar, N. Antepara, J.C. Nicolau, P. Blondin, A. Leizorowicz (Paris and Lyon, FR; Alexandria, EG; Beirut, LB; Mexico city, MX; Medellin, CO; Caracas, VE; Sao Paulo, BR)

Distal protection with thrombectomy reduced death and onset of heart failure at chronic state in patients with reperfused anterior myocardial infarction. P2119

- S. Hosokawa, Y. Hiasa, S. Miyazaki, R. Ogura, T. Takahashi, K. Kishi (Komatsushima, JP)

Intramyocardial percutaneous stem cell injection guided by endocardial mapping in patients early after acute myocardial infarction. P2120

- K. Krause, K. Jaquet, C. Schneider, B. Koektuerk, K.-H. Kuck (Hamburg, DE)

Proton Pump inhibitors and clopidogrel response on cardiovascular major events in patients after acute myocardial infarction. Data from the FAST-MI registry of the French Society of Cardiology. P2121

- T. Simon, P.H. Quandalle, J. Machecourt, R. Sader, L. Ledain, V. Bataille, P.H. Brunel, P. Djiane, J.M. Julliard, N. Danchin (Paris, Roubaix, Grenoble, Laon, La Rochelle, Toulouse, Nantes and Marseille, FR)

Effect of thrombolysis with immediate transport to PCI vs. thrombolysis with ischemia-guided strategy on left ventricular function in ST-elevation myocardial infarction. P2122

- N. Mistry, E. Bohmer, P. Hoffmann, R. Bjornerheim, S.E. Kjeldsen, S. Halvorsen (Oslo and Lillehammer, NO)

The effects of pioglitazone treatment on inflammatory activity of monocytes in patients with acute coronary syndrome. P2123

- W.P. Zhang, Y. Wu, Y. Liu, Z.Y. Yuan (Xi'an, CN)

- Pharmacologic inhibition of MyD88 ameliorates adverse cardiac remodeling and apoptosis after experimental acute myocardial infarction.** P2124
 – B. Van Tassel, F.N. Salloum, L. Smithson, A. Varma, N.H. Hoke, I.M. Seropian, C. Gelwix, V. Chau, A. Abbate (Richmond, US)
- Follow-up results after interventional treatment of infarct related saphenous vein graft occlusion.** P2125
 – R. Hoffmann, G. Nitendo, V. Deserno, M. Kelm, U. Adamu (Aachen, DE)
- Long-term effects of music therapy on patients with acute myocardial infarction and prolonged revascularisation; 7-year experience.** P2126
 – P.M. Mitrovic, B. Stefanovic, Z. Vasiljevic, M. Radovanovic, N. Radovanovic, G. Krjancic, D. Rajic, G. Matic, A. Novakovic, M. Ostojic (Belgrade, RS)
- The effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with type 2 diabetes mellitus after myocardial infarction.** P2127
 – H. Yokoe, F. Yuasa, T. Sugiura, T. Iwasaka (Osaka and Kochi, JP)
- Implementation of the ESC guidelines on the management of AMI in community hospitals.** P2128
 – J. Ferrieres, J.B. Ruidavets, D. Arveiler, J. Dallongeville, B. Haas, M. Montaye, A. Bingham, V. Bongard, P. Ducimetiere (Toulouse, Strasbourg, Lille and Villejuif, FR)
- Emergency department bypass reduces the time to reperfusion therapy.** P2129
 – V. Gomes, J. Trigo, P. Gago, J. Mimoso, R. Faria, N. Marques, W. Santos, V. Brandao (Faro, PT)
- The effect of prehospital remote ischemic preconditioning on left ventricular function in STEMI patients treated with primary angioplasty: a randomised study.** P2130
 – K. Munk, N.H. Andersen, M.R. Schmidt, S.S. Nielsen, C.J. Terkelsen, E. Sloth, H.E. Botker, T.T. Nielsen, S.H. Poulsen (Aarhus, DK)
- The radial approach reduces bleeding complications in STEMI patients without increasing the time to revascularisation.** P2131
 – D. Arzamendi Aizpurua, J.F. Tanguay, H.Q. Ly, P. Lavoie-L'allier, R. Ibrahim, Y. Reyna, R. Gallo, P. Deguise, G. Gosselin, S. Doucet (Montreal, CA)
- Mortality reduction in acute myocardial infarction following organization of a regional network in a population of 1 million inhabitants with low-adherence to European guidelines.** P2132
 – I.S. Benedek, M. Chitu, I. Kovacs, A. Sarbu, M. Kurtinecz, C. Matei, S.Z. Madaras, G. Kozma, I. Benedek, T. Benedek (Targu Mures, RO)
- RADial vs femoral approach with the usage StarClose for PCI for patients with acute myocardial infarction. The RADIAMI II study, prospective, randomized, single center trial.** P2133
 – P. Chodor, T. Kurek, A. Kowalczyk, M. Swierad, T. Was, G. Honisz, A. Swiatkowski, W. Streb, Z. Kalarus (Zabrze, PL)
- Early versus late invasive strategy in successful thrombolysis reperfused acute myocardial infarction.** P2134
 – S. Champagne, D. Pongas, E. Aptecar, P. Dupouy, R. Cohen, S. Elhadad, J.L. Dubois-Rande, E. Teiger (Creteil, Melun and Lagny/Marne, FR)
- Efficacy of statin therapy in patients with acute myocardial infarction is determined by polymorphism of eNOS gene promoter.** P2135
 – Y.A. Lutay, A.N. Parkhomenko, V.E. Dosenko, A.A. Moibenko (Kiev, UA)
- Early statin treatment prior to primary PCI for acute myocardial infarction: a randomized placebo controlled trial.** P2136
 – S. Post, M.C. Post, F.D. Eefting, M.J. Goumans, M.A. Bosschaert, P.R. Stella, F.H. De Man, B.J. Rensing, P.A. Doevendans (Utrecht and Nieuwegein, NL)
- Reperfusion hemorrhage: a new therapeutic target in ST-elevation myocardial infarction.** P2137
 – A. Kumar, J.D. Green, V. Sabhaney, S. Poeschko, R. Dietz, M.G. Friedrich (Calgary, CA; Berlin, DE)
- Early vs. late referral for coronary angiography after thrombolysis for STEMI.** P2138
 – G. Almpanis, P. Davlouros, G. Vagenakis, Z. Kopsida, K. Sheffneux, M. Papatheasiou, G. Hahalas, A. Mazarakis, J. Chiladakis, D. Alexopoulos (Patras, GR)

ECHOCARDIOGRAPHY IN CARDIOMYOPATHY

- Prognostic implications of left ventricular dyssynchrony early after non-ST elevation myocardial infarction without congestive heart failure.** P2139
 – C.T.A. Ng, D.T. Tran, C. Allman, J. Vidaic, D.Y. Leung (Sydney, AU)
- Early detection of functional abnormalities in asymptomatic arrhythmogenic right ventricular cardiomyopathy gene carriers using echocardiographic deformation imaging.** P2140
 – A.J. Teske, M.G. Cox, B.W. De Boeck, P.A. Doevendans, R.N. Hauer, M.J. Cramer (Utrecht, NL)
- Identification and characterization of super-responders to cardiac resynchronization therapy: an echocardiographic study.** P2141
 – A. Zaroui, P. Reant, E. Donal, A. Deplagne, A. Mignot, P. Bordachar, A. Solnon, C. Leclercq, R. Roudaut, S. Lafitte (Bordeaux and Rennes, FR)
- Use of tissue Doppler velocity as an index of global myocardial function in atrial fibrillation with preserved left ventricular ejection fraction.** P2142
 – H.J. Yoon, H. Kim, C.D. Han, H.S. Park, H.T. Kim, Y.K. Cho, C.W. Nam, S.H. Hur, Y.N. Kim, K.B. Kim (Daegu, KR)
- Strain ST-T change on the electrocardiogram reflects subendocardial dysfunction: Demonstration using 2D speckle tracking echocardiography.** P2143
 – M. Takeuchi, T. Nishikage, H. Nakai, V. Mor-Avi, R.M. Lang, Y. Otsuji (Kitakyushu, JP; Chicago, US)
- Attenuated coronary flow reserve is associated with subtle changes in left ventricular diastolic function among healthy individuals.** P2144
 – P. Kamvrogianis, E. Alexandridis, G. Karayannis, G. Giamouzis, H. Parissis, A. Chamaidi, G. Sitafidis, J. Skoularigis, J. Butler, F. Triposkiadis (Larissa, GR; Atlanta, US)
- Echocardiographic assessment of left ventricular diastolic pressures validated using an implantable pressure sensor.** P2145
 – T.C. Poerner, B. Goebel, E. Luthardt, C. Schmidt-Winter, S. Otto, J. Gummert, H.R. Figulla (Jena, DE)
- Echocardiographic predictors of global systolic strain in patients with heart failure.** P2146
 – H. Dokainish, J. Nguyen, M. Alam, N. Lakkis, M. Stampehl (Houston, US)
- Semi-automated left ventricular function assessment by real-time three-dimensional echocardiography is ready for prime time.** P2147
 – O.I.I. Soliman, B.M. Van Dalen, M.L. Geleijnse, W.B. Vletter, A.M. Al-Amin, F.J. Ten Cate (Rotterdam, NL; Cairo, EG)
- Strain rate imaging demonstrates impaired regional right ventricular deformation in adult unoperated patients with Marfan syndrome.** P2148
 – A. Kiotsekoglou, G.R. Sutherland, J.C. Moggridge, V. Kapetanakis, B.H. Bijnens, M.J. Mullen, N. Bunce, D.K. Nassiri, A.J. Camm, A.H. Child (London, GB; Leuven, BE)
- Global strain, functional capacity and outcome in patients with dilated cardiomyopathy.** P2149
 – G. Karatasakis, A. Dimopoulos, E. Leontiadis, E. Andreanides, G. Athanasopoulos, S. Polymeros, D.V. Cokkinos (Athens, GR)
- Myocardial tissue Doppler echocardiography and atorvastatin in heart failure.** P2150
 – M. Correale, M. Ceglia, N.D. Brunetti, A. Libertazzi, R. Ieva, M. Di Biase (Foggia, IT)
- Assessment of left ventricular function in heart failure: limits of real-time three-dimensional echocardiography in real life.** P2151
 – P. Mocerl, D. Bertora, P. Gibelin (Nice, FR)
- Correlation of Doppler echocardiographic parameters and N-terminal B-type Natriuretic Peptide (NT-BNP) levels in elderly patients with systolic heart failure.** P2152
 – A. Bernheim, S.Y. Min, M. Wachter, D. Jenny, M. Neuhaus, P. Mussio, L. Joerg, M. Pfisterer, H.P. Brunner-La Rocca, P. Buser (Basel, Baden, Bulach and St. Gallen, CH)
- Usefulness of 2D speckle tracking echocardiography in carcinoid heart disease.** P2153
 – N. Mansencal, E. Mitry, P. Rougier, O. Dubourg (Boulogne, FR)

- Characterization of myocardial deformation in hypertrophic cardiomyopathy using speckle tracking: a comparison with physiological hypertrophy.** P2154
 – H. Badran, M. Saber, A. El-Sherif, A. Farhan, Y. Nassar, S. Moktar, M. Yacoub (Shebin and Cairo, EG; London, GB)
- Usefulness of contrast echocardiography in Tako-Tsubo cardiomyopathy.** P2155
 – N. Mansencal, A. Lamar, A. Beauchet, R. El Mahmoud, R. Pilliere, O. Dubourg (Boulogne, FR)
- Incremental value of subclinical left ventricular systolic dysfunction for the identification of patients with obstructive coronary artery disease.** P2156
 – G. Nucifora, J.D. Schuijf, M. Bertini, V. Delgado, A.J.H.A. Scholte, J.M. Van Werkhoven, J.W. Jukema, E.R. Holman, E.E. Van Der Wall, J.J. Bax (Leiden, NL)
- Effects of cardiac resynchronization therapy on subepicardial and subendocardial left ventricular twist.** P2157
 – M. Bertini, N. Ajmone Marsan, G. Nucifora, V. Delgado, R.J. Van Bommel, C.J.W. Borleffs, G. Boriani, M. Biffi, M.J. Schalij, J.J. Bax (Leiden, NL; Bologna, IT)
- Two-dimensional speckle tracking strain echocardiography in heart transplant patients.** P2158
 – B. Syeda, P. Hoefler, P. Pichler, M. Vertesich, S. Roedler, S. Mahr, S. Graf, J. Bergler-Klein, D. Glogar, T. Binder (Vienna, AT)
- Differences in the cardiomyopathy progression of female and male fabry patients. implications for monitoring and treatment.** P2159
 – M. Niemann, S. Herrmann, F. Breunig, M. Beer, C. Wanner, W. Voelker, G. Ertel, F. Weidemann (Wurzburg, DE)
- Prevalence of mechanical dyssynchrony in patients scheduled for cardiac resynchronization therapy. Comparison of eight echocardiographic methods.** P2160 (W)
 – J. Klimusina, F. Faletra, C. Conca, A. Evangelista, F. Regoli, M. Averaimo, E. Pasotti, G. Pedrazzini, T. Moccetti, A. Auricchio (Lugano, CH)
- Regional distribution of entity of strain and time to peak strain of right ventricle in normal individuals and in heart failure patients.** P2161
 – A. Meris, C. Conca, C. Klersy, A. Evangelista, J. Klimusina, M. Averaimo, A. Auricchio, F. Faletra (Lugano, CH; Pavia, IT)
- Left ventricular dysfunction during right ventricular pacing: volumetric analysis with real-time three-dimensional echocardiography.** P2162
 – T. Wolber, C. Brunckhorst, F. Duru (Zurich, CH)
- Contrast enhancement has no additional value in RV volumetric measurements with real-time 3D echocardiography.** P2163
 – D.H.F. Gommans, A.P.J. Van Dijk, M.A. Brouwer, M.J. Van Der Vlugt (Nijmegen, NL)
- Assessment of right ventricular systolic function: validation of six echocardiographic methods versus cardiac magnetic resonance imaging.** P2164
 – M. Pavlicek, A. Wahl, K. Wustmann, F. Praz, S. De Marchi, M. Scherzmann, T. Rutz, C. Eigenmann, B. Meier, C. Seiler (Berne, CH)
- Right ventricular function in asymptomatic patients with systemic sclerosis.** P2165
 – C. Dumitrascu, A. Dumitrascu, C. Draghici, M. Grigore, C.M. Tanaseanu (Bucharest, RO)
- Left ventricular untwisting in restrictive and pseudo-restrictive left ventricular filling; novel insights into diastology.** P2166
 – B.M. Van Dalen, O.I.I. Soliman, W.B. Vletter, F.J. Ten Cate, M.L. Geleijnse (Rotterdam, NL)
- Can 3D echocardiography be used to investigate the dynamics of cardiac function? A functional data analysis.** P2167
 – K.K. Poppe, G.A. Whalley, R.N. Doughty, C.M. Triggs (Auckland, NZ)
- Noninvasive estimation of left ventricular filling pressure in patients with heart failure independent of systolic function.** P2168
 – F.L. Dini, P. Ballo, L. Badano, P. Barbier, M. Galderisi, S. Ghio, A. Rossi, P.L. Temporelli (Pisa, La Spezia, Udine, Milan, Naples, Pavia, Verona and Veruno, IT)
- Arterial stiffness and coronary flow reserve are independent determinants of LV untwisting in untreated patients with essential hypertension A speckle tracking echocardiography study.** P2169
 – I. Ikonomidis, C. Papadopoulos, J. Lekakis, I. Paraskevidis, H. Triantafyllidi, S. Tzortzis, C. Tsitlakidis, P. Trivloulou, D.T. Kremastinos (Athens, GR)

- Intima media-thickness of the common carotid artery in major vascular surgery patients: a predictor of postoperative and late cardiovascular events.** P2170
 – W.J. Flu, J.P. Van Kuijk, S.E. Hoeks, R. Kuijper, O. Schouten, D. Goei, T. Winkel, Y. Van Gestel, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)
- Influence of abnormal glucose metabolism, on coronary microvascular function after a recent myocardial infarction.** P2171
 – B.B. Loegstrup, D.E. Hoefsten, T.B. Christophersen, J.E. Moeller, H.E. Boetker, P.A. Pellikka, K. Egstrup (Svendborg, Copenhagen and Aarhus, DK; Rochester, US)
- Implication of dynamic variation of left ventricular vortex flow morphology on left ventricular function: a quantitative vorticity imaging study using contrast echocardiography.** P2172
 – G.R. Hong, I.W. Song, S.H. Lee, J.S. Park, D.G. Shin, Y.J. Kim, J.H. Chio (Daegu, KR)
- Comparative effects of levosimendan and dobutamine on left ventricular diastolic function and brain natriuretic peptide in patients with decompensated advanced heart failure.** P2173
 – D. Duman, F. Palit, E. Simsek, O. Yildiz (Istanbul, TR)
- Cardiovascular risk factors and early left ventricular longitudinal systolic dysfunction assessed by TDI in asymptomatic subjects with normal ejection fraction.** P2174
 – G. Di Salvo, S. Carerj, A. Salustri, F. Antonini-Canterin, S. La Carrubba, L. Cossu, P. Caso, A. Pezzano, R. Calabro, V. Di Bello (Milan, IT)
- Myocardial ejection velocities and strain underestimate electrical dyssynchrony during left bundle branch block (LBBB).** P2175
 – K. Russell, A. Opdahl, O. Gjesdal, E.W. Remme, H. Skulstad, E. Kongsgaard, T. Edvardsen, O.A. Smiseth (Oslo, NO)
- Apical untwist: An integral component of early diastolic left ventricular function.** P2176
 – U. Gustafsson, P. Lindqvist, M.Y. Henein, A. Waldenstrom (Umea, SE)
- 2D echo speckle tracking-assessed left ventricular torsion in healthy volunteers is gender but not age dependent.** P2177
 – C.J. Finn, L. Zhong, L.K. Tan, L.H. Chua, Z.P. Ding (Singapore, SG)
- Sub-clinical and clinical high altitude pulmonary edema: an ultrasound lung comets study.** P2178
 – L. Pratali, M. Cavana, R. Sicari, E. Picano (Pisa and Aosta, IT)
- Evaluation of non-invasive parameters for estimation of left ventricular filling pressures in heart failure patients after restrictive mitral annuloplasty and surgical ventricular restoration.** P2179
 – E.A. Ten Brinke, M. Bertini, R.J. Klautz, M.L. Antoni, J.J. Bax, P. Steendijk (Leiden, NL)
- Can feature tracking correctly detect motion patterns as they occur in blood inside heart chambers? Validation of Echocardiographic Particle Image Velocimetry using moving phantoms.** P2180
 – R. Faludi, A. Walker, G. Pedrizzetti, J. Engvall, J.U. Voigt (Pecs, HU; Vasteras and Linkoping, SE; Trieste, IT; Leuven, BE)
- Intraoperative real-time 3D transesophageal echocardiography reliably assess left ventricular stroke volume: Direct comparison with thermodilution technique.** P2181
 – H. Yoshitani, M. Takeuchi, H. Nakai, K. Otani, N. Haruki, K. Kaku, Y. Nishimura, G. Ohara, R.M. Lang, Y. Ostuji (Kitakyushu, JP; Chicago, US)
- Routine performance of 3-dimensional transesophageal echocardiography: is there incremental value over 2-dimensional transesophageal echocardiography?** P2182
 – S. Kort, B. Pulipati, D.L. Brown (Stony Brook, US)
- Does ventriculo-arterial coupling change during the course of normal pregnancy? An echocardiographic study.** P2183
 – R.O. Jurcut, O.R. Savu, S. Giusca, I.L. Gussi, R. Enache, B.A. Popescu, J. D'Hooge, J. Deprest, J.U. Voigt, C. Ghinghina (Bucharest, RO; Leuven, BE)
- Comparison between arterial wave intensity and arterial elastance to end-systolic ventricular elastance ratio as indices of ventricular-arterial coupling.** P2184
 – F. Antonini-Canterin, R. Caruso, R. Enache, B.A. Popescu, C. Ghinghina, O. Vriz, D. Pavan, E. Leiballi, S. Carerj, G.L. Nicolosi (Pordenone, Messina, San Daniele Del Friuli and San Vito Al Tagliamento, IT; Bucharest, RO)

Uric acid level is an independent marker of left ventricular hypertrophy and impaired early diastolic relaxation in never treated hypertensives. P2185

– P. Xaplanteris, C. Vlachopoulos, K. Aznaouridis, A. Bratsas, I. Dima, K. Baou, G. Vyssoulis, C. Stefanadis (Athens, GR)

Differential effects of type 2 diabetes mellitus with intensive glucose control on left ventricular myocardial functions. P2186

– C.T.A. Ng, V. Delgado, R.W. Van Deer Meer, M. Bertini, G. Nucifora, D.Y. Leung, N.R. Van De Veire, H.J. Lamb, M.J. Schaliij, J.J. Bax (Leiden, NL; Sydney, AU)

NEW OR IMPROVED: ANGIOGENESIS AND REMODELLING

Whole genome expression analysis in patients with chronic total coronary occlusion confirms negative correlation of interferon-beta with coronary collateralization. P2187

– S.H. Schirmer, A.M. Van Der Laan, J.O. Fledderus, O.L. Volger, M. Boehm, A.J.G. Horrevoets, J.J. Piek, N. Van Royen (Homburg, DE; Amsterdam and Utrecht, NL)

Endothelial microparticles and endothelial repair: identification of biological pathways in microparticle-mediated endothelial repair. P2188

– N. Werner, N. Heiermann, G. Nickenig (Bonn, DE)

The neuropeptide catestatin acts as angiogenic cytokine in vitro and in vivo. P2189

– M. Theurl, W. Schgoer, P. Schratzberger, M. Egger, A. Beer, D. Vasiljevic, J. Patsch, S. Mahata, R. Kirchmair (Innsbruck, AT; San Diego, US)

Metallothionein enhances angiogenesis and arteriogenesis by modulating smooth muscle. P2190

– S. Zbinden, J. Wang, M. Adenike, H. Morsli, S.E. Epstein, M.S. Burnett (Berne, CH; Washington, US)

Beta 2 adrenergic receptor improves the endothelial progenitor cells angiogenic function. P2191

– R. De Rosa, G. Galasso, F. Piscione, G. Santulli, A. Pierrri, D. Sorriento, G. Iaccarino, B. Trimarco, M. Chiariello (Naples, IT)

Stimulation of transmural capillary endothelialization of small-diameter synthetic vascular grafts through local overexpression of a novel recombinant VEGFR2-ligand VEGF-A109. P2192

– J. Hytonen, O. Leppanen, P. Korpisalo, S. Laidinen, D. Bergqvist, K. Alitalo, T.T. Rissanen, S. Yla-Herttuaala (Kuopio and Helsinki, FI; Uppsala, SE)

Angiopietin-like 2 is a pro-angiogenic factor with potent vasodilator and hypotensive activity in mice. P2193

– N. Farhat, N. Thorin-Trescases, A. Drouin, B. Allen, A. Mamarbachi, M.A. Guillis, E. Thorin (Montreal, CA)

Tissue factor gene silencing contributes to inastabilization of neo-vessels formation. P2194

– G. Arderiu, E. Pena, L. Badimon (Barcelona, ES)

Evidence of novel vasculoangiogenic effect of cilostazol. P2195

– T.-H. Chao, S.-Y. Tseng, Y.-H. Li, P.-Y. Liu, G.-Y. Shi, H.-L. Wu, C.-L. Cho, J.-H. Chen (Tainan and Kaohsiung, TW)

Impact of erythroblasts in bone marrow cells on limb salvage after cell implantation in patients with critical limb ischemia. P2196

– Y. Iso, T. Soda, T. Sato, R. Sato, T. Kusuyama, Y. Omori, M. Shoji, S. Koba, Y. Kobayashi, H. Suzuki (Tokyo and Yokohama, JP)

The initial down-regulation of collateral shear force allows perivascular macrophage accumulation and enhances collateral proliferation. P2197

– H. Sager, H. Schunkert, W.D. Ito, J. Weil (Lubeck, DE)

Fibrin improves human peripheral blood endothelial progenitor cells stemness and paracrine function. P2198

– A. Magera, R. Di Stefano, C. Armani, M.C. Barsotti, F. Chiellini, A. Minnocci, M. Alderighi, R. Solaro, G. Soldani, A. Balbarini (Pisa and Massa, IT)

Composite scaffolds for a controlled delivery of bioactive pro-angiogenetic growth factors. P2199

– E. Briganti, D. Spiller, C. Mirtelli, P. Losi, S. Kull, S. Tonlorenzi, R. Di Stefano, G. Soldani (Massa and Pisa, IT)

- The impact of erythropoietin on local balance of angiopoietins and VEGF in a murine model of hind-limb ischemia.** P2200
 – G. Vogiatzi, D. Tousoulis, A. Briassoulis, A. Valatsou, C. Antoniadis, D. Perrea, N. Papageorgiou, K. Marinou, D. Konstantinidis, C. Stefanadis (Athens, GR)
- Development of a 3D nanostructured scaffold with angiogenic potential in cardiovascular applications.** P2201
 – R. Di Stefano, A. Magera, E. Briganti, C. Ristori, M.C. Barsotti, D. Spiller, C. Mirtelli, P. Losi, G. Soldani, A. Balbarini (Pisa and Massa, IT)
- In vivo characterization of the angiogenic properties of T-cadherin.** P2202
 – D. Pfaff, M. Philippova, M.B. Joshi, E. Kyriakakis, P. Erne, T.J. Resink (Basel and Lucerne, CH)
- Gene therapy with AdPDGF-C and -D induces proliferation of fibroblasts and impairs cardiac function.** P2203
 – P. Korpisalo, H. Karvinen, M. Ryhanen, M. Merentie, J. Huusko, M. Hedman, S. Laidinen, J. Kilpijoki, U. Eriksson, S. Yla-Herttuala (Kuopio, FI; Stockholm, SE)
- Collateral vessel formation in patients with documented coronary occlusion: role of gender, smoking and of their combination.** P2204
 – F. Mouquet, F.J. Cuilleret, S. Susen, P.V. Ennezat, T. Letourneau, P.A.M. Doevendans, J. Dallongeville, M.E. Bertrand, B. Jude, E. Van Belle (Lille, FR; Utrecht, NL)
- Effects of endogenous NO and of NO-donors in arteriogenesis.** P2205
 – K. Troidl, S. Tribulova, H. Wustrack, I. Eitenmueller, W. Schierling, W.J. Cai, C. Troidl, W. Schaper (Bad Nauheim and Frankfurt am Main, DE; Xiansha, CN)
- Calcium-dependent gene regulation plays a critical role during shear stress induced arteriogenesis.** P2206
 – C. Troidl, H. Nef, S. Voss, A. Schilp, S. Kostin, K. Troidl, T. Schmitz-Rixen, C.W. Hamm, A. Elsaesser, H. Moellmann (Bad Nauheim, Frankfurt am Main and Oldenburg, DE)
- MARKERS AND MONITORS OF ENDOTHELIAL FUNCTION**
- A multicenter study to assess flow-mediated dilation variability.** P2207
 – L. Ghiadoni, F. Fita, L. De Sisti, A. Biggi, G. Ambrosio, G.A. Lanza, M.L. Muesan, M. Volpe, S. Taddei, F. Cosentino (Pisa, Rome, Parma, Perugia and Brescia, IT)
- Endothelium function and intima-media thickness (IMT) changes in hypertensive patients under the influence of pharmacogenetically determined treatment in relation to five genes polymorphisms.** P2208
 – L. Sydorчук, K.M. Amosova, V.P. Pishak, R.I. Sydorчук, I.I. Sydorчук (Chernivtsi and Kyiv, UA)
- Arterial wave reflections and determinants of endothelial function in erectile dysfunction patients: a hypothesis based on peripheral mode of action.** P2209
 – D. Terentes-Prinzios, C. Vlachopoulos, N. Ioakeimidis, K. Baou, K. Aznaouridis, G. Antoniou, K. Rokkas, A. Askitis, C. Stefanadis (Athens, GR)
- Dynamic reactivity of micro-circulation is less pronounced in type 2 diabetic subjects than in BMI and aged matched controls following a glucose challenge: potential implications for future CVD.** P2210
 – M.S.V. Chittari Macharotu, P.G. McTernan, N. Bawazeer, K. Lois, P.J. O'Hare, M. Ciotola, S. Kumar, A. Ceriello (Coventry, GB)
- Non-invasive measurement of local, regional and systemic arterial function in assessment of cardiovascular risk.** P2211
 – B. Gaszner, L. Priegl, I. Horvath, M. Illyes, A. Cziraki (Pecs and Budapest, HU)
- The role of asymmetric dimethylarginine in lighten the links between low-grade inflammation, endothelial and cardiorenal dysfunction in essential hypertension.** P2212
 – K. Dimitriadis, C. Tsioufis, C. Thomopoulos, D. Syrseloudis, E. Andrikou, I. Andrikou, V. Tzamouri, D. Tousoulis, I. Kallikazaros, C. Stefanadis (Athens, GR)
- Exercise induced gene-expression of DDAH-1 improves retinal microcirculation in obesity.** P2213
 – H. Hanssen, T. Nickel, V. Drexel, G. Hertel, I. Emslander, A. Schmidt-Trucksass, M. Weiss, M. Halle (Munich, DE)

- Asymmetric dimethylarginine regulates endothelial progenitor and endothelial function via the vasodilator stimulated phosphoprotein VASP protein family.** P2214
 – F. Fleissner, J. Fiedler, J. Widder, G. Ertl, J. Bauersachs, T. Thum (Wurzburg, DE)
- An optimized protocol for analysis of circulating angiogenic monocytes and endothelial progenitor cells by flow cytometry.** P2215
 – M. Hristov, S. Schmitz, T. Leyendecker, C. Schuhmann, P. Von Hundelshausen, F. Kroetz, H.Y. Sohn, F. Nauwelaers, C. Weber (Aachen and Munich, DE; Erembodegem, BE)
- Endothelial dysfunction after percutaneous coronary intervention -Is it different according to the kind of stent?-. P2216
 – H. Teragawa, K. Nishioka, N. Mitsuba, S. Mikami, Y. Fujii, J. Soga, N. Fujimura, Y. Higashi, Y. Kihara (Hiroshima, JP)**
- Assessment of endothelial function in patients with Takayasu's arteritis by flow mediated vasodilatation and reactive nitrogen intermediates.** P2217
 – N. Senguttuvan, S. Jain, V. Dhawan, N. Khandelwal, A. Bahl, S. Verma (Chandigarh, IN)
- Adhesive properties and inflammatory response of endothelial cells to wall shear stress in three dimensional stenotic models.** P2218 (W)
 – L. Rouleau, J. Rossi, M.A. Farcas, J.C. Tardif, R. Mongrain, R. Leask (Montreal, CA)
- Correlations between the cardiovascular risk and disease activity in rheumatoid arthritis on the arterial stiffness in hypertensive patients.** P2219
 – R. Musetescu, E. Belu, A.E. Musetescu, D.-D. Ionescu (Craiova, RO)
- Association of endothelial function and nitrooxidative stress with speckle tracking myocardial deformation in patients with rheumatoid arthritis. Effects of chronic inhibition of interleukin-1.** P2220
 – I. Ikonomidis, S. Tzortzis, J. Lekakis, I. Paraskevidis, I. Andreadou, M. Nikolaou, T. Kaplanoglou, G. Skarantavos, P. Soukagos, D.T. Kremastinos (Athens, GR)
- Regulation of endothelial thrombogenic activity under static and dynamic conditions by modulating alternative Splicing of tissue factor.** P2221
 – U. Rauch, A. Eisenreich, A. Zakrzewicz, A. Pries, H.-P. Schultheiss (Berlin, DE)
- Effect of nitric oxide on the AT-2 receptor expression in-vivo.** P2222
 – V.T. Dao, T. Suvorava, O. Kocgirli, S. Agouri, M. Oppermann, V. Balz, G. Kojda (Dusseldorf, DE)
- Humoral changes, expression of endothelial selection ligands and bubble grade following SCUBA (self contained underwater breathing apparatus) dive.** P2223
 – D. Glavas, A. Markotic, Z. Valic, N. Kovacic, I. Palada, R. Martinic, T. Breskovic, D. Bakovic, A.O. Brubakk, Z. Dujic (Split and Zagreb, HR; Trondheim, NO)
- ENDOTHELIAL DYSFUNCTION: CLINICAL STUDIES**
- The incremental effect of sleep apnoea on sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives: a nighttime partner of cardiovascular risk.** P2224
 – C. Thomopoulos, C. Tsioufis, A. Kasiakogias, D. Tsiachris, V. Tzamos, A. Mazaraki, I. Andrikou, I. Darladimas, T. Makris, C. Stefanadis (Athens, GR)
- The relation between endothelial dependent flow mediated dilation of the brachial artery and coronary collateral development.** P2225
 – A. Ongun, S. Gulec, N. Uslu, C. Tulunay Kaya, C. Ozdol, S. Turhan, Y. Atmaca, T. Altin, C. Erol (Ankara, TR)
- Platelet reactivity and endothelial function in children of patients with premature acute myocardial infarction.** P2226
 – L. Barone, G. Scalone, I. Coviello, A. Delogu, A. De Nisco, A. Di Monaco, R. Nerla, F. Infusino, G.A. Lanza, F. Crea (Rome, IT)
- Vascular endothelial function predicts mortality risk in patients with advanced ischemic chronic heart failure.** P2227
 – M. Shechter, S. Matetzky, M. Arad, M.S. Feinberg, D. Freimark (Tel Hashomer, IL)
- Smoking induces lipoprotein-associated Phospholipase A2 (Lp-PLA2) in cardiovascular disease free adults: the ATTICA study.** P2228
 – D. Panagiotakos, A. Tselepis, C. Pitsavos, C. Tellis, C. Chrysohoou, J. Skoumas, C. Stefanadis (Athens and Ioannina, GR)

- Low-dose aspirin protects against coronary endothelial damage by inhibiting LOX-1-dependent uptake of electronegative L5 in acute myocardial infarction.** P2229
 – P.-Y. Chang, S.-C. Lu, J.-K. Lee, Y.-J. Chen, Y.-T. Lee (Taipei, TW)
- Improved vasoreactivity following spironolactone therapy in chronic haemodialysis patients.** P2230
 – P. Flevari, S. Kalogeropoulou, D. Leftheriotis, F. Panou, S. Katsoudas, D. Bacharaki, D. Vlahakos, D. Kremastinos (Athens, GR)
- Relation of digital vascular function and endothelial function by flow-mediated dilation with carotid atherosclerosis in hypertension.** P2231
 – A. Tatasciore, R. Tommasi, F. Santarelli, M. Zimarino, G. Renda, S. Gallina, R. De Caterina (Chieti, IT)
- Graded association of arterial stiffness with asymmetric dimethylarginine, endothelin-1 and osteoprotegerin levels in essential hypertensive patients.** P2232
 – K. Dimitriadis, C. Tsioufis, E. Andrikou, D. Syrseloudis, C. Thomopoulos, I. Andrikou, A. Mazaraki, D. Tousoulis, I. Kallikazaros, C. Stefanadis (Athens, GR)
- Low 25-hydroxyvitamin D levels are associated with elevated plasma ADMA and C-reactive protein concentrations: nexus with cardiovascular disease.** P2233
 – D.T.M. Ngo, A.L. Sverdlov, J.J. Mcneil, J.D. Horowitz (Adelaide and Melbourne, AU)
- Exercise-training restores endothelium-dependent vasorelaxation and reverses endothelial NOSynthase uncoupling in Spontaneously Hypertensive Rats.** P2234
 – S. Thioub, C. Goanvec, F. Guerrero, J.-C. Cornily, J. Mansourati (Brest, FR)
- Relevance of homocysteine on brachial flow-mediated vasodilation and carotid and femoral intima media thickness in sibling of hypertensive patients.** P2235
 – M.F. Elnoamany, H. Badran, H. Ebraheem, A. Reda, N. Elsheelk (Shebeen Elkom Menoufya, EG)
- Intermittent airway obstruction and atherogenesis in hypertension. Risk stratification depends on disease severity.** P2236
 – A. Kasiakogias, C. Tsioufis, C. Thomopoulos, A. Mazaraki, P. Tolis, E. Andrikou, I. Andrikou, V. Tzamou, I. Kallikazaros, C. Stefanadis (Athens, GR)
- Coronary flow reserve is impaired in patients with migraine.** P2237
 – G. Kaynar, L.E. Sade, B. Yetis, H. Bozbas, S. Eroglu, B. Pirat, V. Simsek, B. Ozin, H. Muderrisoglu (Ankara, TR)
- Pentaerithryltetranitrate enhances reactive hyperemia in patients with coronary artery disease. A subanalysis of the randomized, double-blind, clinical PENTA study.** P2238
 – M.A. Ostad, B. Schnorbus, R. Schiewe, C. Medler, D. Wachtlin, T. Munzel, A. Warnholtz (Mainz, DE)
- Early therapy with n-3 Polyunsaturated Fatty Acids improve endothelial function ultrasound parameters and diastolic function index in patients with acute myocardial infarction.** P2239
 – M. Haberka, K. Mizia Stec, M. Mizia, K. Gieszczyk, A. Chmiel, Z. Gasior (Katowice, PL)
- Effect of long-term L-thyroxine treatment on endothelial function and carotid intima media thickness in young adults with congenital hypothyroidism.** P2240
 – M. Arcopinto, A.M. Marra, T. Lettiero, V. Apuzzi, G. Bosso, A. Valvano, F. Calabrese, M.C. Salerno, U. Oliviero, A. Cittadini (Naples, IT)
- Vascular dysfunction in HIV infected patients receiving highly active antiretroviral therapy.** P2241
 – I. Ikonomidis, J. Palios, J. Lekakis, L. Rallidis, S. Tsiodras, G. Poulakou, P. Panagopoulos, A. Papadopoulos, H. Giamarellou, D.T. Kremastinos (Athens, GR)
- Endothelial dysfunction in diabetic patients with myocardial perfusion abnormalities in absence of obstructive epicardial coronary disease.** P2242
 – R. Djaber, J.D. Schuijff, J. Op 't Roodt, A.J. Scholte, T.J. Rabelink, E. De Koning, E.E. Van Der Wall, J.J. Bax, J.W. Jukema (Leiden, NL)

LIPIDS AND STATINS

- The influence of statins on late cancer mortality in vascular surgery patients with chronic obstructive pulmonary disease.** P2243
 – Y.R.B.M. Van Gestel, S.E. Hoeks, D.D. Sin, V. Huzeir, H. Stam, F.W. Mertens, J.J. Bax, H.J.M. Verhagen, R.T. Van Domburg, D. Poldermans (Rotterdam and Leiden, NL; Vancouver, CA)
- Colesevelam added to a stable combination of a maximally tolerated statin and ezetimibe in patients with heterozygous familial hypercholesterolemia; the TRIPLE trial.** P2244
 – R. Huijgen, M.D. Trip, E. Bruckert, A.F.H. Stalenhoef, B.P.M. Imholz, P.N. Durrington, M. Eriksson, F.L.J. Visseren, J.R. Schaefer, J.J. Kastelein (Huddinge, SE; Paris, FR; Nijmegen, Waalwijk and Utrecht, NL; Manchester, GB; Marburg, DE)
- The role of conventional risk factors in explaining residual risk in statin-treated post myocardial infarction patients. Results from the IDEAL study.** P2245
 – A.G. Olsson, C. Lindahl, R. Fayyad, I. Holme (Linköping and Sollentuna, SE; New York, US; Oslo, NO)
- Combination niacin extended-release and simvastatin treatment causes greater reduction in atherogenic particles compared to atorvastatin monotherapy.** P2246
 – W. Insull Jr, P.P. Toth, H.R. Superko, R. Thakkar, P. Jiang, R. Pareno, R.J. Padley (Houston, Peoria, Atlanta and Abbott Park, US)
- Reduction in cardiovascular events and associated cost after treatment initiation with niacin extended-release plus simvastatin combination therapy versus simvastatin plus ezetimibe fixed dose therapy.** P2247
 – R. Simko, R. Quimbo, M.J. Cziraky, S. Balu (Abbott Park and Wilmington, US)
- Increased cholesterol absorption in patients treated with strong statins.** P2248
 – M. Eto, M. Akishita, T. Akiyoshi, H. Ota, K. Nomura, K. Yamaguchi, S. Ogawa, K. Iijima, Y. Ouchi (Tokyo, JP)
- cardiovascular event reduction after treatment initiation with simvastatin plus niacin extended-release combination therapy versus statin monotherapy among managed care dyslipidemia patients.** P2249
 – R. Simko, R. Quimbo, M. Cziraky, S. Balu (Abbott Park and Wilmington, US)
- Attainment of normal lipid levels in French patients receiving er niacin/laropirant added to statin therapy.** P2250
 – B. Ambegaonkar, G. Davies, H. Phatak, T. Souchet, V. Sazonov (Whitehouse Station and Upper Gwynedd, US; Paris, FR)
- Beneficial effect of statin treatment on carotid atherosclerosis in patients with stable coronary artery disease stratified by renal function.** P2251
 – T. Ishizu, Y. Seo, N. Murakoshi, S. Watanabe, K. Aonuma (Tsukuba, JP)
- Evidence of myocardial adrenergic innervation abnormalities in hyperlipidemic subjects: the beneficial effect of statins.** P2252
 – E.A. Zacharis, M.E. Marketou, S.I. Koukouraki, V.K. Prassopoulos, I. Karalis, G.F. Diakakis, F.I. Parthenakis, N.S. Karkavitsas, P.E. Vardas (Heraklion, GR)
- High prevalence of persistent lipid abnormalities in patients with sedentary lifestyle treated with statins in Germany: results of the dyslipidemia international study.** P2253
 – A.K. Gitt, C. Juenger, K. Bestehorn, F. Chazelle, W. Smolka, J. Senges, J.P.P. Kastelein (Ludwigshafen am Rhein and Haar, DE; Paris, FR; Amsterdam, NL)
- Comparative efficacy of ezetimibe added to atorvastatin vs uptitration of atorvastatin in attainment of recommended lipid targets in patients at high risk of coronary heart disease (CHD).** P2254
 – L. Leiter, H. Bays, S. Conard, J. Lin, M. Hanson, A. Shah, A.M. Tershakovec (Toronto, CA; Louisville, Dallas and North Wales, US)
- Influence of coenzyme Q10 supplementation in statin treated patients on left ventricular diastolic dysfunction. Results of randomised double-blind clinical study.** P2255
 – J. Fedacko, D. Pella, R. Rybar (Kosice, SK)
- Understanding the awareness of hypercholesterolemia and the adherence to lipid-lowering treatment in Brazil: the CORE project.** P2256
 – A.C. Sposito, J.E. Dos Santos, F.A. Fonseca, J.R. Faria-Neto, R.D. Santos, J.A.F. Ramires, M.C. Bertolami, O.R. Coelho, E. Tūtihashi, F.H.Y. Cesena (Sao Paulo, BR)

Heart rate variability and plasma lipids before and after treatment with rosuvastatin in hypercholesterolaemic patients without coronary artery disease. P2257

- E.A. Zacharis, M.E. Marketou, E.I. Skalidis, I. Karalis, A.P. Patrianakos, K. Stokkos, E. Ganotakis, F.I. Parthenakis, P.E. Vardas (Heraklion, GR)

Sex differences in the effect of hypertension on lipid profiles in Chinese patients. P2258

- X. Fan, Y. Wang, K. Sun, H. Wang, X. Song, W. Song, W. Zhang, H. Wu, X. Zhou, R. Hui (Beijing, CN)

Beneficial modulation of heart rate variability indices after rosuvastatin treatment in type 2 diabetic patients. P2259

- E.A. Zacharis, M.E. Marketou, E.I. Skalidis, I. Karalis, K. Stokkos, A.P. Patrianakos, G.F. Diakakis, E. Ganotakis, F.I. Parthenakis, P.E. Vardas (Heraklion, GR)

OTHER TOPICS

A comparison of non-HDL and LDL-cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. P2260 (W)

- R.D. Santos, D.D. Waters, M. Messig, L. Tarasenko, J.W. Jukema, C.-W. Chiang, J. Ferrieres, J. Verdejo (Sao Paulo, BR; San Francisco and New York, US; Leiden, NL; Taipei, TW; Toulouse, FR; Tlalpan, MX)

Identification of an electronegative LDL as potential novel biomarker for acute coronary syndrome. P2261

- P.-Y. Chang, J.-K. Lee, Y.-J. Chen, S.-C. Lu, Y.-T. Lee, K.-C. Chang, P.-Y. Pai, C.-H. Chen (Taipei and Taichung, TW; Houston, US)

Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. P2262

- A. Muendlein, S. Rhomberg, C.H. Saely, T. Winder, G. Sonderegger, P. Rein, S. Beer, A. Vonbank, H. Drexel (Feldkirch, AT; Triesen, LI)

Relationships between modulation of functional characteristics of plasma lipoproteins and changes in their size and composition by short-term exercise in patients with metabolic syndrome. P2263

- A.C.F. Casella-Filho, F.H.Y. Cesena, I.C. Trombetta, V. Monteiro-Silva, C. Denardi, C.C. Magalhaes, C.E. Negrao, R.C. Maranhao, P.L. Daluz, A.C.P. Chagas (Sao Paulo, BR)

Low HDL - high inflammatory markers in heart failure induced by high frequency pacing in minipigs. P2264

- B. Pennato, V. Lionetti, F. Bigazzi, M. Puntoni, A. Simioniuc, M. Campan, F.A. Recchia, T. Sampietro (Pisa, IT)

The role of lipoprotein-a on major cardiovascular events in patients with familial combined hyperlipidemia and metabolic syndrome. P2265

- C. Masoura, I. Skoumas, C. Pitsavos, K. Aznaouridis, V. Metaxa, L. Papadimitriou, F. Platsouka, T. Tsokanis, N. Giotsas, C. Stefanadis (Athens, GR)

Characterization and validation of a combined oral triglyceride and glucose tolerance test in patients with coronary artery disease. P2266

- C.M. Werner, A. Filmer, M. Fritsch, S. Groenewold, M. Boehm, U. Laufs (Homburg, DE)

Serum omega-6-omega-3 fatty acid balance and pressure wave reflection in middle-aged healthy Japanese men. P2267 (W)

- C. Matsumoto, H. Tomiyama, M. Oodaira, J. Yamada, M. Yoshida, K. Shiina, A. Yamashina (Tokyo, JP)

Postprandial lipemia in familial combined hyperlipidemia, familial hypercholesterolemia and healthy subjects. P2268

- A. Pavlidis, G. Kolovou, K. Anagnostopoulou, P. Petrou, K. Sorodila, A. Valaora, K. Salpea, D. Cokkinos (Athens, GR)

Improvement in the control of hypercholesterolemia in coronary heart disease patients over the decade from 1997 to 2007. P2269

- S. Surowiec, P. Jankowski, R. Wolfshaut, M. Loster, K. Batko, A. Pajak, K. Kawecka-Jaszcz (Krakow, PL)

Postprandial triglycerides and postprandial inflammation are significantly reduced by eight weeks of eccentric endurance exercise. P2270

- P. Rein, C.H. Saely, A. Vonbank, S. Beer, V. Kiene, S. Aczel, T. Bochdansky, H. Drexel (Feldkirch and Rankweil, AT; Triesen, LI)

- Coronary obstruction detected by computerised tomography angiography in familial hypercholesterolemia is associated with Achilles tendon xanthomata and coronary artery calcification.** P2271
 – M.H. Miname, J. Parga, J. Avila, A.P. Chacra, W. Salgado, C.E. Rochitte, R.D. Santos (Sao Paulo, BR)
- Percentage lipid abnormalities in statin treated patients. The dyslipidemia international survey study (DYSIS-SPAIN).** P2272
 – J.R. Gonzalez-Juanatey, J. Millan, C. Guijarro, E. Alegria, J.V. Lozano, V. Inaraja, G. Vitale, L. Cea-Calvo (Santiago de Compostela, Madrid, Pamplona and Valencia, ES)
- Controlling lipids in a high risk population with documented coronary artery disease for secondary prevention: are we doing enough?** P2273
 – M. Singh, S. Chin, P. Giles, D. Carothers, K. Al-Allaf, J. Khan (North Chicago, US; Walsall, GB)
- Body mass index independently predicts the variation in plasma levels of triglycerides and the triglycerides/HDL-cholesterol ratio after short-term red wine consumption.** P2274
 – F.H.Y. Cesena, A.C.M. Andrade, S.R. Coimbra, A.M. Benjo, P.L. Da Luz (Sao Paulo, BR)
- Cholesterol metabolism and hepatic function in cardiovascular patients aged 75 years and older.** P2275
 – T. Strandberg, M.H. Hovinen, K.H. Pitkala, T.A. Miettinen, R.S. Tilvis (Oulu and Helsinki, FI)
- Familial hypercholesterolaemia - an opportunity for preventive medicine.** P2276
 – A.M. Medeiros, A.C. Alves, V. Francisco, S. Silva, M. Bourbon (Lisbon, PT)
- The correlation of the long pentraxin 3 (PTX3) to lipids in patients hospitalized with acute chest pain.** P2277
 – T. Brugger-Andersen, V. Ponitz, F. Kontrny, H. Staines, H. Grundt, K. Miyamoto, C. Miyazawa, T. Matsuura, M. Sagara, D.W.T. Nilsen (Stavanger and Oslo, NO; Balmullo, GB; Tokyo, JP)
- Cigarette smoking blocks the protective expression of Nrf2/ARE pathway in blood cells of young heavy smokers favouring inflammation: relation to endothelial function and carotid intima-media thickness.** P2278
 – C. Mozzini, A. Fratta Pasini, U. Garbin, A. Pasini, S. Manfro, C. Stranieri, L. Cominacini (Verona, IT)
- Genetic variant rs1051730 C>T in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24 significantly predicts smoking severity in coronary artery disease patients.** P2279
 – C.H. Saely, A. Muendlein, A. Vonbank, P. Rein, S. Beer, J. Breuss, B. Gaensbacher, H. Drexel (Feldkirch, AT; Triesen, LI)
- Synergistic effect of smoking and early-stage pulmonary dysfunction on abnormal pressure wave reflection in men.** P2280
 – K. Shiina, H. Tomiyama, C. Matsumoto, M. Odaira, M. Yoshida, A. Yamashina (Tokyo, JP)
- Smokers benefit more from early invasive treatment of acute myocardial infarction than non-smokers.** P2281
 – E. Aune, J. Hjelmessaeth, K. Endresen, J.E. Otterstad (Toensberg and Oslo, NO)
- Smoking cessation increases serum adiponectin levels in an apparently healthy greek population.** P2282
 – S. Efstathiou, I. Skeva, C. Dimas, A. Panagiotou, K. Parisi, L. Janoumis, A. Kafouri, K. Bakratsas, T. Mountokalakis (Athens, GR)
- Passive smoking is associated with masked hypertension in clinically normotensive non-smokers: cross-sectional results in a smoke-filled environment.** P2283
 – C. Thomopoulos, D.P. Papadopoulos, S. Massias, E. Michalopoulou, A. Bratsas, O. Papazachou, T.H. Makris (Athens, GR)
- Smoking is related to subclinical inflammation and impairment of thrombolysis/fibrinolysis system in essential hypertensive subjects: an insight into the tobacco-related vascular disease.** P2284
 – K. Dimitriadis, C. Tsioufis, A. Kasiakogias, A. Miliou, E. Andrikou, A. Mazaraki, C. Thomopoulos, D. Tsiachris, D. Tousoulis, C. Stefanadis (Athens, GR)
- Chewing tobacco produces coronary vasoconstriction.** P2285
 – S. Ramakrishnan, R. Thangjam, A. Roy, S. Singh, S. Seth, R. Narang, B. Bhargava (New Delhi, IN)

- Smoking is associated with subclinical inflammation, impairment of thrombolysis/fibrinolysis system and increased osteoprotegerin levels in essential hypertensives.** P2286
 – K. Dimitriadis, C. Tsioufis, E. Andrikou, D. Syrseloudis, C. Thomopoulos, I. Andrikou, A. Mazaraki, V. Tzamou, I. Kallikazaros, C. Stefanadis (Athens, GR)
- Aspirin use does not affect lipid efficacy of niacin extended-release treatment.** P2287
 – R. Thakkar, H.A. Punzi, M.H. Davidson, S. Krause, P. Jiang, C. Lovell, R.J. Padley (Abbott Park, Dallas and Chicago, US)
- Prediction of cardiovascular events by MMP-9 in elderly men.** P2288
 – T.W. Weiss, E.B. Furenes, M. Troseid, S. Solheim, I. Seljeflot, H. Arnesen (Oslo, NO)
- POPULATION TRENDS**
- Economic status and cardiovascular risk factors in rapidly developing country: Comparison between 1998 and 2005 in South Korea.** P2289
 – S.J. Ahn, S.Y. Jang, J.I. Park, S.Y. Park, S.J. Park, J.H. Cho, J.O. Jeong, Y.K. Kim, S.Y. Kim, Y.J. Kim (Seoul, KR)
- The time course of risk of death following acute myocardial infarction and diabetes.** P2290
 – M.L. Norgaard, S.S. Andersen, T.K. Schramm, G.H. Gislason, F. Folke, M.L. Hansen, D.M. Bretler, L. Koeber, C. Torp-Pedersen (Hellerup and Copenhagen, DK)
- Control of dyslipidemia in western switzerland: a long way to go.** P2291
 – P. Marques-Vidal, M. Firmann, F. Paccaud, V. Mooser, N. Rodondi, G. Waeber, P. Vollenweider (Lausanne, CH; Philadelphia, US)
- Trends in cardiovascular risk factors in switzerland, 1992-2007: data from the national health surveys.** P2292
 – P. Marques-Vidal, A. Chiolero, F. Paccaud (Lausanne, CH; Quebec, CA)
- Change in medical treatment of European patients included in the REACH registry: comparison between the disease territories.** P2293
 – C. Suarez, U. Zeymer, T. Limbourg, J. Rother, P.G. Steg, D.L. Bhatt (Madrid, ES; Ludwigshafen am Rhein and Minden, DE; Paris, FR; Boston, US)
- Improved survival of incident dialysis patients with coronary disease in the United States: 1995-2006.** P2294
 – A.N. Nealon, I. Yousif, C.A.M. Wall, A.G. Stack (Letterkenny and Dublin, IE)
- Prevalence and risk factors for coronary artery disease in the primary health care. Insights of the VALSIM study.** P2295
 – M.M. Fiuza, N. Cortez-Dias, S. Martins, A. Belo (Lisbon, PT)
- Young adults positively changed their cardiovascular risk over 16 years - a prospective registry with good news.** P2296
 – P.J. Sousa, M. Miranda, B. Monteiro, J. Ferreira, M. Mendes, J.C. Monge, H. Nunes, J. Varandas (Lisbon, PT)
- Cardiovascular profile of 15-18 years old adolescents.** P2297
 – T.M.R. Rocha, E. Paixao, A.C. Alves, V. Francisco, A.M. Medeiros, T. Santos, S. Silva, M. Bourbon (Lisbon, PT)
- Trends in Q-wave myocardial infarction case-fatality from 1978 to 2006.** P2298
 – C. Sala, M. Grau, J. Vila, R. Masia, J. Aboal, A. Sureda, J. Marrugat, J. Sala, R. Elosua (Manresa, Barcelona and Girona, ES)
- Increased risk of acute myocardial infarction in patients with epilepsy: a nationwide study.** P2299
 – J.B. Olesen, P.R. Hansen, G.H. Gislason, C. Torp-Pedersen, P. Weeke, D.M. Bretler, C.H. Jorgensen, S.Z. Abildstrom (Copenhagen, DK)
- Trends in management and outcome of acute myocardial infarction in Portugal, Switzerland and the United States.** P2300
 – P. Marques-Vidal, N. Rodondi, C. Matias Dias, F. Paccaud (Lausanne, CH; Lisbon, PT)
- Efficacy evaluation of the national program of arterial hypertension monitoring.** P2301
 – A.D. Deev, S.A. Shalnova, V.V. Konstantinov (Moscow, RU)
- Russian multicentral epidemiological survey: morbidity, mortality, quality of diagnostics and management of acute CHD (RESONANCE).** P2302
 – S.A. Boytsov, N.N. Nikulina, S.S. Yakushin, R.A. Liferov, G.I. Furmenko, S.A. Akinina (Moscow, Ryazan, Voronezh and Khanty-Mansiysk, RU)

CORONARY SURGERY – VALVULAR HEART DISEASE

Prosthesis patient mismatch after mitral valve replacement is associated with persistent pulmonary arterial hypertension. P2303

– A. Tugcu, O. Kose, O. Yildirimturk, Y. Tayyareci, V. Aytekin, I.C.C. Demiroglu, S. Aytekin (Istanbul, TR)

Speckle-tracking correlates better than traditional parameters with the long-term systolic function decrease after mitral valve replacement. P2304

– J.A. De Agustin Loeches, J. Zamorano, L. Perez De Isla, C. Almeria, J.L. Rodrigo, A. Aubele, D. Herrera, C. Fernandez-Golfín, P. Marcos-Alberca, C. Macaya (Madrid, ES)

Clinical and echocardiographic long term follow up of patients undergoing Ross procedure according to the predominant aortic valve lesion. P2305

– M. Delgado Ortega, M. Ruiz Ortiz, M. Mesa Rubio, E. Romo Penas, F. Toledano Delgado, M.C. Leon Del Pino, M. Anguita Sanchez, J.C. Castillo Dominguez, J. Casares Mediavilla, J. Suarez De Lezo Cruz Conde (Cordoba, ES)

Autograft failure in the follow-up of Ross operation: a descriptive study and predictive factors in a prospective series. P2306

– M. Ruiz Ortiz, M. Delgado Ortega, D. Mesa Rubio, E. Romo Penas, F. Toledano, C. Leon, A. Lopez Granados, J.M. Arizon Del Prado, P. Alados Arboledas, J. Suarez De Lezo (Cordoba, ES)

When repair, when rather replacement for chronic ischemic mitral regurgitation-medium term results of undersized ring annuloplasty with echocardiographic follow-up. P2307

– D. Puszczewicz, R. Przybylski, S.Z. Pawlak, T. Niklewski, J. Pacholewicz, T. Kukulski, A. Kowalczyk, M. Zembala (Zabrze, PL)

Decellularization reduces inflammatory reaction, calcification and extracellular matrix degeneration in pulmonary heart valve allografts. P2308

– P. Akhyari, H. Kamiya, P. Mambou, R. Tschierschke, M. Barth, S. Schilp, I. Berger, W.W. Franke, M. Karck, A. Lichtenberg (Jena, Heidelberg and Kassel, DE)

Surgical coronary artery revascularisation versus medical management before high risk non-cardiac surgery: a meta-analysis. P2309

– P. Singh, S. Adigopula, U. Bedi, M. Singh, J. Molnar, R. Arora, S. Khosla (North Chicago, US)

Association between C-reactive protein, systemic inflammatory response syndrome and adverse outcomes in cardiac surgery. P2310

– H. Cohen Arazi, S.V. Waldman, R. Poggio, L.R. Carrizo, R. Spampinato Torcivia, H. Grancelli, M. Carnevalini, W. Rodriguez, C.E. Pensa, C. Nojek (Buenos Aires, AR)

Redox state in arterial grafts predicts left ventricular functional restoration after coronary artery bypass grafting. P2311

– C. Antoniadou, T. Van-Assche, A.S. Antonopoulos, D. Tousoulis, C. Stefanadis, D. Taggart, K.M. Channon, P. Leeson (Oxford, GB; Athens, GR)

Coronary surgery: does patient risk profile change over years? P2312

– B. Mihajlovic, S. Nicin, N. Cemerlic Adjic, K. Pavlovic, S. Dodic, M. Fabri (Sremska Kamenica, RS)

Proinflammatory cytokines and the risk of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting. P2313

– M. Sniezek-Maciejewska, E.L. Stepień, A. Undas, K. Sztętko, B. Kapelak, J. Sadowski (Krakow, PL)

Risk-prediction models for major postoperative morbidity in coronary surgery. P2314

– P.E. Antunes, J.F. Oliveira, M.J. Antunes (Coimbra, PT)

Coronary artery graft patency on a 64-MDCT angiography: single centre experience in 300 patients. P2315

– M. Sosnowski, A. Gola, K. Chromik, A. Sobczak, R. Bachowski, A. Bochenek, P. Buszman, Z. Gasior, M. Trusz-Gluza, M. Tendra (Katowice, PL)

Long term (7-to-20-year) patency of the radial artery as a coronary bypass conduit assessed by computed tomographic angiography. P2316

– R. Boutekadjirt, D. Toledano, P. Achouh, K. Ould Isselmou, P. Goube, B. Lancelin, R. Fouquet, C. Acar (Paris, Corbeil and Le Chesnay, FR)

Predictors of early outcome after coronary artery bypass grafting in the elderly. P2317

– S.M. Oliveira, A. Goncalves, R. Almeida, A. Azevedo, P. Dias, P. Pinho (Porto, PT)

- Impact of diabetes in elective on-pump and off-pump coronary artery bypass surgery in patients with multivessel coronary artery disease and preserved ventricular function.** P2318
 – E.G. Lima, R.D. Vieira, N.H. Lopes, F.S. Paulitsch, R. Rahmi, A. Hueb, A.C. Pereira, J.A.F. Ramires, M. Farkouh, W.A. Hueb (Sao Paulo, BR; New York, US)
- Myocardial bridge: Surgical outcome and midterm follow up.** P2319
 – A. Sajjadih Khajouei, R. Parvizi (Isfahan and Tabriz, IR)
- Effects of surgical technique options in the mid-term results of coronary revascularisation in octogenarians.** P2320
 – M. Serrao, F. Graca, M. Marques, M. Abecasis, J. Calquinha, R. Rodrigues, J. Neves, A. Moradas, J. Queiros E Melo (Funchal and Lisbon, PT)
- Long-term clinical outcomes after drug-eluting stent implantation versus surgical treatment in patients with a single vessel disease.** P2321
 – C. Patsa, K. Toutouzias, E. Tsiamis, C. Tsioufis, A. Spanos, I. Chlorogiannis, E. Pattakos, M. Panagiotou, D. Iliopoulos, C. Stefanadis (Athens, GR)
- Tissue engineering: optimal coating of inflow cannulae from cardiac assist devices placed in the apex of the left ventricular cavity.** P2322
 – J. Mueller, B. Kapeller, K. Brandes, K. Macfelda (Berlin, DE; Vienna, AT)
- HEART TRANSPLANTATION AND LEFT-VENTRICULAR ASSIST DEVICES – MINIMALLY INVASIVE AND ROBOTIC SURGERY**
- Cyclosporine A modifies immune-mediating and therapeutic efficacy of allogeneic perivascular porcine endothelial cell implants.** P2323
 – H. Methé, M. Nanasato, A.-M. Spognardi, A. Groothuis, E.R. Edelman (Munich, DE; Cambridge, US)
- Custodiol-n, a novel organ preservation solution, reduces ischemia/reperfusion injury in a rat heart transplantation model.** P2324
 – S. Loganathan, T. Radovits, K. Hirschberg, A. Koch, S. Korkmaz, P. Neugebauer, M. Karck, G. Szabo (Heidelberg, DE)
- Pretransplantation cytomegalovirus mismatch serology (D+R-) is a risk factor for four year mortality after heart transplantation.** P2325
 – E. Bollano, B. Rundqvist, B. Andersson, U. Nystrom, V. Sigurdardottir, F. Nilsson, N. Selimovic (Gothenburg, SE)
- Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients, a prospective case controlled study.** P2326 (W)
 – S. Kofler, N. Shvets, A.K. Bigdeli, M. Vogeser, G. Steinbeck, B. Reichart, I. Kaczmarek (Munich, DE)
- Preventing chronic rejection post transplantation: the effects of statins and immunosuppressive drugs on IL1beta and IL1 receptor antagonist release from the human myelo-monocytic cell line U937.** P2327 (W)
 – R. Shakur, S. Metcalfe, J.A. Bradley (Oxford, GB)
- Cyclosporine A decreases muscular mitochondrial energetics by the effects of its vehicle without significant long term toxicity in the heart and muscle of heart transplant patients.** P2328
 – B. Mettauer, B. N'guessan, J. Zoll, E. Epailly, J.P. Mazzucotelli, E. Lampert, F. Piquard, X. Bigard, B. Geny, R. Ventura-Clapier (Colmar, Strasbourg, La Tronche and Chatenay-Malabry, FR; Abidjan, CI)
- Absence of smoking cessation: a major predictive factor of chronic allograft vasculopathy in heart-transplanted patients.** P2329
 – S. Lemoine, M. Angioi, S. Mattei, C. Sirbu, N. Benzaghoul, H. Aloui, O. Marcon, J.P. Carreaux, E. Aliot, J.P. Villemot (Vandoeuvre les Nancy, FR)
- Circulating anti-heart autoantibodies are non-invasive markers of high cellular rejection burden in heart transplantation.** P2330
 – A.L.P. Caforio, A. Angelini, S. Bottaro, F. Tona, G. Thiene, G. Gerosa, S. Iliceto (Padua, IT)
- Time process of structural, functional and neurohormonal recovery during chronic mechanical circulatory support in end-stage heart failure patients.** P2331 (W)
 – S. Drakos, K. Malliaras, S. Nanas, N. Diakos, D. Koudoumas, S. Theodoropoulos, M. Anastasiou-Nana, M. Yacoub (Athens, GR; Harefield, GB)

- Detection and prognostic impact of echocardiographically assessed diastolic dysfunction in heart transplant recipients.** P2332
 – P. Jung, K. Berlinger, J. Rieber, F. Kroetz, M. Leibig, A. Koenig, P. Schneider, H. Gross, H.Y. Sohn, V. Klauss (Munich, DE)
- Cardiac allograft vasculopathy (CAV) is different in CMV high-risk patients after heart transplantation.** P2333
 – T.H. Oberndorfer, M. Frick, C.H. Mussner-Seeber, D. Hoefler, H. Antretter, G. Poelzl (Innsbruck, AT)
- Resting and exercise haemodynamic and metabolic responses to acute reduction of continuous-flow left ventricular assist device support.** P2334
 – D. Jakovljevic, R.S. George, G. Donovan, D. Nunan, R.S. Bougard, M.H. Yacoub, E.J. Birks, D.A. Brodie (Buckinghamshire and London, GB)
- Subclinical Epstein-Barr virus (EBV) infection is frequent in long-term cardiac transplant recipients.** P2335
 – C.H. Mussner-Seeber, M. Frick, H. Antretter, D. Hoefler, G. Weiss, G. Poelzl (Innsbruck, AT)
- Effects of left ventricular assist devices on heart rate and Vo2 recovery trends following peak exercise: optimal vs reduced unloading speed.** P2336
 – G.C. Donovan, R.S. George, D.J. Jakovljevic, D. Nunan, R.S. Bougard, M.H. Yacoub, E.J. Birks, D.A. Brodie (Chalfont St Giles and London, GB)
- Chronic mechanical assistance improves sympathetic innervation of the failing heart.** P2337 (W)
 – N. Diakos, S. Drakos, A. Athanasoulis, C. Pantsios, D. Koudoumas, J. Terrovitis, E. Tseliou, M. Anastasiou-Nana (Athens, GR)
- Percutaneous left ventricular assist devices versus intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials.** P2338
 – J.M. Cheng, C.A. Den Uil, S.E. Hoeks, M. Van Der Ent, L.S.D. Jewbali, R.T. Van Domburg, P.W. Serruys (Rotterdam, NL)
- Chronic mechanical circulatory support is accompanied by an increase in lean tissue mass and exercise capacity.** P2339 (W)
 – P. Zotos, S. Drakos, S. Nanas, A. Petrou, E. Repasos, A. Ntalianis, M. Anastasiou-Nana, M. Yacoub (Athens, GR; Harefield, GB)
- Predictors of mortality and clinical usefulness of NT-proBNP, troponin T and C-reactive protein in follow-up after heart transplantation.** P2340
 – D. Milicic, J. Ljubas, B. Skoric, I. Gornik, D. Jelasic, J. Samardzic (Zagreb, HR)
- Perioperative asymptomatic troponin release after endovascular abdominal aneurysm repair is associated with poor long-term outcome.** P2341
 – O. Schouten, T.A. Winkel, S.E. Hoeks, J.P. Van Kuijk, W.J. Flu, Y.R.B.M. Van Gestel, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)
- Quality of Life Three Years after MIDCAB versus Isolated RIVA-Stenting.** P2342
 – M. Breuer, B. Georgii, M. Ferrari (Jena, DE)
- The role of echocardiography parameters in monitoring of patients treated with Transcatheter Heart Valve Implantation procedures (THVI).** P2343
 – T. Niklewski, R. Przybylski, K. Wilczek, M. Krason, P. Chodor, P. Nadziakiewicz, S.Z. Pawlak, J. Glowacki, M. Zembala (Zabrze, PL)
- Endoscopic removal of dislocated atrial septal closure devices and ASD repair.** P2344
 – T. Schachner, N. Bonaros, D. Wiedemann, S. Mueller, T. Bartel, A. Daburger, O. Pachinger, G. Laufer, J. Bonatti (Innsbruck, AT)
- NON-CORONARY CARDIAC INTERVENTIONS**
- Transcatheter therapy of tricuspid regurgitation by heterotopic valve implantation: experimental results.** P2345
 – A. Lauten, M. Ferrari, C. Willich, H. Schubert, S. Bischoff, H.-R. Figulla (Jena, DE)
- Italian patent foramen ovale survey (I.P.O.S.): early results.** P2346
 – G. Butera, G. Sangiorgi, A. Aprile, G. Ussia, I. Spadoni, E. Onorato, L. Caputi, A. Benassi, G. Anzola, M. Carminati (San Donato Milanese, Modena, Bergamo, Catania, Massa, Brescia and Milan, IT)

- Patent foramen ovale closure limits recurrence of cryptogenic stroke: MRI-based long-term follow-up study.** P2347
 – P. Guerin, T. Manigold, B. Guillon, H. Desal, E. Auffray-Calvier, J.M. Langlard, B. Delasalle, R. Fressonnet, N. Piriou, D. Crochet (Nantes, FR)
- Cardiac veins and coronary arteries: relevant data for percutaneous indirect annuloplasty.** P2348
 – R. Del Valle Fernandez, V. Jelnin, G. Panagopoulos, C.E. Ruiz (New York, US)
- Migraine evolution after percutaneous closure of patent foramen ovale.** P2349
 – A. Wahl, F. Praz, T. Tai, M. Schwerzmann, S. Windecker, H.P. Mattle, B. Meier (Berne, CH)
- Catheter closure of large atrial septal defects associated with deficient aortic and posterior rims using the greek maneuver.** P2350
 – B.D.T. Thanopoulos, P.D. Dardas, N.E. Eleftherakis, E.K. Karanasios, N.V. Ninios (Athens and Thessaloniki, GR)
- Clinical results of large secundum atrial septal defect closure in adult using percutaneous cocoon atrial septal occluder.** P2351
 – K. Lairakdomrong, S. Srimahachota, P. Lertsapcharoen, J. Chaipromprasit, S. Boonyaratavej, P. Kaewsukkho (Bangkok, TH)
- Long-term outcome of percutaneous balloon mitral valvotomy using multi-track technique in Kenya.** P2352
 – G. Yonga, P. Bonhoeffer, C. Jowi (Nairobi, KE; London, GB)
- Clinical and hemodynamic results in percutaneous mitral valvuloplasty with mitral stenosis and pulmonary hypertension.** P2353
 – L. Abid, I. Trabelsi, D. Abid, M. Hadrich, R. Hammami, S. Krichene, S. Mallek, F. Triki, M. Hentati, S. Kammoun (Sfax, TN)
- Safety and efficacy of biostar bioadsorbable atrial septal device for percutaneous patent foramen ovale closure.** P2354
 – G. Gioffre, M. Iamele, A. Giardina, R. Licitra, S. Rossi, L. Befani, G. Stefanini, G. Pendenza, C. Iani, A. Gaspardone (Rome, IT)
- Midterm follow-up after percutaneous closure of patent foramen ovale in patients with cerebral ischemia - experience with the Amplatzer PFO Occluder system.** P2355
 – D. Fischer, A. Schaefer, M. Fuchs, G. Klein, B. Schieffer, G.P. Meyer (Hannover, DE)
- Atrial septostomy in patients with end-stage pulmonary hypertension. Novel approach to trans-septal puncture.** P2356
 – R. Baglini (Palermo, IT)
- Percutaneous closure of large patent ductus arteriosus in adult patients.** P2357
 – F. Hernandez, J. Garcia-Tejada, M.T. Velazquez, I. Gomez, T. Bastante, L. Unzue, A. Gonzalez, M. De Riva (Madrid, ES)
- Transvenous removal of pacing and defibrillating leads using mechanical dilatation: a single center long term experience.** P2358
 – M.G. Bongiorno, E. Soldati, G. Zucchelli, A. Di Cori, L. Segreti, R. De Lucia, G. Solarino, G. Coluccia (Pisa, IT)
- Biodegradable magnesium stents in emergency interventions in critically ill babies. First clinical experiences.** P2359
 – P.A. Zartner, M. Sigler, D. Schranz, M.B.E. Schneider (Sankt Augustin, Gottingen and Giessen, DE)
- Papillary muscle rupture after percutaneous extraction of pacemaker leads.** P2360
 – P. Rucinski, A. Tomaszewski, A. Kutarski, B. Malecka, A. Zabek (Lublin and Krakow, PL)
- Percutaneous leads extraction using mechanical system in 188 patients - single centre experience.** P2361
 – A. Kutarski, B. Malecka, P. Rucinski, A. Zabek (Lublin and Krakow, PL)

IMAGING AND INTERVENTION IN CONGENITAL HEART DISEASE

- High intensity transient signals measured by transcranial Doppler during transcatheter closure of atrial septal defect.** P2362
 – K. Suda, Y. Kudo, Y. Tananari, S. Itoh, H. Ishii, H. Nishino, M. Iemura, Y. Maeno, H. Yasunaga, T. Matsuishi (Kurume, JP)

- Left ventricular twist and untwisting in patients undergoing transcatheter closure of secundum atrial septal defect.** P2363
 – L.L. Dong, X.H. Shu, D.X. Zhou, L.H. Guan, H.Y. Chen, C.Z. Pan, H.Z. Chen (Shanghai, CN)
- Intracardiac ultrasound imaging during percutaneous atrial septal defect or patent foramen ovale closure. Comparison with transesophageal ultrasound findings before the procedure.** P2364
 – M. Vavouranakis, C. Kavouras, I. Vlasseros, S. Vaina, T. Papaioannou, E. Sanidas, K. Speggos, D. Flessas, I. Kalikazaros, C. Stefanadis (Athens, GR)
- Efficacy of percutaneous closure of patent foramen ovale: comparison between three commonly used devices.** P2365
 – R. Thaman, G. Faganello, M. Nelson, G.V. Szanthy, G.R. Gimeno, S. Curtis, R. Martin, M. Turner (Bristol, GB)
- The effect of percutaneous atrial septal defect closure on echocardiographic parameters of the left and right heart.** P2366
 – O.J. Monfredi, M. Luckie, H. Buckley, B. Clarke, V.S. Mahadevan (Manchester, GB)
- Results of transcatheter closure of unroofed coronary sinus defect.** P2367
 – J.-K. Wang, M.H. Wu (Taipei, TW)
- The effect of interatrial septal defect closure on migraine burden, five year single centre experience.** P2368
 – K.N. Asrress, O. Ormerod, N. Wilson, A.R.J. Mitchell (Oxford, GB)
- Usefulness of 64-slice cardiac computed tomography in the assessment of atrial septal defects in patients undergoing percutaneous occlusion.** P2369
 – S. Ojeda, M. Pan Alvarez-Osorio, M. Romero, J. Suarez De Lezo, S. Espejo, R. Isamat, D. Mesa, D. Garcia, L. Burgos, A. Medina (Cordoba and Las Palmas De Gran Canaria, ES)
- The influence of atrial septal defect percutaneous device on left ventricular mechanics: a bidimensional strain study.** P2370
 – B. Castaldi, F. Fratta, G. Di Salvo, G. Santoro, G. Gaio, C. Iacono, L. Baldini, G. Pacileo, M.G. Russo, R. Calabro (Naples, IT)
- The safety and efficacy of transcatheter closure of perimembranous ventricular septal defect.** P2371
 – B. Han, L. Zhao, J. Zhang, Y. Wang, Y. Jin, Y. Yi (Jinan, CN)
- Transcatheter closure of the patent ductus arteriosus using the amplatzer duct occluder in symptomatic infants with low weight.** P2372
 – F. Godart, C. Francart, I. Bouzguenda, A. Richard, C. Rey (Lille, FR)
- Transcatheter closure of patent ductus arteriosus using the new Amplatzer duct occluder (ADO II). 1-year experience.** P2373
 – B.D.T. Thanopoulos, N.G.E. Elefterakis, S.L. Loukopoulou (Athens, GR)
- Ductal stenting for duct-dependent pulmonary circulation: a multi-center experience.** P2374
 – N. Sreeram, H. Hamza, H. Agha, V. Kohli, M. Emmel, G. Bennink (Cologne, DE; Cairo, EG; New Delhi, IN)
- Percutaneous Closure of Hypertensive Ductus Arteriosus.** P2375
 – C. Zabal, J.A. Garcia Montes, A. Buendia, J. Calderon Colmenero, E. Patino Bahena, A. Juanico, F. Attie (Mexico City, MX)
- Echocardiographic determinants of successful balloon dilation in pulmonary atresia with intact ventricular septum.** P2376
 – A. Drighil, M. Al Jufan, A. Slimi, S. Yamani (Casablanca, MA; Riyadh, SA)
- covered stents for moderate-severe native aortic coarctation.** P2377
 – S. Abadir, S. Noble, G. Sarquella-Brugada, R. Ibrahim, N. Dahdah, J. Miro (Montreal, CA)
- Stent implantation for the treatment of aortic coarctation in children: Initial and five-year results.** P2378
 – N.G.E. Elefterakis, S.L. Loukopoulou, E.S.K. Karanasios, B.D.T. Thanopoulos (Athens, GR)
- Aortic valvuloplasty in children: impact of rapid ventricular pacing.** P2379
 – G. Sarquella Brugada, S. Abadir, J. Rodes Cabau, C. Houde, A. Dancea, N. Dahdah, J. Miro (Montreal and Quebec, CA)

Three-dimensional diagnosis of pulmonary-ductus descending aorta trunk in hypoplastic left heart syndrome and interrupted aortic arch with multi-slice CT for stent implantation. P2380

– I. Shiraishi Isao (Suita, JP)

Cardiac catheterisation-related thrombosis in children with congenital heart disease is associated with 4G/5G polymorphism of PAI-1 gene. P2381

– M. Del Fiandra, V. De Lucia, N. Botto, I. Spadoni, S. Giusti, L. Ait-Ali, M.G. Andreassi (Massa, IT)

Neutrophil Gelatinase-Associated Lipocalin (NGAL): Is it a good predictor of radiocontrast nephrotoxicity in children undergoing angiography? P2382

– D. Oguz, R. Olgunturk, F.S. Tunaoglu, C. Sanli, A. Eren (Ankara, TR)

Anomalous origin of the Left Coronary Artery from the Pulmonary Artery (ALCAPA): clinical and echocardiographic aspects in 13 consecutive cases. P2383

– O. Milanesi, M.C. Baratella, A. Cerutti, E. Reffo, N. Maschietto, R. Biffanti, G. Stellin (Padua and Dolo, IT)

Do maternal cardiac structural abnormalities predispose to high resistance uterine artery Doppler indices? P2384

– K. Melchiorre, G.R. Sutherland, A.T. Baltabaeva, B. Thilaganathan (London, GB)

Quantitative assessment of dynamic change of tricuspid valve geometry in hypoplastic left heart syndrome using real-time 3D echocardiography. P2385

– K. Takigiku, S. Yasukochi, K. Takei, I. Kajimura, Y. Nakano, N. Inoue, S. Tazawa (Nagano, JP)

Total isovolumic time relates to exercise capacity in patients with transposition of the great arteries after atrial switch. P2386

– E. Tay, M. Josen, D.G. Gibson, R. Inuzuka, R. Alonsa Gonzalez, G. Giannakoulas, W. Li, M. Bartsota, K. Dimopoulos, M.A. Gatzoulis (London, GB)

Evaluation of pulmonary arterial anatomy in children with pulmonary atresia using non ECG gated MDCT. P2387

– M. Ghazy, M. El Sayed, A. El Fiky, G. El Shahed, H. Abd El Moniem, A. Roshdy, M. Abd El Kader, O. El Farouk (Cairo, EG)

CMR tagging for measurements of the long axis function of the systemic right ventricular free wall. P2388

– S. Chen, J. Keegan, A.W. Dowsey, R. Wage, D.N. Firmin, G.Z. Yang, P.J. Kilner (London, GB)

MITRAL, TRICUSPID AND RHEUMATIC VALVE DISEASE

Early Results of the RHEUMATIC (Rheumatic Heart Echo Utilization and Monitoring Actuarial Trends in Indian Children) study. P2389

– A. Saxena, S. Ramakrishnan, A. Roy, S. Seth, A. Krishnan, S.K. Reddy, P. Misra, B. Bhargava, P.A. Poole-Wilson (New Delhi, IN)

Plasma NT-proBNP level is associated with valve calcification in patients with rheumatic heart disease. P2390 (W)

– S.M. Kang, H.Y. Won, J. Oh, N.-K. Hong, Y. Jang, N. Chung (Seoul, KR)

Right ventricular pacing increases tricuspid regurgitation grade regardless the mechanical effect of the electrode placement. P2391

– M. Vaturi, J. Kuzniec, Y. Shapira, M. Perlmutter-Weiser, B. Strasberg, A. Sagie (Petah Tikva, IL)

Mechanism of functional, isolated tricuspid regurgitation A quantitative clinical study. P2392

– T.Y. Topilsky, M.E.S. Enriquez-Sarano (Rochester, US)

Left ventricular regional predictors of outcome post mitral valve repair in patients with functional ischemic mitral regurgitation. P2393

– T. Kukulski, A. Leopold, W. Streb, T. Niklewski, M. Zembala, Z. Kalarus (Zabrze and Katowice, PL)

Late referral of women for valve surgery - implications for complications and survival. P2394

– K. Zareba, R.O. Bonow, N. Akhter, B.R. Lapin, P.M. Mccarthy, V.H. Rigolin (Chicago, US)

- Comprehensive annular and subvalvular repair of chronic ischemic MR provides best long-term results with least ventricular remodeling.** P2395
 – C. Szymanski, A. Bel, I. Cohen, M.D. Handschumacher, M. Desnos, A. Carpentier, P. Menasche, A.A. Hagege, R.A. Levine, E. Messas (Paris, FR; Boston, US)
- Determinants and consequences of left atrial fibrosis in patients with mitral valve disease.** P2396
 – T. Mularek-Kubzdela, W. Seniuk, S. Grajek, A. Marszalek, A. Olasinska-Wisniewska, M. Jemielity, W. Stachowiak, W. Sarnowski, P. Breborowicz, M. Prech (Poznan, PL)
- Long-term contribution of functional mitral regurgitation after a first non-ST segment elevation acute coronary syndrome to left ventricular enlargement.** P2397
 – I. Nunez-Gil, J. Zamorano, L. Perez De Isla, C. Almeria, J.L. Rodrigo, C. Fernandez-Golfín, P. Marcos-Alberca, D. Herrera, A. Aubele, C. Macaya (Madrid, ES)
- Subclinical left ventricular dysfunction in rheumatic mitral stenosis: correlation with high sensitivity C-reactive protein levels.** P2398
 – E. Khalifa (Cairo, EG)
- Does degenerative mitral regurgitation severity change during exercise echocardiography?** P2399
 – J. Magne, M. Moonen, K. O'Connor, P. Pibarot, L.A. Piérard, P. Lancellotti (Liège, BE; Quebec, CA)
- Left ventricular twist on exercise deteriorates with increased volume overload in chronic mitral regurgitation.** P2400
 – R.A. Argyle, R.P. Beynon, R. Aghamohammadzadeh, K.A. Pearce, A.N. Borg, S.G. Ray (Manchester and Blackpool, GB)
- Functional mitral regurgitation and Non ST-segment elevation myocardial infarction: very long-term prognosis.** P2401
 – I. Nunez-Gil, J. Zamorano, L. Perez De Isla, C. Almeria, J.L. Rodrigo, C. Fernandez-Golfín, P. Marcos-Alberca, M. Quezada, V. Serra, C. Macaya (Madrid, ES)
- Prospective single center registry of patients with ischemic mitral regurgitation considered for revascularisation (PRAGUE 9 study registry) with one year clinical follow up.** P2402
 – V. Kocka, P. Widimsky, M. Penicka, H. Linkova, T. Budesinsky, J. Dvorak, L. Lisa, P. Tousek (Prague, CZ)
- Pulmonary vascular resistances evaluation during exercise in patients with mitral valve stenosis.** P2403
 – A.R. Almeida, C. Cotrim, H. Vinhas, R. Miranda, S. Almeida, L.R. Lopes, I. Joao, P. Fazendas, M. Carrageta (Almada, PT)
- The effect of severity of mitral regurgitation on ejection fraction and end-diastolic volume.** P2404
 – D.H. Maciver (Taunton, GB)
- Three dimensional dobutamine stress echocardiography predicts the outcome of patients with functional mitral regurgitation.** P2405
 – K. Obase, N. Watanabe, N. Wada, A. Hayashida, Y. Neishi, T. Kawamoto, H. Okura, K. Yoshida (Kurashiki, JP)
- The association of natriuretic peptides to symptoms, severity and left ventricular remodeling in patients with organic mitral regurgitation.** P2406
 – M. Potocki, J. Mair, M. Weber, N. Jander, T. Burkard, P. Buser, C.H. Mueller (Basel, CH; Innsbruck, AT; Bad Nauheim and Bad Krozingen, DE)
- PROSTHETIC HEART VALVES**
- Platelet reactivity in patients with a history of obstructive prosthetic valve thrombosis.** P2407
 – E. Lev, T. Bouganim, Y. Shapira, M. Vaturi, A. Battler, R. Kornowski, A. Sagie (Petah Tikva, IL)
- Comparison of dabigatran, unfractionated heparin and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves, results of an in vitro study.** P2408
 – L. Maegdefessel, T. Linde, F. Krapiec, U. Steinseifer, J. Van Ryn, B. Hauroeder, U. Raaz, M. Buerke, K. Werdan, A. Schlitt (Halle, Aachen, Biberach and Koblenz, DE)

- Twenty-years clinical outcome and hemodynamic performance of the Hancock II bioprosthesis.** P2409
 – C. Valfre, G. Minniti, L. Salvador, V. Salandini, E. Cavarretta, F. Cesari, P. Ius (Treviso, IT)
- Clinical and echocardiographic study in patients reoperated for the prosthetic valve dysfunction.** P2410
 – M. Maciejewski, K. Piestrzeniewicz, A. Bielecka, M. Piechowiak, M. Lelonek, R. Jaszewski, J. Drozd (Lodz, PL)
- Management of prosthetic valve thrombosis with low dose, prolonged infusion of tissue type plasminogen activator under the guidance of serial transesophageal echocardiography during pregnancy.** P2411
 – A.E. Oguz, N.E. Duran, M. Yildiz, M. Biteker, S. Gunduz, H. Kaya, A.C. Aykan, M.A. Astarcioglu, E. Erturk, M. Ozkan (Istanbul, TR)
- Prognostic value of geriatric assessment prior to aortic valve replacement in the elderly - the Albertinen study of Geriatric Care and Cardiac Surgery (AGE-CCS).** P2412
 – B. Frilling, F.C. Riess, W. Von Renteln-Kruse (Hamburg, DE)
- Stentless aortic valve bioprosthesis dehiscence. A possible infective endocarditis with atypical presentation but serious consequences.** P2413
 – L. Lepage, L. Krapf, G. Hekimian, X. Duval, P. Nataf, B. Lung, U. Hvass, A. Vahanian, D. Messika-Zeitoun (Paris, FR)
- One year experience with the 2nd generation 3F-Enable sutureless aortic valve prosthesis.** P2414
 – A. Kadner, F. Eckstein, L. Englberger, M. Stalder, T. Aymard, M. Grapow, N. Walpöth, C. Zobrist, T. Carrel (Berne and Basel, CH)
- Thrombolysis as first line treatment in prosthetic mitral valve thrombosis.** P2415
 – A. Nagy, M. Denes, M. Lengyel (Budapest, HU)
- Bovine pericardial single suture line stentless aortic valve: observational clinical and echocardiographic prospective study.** P2416
 – A. Repossini, P. Piccoli, E. Chiari, A. Manzato, N. Berlinghieri, C. Muneretto (Brescia, IT)
- Clinical significance of prosthetic valve fibrin strands and associations with anticoagulant status.** P2417
 – M. Kiavar, A. Sadeghpour, H. Bassiri, P. Tayyebi, M. Parsaee, M. Esmailzadeh, M. Maleki (Tehran, IR)
- ATRIAL FIBRILLATION. SPECIAL ISSUES**
- Amiodarone versus sotalol: Safer antiarrhythmic treatment by amiodarone in heart failure due to lack of effect on dispersion of repolarization and creation of a rectangular action potential morphology.** P2418
 – G. Frommeyer, P. Millberg, P. Witte, J. Stypmann, G. Moennig, M. Luecke, G. Breithardt, L. Eckardt (Munster, DE)
- Efficacy, safety and advantages of a brief post-cardioversion anticoagulation protocol in patients with persistent atrial fibrillation and no long term indication to anticoagulation.** P2419
 – A. Conversano, C. Gardini, G. Fragasso, A. Mailhac, A. Margonato (Milan, IT)
- Impact of epicardial fat pads ablation on acute atrial electrical remodeling.** P2420
 – D. Chang, S. Zhang, L. Gao, D. Yang, Y. Lin, Z. Zhen, X. Yin, X. Xiao, P. Jiang, Y. Yang (Dalian, CN)
- Arrhythmia vulnerability of aged haploinsufficient Cx43 mice is determined by heterogeneous downregulation of Cx43 combined with increased fibrosis.** P2421
 – J.A. Jansen, T.A. Van Veen, R. Van Der Nagel, M.A. Vos, J.M. De Bakker, H.V.M. Van Rijen (Utrecht, NL)
- The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.** P2422
 – D. Thomas, J. Gierden, A.K. Rahm, R. Bloehs, K. Schloemer, J. Kisselbach, I. Staudacher, S. Obers, P.A. Schweizer, H.A. Katus (Heidelberg, DE)
- Left atrial pressure as significant predictor of long-term success after pulmonary vein ablation.** P2423
 – L. Mittmann-Braun, M. Linhardt, O. Balta, G. Nickenig, L. Lickfett (Bonn, DE)

- are rate-control drugs and antithrombotic therapies appropriately prescribed in atrial fibrillation? a survey of clinical practice.** P2424
 – G. Matharu, D. Wilson, A. Gunaratne, G.Y.H. Lip (Birmingham, GB)
- Comparison of pulmonary veins anatomy in patients with and without atrial fibrillation: analysis by multislice tomography.** P2425
 – I. Wozniak-Skowerska, M. Skowerski, A.M. Wnuk-Wojnar, A. Gola, M. Sosnowski, A. Hoffmann, M. Trusz-Gluza (Katowice, PL)
- Non-uniform anisotropy and enhanced arrhythmogenesis in patients with lone atrial fibrillation.** P2426
 – C.X. Wong, M.K. Stiles, B. John, A.G. Brooks, D.H. Lau, H. Dimitri, P. Kuklik, N. Namboodiri, G.D. Young, P. Sanders (Adelaide, AU)
- Catheter ablation for persistent AF: assessing impact of ablation on autonomic tone.** P2427
 – J. Tuan, M. Jeilan, S. Kundu, P.J. Stafford, G.A. Ng (Leicester, GB)
- NT-proBNP in the diagnosis of new-onset persistent and paroxysmal atrial fibrillation.** P2428
 – R. Wachter, F. Edelmann, T. Grueter, H.D. Duengen, F. Weidemann, M. Zabel, L. Binder, C. Herrmann-Lingen, G. Hasenfuss, B. Pieske (Göttingen, Berlin and Würzburg, DE; Graz, AT)
- Magnetically obtained remote-controlled left atrial reconstruction is comparable to manually acquired LA anatomy.** P2429
 – B. Koektuerk, J. Chun, M. Konstantinidou, E. Wissner, B. Schmidt, A. Metzner, T. Zerm, F. Ouyang, K.H. Kuck (Hamburg, DE)
- Atrial myocardial deformation properties in patients with persistent and paroxysmal atrial fibrillation.** P2430
 – S. Eroglu, E. Sade, E. Polat, I. Atar, B. Ozin, H. Muderrisoglu (Ankara, TR)
- Dynamic-CT integration in CARTO mapping system for atrial fibrillation ablation: validation of the technique in humans.** P2431
 – P. Vergara, P. Mazzone, M. Saviano, S. Sacchi, S. Crisa, G. Maida, V. Santinelli, G. Vicedomini, C. Pappone (Milan, IT)
- Predictors for long-term sinus rhythm maintenance in patients treated with episodic versus continuous amiodarone treatment.** P2432
 – S. Ahmed, A.C.P. Wiesfeld, M. Rienstra, D.J. Van Veldhuisen, I.C. Van Gelder (Groningen, NL)
- Male gender is independent predictor of increased risk of tachycardiomyopathy in patients with nonvalvular atrial fibrillation.** P2433
 – T. Potpara, M. Polovina, M. Grujic, B. Vujisic-Tesic, M. Ostojic (Belgrade, RS)
- Atrial resynchronisation therapy can be used to treat paroxysmal atrial fibrillation in the modern treatment era in patients with prolonged inter-atrial conduction.** P2434
 – R. Sankaranarayanan, M.A. James, H. Gonna, S. Burtchaell, R. Holloway (Blackpool, Taunton and Worthing, GB)
- Evaluation of prognostic echocardiographic predictors of success of pulmonary vein isolation for treatment of atrial fibrillation.** P2435
 – E. Wellnhofer, T. Kim, C.H. Kriatselis, J.-H. Gerds-Li, E. Fleck, M. Graefe (Berlin, DE)
- Endothelial dysfunction is a risk factor for thromboembolism in atrial fibrillation.** P2436
 – H.W. Park, J.S. Koh, N.S. Yoon, Y.J. Hong, J.H. Kim, Y.K. Ahn, M.H. Jeong, J.G. Cho, J.C. Park, J.C. Kang (Gwangju, KR)
- Management of patients with implantable cardioverter defibrillators and atrial fibrillation by using medtronic carelink network - remote monitoring system.** P2437
 – K. Thudt, C.H. Wollmann, S. Rhabek, P. Vock, H. Mayr (St. Poelten and Vienna, AT)
- Is outpatient bleeding risk index useful in patients on vitamin K antagonists undergoing PCI - The AFCAS trial.** P2438
 – H. Lahtela, A. Schliitt, M. Niemela, A. Ylitalo, P. Kirchhof, S. Vikman, J. Valencia, M. Puurunen, A. Rubboli, K.E.J. Airaksinen (Turku, Oulu, Pori, Tampere and Helsinki, FI; Halle and Munster, DE; Alicante, ES; Bologna, IT)
- The efficacy and the safety of long-term vitamin K antagonists therapy: the genetic predictors of bleedings.** P2439
 – Y.A. Mikheeva, E.S. Kropacheva, D.A. Sychev, A.B. Dobrovolsky, E.P. Panchenko (Moscow, RU)

- A critical pathway for electrical cardioversion for atrial fibrillation as a vehicle to get to the guidelines.** P2440
 – E.G. Zwaan, V.A. Umans, G. Kimman (Alkmaar, NL)
- Dominant frequency of atrial fibrillation correlates poorly with atrial fibrillation cycle length.** P2441
 – A. Elvan, A.C. Linnenbank, M.W. Van Bommel, W.P. Beukema, P.P.H.M. Delnoy, A.R. Ramdat Misier, J.M.T. De Bakker (Zwolle and Amsterdam, NL)
- Predictors of normal left atrial appendage flow velocity profile one week after cardioversion of non-valvular atrial fibrillation.** P2442
 – A. Palinkas, A. Pizzuti, E. Antonielli, E. Nagy, B. Doronzo, A. Varga, T. Forster, E. Picano (Hodmezovasarhely and Szeged, HU; Turin, Savigliano and Pisa, IT)
- Surface electrocardiogram predicts successful cardioversion of atrial fibrillation.** P2443
 – C.X. Wong, M.K. Stiles, P. Kuklik, A.G. Brooks, B. John, D.H. Lau, H. Dimitri, S.R. Willoughby, G.D. Young, P. Sanders (Adelaide, AU)
- Differences in clinical and echocardiographical parameters between paroxysmal and persistent atrial flutter in the AURUM 8 study: identification of factors perpetuating the arrhythmia?** P2444
 – L. Lickfett, E.L. Mittmann-Braun, J. Holzmann, W. Bauer, C. Weiss, C. Mewis, S. Spencker, W. Jung, W. Haverkamp, T. Lewalter (Bonn, Berlin, Würzburg, Mainz, Homburg and Villingen-Schwenningen, DE)
- Novel circular multielectrode ablation catheter for atrial fibrillation ablation: assessment of the level of pulmonary venous isolation by voltage mapping.** P2445 (W)
 – S. Raffa, A. Grosse, M. Brunelli, K. Wauters, J. Yu, J.C. Geller (Bad Berka, DE)
- Changes of cytokine concentration after successful thoracoscopic ablation of atrial fibrillation.** P2446
 – P. Osmancik, Z. Peroutka, D. Herman, P. Stros, P. Budera, Z. Straka (Prague, CZ)
- Wide area circumferential ablation for pulmonary vein isolation in patients with atrial fibrillation and pulmonary vein stenosis.** P2447
 – G.M. Nair, L. Armaganjian, A. Venancio, M. Hussein, S. Divakaramenon, S.C. Ribas, J.S. Healey, S.J. Connolly, C.A. Morillo (Hamilton, CA)
- Management of pericardial effusion during and after ablation for atrial fibrillation in patients on Coumadin therapy.** P2448
 – L. Di Biase, J.D. Burkhardt, R. Horton, J. Sanchez, G. Gallinghouse, P. Mohanty, D. Patel, W. Lewis, S. Beheiry, A. Natale (Austin, Cleveland and San Francisco, US)
- Longterm outcome in patients after cardioversion for persisting atrial fibrillation: prognostic value of clinical - and laboratory parameters and drug therapy.** P2449
 – W. Rademacher, A. Lauten, J. Schumm, D. Prochnau, R. Surber, H.R. Figulla (Jena, DE)
- Long term efficacy of catheter ablation for atrial fibrillation.** P2450
 – R. Hunter, T.J. Berriman, G. Thomas, L. Richmond, V. Baker, M. Dhinoja, D. Abrams, M.J. Earley, S. Sporton, R.J. Schilling (London, GB)
- Magnetic resonance imaging for acute and long-term identification of myocardial injury in patients undergoing pulmonary vein antrum isolation.** P2451
 – A.M. Sinha, N. Burgon, C. Mahnkopf, G. Ritscher, T. Haslam, T.J. Badger, M.P. Kunzelmann, M. Schmidt, N.F. Marrouche, J. Brachmann (Coburg, DE; Salt Lake City, US)
- Validation of voltage mapping criteria for catheter ablation of ischemic ventricular tachycardia by myocardial viability assessment using FDG PET.** P2452
 – J. Schreieck, K. Kettering, A.C. Schwegler, M. Reimold, H.J. Weig, R. Laszlo, S. Weretka, M. Gawaz (Tübingen and Mainz, DE)
- IMPLEMENTABLE CARDOVERTER-DEFIBRILLATOR – RELATED ISSUES**
- Early failure of sprint fidelis high-voltage implantable cardioverter-defibrillator lead. Our experience.** P2453
 – S. Rocha Costa, S. Almeida, R. Candeias, R. Gomes, J. Silva, D. Cavaco, V. Sanfins, P. Adragao, A. Silva (Lisbon and Guimaraes, PT)

- Ventricular pro-arrhythmic effect of chronic atrial fibrillation in patients with left ventricular dysfunction and implantable cardioverter-defibrillator.** P2454
 – S. Almeida, R. Gomes, S. Rocha, J. Silva, D. Cavaco, K. Santos, F. Morgado, P. Adragao, A. Silva (Lisbon, PT)
- Indications and outcome of laser lead extraction: a single centre experience.** P2455
 – P. Vergara, P. Mazzone, N. Sora, A. Marzi, A. Cuko, G. Paglino, G. Vicedomini, V. Santinelli, C. Pappone (Milan, IT)
- Influence of native QRS complex duration on Antitachycardia Pacing effectiveness: a prospective study.** P2456
 – J. Jimenez-Candil, A. Martin, J. Morinigo, C. Ledesma, C. Martin-Luengo (Salamanca, ES)
- Remote device monitoring for CRT-D leads to substantial reduction in the need for 'routine' visits to a pacing clinic.** P2457
 – L. Trembath, C. Azucena, N. Stain, M.R. Cowie (London, GB)
- Estimation of SCD primary prophylaxis need in patients with high-risk myocardial infarction treated with primary PCI.** P2458
 – A. Filipceki, K. Wita, Z. Tabor, W. Orszulak, J. Myszor, W. Kwasniewski, M. Turski, D. Urbanczyk-Swic, M. Trusz-Gluza (Katowice, PL)
- Dynamic impedance for arrhythmia discrimination.** P2459
 – K. Jarverud, M. Broome, K. Noren, T. Svensson, S. Hjelm, A. Bjorling (Jarfalla and Solna, SE)
- Survival in patients with implantable cardioverter defibrillators - does age matter?** P2460
 – I. Chung, W. Nicholson, I. Loke, M. Jeilan, G.A. Ng, P.J. Stafford (Leicester, GB)
- Remote Follow-up for ICD-Therapy in Patients Meeting MADIT II Criteria - The REFORM trial.** P2461
 – U. Wetzel, J.C. Geller, J. Kautzner, H. Moertel, B. Schumacher, G. Hindricks (Leipzig, Bad Berka, Erlangen and Bad Neustadt, DE; Prague, CZ)
- Contemporary results and health care utilisation after ICD therapy for primary prevention in coronary artery disease and dilated cardiomyopathy.** P2462
 – T. Smith, J.L. Bosch, R.T. Van Domburg, A. Muskens-Heemskerker, D.A. Theuns, L. Jordaens (Rotterdam, NL)
- Importance of implantable cardioverter defibrillators in idiopathic ventricular tachyarrhythmias.** P2463
 – J. Delgado Silva, R. Gomes, S. Almeida, S. Rocha, K. Reis Santos, D. Cavaco, F. Bello Morgado, P. Adragao, A. Silva (Lisbon, PT)
- A comparison of induction by direct current pulse versus 50-Hz pacing on ventricular fibrillation and defibrillation.** P2464
 – H.S. Lim, S. Flannigan, H. Marshall (Birmingham, GB)
- Implantable cardioverter defibrillators at the end of life: How much do patients want to know?** P2465
 – C.E. Raphael, N. Stain, I. Wright, M. Koa-Wing, P. Kanagaratnam, D.P. Francis (London, GB)
- Indications and effectiveness of the 'Halo' subcardiac defibrillator lead.** P2466 (W)
 – J.E. Molina, K.L. Brethorst, L. Abresch, D.W. Benditt, A. Dunnigan (Minneapolis, US)
- Preliminary results of the sprint fidelis recall.** P2467
 – J.B. Van Rees, C.J.W. Borleffs, J.J. Bax, L. Van Erven, M.J. Schalij (Leiden, NL)
- Is one major risk factor for sudden death enough to indicate an Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy?** P2468
 – F. Landeta, A. Fernandez, J.L. Gonzalez, J.H. Casabe, E. Guevara, L. Medesani, N. Galizio (Buenos Aires, AR)
- Pacemaker and ICD device related infections - Diagnosis and treatment of a serious problem - A growing challenge.** P2469
 – V. Moller, M. Schoepp, M. Seifert, M. Schau, J. Meyhoefer, C. Butter (Bernau bei Berlin, DE)
- Catheter ablation for monomorphic VT induced by programmed electrical stimulation, reduced electrical storm in patients with ICD.** P2470
 – K. Tanno, T. Onuki, Y. Minoura, T. Asano, Y. Kobayashi (Tokyo, JP)

Upgrade of implantable cardioverter-defibrillator to cardiac resynchronization therapy: rate of progression and baseline predictors. P2471

– G.L. Sumner, R. Sheldon, P. Cassidy, A. Gillis, D. Exner, R. Quinn, G. Veenhuysen, H. Duff, K. Kavanagh, B. Mitchell (Calgary, CA)

Antitachycardia pacing effectiveness in monomorphic ventricular tachycardias spontaneously occurred in ICD patients: importance of the cycle length fluctuations. P2472

– J. Jimenez-Candil, A. Martin, J.L. Morinigo, M. Ruiz Olgado, C. Ledesma, C. Martin-Luengo (Salamanca, ES)

arrhythmia specialists predict progression to upgrade of implantable cardioverter-defibrillator to cardiac resynchronization therapy more accurately than do clinical factors. P2473

– G.L. Sumner, R. Sheldon, P. Cassidy, D. Exner, R. Quinn, K. Kavanagh, H. Duff, A. Gillis, G. Wyse, B. Mitchell (Calgary, CA)

PHARMACOLOGICAL THERAPY OF HEART FAILURE

Ivabradine improves systolic function and enhances FKBP12 expression after myocardial infarction followed by 3 weeks of reperfusion. P2474

– N. Couvreur, R. Tissier, S. Pons, V. Chetboul, V. Gouni, J.L. Pouchelon, P. Bruneval, J.L. Dubois-Rande, B. Ghaleh, A. Berdeaux (Creteil and Paris, FR)

L-4F reverts left ventricular dysfunction in db/db mice via increases in pAMPK, peNOS and HO-1 expression. P2475

– C. Vecoli, L. Vanella, D. Neglia, S. Peterson, D. Bedja, N. Paolucci, N.G. Abraham, A. L'Abbate (Pisa, IT; New York and Baltimore, US)

Activation of histone/protein deacetylase SIRT1 by resveratrol induces MnSOD up-regulation via FOXO3a and improves survival of heart failure animals. P2476

– A. Kuno, M. Tanno, T. Miura, Y. Horio, K. Shimamoto (Sapporo, JP)

Beta-blockers improve survival in patients with heart failure regardless of renal function. An analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II) trial. P2477

– D. Castagno, P.S. Jhund, J.J.V. McMurray, E. Erdmann, F. Zannad, W.J. Remme, J.L. Lopez Sendon, P. Lechat, H.J. Dargie (Turin, IT; Glasgow, GB; Cologne, DE; Nancy and Saint Denis, FR; Rhon, NL; Madrid, ES)

The anti-diabetic drug voglibose reduces myocardial infarct size and improves left ventricular function via stimulation of GLP-1 receptors and PI3 kinase-Akt-eNOS pathway in rabbits. P2478

– M. Iwasa, H. Kobayashi, S. Yasuda, S. Sumi, H. Ushikoshi, K. Nishigaki, G. Takemura, T. Fujiwara, H. Fujiwara, S. Minatoguchi (Gifu, Kyoto and Hyogo, JP)

Determinants and clinical relevance of cardiac function recovery in anthracycline-induced cardiomyopathy. P2479

– D. Cardinale, G. De Giacomi, A. Colombo, C. Pandini, M. Civelli, N. Colombo, G. Lamantia, C. Fiorentini, C.M. Cipolla (Milan, IT)

Discontinuation of high-dose rosuvastatin treatment deteriorates endothelial function in patients with chronic heart failure. P2480

– E.B. Beck, S. Erbs, V. Adams, A. Linke, N. Kraenkel, R. Hoellriegel, S. Moebius-Winkler, R. Hambrecht, G. Schuler (Leipzig and Bremen, DE)

Percutaneous aortic valve implantation for severe aortic stenosis using self expanding prosthesis: initial spanish experience. P2481

– P. Avanzas Fernandez, A.J. Munoz Garcia, J. Segura Saint-Gerons, M.F. Jimenez Navarro, M. Pan Alvarez-Ossorio, I. Lozano, C. Moris, J. Suarez De Lezo, J.M. Hernandez Garcia (Oviedo, Malaga and Cordoba, ES)

Soluble guanylyl cyclase activation with HMR 1766 provides additional benefit to ACE inhibition on cardiac remodeling postinfarction. P2482

– J. Bauersachs, D. Fracarrolo, P. Galuppo, S. Motschenbacher, H. Ruetten, A. Berbner, S. Schraut, A. Schaefer, G. Ertl (Wurzburg and Frankfurt Am Main, DE)

Myelosuppressives protect post-myocardial infarction heart by activating cell survival signal, SDF-1/CXCR4 axis and attenuating fibrosis and apoptosis. P2483

– H. Ushikoshi, Y. Misao, Y. Li, T. Ohno, N.C. Khai, G. Takemura, T. Fujiwara, H. Fujiwara, S. Ogura, S. Minatoguchi (Gifu, Nagoya and Kyoto, JP)

- Effects of parasympathetic preservation on noninvasive myocardial function in Wistar rats with myocardial infarction.** P2484
 – R.A. Sirvente, R.N. Fuente, L.E. Souza, I.C.M. Silva, G.O. Candido, C. Mostarda, S. Lacchini, M.C. Irigoyen, V.M.C. Salemi (Sao Paulo, BR)
- Beta-blocker CONTinuation Versus INTerruption in patients with Congestive heart failure hospitalized for a decompensation episode.** P2485
 – G. Jondeau, P. Lechat (Paris, FR)
- Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.** P2486
 – G.M. Felker, J.R. Teerlink, P. Ponikowski, A.A. Voors, G. Filippatos, B.H. Greenberg, S.L. Teichman, G. Cotter, B.D. Weatherley, M. Metra (Durham, San Francisco, San Diego and San Mateo, US; Wroclaw, PL; Groningen, NL; Athens, GR; Brescia, IT)
- A natural p300-specific histone acetyltransferase inhibitor, curcumin, can prevent the development of heart failure in addition to ACE inhibitor after myocardial infarction in rats.** P2487
 – T. Morimoto, M. Fujita, Y. Sunagawa, H. Wada, T. Takaya, S. Yanagi, A. Marui, T. Ikeda, A. Shimatsu, K. Hasegawa (Shizuoka and Kyoto, JP)
- Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy.** P2488
 – D.N. Tziakas, S. Chatzikiyakou, G. Chalikias, D. Stakos, A. Thomaidi, S. Manousakis, H. Boudoulas (Alexandroupolis and Athens, GR)
- Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).** P2489
 – M. Metra, J.R. Teerlink, A.A. Voors, G.M. Felker, P. Ponikowski, B.D. Weatherley, G.S. Filippatos, E. Unemori, S. Teichman, G. Cotter (Brescia, IT; San Francisco, Durham and San Mateo, US; Groningen, NL; Wroclaw, PL; Athens, GR)
- Initial observations of intravenous CD-NP, chimeric natriuretic peptide, on renal function in chronic heart failure patients.** P2490
 – H.D. Lieu, S.R. Goldsmith, J.M. Neutel, B.M. Massie, D.L. Mann, M. Komajda, J.B. Young, J. Hodge, H.H. Chen, J.C. Burnett (San Francisco, Minneapolis, Irvine, St Louis, Cleveland and Rochester, US; Paris, FR)
- Is there a role to erythropoiesis-stimulating proteins in the treatment of anemic chronic heart failure patients: a meta-analysis of randomized controlled trials.** P2491
 – F. Canario-Almeida, L. Azevedo, F. Ferreira, O. Azevedo, J. Guardado, F. Sousa, J. Almeida, A. Costa-Pereira (Porto and Guimaraes, PT)
- The olive constituent oleuropein prevents the doxorubicin-induced heart failure in anesthetized rats.** P2492
 – I. Andreadou, F. Sigala, K.N. Naka, K. Ioannidis, N. Kavantzias, N. Aligiannis, A.L. Skaltsounis, E. Mikros, E.K. Iliodromitis, D.T. Kremastinos (Athens and Ioannina, GR)
- Nebivolol is effective and safe in elderly heart failure patients with impaired renal function.** P2493
 – D. Kotecha, A. Cohen-Solal, D.J. Van Veldhuisen, M. Bohm, A.J.S. Coats, M. Roughton, D. Babalis, P. Poole-Wilson, L. Tavazzi, M. Flather (London, GB; Paris, FR; Groningen, NL; Homburg, DE; Sydney, AU; Cotignola, IT)
- Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope.** P2494
 – T. Phan, G. Nallur Shivu, A. Choudhury, K. Abozguia, C. Davies, M. Nassimzadeh, A. Nassimzadeh, I. Ahmed, Z. Yousef, M. Frenneaux (Birmingham and Cardiff, GB)
- Effect of n-3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI-heart failure trial.** P2495
 – R. Marchioli, M.G. Franzosi, R. Latini, A.P. Maggioni, R.M. Marfisi, G.L. Nicolosi, E. Picchio, M. Porcu, D. Severini, L. Tavazzi (Santa Maria Imbaro, Milan, Florence, Pordenone, Rome, Cagliari, Citta Di Castello and Cotignola, IT)
- Beneficial effects of correction of growth hormone deficiency in chronic heart failure: a randomized, controlled, single-blind study.** P2496
 – A. Cittadini, G. Carlomagno, L. Saldamarco, A.M. Marra, M. Arcopinto, F. Calabrese, S. Fazio, C. Vigorito, B. Merola, L. Sacca (Naples, IT)

- Effects of different beta-blockers on arterial wall properties and markers of inflammation in patients with systolic ischemic heart failure used alone or in combination with atorvastatin.** P2497
 – E.M. Ozova, G.K. Kiyakbaev, Z.H.D. Kobalava, V.S. Moiseev (Moscow, RU)
- Comparative efficacy of carvedilol and ivabradine in severe chronic heart failure of ischemic origin with baseline heart rate below and above 70 beat per minute.** P2498
 – L.R. Tumasyan, K.G. Adamyan (Yerevan, AM)
- Heart rate reduction by ivabradine reduces diastolic dysfunction and atrial fibrosis in hypercholesterolemic rabbits.** P2499
 – D. Busseuil, Y. Shi, M. Mecteau, E. Thorin, T.K. Leung, M. Bouly, E. Rheaume, J.-C. Tardif (Montreal, CA; Courbevoie, FR)
- Potential effects of trimetazidine with exercise training in patients with dilated cardiomyopathy.** P2500
 – M. Gad, H. Soliman, S. Mehani, K. Leon, M. Abd Elrhman (Cairo, EG)
- Study of clinical efficacy of nebivolol and carvedilol administration in complex therapy of chronic heart failure due to coronary heart disease combined with chronic obstructive pulmonary disease.** P2501 (W)
 – V. Evdokimov, E. Kovalenko, O. Tereschenko, A.G. Evdokimova, A.B. Evdokimova (Moscow, RU)
- Aldosterone blocking agents usage in patients with heart failure.** P2502
 – M. Gheorghiadu, J. Margolis, K. Pan, C. Roberts, P. Gordon, R.A. Gerber (Chicago, Bala Cynwyd, Cambridge and New London, US)
- Comparison of nitroglycerine and nicorandil in acute congestive cardiac failure.** P2503
 – V. Singh, B. Shah (King's Lynn, GB; Ahmedabad, IN)
- Beneficial electrophysiological effects of trimetazidine in patients with post-ischemic chronic heart failure.** P2504
 – M. Cera, A. Salerno, G. Fragasso, C. Montanaro, C. Gardini, G. Marinosci, F. Arioli, R. Spoladore, A. Facchini, A. Margonato (Milan, IT)
- The influence of atorvastatin on the parameters of inflammation and the function of left ventricle in patients with dilated cardiomyopathy.** P2505
 – A. Bielecka-Dabrowa, J.H. Goch, J. Rysz, M. Maciejewski, M. Michalska, M. Banach (Lodz, PL)
- Elevated HDL cholesterol and male gender predict adequate response to intensified ASA treatment in heart failure patients with ischemic etiology.** P2506
 – M.T. Dominiak, T. Wcislo, J. Drodz, J.D. Kasprzak (Lodz, PL)
- Preliminary data on a cardioprotective effect of telmisartan in cancer patients treated with epirubicin.** P2507
 – A. Piras, C. Cadeddu Dessalvi, M. Dessi, M. Deidda, G. Binaghi, C. Madeddu, E. Massa, G. Mantovani, G. Mercurio (Monserrato, IT)
- Ethnic difference in the response to beta-adrenoreceptor blockade in the treatment of heart failure.** P2508
 – C.P. Edwards, J. Rawlins, N. Chandra, J. De Courcey, C. Chitty, M. Papadakis, S. Sharma (London, GB)
- Symptomatic and asymptomatic heart failure in patients undergoing major vascular surgery: prevalence and pharmacological treatment.** P2509
 – W.J. Flu, J.P. Van Kuijk, S.E. Hoeks, R. Kuijper, O. Schouten, Y. Van Gestel, T. Winkel, D. Goei, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)
- Short-term heart rate reduction induced by ivabradine administered to rats with well-established heart failure improves cardiac function, augments neo-angiogenesis and reduces myocardial hypoxia.** P2510
 – P. Mulder, Y. Fang, F. Bauer, E. Brakenhielm, F. Lallemand, P. Gluais, J. Roussel, C. Thuillez (Rouen and Courbevoie, FR)
- Does the kind of beta-blocker therapy influence the effect of physical training in heart failure patients?** P2511
 – E. Piotrowicz, M. Bilinska, M. Piotrowska, T. Zielinski, R. Baranowski, R. Piotrowicz (Warsaw, PL)

Echocardiographic detection of increases in ejection fraction in patients with heart failure receiving the selective cardiac myosin activator, CK-1827452. P2512

– J.H. Goldman, J.R. Teerlink, K.G. Saikali, F. Malik, A.A. Wolff (Warrington, San Francisco and South San Francisco, US)

The combination of low dose furosemide and low dose dopamine is effective and prevents worsening of renal function and hypokalemia during hospitalization for acute decompensated heart failure. P2513

– G. Giamouzis, D. Economou, G. Karayannis, D. Rovithis, I. Nastas, T. Kyrlidis, T. Tsaknakis, J. Skoularigis, J. Butler, F. Triposkiadis (Atlanta, US; Larissa and Volos, GR)

Imaging options for the selection of anatomically suitable patients for transcatheter aortic valve implantation. P2514

– A.W. Asgar, B. Rana, M. Rubens, N. Delahunty, S. Davies, M.J. Mullen, N. Moat, R. Mohiaddin (London, GB)

PHARMACOLOGICAL AND NON-PHARMACOLOGICAL THERAPY OF HEART FAILURE

The price of being BEAUTIFUL: Does the benefit of Ivabradine in heart failure justify the cost? P2515

– G.J. Wynn, H. Seetha Rammohan, N. Jakka, N.M. Hawkins, M.I. Burgess (Liverpool, GB)

Is there room for further heart rate modulation therapy in a stable heart failure population. P2516

– H.M. Sulaiman, N.F. Murphy, C. O'Loughlin, M. Ledwidge, D. McCaffrey, K. McDonald (Dublin, IE)

Eplerenone improves endothelium function in patients with chronic heart failure. P2517

– A. Tiritilli, C. Le Gac, J. Clerc, P. Viard, P. Aouate (Creil, FR)

Time course analysis of the effect of n-3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI-HF trial. P2518

– R. Marchioli, G. Cucchi, A. Gualco, M.G. Franzosi, G. Levantesi, A.P. Maggioni, R.M. Marfisi, G.L. Nicolosi, M. Porcu, L. Tavazzi (Santa Maria Imbaro, Sondrio, Pavia, Milan, Florence, Pordenone, Cagliari and Cotignola, IT)

Phase II safety study evaluating the novel cardiac myosin activator, CK-1827452, in patients with ischemic cardiomyopathy and angina. P2519

– B. Greenberg, W. Chou, R. Escandon, J. Lee, M. Chen, K. Saikali, F. Malik, A. Wolff, T. Shaburishvili (San Diego and South San Francisco, US; Tbilisi, GE)

Angiotensin converting enzyme inhibitors in heart failure, do Afro-Caribbean patients gain the beneficial effects observed in Caucasians? P2520

– C.P. Edwards, N. Chandra, J. Rawlins, M. Papadakis, J. De Courcey, S. Sharma (London, GB)

Prescription of betablockers at hospital discharge and beyond in patients with heart failure. Results from the DEVENIR study. P2521

– A. Cohen-Solal, P. Assyag, M. Guenoun, I. Leurs, P. Poncelet, P.L. Prost, J.F. Thebaut, C. Contre (Paris, Plan De Cuques, Rungis and Sarcelles, FR)

Tranilast in a pharmacological dose has no beneficial effect on the cardiac remodeling and mortality in chronic ischemic heart failure after large myocardial infarction in rats. P2522

– S. Betge, H.R. Figulla (Jena, DE)

Subclinical inflammation and oxidative stress following de novo cardiac transplantation: similar impact of tacrolimus vs. cyclosporine microemulsion. P2523

– M. White, B. Cantin, H. Haddad, J. Kobashigawa, H. Ross, M. Carrier, L. Whittom, I. Ali, D. Isaac, S.H. Wang (Montreal, Quebec, Toronto, Halifax, Calgary and Edmonton, CA; Sion, CH; Los Angeles, US)

Negative pre-transplant serostatus for toxoplasma gondii is associated with impaired survival after heart transplantation. P2524

– A.O. Doesch, K. Ammon, S. Celik, M. Konstandin, A. Kristen, L. Frankenstein, F.-U. Sack, H.A. Katus, T.J. Dengler (Heidelberg, DE)

Characteristics of the interleukin family biomarker ST2 after heart transplantation. P2525

– D.A. Pascual Figal, I.P. Garrido, R.M. Blanco, J. Sanchez-Mas, A. Minguela, R. Gracia, M.D. Martinez, J. Ordonez, A. Bayes-Genis, M. Valdes (Murcia and Barcelona, ES)

HAEMODYNAMICS, HEART AND HYPERTENSION

- Gender differences in hypertension; risk factor identifiers in favour of women?** P2526
 – A.J. Hogarth, D.A.S.G. Mary, S.G. Ball, J.P. Greenwood (Leeds, GB)
- Association between serum uric acid and large artery stiffness in essential hypertensives: focus on gender differences.** P2527
 – G. Vysoulis, E. Karpanou, S.-M. Kyvelou, V. Tzamou, D. Adamopoulos, G. Antonakoudis, C. Vlachopoulos, D. Cokkinos, C. Stefanadis (Athens, GR)
- Renal artery stenting impacts left ventricle structure and serum aldosterone concentration.** P2528
 – D. Rzeznik, T. Przewlocki, A. Kablak-Ziemicka, A. Roslawiecka, A. Kozanecki, J. Lach, M. Kostkiewicz, W. Tracz (Krakow, PL)
- Endothelium under attack in hypertensives with obstructive sleep apnoea: relation of disease severity with biological markers.** P2529
 – A. Kasiakogias, C. Tsioufis, C. Thomopoulos, A. Mazaraki, P. Tolis, E. Andrikou, E. Stefanadi, I. Kallikazaros, D. Tousoulis, C. Stefanadis (Athens, GR)
- Influence of salt intake on carotid structure and hemodynamics in hypertensive subjects.** P2530
 – M.C.S. Ferreira-Sae, J.A. Cipolli, M. Cornelio, J.R. Matos-Souza, R. Schreiber, K.G. Franchini, R.C. Rodrigues, M.C.J. Gallani, W. Nadruz Junior (Campinas, BR)
- Hyperleptinemia is accompanied by a state of increased arterial stiffness in a community population sample.** P2531
 – K. Baou, C. Vlachopoulos, I. Dima, N. Ioakeimidis, D. Terentes-Printzios, G. Antoniou, K. Aznaouridis, A. Bratsas, C. Stefanadis (Athens, GR)
- The value of systemic endothelial dysfunction and increased arterial stiffness for identifying wall motion abnormalities during stress echocardiography in hypertensive men with erectile dysfunction.** P2532
 – N. Ioakeimidis, C. Vlachopoulos, C. Aggeli, K. Aznaouridis, G. Antoniou, D. Terentes-Printzios, G. Roussakis, K. Rokkas, C. Fassoulakis, C. Stefanadis (Athens, GR)
- The mean platelet volume in patients with non-dipper hypertension compared to dippers and normotensives.** P2533
 – M.G. Kaya, M. Yarlioglues, O. Gunebakmaz, T. Inanc, A. Dogan, E. Gunturk, A. Oguzhan, N.K. Eryol, R. Topsakal (Kayseri, TR)
- The effect of acute inhibition of renin-angiotensin system on coronary flow reserve in hypertensives.** P2534
 – K. Stamatelopoulos, D. Bramos, E. Alexaki, C. Trika, E. Manios, N. Zakopoulos, S. Toumanidis (Athens, GR)
- Waist circumference as a determinant of left atrial size in newly diagnosed subjects with essential hypertension.** P2535
 – E. Taxiarchou, C. Tsioufis, D. Syrseloudis, D. Chatzis, D. Tsiachris, I. Skiadas, N. Trikalinos, I. Vlasseros, D. Tousoulis, C. Stefanadis (Athens, GR)
- Pronounced nocturnal blood pressure levels lead to erectile dysfunction in male hypertensives.** P2536
 – A. Kakkavas, C. Tsioufis, D. Tsiachris, D. Syrseloudis, V. Tzamou, D. Tousoulis, H. Tatsis, A. Trikas, C. Stefanadis (Athens, GR)
- B-Type Natriuretic Peptide identifies asymptomatic hypertensive patients with abnormal diurnal blood pressure variation and increased LA volume.** P2537
 – D. Phelan, E. Omar, B. Hennigan, M. Ledwidge, D. O'Shea, K. McDonald (Dublin, IE)
- Excessive inotropic response during exercise as a marker of regional and systemic arterial stiffness in newly diagnosed essential hypertension.** P2538
 – D. Tsiachris, C. Tsioufis, C. Thomopoulos, A. Kasiakogias, D. Syrseloudis, D. Soulis, T. Papaioannou, A. Mazaraki, D. Tousoulis, C. Stefanadis (Athens, GR)
- Masked, white-coat and sustained hypertension: Associations with subclinical inflammation, arterial stiffness and thrombolysis/fibrinolysis system.** P2539
 – K. Dimitriadis, C. Tsioufis, D. Syrseloudis, A. Mazaraki, A. Gennadi, M. Selima, V. Tzamou, I. Darladimas, I. Kallikazaros, C. Stefanadis (Athens, GR)

- Arterial stiffness leads to impaired microcirculation of the brain represented as cognitive dysfunction in non-dippers with newly-diagnosed essential hypertension.** P2540
– H. Triantafyllidi, C. Arvaniti, J. Lekakis, I. Ikonomidis, P. Trivilou, S. Tzortzis, K. Kotsas, D. Kremastinos (Athens, GR)
- White coat hypertension vs. masked hypertension: influence on the development of sustained hypertension in children and adolescents.** P2541
– C. Esis, M. Bracho, A. Gonzalez, E. Silva, S. Briceno, G. Bermudez, J. Villasmil (Maracaibo, VE)
- Relationship between urine albumin/creatinine ratio and left ventricular mass in patients with hypertension and left ventricular hypertrophy: aliskiren in left ventricular hypertrophy (allay) study.** P2542
– A. Pouleur, A. Shah, A. Desai, E. Appelbaum, V. Lukashovich, B.A. Smith, B. Dahlöf, S.D. Solomon (Boston and East Hanover, US; Gothenburg, SE)
- Whether income is associated with blood pressure levels in a population sample?** P2543
– S. Malyutina, M. Bobak, S. Soboleva, D. Malyutina, A. Peasey, E. Veryovkin (Novosibirsk, RU; London, GB)
- Hypertension: determinants of blood pressure control in primary health care in Portugal. Insights of VALSIM study.** P2544
– M.S. Robalo Martins, N. Cortez-Dias, A. Belo, M. Fiuza (Lisbon, PT)
- Severe uncontrolled hypertension treated with microvascular decompression of the brainstem.** P2545
– V. Kapil, G. Rull, J. Wadley, M. Lobo (London, GB)

**A MULTI-DISCIPLINARY
APPROACH TO CREATING AN
EFFECTIVE PRIMARY PERCUTANEOUS CORONARY
INTERVENTION TRANSFER SYSTEM**

Lunch Time Workshop

Chairperson(s): J. Fajadet (Toulouse, FR)

Lunch Time Workshop organised by Abbott Vascular

- | | | |
|-------|---|-------------|
| 12:45 | Introduction.
– J. Fajadet (Toulouse, FR) | 2546 |
| 12:50 | The role of the interventional cardiologist.
– J. McLenachan (Glasgow, GB) | 2547 |
| 12:55 | Discussion.
– J. Fajadet, J. McLenachan, M. Tubaro (Toulouse, FR; Glasgow, GB; Rome, IT) | 2548 |
| 13:10 | The role of the clinical cardiologist.
– M. Tubaro (Rome, IT) | 2549 |
| 13:15 | Discussion and conclusion.
– J. Fajadet, J. McLenachan, M. Tubaro (Toulouse, FR; Glasgow, GB; Rome, IT) | 2550 |

**POPULATIONS VERSUS THE
INDIVIDUAL: THE PRESCRIBING
PREDICAMENT**

Lunch Time Workshop

Chairperson(s): C. Brotos (Barcelona, ES); D.A. Wood (London, GB)
Lunch Time Workshop organised by Pfizer Ltd.

- | | | |
|-------|---|------|
| 12:45 | Introduction.
– D.A. Wood (London, GB) | 2551 |
| 12:50 | The prescribers predicament: a debate.
Doctors have a responsibility to prescribe for the benefit of a population.
– C. Brotos (Barcelona, ES) | 2552 |
| 13:00 | The prescribers predicament: a debate.
Doctors have a responsibility to prescribe for the benefit of the individual patient.
– F. Dievart (Dunkerque, FR) | 2553 |
| 13:10 | Audience Q & A.
– D.A. Wood (London, GB) | 2554 |
| 13:25 | Concluding remarks.
– D.A. Wood (London, GB) | 2555 |

**LINKING SLEEP APNOEA,
CARDIOLOGY AND DIABETES:
WHAT YOU DON'T KNOW MAY SURPRISE YOU!**

Lunch Time Workshop

Chairperson(s): F. Zannad (Dommartin-Les-Toul, FR); J.M. Montserrat (Barcelona, ES)
Lunch Time Workshop organised by ResMed

- | | | |
|-------|---|-------------|
| 12:45 | Introduction: sleep disordered breathing (SDB) and co-morbidities. | 2556 |
| | – F. Zannad (Dommartin-Les-Toul, FR) | |
| 12:50 | Managing SDB in high-risk asymptomatic metabolic syndrome. | 2557 |
| | – J.M. Montserrat (Barcelona, ES) | |
| 13:05 | Outcomes of appropriate treatment of SDB in co-morbidities. | 2558 |
| | – F. Zannad (Dommartin-Les-Toul, FR) | |
| 13:20 | Conclusion. | 2559 |
| | – J.M. Montserrat, F. Zannad (Barcelona, ES; Dommartin-Les-Toul, FR) | |

**DISEASE MANAGEMENT USING
IMPLANTABLE DEVICES –
OPTIONS AND OPPORTUNITIES**

Lunch Time Workshop

Chairperson(s): K. Dickstein (Stavanger, NO); A.J. Camm (London, GB)
Lunch Time Workshop organised by Medtronic

- | | | |
|-------|---|-------------|
| 12:45 | Introduction. | 2560 |
| | – A.J. Camm (London, GB) | |
| 12:50 | The role of implantable cardiac monitors: indications and clinical benefits. | 2561 |
| | – M. Brignole (Lavagna, IT) | |
| 13:05 | Remote monitoring of fluid status: where we are? | 2562 |
| | – M.R. Cowie (London, GB) | |
| 13:20 | Panel discussion. | 2563 |
| | – K. Dickstein (Stavanger, NO) | |

TRANSCATHETER AORTIC VALVE Lunch Time Workshop
IMPLANTATION (TAVI) AS AN
ALTERNATIVE FOR HIGH RISK AORTIC STENOSIS PATIENTS

Chairperson(s): S.J.D. Brecker (London, GB); J.-C. Laborde (Breda, NL)

Lunch Time Workshop organised by Medtronic Corevalve

- | | | |
|-------|--|-------------|
| 12:45 | Introduction.
– J.-C. Laborde (Breda, NL) | 2564 |
| 12:50 | Subclavian approach versus transfemoral.
– S.J.D. Brecker (London, GB) | 2565 |
| 13:05 | Subclavian approach versus transfemoral.
– J.-C. Laborde (Breda, NL) | 2566 |
| 13:20 | Conclusion.
– S.J.D. Brecker (London, GB) | 2567 |

**CARDIAC RESYNCHRONIZATION
THERAPY IN HEART FAILURE
PATIENTS WITH NARROW QRS**

Lunch Time Workshop

Chairperson(s): D. Gras (Nantes, FR)

Lunch Time Workshop organised by Biotronik

- | | | |
|-------|--|-------------|
| 12:45 | Cardiac resynchronization therapy: where do we stand? | 2568 |
| | – C. Linde (Stockholm, SE) | |
| 13:05 | Rationale and design of the echo-cardiac resynchronization therapy trial. | 2569 |
| | – W.T. Abraham (Columbus, US) | |
| 13:25 | Summary. | 2570 |
| | – D. Gras (Nantes, FR) | |

FRACTIONAL FLOW RESERVE IN COMPLEX CORONARY INTERVENTIONS

EBAC Accredited Educational Programme organised by the Cardiovascular Research Center, Aalst
Course Director: B. De Bruyne (Aalst, BE)

Chairperson(s): P.A. MacCarthy (London, GB)

- | | | |
|-------|--|-------------|
| 12:45 | Introduction.
– P.A. MacCarthy (London, GB) | 2571 |
| 12:50 | FFR - Fractional Flow Reserve: optimizing stenting outcomes.
– N.H.J. Pijls (Eindhoven, NL) | 2572 |
| 13:05 | FFR - Fractional Flow Reserve: functional imaging at the tip of the wire.
– B. De Bruyne (Aalst, BE) | 2573 |
| 13:20 | Conclusion.
– P.A. MacCarthy (London, GB) | 2574 |



"This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)."

Programme supported by an unrestricted educational grant from Radi Medical Systems, part of St Jude Medical

**CARDIORENAL BIOMARKERS AND LUNCH TIME WORKSHOP
THEIR ROLE IN THE MANAGEMENT
OF HEART FAILURE AND ACUTE KIDNEY INJURY (AKI)**

Chairperson(s): A. Maisel (San Diego, US); K. Schmidt-Ott (Berlin, DE)

Lunch Time Workshop organised by Abbott Diagnostics

- | | | |
|-------|---|------|
| 12:45 | Chairperson welcome.
– A. Maisel (San Diego, US) | 2575 |
| 12:50 | Diagnosis and management of heart failure with brain natriuretic peptide (BNP) and neutrophil gelatinase-associated lipocalin (NGAL).
– A. Maisel (San Diego, US) | 2576 |
| 13:05 | Prediction and diagnosis of AKI with urine NGAL.
– K. Schmidt-Ott (Berlin, DE) | 2577 |
| 13:20 | Discussion.
– A. Maisel, K. Schmidt-Ott (San Diego, US; Berlin, DE) | 2578 |



**SYNCOPE IN DAILY PRACTICE. HOW TO
RECOGNISE MALIGNANCY**

Meet the Experts

Chairperson(s): J. Brugada Terradellas (Barcelona, ES); J.-J. Blanc (Brest, FR)

- 12:45 **14 year old girl with recurrent syncopal episodes at social events.** 2579
– J. Brugada Terradellas (Barcelona, ES)
- 12:55 **Panel discussion.** 2580
– C. Wolpert, A. Moya I Mitjans, R. Sutton (Mannheim, DE; Barcelona, ES; London, GB)
- 13:10 **Single syncopal episode in a 65 years-old man with a first degree atrioventricular block.** 2581
– J. Brugada Terradellas (Barcelona, ES)
- 13:20 **Panel discussion.** 2582
– C. Wolpert, A. Moya I Mitjans, R. Sutton (Mannheim, DE; Barcelona, ES; London, GB)
- 13:35 **What do the Guidelines tell us?** 2583
– J.-J. Blanc (Brest, FR)



**MANAGEMENT OF ANTI-THROMBOTIC
THERAPY IN ATRIAL FIBRILLATION**

Meet the Experts

Chairperson(s): F. Andreotti (Rome, IT)

- 12:45 **Atrial fibrillation after unplanned major surgery and recent drug-eluting stent.** 2584
– K. Huber (Vienna, AT)
- 12:50 **Panel discussion.** 2585
– K. Huber, G.Y.H. Lip, P. Kirchhof, L. Ryden (Vienna, AT; Birmingham, GB; Munster, DE; Stockholm, SE)
- 13:00 **Atrial fibrillation in elderly woman with bleeding ulcer and previous stroke.** 2586
– G.Y.H. Lip (Birmingham, GB)
- 13:05 **Panel discussion.** 2587
– K. Huber, G.Y.H. Lip, P. Kirchhof, L. Ryden (Vienna, AT; Birmingham, GB; Munster, DE; Stockholm, SE)
- 13:15 **Catheter ablation of atrial fibrillation and antithrombotic management.** 2588
– P. Kirchhof (Munster, DE)
- 13:20 **Panel discussion.** 2589
– K. Huber, G.Y.H. Lip, P. Kirchhof, L. Ryden (Vienna, AT; Birmingham, GB; Munster, DE; Stockholm, SE)
- 13:30 **What do the Guidelines say?** 2590
– L. Ryden (Stockholm, SE)



MANAGEMENT OF ACUTE HEART FAILURE

Meet the Experts

Chairperson(s): M. Komajda (Paris, FR)

- | | | |
|-------|---|-------------|
| 12:45 | A patient with acutely decompensated chronic heart failure.
– M. Komajda (Paris, FR) | 2591 |
| 12:55 | Panel discussion.
– J.L. Lopez-Sendon, M. Metra, M. Boehm (Madrid, ES; Brescia, IT; Homburg/Saar, DE) | 2592 |
| 13:10 | A patient with de novo acute heart failure.
– M. Komajda (Paris, FR) | 2593 |
| 13:20 | Panel discussion.
– M. Boehm, J.L. Lopez-Sendon, M. Metra (Homburg/Saar, DE; Madrid, ES; Brescia, IT) | 2594 |
| 13:35 | What do the Guidelines say?
– M. Komajda (Paris, FR) | 2595 |

**NON-INVASIVE
REVASCULARISATION BY
CARDIAC SHOCK WAVE THERAPY – A NEW
TREATMENT OPTION FOR REFRACTORY ANGINA PECTORIS**

Lunch Time Workshop

Chairperson(s): B. Meier (Berne, CH); E.H. Marlinghaus (Taegerwilen, CH)

Lunch Time Workshop organised by Storz Medical AG

- | | | |
|-------|--|-------------|
| 12:45 | Treatment options for non-revascularisable angina pectoris. | 2596 |
| | – B. Meier (Berne, CH) | |
| 12:51 | Non-invasive revascularisation by CSWT in chronic ischemia, animal and clinical studies. | 2597 |
| | – H. Shimokawa (Sendai, JP) | |
| 13:05 | CSWT in every day practice. | 2598 |
| | – A.A. Khattab (Bad Segeberg, DE) | |
| 13:13 | CSWT - prospective, randomised, placebo controlled study. | 2599 |
| | – J.-P. Schmid (Berne, CH) | |
| 13:20 | CSWT - 5 years follow-up. | 2600 |
| | – A. Gutersohn (Hamburg, DE) | |
| 13:27 | Q & A. | 2601 |
| | – A.A. Khattab, E.H. Marlinghaus, B. Meier, J.-P. Schmid, H. Shimokawa, A. Gutersohn (Bad Segeberg and Hamburg, DE; Taegerwilen and Berne, CH; Sendai, JP) | |

INNOVATIVE IMAGING SOLUTIONS Lunch Time Workshop
FOR CHEST PAIN / CORONARY
ARTERY DISEASE

Chairperson(s): R.H. Strasser (Dresden, DE)
Lunch Time Workshop organised by GE Healthcare

- | | | |
|-------|--|-------------|
| 12:45 | Low dose cardiac computed tomography. | 2602 |
| | – G. Morgan-Hughes (Plymouth, GB) | |
| 13:00 | Quantitative assessment of myocardial perfusion after percutaneous coronary intervention for STEMI in the cath lab. | 2603 |
| | – M. Angioi (Vandoeuvre-les-Nancy, FR) | |
| 13:15 | The role of 3.0T cardiac magnetic resonance for patients with chest pain. | 2604 |
| | – R.H. Strasser (Dresden, DE) | |

NEW INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY Lunch Time Workshop

Chairperson(s): A. Linhart (Prague, CZ); F. Cecchi (Florence, IT)
Lunch Time Workshop organised by Genzyme Europe BV

- | | | |
|-------|---|-------------|
| 12:45 | Unknown causes of hypertrophic cardiomyopathy.
– A. Linhart (Prague, CZ) | 2605 |
| 13:00 | Towards diagnostic consciousness of Fabry cardiomyopathy.
– F. Cecchi (Florence, IT) | 2606 |
| 13:15 | Treatment recommendations and expectations in Fabry cardiomyopathy.
– F. Weidemann (Wurzburg, DE) | 2607 |

**MANAGEMENT OF PULMONARY LUNCH TIME WORKSHOP
ARTERIAL HYPERTENSION (PAH)
ASSOCIATED WITH CONGENITAL HEART DISEASE (CHD):
FROM EARLY CHILDHOOD TO ADULTHOOD**

Chairperson(s): N. Galie (Bologna, IT)

Lunch Time Workshop organised by Actelion Pharmaceuticals Ltd

12:45	Introduction. – N. Galie (Bologna, IT)	2608
12:50	PAH in the paediatric population. – M. Beghetti (Geneva, CH)	2609
13:05	PAH associated with CHD - Transition to adulthood. – M.A. Gatzoulis (London, GB)	2610
13:20	Questions & Answers. – N. Galie (Bologna, IT)	2611

**SLEEP APNOEA &
CARDIOVASCULAR DISEASE**

Lunch Time Workshop

Chairperson(s): P. Bordier (Langon, FR); T. Podszus (Hof, DE)

Lunch Time Workshop organised by Philips Respirationics

- | | | |
|-------|---|-------------|
| 12:45 | Sleep and the heart.
– P. Levy (Grenoble, FR) | 2612 |
| 12:50 | Obstructive sleep apnoea and cardiovascular disease.
– P. Levy (Grenoble, FR) | 2613 |
| 13:08 | Complicated breathing patterns during sleep in heart failure.
– D. Skowasch (Bonn, DE) | 2614 |
| 13:25 | Should cardiologists screen their patients for sleep disordered breathing.
– T. Podszus (Hof, DE) | 2615 |

13:45–15:15

**CARDIOVASCULAR MAGNETIC
RESONANCE IN CARDIOMYOPATHIES AND
MYOCARDITIS (LEVEL II)**

Hands-on Tutorial

Chairperson(s): G. von der Recke (Bonn, DE)
Hands-on Tutorial organised by Siemens AG, Healthcare Sector

15:30–17:00

**READING OF CORONARY COMPUTED
TOMOGRAPHY ANGIOGRAPHY DATASETS
(LEVEL II)**

Hands-on Tutorial

Chairperson(s): M. Marwan (Erlangen, DE)
Hands-on Tutorial organised by Siemens AG, Healthcare Sector

14:00–15:00

**REVASCULARISATION AND THE PATIENT
WITH DIABETES: KEY ISSUES?
REVASCULARISATION IN THE DIABETIC
PATIENT. WHAT DOES THE EVIDENCE
SHOW?**

Hands-on Tutorial

Chairperson(s): M. Sabate Tenas (Barcelona, ES)
Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company

15:30–17:00

**VASCULAR CLOSURE DEVICE WORKSHOP.
INFORMATION AND PRACTICE ON THE
DEPLOYMENT OF NEW CORDIS VASCULAR
CLOSURE DEVICE**

Hands-on Tutorial

Chairperson(s): To be announced
Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company



CHALLENGES IN SPORTS CARDIOLOGY AND PRE-PARTICIPATION SCREENING **Clinical Seminar**

Chairperson(s): H. Bjornstad (Bergen, NO); F. Carre (Rennes, FR)



14:00	Electrical repolarisation changes in young athletes; what is abnormal? – D. Corrado (Padua, IT)	2616
14:22	Asymptomatic ventricular extrasystoles in athletes: benign or potentially fatal? – A. Biffi (Rome, IT)	2617
14:44	Impact of ethnicity on electrocardiogram and cardiac dimensions in young athletes. – S. Sharma (London, GB)	2618
15:06	Evaluation of the right ventricle in highly trained young athletes. – A. La Gerche (Leuven, BE)	2619

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



CONTENTIOUS ISSUES IN SPORTS CARDIOLOGY

Chairperson(s): M. Borjesson (Gothenburg, SE); L. Monserrat (A Coruna, ES)

Debate

All children should undergo pre-participation screening.

16:30	Pro. – E.J. Meijboom (Lausanne, CH)	2620
16:45	Contra. – A. Hirth (Bergen, NO)	2621
	Rebuttal.	
17:00	Pro. – E.J. Meijboom (Lausanne, CH)	2622
17:05	Contra. – A. Hirth (Bergen, NO)	2623
17:10	Conclusion.	2624
	Ultra-endurance exercise is deleterious for the normal heart.	
17:15	Pro. – H. Heidbuchel (Leuven, BE)	2625
17:30	Contra. – F. Carre (Rennes, FR)	2626
	Rebuttal	
17:45	Pro. – H. Heidbuchel (Leuven, BE)	2627
17:50	Contra. – F. Carre (Rennes, FR)	2628
17:55	Conclusion.	2629



EXERCISE UNDER EXTREME CONDITIONS

Symposium

Chairperson(s): L.E.M. Vanhees (Leuven, BE); E.V. Shlyakhto (St. Petersburg, RU)

- | | | |
|-------|--|-------------|
| 14:00 | Effects of heat and humidity on physical performance: the iron-man contest. | 2630 |
| | – J. Niebauer (Salzburg, AT) | |
| 14:18 | Metabolic adaptations to exercise in the cold. | 2631 |
| | – F. Schena (Rovereto, IT) | |
| 14:36 | Exercise at high altitudes: effects on the cardiac performance. | 2632 |
| | – C. Reboul (Avignon, FR) | |
| 14:54 | High-altitude mountain climbing and pulmonary hypertension. | 2633 |
| | – C. Sartori (Lausanne, CH) | |
| 15:12 | Cardiovascular changes during apnoea diving. | 2634 |
| | – G. Ferretti (Geneva, CH) | |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

15:35–16:25

MEET THE TRIALIST 3

Chairperson(s): C.W. Hamm (Bad Nauheim, DE)

- | | | |
|-------|---|-------------|
| 15:35 | Unprotected left main revascularisation in patients with acute coronary syndromes (GRACE left main). | 2635 |
| | – G. Montalescot (Paris, FR) | |



THE FOUNTAIN OF YOUTH: STEM CELLS AND CLINICAL ARTERIAL DISEASE?

Symposium

Chairperson(s): G. Kojda (Dusseldorf, DE);
O. Ellingsen (Trondheim, NO)

Webcast

- | | | |
|-------|---|-------------|
| 16:30 | Characterisation and functional role of endothelial progenitor cells in the arterial wall. | 2636 |
| | – S. Dimmeler (Frankfurt, DE) | |
| 16:52 | Clinical impact of endothelial progenitor cells on atherosclerotic disease. | 2637 |
| | – U. Landmesser (Zurich, CH) | |
| 17:14 | Role of endogenous cardiac progenitor cell for cardiac revascularisation. | 2638 |
| | – A.H.P. Linke (Leipzig, DE) | |
| 17:36 | Role of stem cells in plaque growth and destabilisation. | 2639 |
| | – J.F. Martin (London, GB) | |



LIFESTYLE MODIFICATION: IS IT WORTHWHILE?

Abstracts

Chairperson(s): P. Puska (Helsinki, FI); W. Rutishauser (Cologny, CH)

- 14:00 **Weight loss effect on hs-CRP and fibrinogen levels in patients with metabolic syndrome.** 2640
 – E. Paschalidou, I. Efthimiadis, F. Dogramatzi, A. Efthimiadis (Thessaloniki, GR)
- 14:15 **Improved exercise capacity has a beneficial effect in long term mortality risk of prediabetics.** 2641
 – A. Pittaras, J. Myers, E.S. Nylen, J.P. Kokkinos, M. Kallistratos, A. Giannakopoulos, H. Grassos, P. Narayan, A.J. Manolis, P.F. Kokkinos (Athens, GR; Palo Alto and Washington Dc, US)
- 14:30 **Impact of Poly Unsaturated Fatty Acids(PUFAs) on positive remodeling of coronary plaques, a study by 64 slice MDCT(MultiDetector Computed Tomography).** 2642
 – T. Domei, S. Kuramitsu, K. Yamaji, Y. Soga, K. Ando, H. Yokoi, M. Iwabuchi, M. Nobuyoshi (Kitakyusyu, JP)
- 14:45 **Adherence to the Mediterranean diet and risk of atrial fibrillation.** 2643
 – A.V. Mattioli, A. Farinetti, C. Miloro, P. Pedrazzi, R. Melotti (Modena, IT)
- 15:00 **Interrelationship of lifestyle characteristics with dietary habits and childhood obesity among Greek adolescents. Preliminary data from the 3L Study.** 2644
 – D. Tsiachris, C. Tsioufis, D. Syrseloudis, C. Thomopoulos, E. Andrikou, E. Stefanadi, A. Mazaraki, D. Chatzis, D. Tousoulis, C. Stefanadis (Athens, GR)
- 15:15 **Good cholesterol control in a large disease management initiative: lessons from the LIVE program.** 2645
 – K.T. Ho, R.S. Hameed, J.D. Molina, A. Razakjr, H.Y. Ong, B.H. Heng (Singapore, SG)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**

15:35–16:25

MEET THE TRIALIST 4

Chairperson(s): A. Lafont (Paris, FR)

- 15:35 **Routine upfront abciximab versus standard peri-procedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock. The PRAGUE-7 Study.** 2646
 – P. Widimsky (Prague, CZ)



THE OBESITY PARADOX: IS IT REAL?

Abstracts

Chairperson(s): C. Von Schacky (Munich, DE); S. Sans Menendez (Barcelona, ES)

- 16:30 **Is there an obesity paradox after percutaneous coronary intervention (PCI) in the contemporary era? Findings from a large multicentre Australian coronary angioplasty registry.** 2647
 – T. Lancefield, D. Clark, N. Andrianopoulos, A. Brennan, C. Reid, J. Johns, K. Charter, S. Duffy, J. Proietto, O. Farouque (Melbourne, AU)
- 16:45 **Obesity, metabolic health and incidence of peripheral vascular disease during 9-years follow-up of the D.E.S.I.R. cohort.** 2648
 – M. Skilton, J. Chin-Dusting, C. Lange, J. Tichet, B. Balkau (Melbourne, AU; Villejuif and La Riche, FR)
- 17:00 **Obesity paradox in type 2 DM of the PROactive study population: Weight reduction but not weight gain is associated with increased mortality in patients with type 2 DM and high cardiovascular risk.** 2649
 – W. Doehner, E. Erdmann, R. Cairns, J.A. Dormandy, E. Ferrannini, S.D. Anker (Berlin and Cologne, DE; Nottingham and London, GB; Pisa, IT)
- 17:15 **Prevalence and trends of the metabolic syndrome in French adults: the MONA LISA study.** 2650
 – A. Wagner, B. Haas, V. Bongard, J. Dallongeville, D. Cotel, J. Ferrieres, D. Arveiler (Strasbourg, Toulouse and Lille, FR)
- 17:30 **Obesity is associated with better prognosis after implantation drug-eluting stents: the paradox of obesity.** 2651
 – M. Serrao, N. Santos, D. Pereira, J. Araujo (Funchal, PT)
- 17:45 **Obesity, waist circumference and metabolic syndrome in the Portuguese population. Insights of the VALSIM study.** 2652
 – M.M. Fiuza, N. Cortez-Dias, S. Martins, A. Belo (Lisbon, PT)



SURROGATE ENDPOINTS IN HYPERTENSION TRIALS: STILL VALID AND FOR WHICH OUTCOME? Symposium

Chairperson(s): K. Narkiewicz (Gdansk, PL); M. Dorobantu (Bucharest, RO)

- | | | |
|-------|--|------|
| 14:00 | Left-ventricular hypertrophy.
– R. Fagard (Leuven, BE) | 2653 |
| 14:22 | Ankle-brachial blood pressure index.
– D. Hayoz (Fribourg, CH) | 2654 |
| 14:44 | Proteinuria.
– P. Verdecchia (Perugia, IT) | 2655 |
| 15:06 | Carotid-intima media-thickness.
– E. Agabiti-Rosei (Brescia, IT) | 2656 |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

MULTIMODALITY IMAGING IN VALVULAR HEART DISEASE Read with the Experts

Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); M. Vannan (Columbus, US)

- | | | |
|-------|---|------|
| 15:35 | Echo or magnetic resonance imaging for the assessment of aortic regurgitation?
– M. Lombardi (Pisa, IT) | 2657 |
| 15:45 | Panel discussion.
– M. Lombardi, M.J. Monaghan (Pisa, IT; London, GB) | 2658 |
| 16:00 | 2D or 3D for the assessment of mitral valve disease.
– M.J. Monaghan (London, GB) | 2659 |
| 16:10 | Panel discussion.
– M. Lombardi, M.J. Monaghan (Pisa, IT; London, GB) | 2660 |

CONTROVERSIES IN HYPERTENSION Debate

Chairperson(s): R. Fagard (Leuven, BE); F. Ruschitzka (Zurich, CH)

There is still a place for renin-angiotensin-aldosterone system double-blockade (angiotensin-converting enzyme-inhibitors/angiotensin II receptor blockers).

- | | | |
|-------|--|------|
| 16:30 | Pro.
– H. Haller (Hannover, DE) | 2661 |
| 16:45 | Contra.
– F. Zannad (Dommartin-Les-Toul, FR) | 2662 |
| | Rebuttal. | |
| 17:00 | Pro.
– H. Haller (Hannover, DE) | 2663 |
| 17:05 | Contra.
– F. Zannad (Dommartin-Les-Toul, FR) | 2664 |
| 17:10 | Conclusion. | 2665 |
| | The J curve does exist. | |
| 17:15 | Pro.
– F.H. Messerli (New York, US) | 2666 |
| 17:30 | Contra.
– R. Cifkova (Prague, CZ) | 2667 |
| | Rebuttal. | |
| 17:45 | Pro.
– F.H. Messerli (New York, US) | 2668 |
| 17:50 | Contra.
– R. Cifkova (Prague, CZ) | 2669 |
| 17:55 | Conclusion. | 2670 |



NEW ASPECTS IN CARDIOVASCULAR DRUG THERAPY

Abstracts

Chairperson(s): K.P. Kjeldsen (Copenhagen, DK); C. Vlachopoulos (Athens, GR)

- 14:00 **Survival benefit of combined secondary prevention therapy after acute myocardial infarction: Data from the UK Myocardial Infarction National Audit Project (MINAP).** 2671
 – I.B. Squire, R. Chen, J.S. Birkhead, H. Hemingway, A. Timmis (Leicester, London and Northampton, GB)
- 14:15 **Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension.** 2672
 – J. Pepke-Zaba, A. Beardsworth, M. Chan, M. Angalakuditi (Cambridge, GB; Indianapolis, US; Toronto, CA)
- 14:30 **Effects of insulin sensitivity and anti-inflammation after supplement with N-3 polyunsaturated fatty acid in metabolic syndrome.** 2673
 – J.Y. Kim, J. Yoon, Y.J. Youn, J.K. Seong, N.S. Lee, H.S. Wang, K.H. Lee, S.H. Lee, K.H. Choe, H.M. Choe (Wonju and Ilsan, KR)
- 14:45 **The use of beta-blockers in patients with moderate pulmonary obstruction.** 2674
 – A. Hummel, M. Doerr, K. Empen, A. Staudt, T. Reffelmann, M. Probst, J. Dahm, S.B. Felix (Greifswald and Göttingen, DE)
- 15:00 **Heart rate control of beta-blockers is modulated by a common polymorphism in the G protein beta-3 subunit gene.** 2675
 – M. Dorr, C.O. Schmidt, K. Empen, H.K. Kroemer, H. Volzke, S.B. Felix, D. Roskopf (Greifswald, DE)
- 15:15 **Inhibition of angiotensin-converting enzyme augments coronary tissue plasminogen activator release in hypertensive women.** 2676
 – T. Matsumoto, I. Nakae, T. Yamane, H. Takashima, M. Horie (Otsu, JP)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**



CHALLENGES FOR THE CLINICIAN

Abstracts

Chairperson(s): K. Stoschitzky (Graz, AT); G.Y.H. Lip (Birmingham, GB)

- 16:30 **Optimizing warfarin doses in chronically anticoagulated patients: the answer is in their genes.** 2677
 – E. Azenha Balhau Jorge, J. Pego, R. Baptista, M. Lourenco, I. Marques, A. Correia, P. Monteiro, L.A. Providencia, F. Antunes (Coimbra, PT)
- 16:45 **First in patient experience with a new, direct acting, reversible p2y12 inhibitor, elinogrel (prt060128): evaluation in patients with high platelet reactivity during clopidogrel therapy.** 2678
 – P.A. Gurbel, K.P. Bliden, M.J. Antonino, P. Andre, G. Sephens, D.D. Gretler, M.M. Jurek, A. Hutchaleelaha, P.B. Conley, U.S. Tantry (Baltimore and San Francisco, US)
- 17:00 **Proton pump inhibitors in patients treated with aspirin and clopidogrel.** 2679
 – A. Gaspar, S. Ribeiro, S. Nabais, S. Rocha, P. Azevedo, M. Pereira, A. Brandao, A. Correia (Braga, PT)
- 17:15 **Interaction of proton pump inhibitors (PPIs) with the antiplatelet effect of clopidogrel in patients undergoing coronary stenting.** 2680
 – C.S. Zuern, T. Geisler, N. Lutlisky, A.E. May, C. Herdeg, S. Winter, M. Schwab, M. Gawaz (Tübingen and Stuttgart, DE)
- 17:30 **Is there a rebound effect after clopidogrel cessation in patients undergoing percutaneous coronary intervention and drug-eluting stent implantation?** 2681
 – G. Lemesle, R. Torguson, L. Bonello, A. De Labriolle, G. Maluenda, A. Margulies, Z. Xue, J. Lindsay, A. Pichard, R. Waksman (Washington, US)
- 17:45 **Which platelet function test is the most sensitive for the in vivo effects of clopidogrel? A pharmacokinetic analysis.** 2682
 – H.-J. Bouman, J.W. Van Werkum, N. Breet, C.M. Hackeng, J.M. Ten Berg, D. Taubert (Nieuwegein, NL; Cologne, DE)



PREVENTION CENTRE: A NOVEL CONCEPT IN CARDIAC REHABILITATION **Symposium**

Chairperson(s): B. Bjarnason-Wehrens (Cologne, DE); G. De Backer (Ghent, BE)

- | | | |
|-------|--|-------------|
| 14:00 | A paradigm shift in cardiovascular health care? | 2683 |
| | – H. McGee (Dublin, IE) | |
| 14:22 | The Italian experience. | 2684 |
| | – D. Vannuzzo (Udine, IT) | |
| 14:44 | The Swiss experience. | 2685 |
| | – H. Saner (Berne, CH) | |
| 15:06 | The United Kingdom experience. | 2686 |
| | – D.A. Wood (London, GB) | |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



EUROPEAN FORUM FOR CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE - FROM GUIDELINES TO EFFECTIVE ACTION

Symposium
Webcast

Chairperson(s): I.M. Graham (Dublin, IE); L. Ryden (Stockholm, SE)

- | | | |
|-------|--|-------------|
| 16:30 | Welcome. | 2687 |
| | – I.M. Graham (Dublin, IE) | |
| 16:35 | Barriers to implementation. | 2688 |
| | – I.M. Graham (Dublin, IE) | |
| 16:50 | Political alliances and engagement - prerequisites for success. | 2689 |
| | – L. Ryden, S. Logstrup (Stockholm, SE; Brussels, BE) | |
| 17:05 | Factors influencing physician and patient behaviour. | 2690 |
| | – C. Albus (Cologne, DE) | |
| 17:20 | A national plan for cardiovascular disease prevention. | 2691 |
| | – C. Erol (Ankara, TR) | |
| 17:35 | The 'Call for Action': putting strategy into practice. | 2692 |
| | – G. De Backer (Ghent, BE) | |
| 17:55 | Concluding remarks - practical take home messages. | 2693 |
| | – L. Ryden (Stockholm, SE) | |

CLINICAL TRIAL UPDATE II

Clinical Trial Update

Chairperson(s): A.G. Fraser (Cardiff, GB); C. Yancy (Dallas, US)



14:00	The Risk of Cardiovascular Event for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial.	2694
	– M. O'Donoghue (Boston, US)	
14:10	Discussant.	2695
	– K. Huber (Vienna, AT)	
14:15	Effect of rosiglitazone on coronary events in the RECORD study.	2696
	– J.J.V. McMurray (Glasgow, GB)	
14:25	Discussant.	2697
	– B. Charbonnel (Nantes, FR)	
14:30	Effect of ivabradine on cardiovascular outcomes in patients with stable CAD and LV dysfunction with limiting angina: a subgroup analysis of the BEAUTIFUL trial.	2698
	– R. Ferrari (Ferrara, IT)	
14:40	Discussant.	2699
	– G. Heusch (Essen, DE)	
14:45	Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older. JUPITER.	2700
	– R. Glynn (Boston, US)	
14:55	Discussant.	2701
	– P.G. Steg (Paris, FR)	
15:00	International impact of atherothrombotic vascular disease and events: 3-year data from the REACH Registry.	2702
	– M. Alberts (Chicago, US)	
15:10	Discussant.	2703
	– N. Danchin (Paris, FR)	
15:15	Nonfasting cholesterol and triglycerides, myocardial infarction, and early death. Copenhagen City Heart.	2704
	– B.G. Nordestgaard (Herlev, DK)	
15:25	Discussant.	2705
	– V. Fuster (New York, US)	

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



**THE NEW ESC GUIDELINES ON
PREOPERATIVE CARDIAC RISK ASSESSMENT
AND PERIOPERATIVE CARDIAC MANAGEMENT
IN NON-CARDIAC SURGERY**

Clinical Seminar



Chairperson(s): R.J.C. Hall (Norwich, GB); J.L. Lopez-Sendon (Madrid, ES)
The Committee for Practice Guidelines

16:30	An outline of the new guidelines.	2706
	– D. Poldermans (Rotterdam, NL)	
16:48	The ACC/AHA Guidelines for perioperative cardiac management in non-cardiac surgery.	2707
	– S. Smith (Chapel Hill, US)	
17:06	Perioperative beta-blockers.	2708
	– B. Lung (Paris, FR)	
17:24	Perioperative statins.	2709
	– H. Sillesen (Copenhagen, DK)	
17:42	Perioperative anti-platelet therapy after coronary artery stenting.	2710
	– E. Eckhout (Lausanne, CH)	



GENOME-WIDE STUDIES IN CARDIOVASCULAR DISEASE - HAS THE PROMISE BEEN FULFILLED? **Symposium**

Chairperson(s): J.T. Salonen (Kuopio, FI); A. Hingorani (London, GB)

- | | | |
|-------|--|------|
| 14:00 | Genome-wide studies at the Sanger Institute.
– P. Deloukas (Cambridge, GB) | 2711 |
| 14:22 | New insights from the cardiogenics.
– F. Cambien (Paris, FR) | 2712 |
| 14:44 | The ARIC, MESA and GENOA studies.
– To be announced | 2713 |
| 15:06 | Genome-wide association studies in coronary artery disease: promises and problems.
– N. Samani (Leicester, GB) | 2714 |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



LA DOLCE VITA: WHAT EVERY CARDIOLOGIST WANTS TO KNOW ABOUT EATING, DRINKING AND BEING ACTIVE **Symposium**

Webcast

Chairperson(s): J.T. Salonen (Kuopio, FI); A. Cohen-Solal (Paris, FR)

- | | | |
|-------|---|------|
| 16:30 | Olive oil, berries and chocolate.
– M. De Lorgeril (La Tronche, FR) | 2715 |
| 16:52 | Grain, grape or potato.
– P. Sleight (Oxford, GB) | 2716 |
| 17:14 | Hop, skip or jump.
– P. Doherty (York, GB) | 2717 |
| 17:36 | I did it my way.
– To be announced | 2718 |

No session

- 15:30–18:00 **CONGENITAL HEART MALFORMATIONS: CONGENITALLY CORRECTED TRANSPOSITION OF THE HEART ARTERY**
Chairperson(s): A. Bozio (Lyon, FR); S.Y. Ho (London, GB)
Discussants from WG17 and WG22/AEPC
- 15:45 **Live-video demonstration.** 2719
– A. Angelini (Padua, IT)
- 16:45 **Hands-on specimen demonstration.** 2720

14:00–15:30

**PITFALLS IN INTERPRETING THE
ELECTROCARDIOGRAM**

FOCUS Session

Chairperson(s): J. Brugada Terradellas (Barcelona, ES); A.R. Perez Riera (Sao Paulo, BR)

ECG case discussions. 2721

ECG case discussions. 2722

ECG case discussions. 2723

Panel. 2724

– M. Borggreffe (Mannheim, DE), P. Brugada Terradellas (Brussels, BE), J.L.R.M. Smeets (Nijmegen, NL)



15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

16:30–18:00

**PERCUTANEOUS CORONARY INTERVENTIONS
IN PATIENTS WITH MULTIVESSEL DISEASE. LIVE
FROM BARCELONA**

FOCUS Session

LIVE

Chairperson(s): J. Fajadet (Toulouse, FR); D. de Canniere (Brussels, BE)
In collaboration with EuroPCR-EAPCI

Learning objectives. 2725

Live case presentation. 2726

How to integrate the results of randomized control trials in daily practice. 2727

Role of FFR in decision making. 2728

Live case interventionist in the University Hospital De Sant Pau, Barcelona. 2729

– M. Sabate Tenas (Barcelona, ES)

Panel. 2730

– E. Buszman (Katowice, PL), M. Haude (Neuss, DE), G. Pavlides (Athens, GR),
M.R. Thomas (London, GB)



MONDAY
PM

14:00–15:30

REVASCULARISING THE DIABETIC PATIENT

FOCUS Session

Chairperson(s): N. Curzen (Southampton, GB); B. De Bruyne (Aalst, BE)
In collaboration with EuroPCR-EAPCI



A middle aged patient with stable angina and multivessel disease: PCI or surgery? 2731

The diabetic undergoing primary PCI for ST-elevation MI: should treatment be different? 2732

Diabetic control: an important part of a successful revascularisation strategy? 2733

Panel. 2734

– A.H. Gershlick (Leicester, GB), A. Kapur (London, GB), G. Montalescot (Paris, FR)



15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

16:30–18:00

ENDOCARDITIS: APPLYING THE NEW GUIDELINES

FOCUS Session

Chairperson(s): G. Habib (Marseille, FR); L.C. Mueller (Innsbruck, AT)

Webcast



Infective endocarditis associated with neurological complication. 2735

Pacemaker lead infective endocarditis. 2736

Prosthetic valve infective endocarditis. 2737

Panel. 2738

– C. Naber (Essen, DE), B.D. Prendergast (Oxford, GB), F. Thuny (Marseille, FR)

MONDAY
PM





ESC GEOFFREY ROSE LECTURE ON POPULATION SCIENCES

ESC Lecture

Chairperson(s): J. Waltenberger (Maastricht, NL); P. Giannuzzi (Veruno, IT)

- 14:00 **Announcement by the chairpersons.** 2739
 14:01 **Presentation of the awardee.** 2740
 – P. Giannuzzi (Veruno, IT)

- 14:05 **Cardiovascular disease prevention in Europe - challenges and possible solutions.** 2741
 – L. Ryden (Stockholm, SE)

- 14:29 **Diploma by the chairpersons.** 2742



ESC RENE LAENNEC LECTURE ON CLINICAL CARDIOLOGY

ESC Lecture

Chairperson(s): J. Waltenberger (Maastricht, NL); P. Giannuzzi (Veruno, IT)

- 14:30 **Announcement by the chairpersons.** 2743
 14:31 **Presentation of the awardee.** 2744
 – J.L. Zamorano Gomez (Madrid, ES)

- 14:35 **The clinical cardiologist: doomed for extinction or survival through evolution?** 2745
 – J.L. Lopez-Sendon (Madrid, ES)

- 14:59 **Diploma by the chairpersons.** 2746

ESC PHILIP POOLE-WILSON LECTURE ON HEART FAILURE

ESC Lecture

Chairperson(s): J. Waltenberger (Maastricht, NL); P. Giannuzzi (Veruno, IT)

- 15:00 **Introduction.** 2747
 – K.M. Fox (London, GB)

- 15:05 **ESC Philip Poole-Wilson Lecture on Heart Failure.** 2748
 – R. Ferrari (Ferrara, IT)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**



ESC/ESH HYPERTENSION GUIDELINES - WHAT IS NEW IN 2009?

Main Session



Chairperson(s): S.E. Erdine (Istanbul, TR); S. Laurent (Paris, FR)
The European Society of Cardiology and the European Society of Hypertension

- 16:30 **What's new?** 2749
 – G. Mancia (Monza, IT)
- 16:52 **Children and adolescents.** 2750
 – E. Lurbe (Valencia, ES)
- 17:14 **Metabolic risk management.** 2751
 – A.J. Manolis (Athens, GR)
- 17:36 **Blood pressure management.** 2752
 – S.E. Kjeldsen (Oslo, NO)

GENDER DIFFERENCES IN ACUTE CORONARY SYNDROMES **Clinical Seminar**

Chairperson(s): T. Simon (Paris, FR); A.S. Hall (Leeds, GB)

- 14:00 **Pathophysiological mechanisms.** **2753**
– F. Andreotti (Rome, IT)
- 14:22 **Risk factors.** **2754**
– H. Tunstall-Pedoe (Dundee, GB)
- 14:44 **Outcome.** **2755**
– E. Swahn (Linköping, SE)
- 15:06 **A different treatment?** **2756**
– V. Vaccarino (Atlanta, US)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



ASSESSING CORONARY MICROVASCULAR DYSFUNCTION: CLINICAL RELEVANCE

Symposium

Chairperson(s): M. Weis (Munich, DE); R. Bugiardini (Bologna, IT)

- 16:30 **Why should cardiologists care for microvascular dysfunction?** **2757**
– A.R. Pries (Berlin, DE)
- 16:52 **Non-invasive assessment of microvascular dysfunction.** **2758**
– P.G. Camici (London, GB)
- 17:14 **Invasive assessment of microvascular dysfunction.** **2759**
– C. Stefanadis (Athens, GR)
- 17:36 **Clinical relevance.** **2760**
– J.C. Kaski (London, GB)



BIOMARKERS, GENES AND METRICS IN HEART FAILURE

Abstracts

Chairperson(s): U. Laufs (Homburg, DE); D.J. van Veldhuisen (Groningen, NL)

- 14:00 **Myocardial gene expression in peripheral blood of patients with idiopathic dilated cardiomyopathy is associated with myocardial function.** 2761
 – J.E. Kontarakis, A.P. Patrianakos, F.I. Parthenakis, E.G. Nyktari, P.E. Vardas (Heraklion, GR)
- 14:15 **Early changes in intrathoracic impedance and right ventricular pressures in patients predict minor and major heart failure decompensation.** 2762
 – F. Braunschweig, M. Vanderheyden, S. Verstreken, M. Stahlberg, P. Reiters, R. Kessels, R. Houben (Stockholm, SE; Aalst, BE; Maastricht, NL)
- 14:30 **Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.** 2763
 – S. Teichman, E. Unemori, M. Metra, J.R. Teerlink, A.A. Voors, G.M. Felker, P. Ponikowski, B. Weatherley, G. Filippatos, G. Cotter (San Mateo, San Francisco and Durham, US; Brescia, IT; Groningen, NL; Wroclaw, PL; Athens, GR)
- 14:45 **Cystatin C as a marker of acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome.** 2764
 – J.P.E. Lassus, M.S. Nieminen, K. Peuhkurinen, K. Pulkki, K. Siirila-Waris, R. Sund, V.-P. Harjola (Helsinki and Kuopio, FI)
- 15:00 **Telomere length is an independent risk factor for anaemia in patients with chronic heart failure.** 2765
 – L.S.M. Wong, J. Huzen, P. Van Der Harst, R.A. De Boer, G.F.J.D. Benus, A.A. Voors, W.H. Van Gilst, N.J. Samani, T. Jaarsma, D.J. Van Veldhuisen (Groningen, NL; Leicester, GB)
- 15:15 **Hand-held echocardiography in primary care patients with heart failure and heart failure risk factors.** 2766
 – M. Lipczynska, P. Szymanski, A. Klisiewicz, P. Hoffman (Warsaw, PL)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**



DEFINING RISK IN HEART FAILURE SUBSETS

Abstracts

Chairperson(s): R. Latini (Milan, IT); L. Kober (Gentofte, DK)

- 16:30 **Predictors of plasma renin activity, a main prognostic determinant in systolic heart failure.** 2767
 – G. Vergaro, A.L. Iervasi, A. Valleggi, M. Fontana, A. Giannoni, R. Poletti, C. Passino, L.E. Pastormerlo, M. Emdin (Pisa, IT)
- 16:45 **The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders.** 2768
 – L. Frankenstein, B. Remppis, M. Nelles, D. Schellberg, H. Hees, A. Schmidt, H. Katus, C. Zugck (Heidelberg, DE)
- 17:00 **Delayed mortality in peripartum cardiomyopathy indicates need for long-term follow up.** 2769
 – K. Sliwa, O. Forster, K. Tibazarwa, E. Libhaber, A. Becker, A. Yip, D. Hilfiker-Kleiner (Johannesburg and Cape Town, ZA; Hannover, DE)
- 17:15 **Predictive value of N-terminal pro-B-type natriuretic peptide and echocardiographic parameters in patients with peripartum cardiomyopathy.** 2770
 – M. Biteker, N. Duran, H. Kaya, M. Yildiz, T. Gokdeniz, S. Gunduz, I.H. Tanboga, G. Kahveci, T. Akgun, M. Ozkan (Istanbul, TR)
- 17:30 **Mid-region pro-atrial natriuretic peptide and the diagnosis of heart failure in the setting of atrial fibrillation: an exploratory analysis of the biomarkers in acute heart failure (BACH) trial.** 2771
 – K. Singh, N. Parekh, I. Anand, L. Daniels, S. Di Somma, G. Filippatos, C. Mueller, R. Nowak, S. Anker, A. Maisel (San Diego, Minneapolis and Detroit, US; Rome, IT; Athens, GR; Basel, CH; Berlin, DE)
- 17:45 **A score system to predict outcome after mitral valve repair in patients with heart failure.** 2772
 – A. Chrustowicz, K. Matschke, A. Gackowski, R.H. Strasser, G. Simonis (Krakow, PL; Dresden, DE)



NON-INVASIVE RISK ASSESSMENT FOR SUDDEN CARDIAC DEATH: ARE THERE NEW OPPORTUNITIES? Abstracts

Chairperson(s): A. Oto (Ankara, TR); A. Erglis (Riga, LV)

- 14:00 **Holter-based risk stratification in elderly patients with congestive heart failure.** 2773
 – I. Cygankiewicz, W. Zareba, R. Vaquez, A. Bayes-Genis, A. Bardaji, J. Almendral, J.R. Gonzalez Juanatey, V. Nieto, J. Cinca, A. Bayes De Luna (Barcelona, Seville, Tarragona, Madrid, Santiago De Compostela and Las Palmas de Gran Canaria, ES; Rochester, US)
- 14:15 **Non-invasive Wedensky Modulation of T- & RT-wave accurately predicts arrhythmic events.** 2774
 – P.A. Brady, P. Erne, J. Val-Mejias, J. Schwab, R. Schimpf, M. Orlov, T. Mattioni, M. Malik, J. Amlie (Rochester, Wichita, Boston and Scottsdale, US; Lucerne, CH; Bonn and Mannheim, DE; London, GB; Oslo, NO)
- 14:30 **Distribution of microvolt T wave alternans in a general population of patients undergoing a clinically indicated exercise ECG.** 2775
 – C. Cohen, M. Tafflet, P. Jourdain, P. Bareiss, M. Chauvin, G. Roul (Strasbourg, Villejuif and Pontoise, FR)
- 14:45 **Heart rate variability predicts arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy.** 2776
 – P. Santangeli, A. Macchione, F. Marzo, A. Dello Russo, M. Casella, G. Pelargonio, F. Bellocchi, M. Pieroni, G.A. Lanza, F. Crea (Rome, IT)
- 15:00 **Value for paced QRS duration to detect left ventricular dysfunction.** 2777
 – Y.G. Su, W.Z. Pan, X. Gong, X.H. Shu, J.B. Ge (Shanghai, CN)
- 15:15 **Prognostic value of short-term ECG monitoring in patients with congestive heart failure.** 2778
 – I. Cygankiewicz, W. Zareba, R. Vazquez, A. Bayes-Genis, M. Fiol, M. Valdes, J. Cinca, A. Bayes De Luna (Barcelona, Seville, Palma de Mallorca and Murcia, ES; Rochester, US)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**

DRUGS FOR ATRIAL FIBRILLATION: A CONTINUING EFFORT Abstracts

Chairperson(s): P. Raatikainen (Oulu, FI); I. Savelieva (London, GB)

- 16:30 **Effects of dronedarone on clinical outcomes in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA study.** 2779
 – H.J.G.M. Crijns, S.J. Connolly, C. Gaudin, M. Van Eickels, R.L. Page, C. Torp-Pedersen, S.H. Hohnloser (Maastricht, NL; Hamilton, CA; Paris, FR; Frankfurt Am Main, DE; Seattle, US; Hellerup, DK)
- 16:45 **Oral vernakalant for the prevention of atrial fibrillation recurrence post-cardioversion.** 2780
 – C. Torp-Pedersen, Y. Karpenko, D. Raev, J. Kaik, G. Dickinson, B. Mangal, G.N. Beatch (Hellerup, DK; Odessa, UA; Sofia, BG; Haabneeme, EE; Vancouver, CA)
- 17:00 **Impact of dronedarone on hospitalization for atrial fibrillation: insights from ATHENA.** 2781
 – R.L. Page, H.J.G.M. Crijns, S.J. Connolly, C. Gaudin, M. Van Eickels, C. Torp-Petersen, S.J. Hohnloser (Seattle, US; Maastricht, NL; Hamilton, CA; Frankfurt Am Main, DE; Hellerup, DK)
- 17:15 **Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials.** 2782
 – K. Rahimi, J. Emberson, P. Mcgale, W. Majoni, A. Merhi, F. Asselberg, P.W. Macfarlane, C. Wanner, J. Armitage, C. Baigent (Oxford and Glasgow, GB; Groningen, NL; Wurzburg, DE)
- 17:30 **Beneficial effect of atorvastatin in patients with recurrent atrial fibrillation and ischemic heart failure with preserved systolic function.** 2783
 – Y.M. Lopatin, E.E. Kozlova, E.E. Galaktionova, F.A. Nemchuk (Volgograd, RU)
- 17:45 **How safe is flecainide treatment in clinical practice? Long-term incidence of sudden death and proarrhythmic events in an unselected group of patients with lone AF.** 2784
 – H. Almroth, T. Andersson, P. Linde, E. Fengsrud, A. Englund (Orebro, SE)



CARDIAC RESYNCHRONISATION THERAPY: BEYOND THE GUIDELINES

Symposium



Chairperson(s): J.C. Daubert (Rennes, FR); P.P. Adragao (Carnaxide, PT)

- | | | |
|-------|---|------|
| 14:00 | Cardiac resynchronisation therapy in patients with mild heart failure.
– C. Linde (Stockholm, SE) | 2785 |
| 14:22 | Cardiac resynchronisation therapy in heart failure patients with atrial fibrillation.
– A. Auricchio (Lugano, CH) | 2786 |
| 14:44 | Left-ventricular based pacing for bradycardia.
– E. Simantirakis (Heraklion, GR) | 2787 |
| 15:06 | Upgrading conventional pacing to biventricular pacing.
– L. Mont (Barcelona, ES) | 2788 |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

CARDIAC RESYNCHRONISATION THERAPY: DOES EVOLVING TECHNOLOGY ENHANCE EFFICIENCY?

Clinical Seminar

Chairperson(s): M. Gasparini (Rozzano, IT); C.M. Yu (Hong Kong, HK)

- | | | |
|-------|--|------|
| 16:30 | New imaging techniques to improve patient selection.
– G.R. Sutherland (London, GB) | 2789 |
| 16:52 | Tools for coronary sinus cannulation: better facilities for improved results.
– C. Leclercq (Rennes, FR) | 2790 |
| 17:14 | Devices incorporated algorithms to optimise the outcome.
– P. Ritter (Pessac, FR) | 2791 |
| 17:36 | Follow up and solving technical issues.
– H.-F. Tse (Hong Kong, HK) | 2792 |

DILEMMAS IN THE USE OF CARDIAC RHYTHM MANAGEMENT DEVICES

Debate

Chairperson(s): R.N.W. Hauer (Utrecht, NL); E. Aliot (Vandoeuvre-les-Nancy, FR)

Ventricular tachycardia ablation has the potential to eliminate the need for an implantable cardioverter-defibrillator in patients with stable ventricular tachycardia.

14:00	Pro. – V.Y. Reddy (Miami, US)	2793
14:15	Contra. – H.U. Klein (Rochester, US)	2794
	Rebuttal.	
14:30	Pro. – V.Y. Reddy (Miami, US)	2795
14:35	Contra. – H.U. Klein (Rochester, US)	2796
14:40	Conclusion.	2797
	Every cardiac rhythm managing device should provide remote monitoring.	
14:45	Pro. – A.P. Fitzpatrick (Manchester, GB)	2798
15:00	Contra. – N.A. Sulke (Eastbourne, GB)	2799
	Rebuttal.	
15:15	Pro. – A.P. Fitzpatrick (Manchester, GB)	2800
15:20	Contra. – N.A. Sulke (Eastbourne, GB)	2801
15:25	Conclusion.	2802

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

HIGHLIGHTS OF THE EUROPEAN HEART RHYTHM ASSOCIATION'S CONSENSUS DOCUMENTS

Symposium

Chairperson(s): A. Auricchio (Lugano, CH); A. Moya I Mitjans (Barcelona, ES)

16:30	Catheter ablation of ventricular arrhythmias. – E. Aliot (Vandoeuvre-les-Nancy, FR)	2803
16:52	Implantable cardioverter-defibrillators and driving. – J. Vijgen (Hasselt, BE)	2804
17:14	Indications and use of implantable and non-implantable electrocardiogram loop recorders. – M. Brignole (Lavagna, IT)	2805
17:36	Imaging in electrophysiology. – C. Blomstrom-Lundqvist (Uppsala, SE)	2806



THE 12-LEAD ELECTROCARDIOGRAM: THE CRYSTAL BALL IN INHERITED DISEASES? **Clinical Seminar**

Chairperson(s): H.J. Wellens (Maastricht, NL); J. Farre (Madrid, ES)

- 14:00 **Hypertrophic cardiomyopathy.** **2807**
– M. Glikson (Ramat Gan, IL)
- 14:22 **Arrhythmogenic right ventricular cardiomyopathy.** **2808**
– T. Wichter (Osnabrueck, DE)
- 14:44 **Channelopathies.** **2809**
– R. Schimpf (Mannheim, DE)
- 15:06 **Ischaemic heart disease.** **2810**
– D.V. Cokkinos (Athens, GR)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

PATIENTS' PERSPECTIVES AND HEALTH CARE SYSTEMS IN EUROPE **Clinical Seminar**

Chairperson(s): R. Cappato (San Donato Milanese, IT); J. Hradec (Prague, CZ)

- 16:30 **Distributing the limited health care resources.** **2811**
– N. Maniadakis (Piraeus, GR)
- 16:52 **Lowering disease-related costs with prevention.** **2812**
– M.J. Schalij (Leiden, NL)
- 17:14 **Involving patients in decision-making.** **2813**
– T. Lobban (Stratford Upon Avon, US)
- 17:36 **Health care systems: the doctor's view.** **2814**
– P. Brugada Terradellas (Brussels, BE)



NOVEL TREATMENTS FOR STABLE ANGINA: FROM OLD DRUGS TO STEM CELLS

Abstracts

Chairperson(s): F. Crea (Rome, IT); C. Daly (Dublin, IE)

- 14:00 **High dose allopurinol prolongs total exercise time and time to exercise induced ischaemia in chronic stable angina.** **2815**
 – A. Noman, D. Ang, C.C. Lang, A.D. Struthers (Dundee, GB)
- 14:15 **Autologous mesenchymal stromal cell-derived endothelial progenitors therapy to improve vascularisation and symptoms in patients with chronic coronary artery disease.** **2816**
 – J. Kastrup, T. Friis, M. Haack-Soerensen, R.S. Ripa, U.S. Kristoffersen, A.B. Mathiasen, B. Hesse, A. Kjaer, E. Dickmeiss, E. Joergensen (Copenhagen, DK)
- 14:30 **Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease.** **2817**
 – Y. Minami, M. Satoh, T. Tabuchi, Y. Takahashi, T. Itoh, M. Nakamura (Morioka, JP)
- 14:45 **Direct evidence for therapeutic induction of arteriogenesis in patients with stable angina pectoris via external counterpulsation: a prospective controlled proof of concept trial.** **2818**
 – E. Buschmann, N. Pagonas, W. Utz, J. Schulz-Menger, A. Busjahn, L. Thierfelder, R. Dietz, V. Klauss, M. Gross, I. Buschmann (Berlin and Munich, DE)
- 15:00 **Intramyocardial injection of bone marrow-derived mononuclear cells for chronic myocardial ischemia: a randomized, double-blind, placebo-controlled trial.** **2819**
 – J. Van Ramshorst, J.J. Bax, S.L.M.A. Beeres, P. Dibbets-Schneider, S.D. Roes, M.P.M. Stokkel, W.E. Fibbe, E. Boersma, M.J. Schalij, D.E. Atsma (Leiden, NL)
- 15:15 **Long-term effects of spinal cord stimulation in refractory angina pectoris - 3-year results from the European Angina Registry Link (EARL).** **2820**
 – A. J. Andrell, W. Yu, L. Gillberg, K. Pehrsson, A. Stahle, P. Gersbach, I. Hardy, C. Andersen, C. Mannheimer (Gothenburg, Stockholm and Kristianstad, SE; Lausanne, CH; Cambridge, GB; Odense, DK)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

ADJUNCTIVE THERAPY FOR CORONARY ARTERY DISEASE – Abstracts
WHAT IS HOT, WHAT IS NOT

Chairperson(s): J. Leor (Tel Hashomer, IL); M. Heras (Barcelona, ES)

- 16:30 **Ten years positive experience of long-term home self-treatment with thoracic epidural analgesia in patients with refractory angina pectoris: effects on angina, quality of life and exercise test.** **2821**
 – A. J. Richter, I. Cederholm, M. Fredrikson, P. Wodlin, M. Gjerde, C. Mucchiano, B. Janerot Sjöberg (Linköping and Eksjö, SE)
- 16:45 **Aborted myocardial infarction in i.c. compared with i.v. bolus abciximab application in patients with STEMI undergoing primary PCI.** **2822**
 – I. Eitel, G. Fuernau, M. Sareban, M. Gutberlet, G. Schuler, H. Thiele (Leipzig, DE)
- 17:00 **Routine use of Fondaparinux in acute coronary syndromes. A two year, multicentre experience and a comparison with Enoxaparin.** **2823**
 – F. Schiele, N. Meneveau, M.F. Seronde, V. Descotes-Genon, J. Dutheil, R. Chopard, J.P. Bassand (Besançon, FR)
- 17:15 **Ivabradine reduces angina pectoris in patients after PCI: a subgroup analysis from the REDUCTION-study.** **2824**
 – R. Koester, J. Kaehler, T. Meinertz (Hamburg, DE)
- 17:30 **Effects of nicorandil on cardiovascular events in patients with coronary artery disease from the Japanese Coronary Artery Disease (JCAD) study.** **2825**
 – S. Horinaka, A. Yabe, H. Yagi, H. Hara, H. Natsuoka, T. Yamazaki, S. Suzuki, T. Kohro, R. Nagai (Mibu and Tokyo, JP)
- 17:45 **Does intracoronary infusion of metabolic cytoprotectors immediately after blood flow restoration in the infarct-related artery influence the limitation of myocardial injury in AMI?** **2826**
 – D. Iosseliani, A. Koledinsky, D. Gromov, I. Topchian, O. Sukhorukov (Moscow, RU)



THE DIABETIC PLATELET – AN UNSOLVED PROBLEM **Clinical Seminar**

Chairperson(s): M.C. Alessi (Marseille, FR); S. Coccheri (Bologna, IT)

- 14:00 **Platelet function in diabetes.** **2827**
– A. Siegbahn (Uppsala, SE)
- 14:22 **Variable response to antiplatelet drugs in diabetes.** **2828**
– D.J. Angiolillo (Jacksonville, US)
- 14:44 **Should aspirin be given to all type 2 diabetic patients?** **2829**
– C. Patrono (Rome, IT)
- 15:06 **Advances in the prevention of atherothrombosis in diabetes.** **2830**
– F.W.A. Verheugt (Amsterdam, NL)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

THE UNMET CHALLENGE OF NO REFLOW **Clinical Seminar**

Chairperson(s): S. Janssens (Leuven, BE); S. Hiremath (Pune, IN)

- 16:30 **Mechanisms.** **2831**
– G. Niccoli (Rome, IT)
- 16:52 **Diagnosis.** **2832**
– R.A. Hernandez Antolin (Madrid, ES)
- 17:14 **Prevention.** **2833**
– A.W.J. Van 't Hof (Zwolle, NL)
- 17:36 **Treatment.** **2834**
– A.D. Kugelmass (Detroit, US)



NEWS AND VIEWS ON BETA-ADRENERGIC RECEPTORS Symposium

Chairperson(s): S.E. Harding (London, GB); D. Dobrev (Dresden, DE)

- 14:00 **Compartmentalisation of cardiac beta-adrenergic inotropy by nitric oxide.** 2835
– J.L. Balligand (Brussels, BE)
- 14:22 **Beta3-adrenergic receptor and myocardial neuronal nitric oxide synthase: two strange bedfellows?** 2836
– B. Casadei (Oxford, GB)
- 14:44 **New roles of GRK2 and GRK5 in the regulation of hypertrophy in vitro and in vivo.** 2837
– G. Iaccarino (Naples, IT)
- 15:06 **Cardiac reduction in STAT3 sensitises mice for heart failure under chronic beta-adrenergic stress.** 2838
– D. Hilfiker-Kleiner (Hannover, DE)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

- 15:40–16:10 **European Union research grant: how to write and apply?** 2839
– V. Dambrauskaite, B.M. Pieske, R. Laaksonen (Brussels, BE; Graz, AT; Espoo, FI)



THE ENIGMA OF CARDIAC REMODELLING: NEW VIEWPOINTS Symposium

Chairperson(s): C. Jacobshagen (Göttingen, DE); L.M. Goncalves (Coimbra, PT)

- 16:30 **Calcium regulation in the cardiac myocyte as signal for cellular remodelling.** 2840
– L.J. De Windt (Utrecht, NL)
- 16:52 **Phospholamban binding partners and myocyte survival.** 2841
– E.G. Kranias (Cincinnati, US)
- 17:14 **Metabolic remodelling: cardiac metabolism on a swing.** 2842
– M. Van Bilsen (Maastricht, NL)
- 17:36 **Post-infarct remodelling: the heart as a wound.** 2843
– G. Ertl (Wurzburg, DE)

CARDIOLOGICAL ISSUES IN HAEMATOLOGY

Symposium

Chairperson(s): P. Gallagher (Southampton, GB); S. Pankuweit (Marburg, DE)

- | | | |
|-------|--|-------------|
| 14:00 | Endomyocardial diseases. | 2844 |
| | – G. Thiene (Padua, IT) | |
| 14:22 | Amyloid heart disease. | 2845 |
| | – C. Rapezzi (Bologna, IT) | |
| 14:44 | Iron overload. | 2846 |
| | – D.T. Kremastinos (Athens, GR) | |
| 15:06 | Cardiomyopathies induced by ‘old’ and new chemotherapeutic drugs. | 2847 |
| | – P.M. Elliott (London, GB) | |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

TREATMENT OF RECURRENT PERICARDIAL EFFUSION

Symposium

Chairperson(s): I. Cikes (Zagreb, HR); Z.T. Bilinska (Warsaw, PL)

- | | | |
|-------|---|-------------|
| 16:30 | Treatment modalities in autoreactive and viral pericardial effusion. | 2848 |
| | – B. Maisch (Marburg, DE) | |
| 16:52 | Treatment with colchicine and corticosteroids in recurrent pericardial effusion. | 2849 |
| | – M. Imazio (Turin, IT) | |
| 17:14 | Management of recurrent or persistent tuberculous pericardial effusion. | 2850 |
| | – B.M. Mayosi (Cape Town, ZA) | |
| 17:36 | Treatment of recurrent malignant pericardial effusion. | 2851 |
| | – A.D. Ristic (Belgrade, RS) | |

TRANSCATHETER AORTIC VALVE IMPLANTATION

Symposium

Chairperson(s): V. Gama Ribeiro (Vila Nova De Gaia, PT); M. Jahangiri (London, GB)

- 14:00 **Results from the 'gold standard'.** 2852
– N. Al-Attar (Paris, FR)
- 14:22 **Building a programme.** 2853
– G.C. Schuler (Leipzig, DE)
- 14:44 **The rationale for team work.** 2854
– F. Maisano (Milan, IT)
- 15:06 **Time has come for a 'SYNTAX' like trial.** 2855
– A.P. Kappetein (Rotterdam, NL)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

THE SYNTAX TRIAL: ONE YEAR ON

Clinical Seminar

Chairperson(s): M. Sousa Uva (Lisbon, PT); A. Colombo (Milan, IT)

- 16:30 **The view of the non-interventional cardiologist.** 2856
– S. Yusuf (Hamilton, CA)
- 16:52 **SYNTAX re-analysed one year through.** 2857
– F.W. Mohr (Leipzig, DE)
- 17:14 **Conclusions from subgroups.** 2858
– A.P. Kappetein (Rotterdam, NL)
- 17:36 **The patient has the right to know.** 2859
– D. Taggart (Oxford, GB)

ECHOCARDIOGRAPHIC ASSESSMENT OF MECHANICS IN VALVE DISEASE

Abstracts

Chairperson(s): J. Bermejo (Madrid, ES); A. Chenzbraun (Liverpool, GB)

- 14:00 **Impact of net atrioventricular compliance on left atrial systolic function after mitral valve replacement.** **2860**
 – A. Tugcu, Y. Tayyareci, O. Yildirimturk, V. Aytakin, I.C.C. Demiroglu, S. Aytakin (Istanbul, TR)
- 14:15 **The impact of myocardial fibrosis on regional myocardial function and clinical outcome in patients with low gradient aortic valve stenosis.** **2861**
 – S.H. Herrmann, J.S. Strotmann, M.N. Niemann, V.L. Lange, M.B. Beer, S.G. Gattenloehner, W.V. Voelker, G.E. Ertl, F.W. Weidemann (Wurzburg and Kiel, DE)
- 14:30 **Left ventricular torsion in patients with aortic stenosis, normal ejection fraction and diastolic dysfunction.** **2862**
 – A. Calin, C.C. Beladan, B.A. Popescu, M. Rosca, D. Muraru, D. Deleanu, F. Antonini-Canterin, G.L. Nicolosi, C. Gingham (Bucharest, RO; Pordenone, IT)
- 14:45 **Myocardial contractile reserve detected by dobutamine stress tissue Doppler imaging as a preoperative determinant of outcome after valve replacement in chronic mitral regurgitation.** **2863**
 – H. Badran, S. Shalaby, A. Serag, H. Hassan, A. Barbary (Shebin, EG)
- 15:00 **Resting left ventricular longitudinal function predicts exercise pulmonary hypertension in organic mitral regurgitation.** **2864**
 – J. Magne, M. Moonen, K. O'Connor, L.A. Piérard, P. Lancellotti (Liège, BE)
- 15:15 **Left ventricular untwisting on exercise is impaired in advanced chronic mitral regurgitation - a possible mechanism for exercise intolerance.** **2865**
 – R.A. Argyle, R.P. Beynon, R. Aghamohammadzadeh, K.A. Pearce, A.N. Borg, S.G. Ray (Manchester and Blackpool, GB)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

ECHO: A RELIABLE TOOL TO ASSESS CORONARY FLOW RESERVE?!

Abstracts

Chairperson(s): P. Colonna (Bari, IT); J.R.T.C. Roelandt (Rotterdam, NL)

- 16:30 **Coronary flow reserve in the functional assessment of coronary artery stenosis: a head-to-head comparison between high resolution echocardiography and gated single photon emission computed tomography.** **2866**
 – L. Ferrara, M. Damiano, C. De Simone, A. D'Errico, P. Gallo, M. Sidiropoulos, C. Mita, A. Cacace, V. Tedeschi, P. Guarini (Naples, IT)
- 16:45 **Multiparametric prognostic score for patients undergoing dipyridamole stress echocardiography with combined assessment of coronary flow reserve on left anterior descending artery.** **2867**
 – L. Cortigiani, D. Gregori, F. Rigo, S. Gherardi, M. Galderisi, F. Bovenzi, E. Picano, R. Sicari (Lucca, Turin, Mestre, Cesena, Milan and Pisa, IT)
- 17:00 **Effect of coronary calcification on coronary flow velocity reserve in mild - moderate coronary artery disease.** **2868**
 – D. Tsiapras, I. Mastorakou, V. Vartela, O. Karapanagiotou, S. Kyzopoulos, S. Katsilouli, V. Voudris (Athens, GR)
- 17:15 **Determinants of non invasive coronary flow reserve early after successful primary angioplasty for acute anterior myocardial infarction and their relationship to left ventricular function at follow-up.** **2869**
 – P. Meimoun, D. Malaquin, T. Benali, S. Sayah, H. Zehir, J. Boulanger, A. Luyck-Bore, L. Doutrelan, C. Tribouilloy (Compiègne and Amiens, FR)
- 17:30 **The effect of hypoglycaemia on myocardial blood flow reserve and endothelin-1 levels in healthy non-diabetic subjects using myocardial contrast echocardiography.** **2870**
 – O.A. Rana, S. Zouwail, J. Begley, D. Kerr, D.V. Coppini, R. Senior, K. Greaves (Poole, Bournemouth and Harrow, GB)
- 17:45 **Coronary flow reserve at the right coronary artery stenosis using transthoracic Doppler echocardiography.** **2871**
 – A. Boshchenko, A. Vrublevsky, R. Karpov (Tomsk, RU)



ENDOTHELIAL FUNCTION FROM BENCH TO BEDSIDE

Symposium

Chairperson(s): G. Ambrosio (Perugia, IT); A. Koller (Valhalla, US)

- | | | |
|-------|--|-------------|
| 14:00 | Biology of the endothelium.
– T.F. Luescher (Zurich, CH) | 2872 |
| 14:22 | Blood cell - endothelium interaction.
– C. Kupatt (Munich, DE) | 2873 |
| 14:44 | Coronary and peripheral endothelial dysfunction.
– V. Schaechinger (Fulda, DE) | 2874 |
| 15:06 | Reversing endothelial dysfunction.
– G. Mercurio (Monserrato, IT) | 2875 |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)

NON-INDUSTRY SPONSORING OF CARDIOVASCULAR TRIALS

Symposium

Chairperson(s): M. Jessup (Philadelphia, US); A.P. Maggioni (Florence, IT)

- | | | |
|-------|--|-------------|
| 16:30 | Clinical cardiovascular drug research under the EU Research Framework Programmes - what can be expected?
– M. Wehling (Mannheim, DE) | 2876 |
| 16:52 | National Heart Lung and Blood Institute cardiovascular drug trials - future directions?
– T.J. Gardner (Wilmington, US) | 2877 |
| 17:14 | Are industry-sponsored trials more frequently positive and more widely cited?
– L.C. Wallentin (Uppsala, SE) | 2878 |
| 17:36 | Is the implementation of the results of non-industry sponsored studies more difficult?
– L. Tavazzi (Cotignola, IT) | 2879 |



**EMERGING IMAGING FOR CHARACTERISING
VULNERABLE ATHEROSCLEROTIC PLAQUES**

Symposium

Chairperson(s): L. Hofstra (Maastricht, NL); J.H.F. Rudd (Cambridge, GB)

- | | | |
|-------|--|-------------|
| 14:00 | Histological insight to vulnerable plaque.
– E. Falk (Aarhus, DK) | 2880 |
| 14:18 | Invasive imaging of vulnerable plaques.
– T. Akasaka (Wakayama, JP) | 2881 |
| 14:36 | Magnetic resonance imaging: in vivo imaging of non-coronary atherosclerosis.
– S. Mavrogeni (Athens, GR) | 2882 |
| 14:54 | Imaging of vulnerable plaques: the role of computed tomography angiography.
– J. Narula (Orange, US) | 2883 |
| 15:12 | Molecular imaging - closing the gaps between anatomy and biology.
– J.D. Thomas (Cleveland, US) | 2884 |

**15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts,
Meet the Trialist & Hands-on Tutorials)**

**THE DETECTION OF MYOCARDIAL OEDEMA. READY FOR
CLINICIANS?** **Symposium**

Chairperson(s): M. Lombardi (Pisa, IT); A.M.G. Almeida (Lisbon, PT)

- | | | |
|-------|--|-------------|
| 16:30 | How can we detect myocardial oedema?
– C. Bucciarelli Ducci (London, GB) | 2885 |
| 16:52 | Is the detection of myocardial oedema feasible in the acute phase?
– H. Abdel-Aty (Berlin, DE) | 2886 |
| 17:14 | Myocardial oedema and the infarct size.
– A. Aletras (Bethesda, US) | 2887 |
| 17:36 | Ischaemic and non-ischaemic oedema.
– H. Mahrholdt (Stuttgart, DE) | 2888 |

**IS MEDICAL TREATMENT FOR PULMONARY ARTERIAL
HYPERTENSION REALLY EFFECTIVE?**

Debate

Chairperson(s): J.S. Russell Gibbs (London, GB); L. Tavazzi (Cotignola, IT)

Endothelin receptor antagonist is better than phosphodiesterase type 5 inhibition as first line therapy.

- | | | |
|-------|---|-------------|
| 14:00 | Pro.
– G. Simonneau (Clamart, FR) | 2889 |
| 14:15 | Contra.
– H.A. Ghofrani (Giessen, DE) | 2890 |
| | Rebuttal. | |
| 14:30 | Pro.
– G. Simonneau (Clamart, FR) | 2891 |
| 14:35 | Contra.
– H.A. Ghofrani (Giessen, DE) | 2892 |
| 14:40 | Conclusion. | 2893 |
| | Survival is not improved by medical therapy. | |
| 14:45 | Pro.
– A. Macchia (Buenos Aires, AR) | 2894 |
| 15:00 | Contra.
– N. Galie (Bologna, IT) | 2895 |
| | Rebuttal. | |
| 15:15 | Pro.
– A. Macchia (Buenos Aires, AR) | 2896 |
| 15:20 | Contra.
– N. Galie (Bologna, IT) | 2897 |
| 15:25 | Conclusion. | 2898 |

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



ULTRASOUND-DIRECTED GENE AND DRUG THERAPY

Symposium

Chairperson(s): A. DeMaria (San Diego, US); R. Senior (Harrow, GB)

- | | | |
|-------|---|-------------|
| 16:30 | Targeted imaging with microbubbles.
– B. Kaufmann (Basel, CH) | 2899 |
| 16:52 | Ultrasound-directed, site-specific drug/gene delivery systems.
– S.B. Feinstein (Chicago, US) | 2900 |
| 17:14 | Sonolysis in myocardial infarction.
– O. Kamp (Amsterdam, NL) | 2901 |
| 17:36 | Angiogenesis in refractory angina pectoris.
– R. Erbel (Essen, DE) | 2902 |



IMMUNE CELL TRAFFICKING AT THE VASCULAR WALL Symposium

Chairperson(s): C. Weber (Aachen, DE); R. Krams (London, GB)

- 14:00 **Neutrophil secretion and leukocyte recruitment during inflammation.** 2903
 – B.A. Imhof (Geneva, CH)
- 14:22 **Chemokines like it sweet: how sugars influence leukocyte arrest on the vascular wall.** 2904
 – M. Sperandio (Munich, DE)
- 14:44 **Getting through the vascular wall: neutrophil recruitment during inflammation.** 2905
 – F.W. Luscinskas (Boston, US)
- 15:06 **Bitter-sweet contributions of endothelial selectins during the inflammatory recruitment and injury.** 2906
 – A. Hidalgo (Madrid, ES)

15:30 Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)



LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CORONARY HEART DISEASE: A 21ST CENTURY PANDEMIC Symposium

Chairperson(s): L. Tokgozoglu (Ankara, TR); Z. Reiner (Zagreb, HR)
The European Society of Cardiology and the European Atherosclerosis Society

- 16:30 **Why do we face the pandemic of low high-density lipoprotein cholesterol and coronary heart disease?** 2907
 – M.-R. Taskinen (Helsinki, FI)
- 16:52 **High-density lipoprotein and reverse cholesterol transport.** 2908
 – S. Calandra (Modena, IT)
- 17:14 **Modifying high-density lipoprotein cholesterol to reduce cardiovascular risk.** 2909
 – J. Chapman (Paris, FR)
- 17:36 **Novel strategies for raising high-density lipoprotein cholesterol.** 2910
 – J.J.P. Kastelein (Amsterdam, NL)



CELL RECRUITMENT IN CARDIOVASCULAR REPAIR

Abstracts

Chairperson(s): P.A.F.M. Doevendans (Utrecht, NL); H. Drexler (Hannover, DE)

- 14:00 **NFkappa B p50 subunit depletion in circulating cells enhances perfusion restoration after femoral artery ligation in mice.** 2911
 – D. De Groot, R.T. Haverslag, J.L.A. Embrechts, D.P.V. De Kleijn, G. Pasterkamp, I.E. Hoefer (Utrecht, NL)
- 14:15 **G-CSF treatment in postmyocarditic cardiomyopathy enhances homing of bone marrow-derived progenitor cells and increases the number of resident cardiac progenitor cells.** 2912
 – S. Brunner, H.D. Theiss, M. Leiss, R. Fischer, M. Vallaster, B.C. Huber, A. Keithahn, M. Sauter, K. Klingel, W.M. Franz (Munich and Tubingen, DE)
- 14:30 **Impaired in vivo repair capacity of endothelial progenitor cells in patients with chronic heart failure: role of differential microRNA regulation and paracrine factors.** 2913
 – C. Doerries, S. Briand, C. Besler, P. Mocharla, M. Mueller, C. Manes, F.T. Ruschitzka, G. Noll, T.F. Luescher, U. Landmesser (Zurich, CH)
- 14:45 **Time course analysis of bone marrow derived progenitor cell transdifferentiation during neointima formation.** 2914
 – J.M. Daniel, H.H. Tillmanns, D.G. Sedding (Giessen, DE)
- 15:00 **G-CSF application combined with CD26-inhibition as a new therapeutic concept enhances stem cell homing and cardiac function after myocardial infarction in mice.** 2915
 – H.D. Theiss, M.M. Zaruba, M. Vallaster, S. Brunner, R. David, L. Krieg, E. Frank, P. Nathan, G. Steinbeck, W.M. Franz (Munich, DE)
- 15:15 **In situ activation of endogenous cardiac stem cells by intra-coronary administration of IGF-1 and HGF induces myocardial survival and regeneration in the infarcted pig myocardium.** 2916
 – G.M. Ellison, D. Torella, C. Perez-Martinez, A. Perez, S. Purushothaman, C. Vicinanza, V. Galuppo, V. Agosti, F. Fernandez, B. Nadal-Ginard (Liverpool, GB; Catanzaro, IT; Leon and Madrid, ES)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**



CARDIAC SIZE: SIGNS AND SIGNALS

Abstracts

Chairperson(s): M.D. Schneider (London, GB); G. Hasenfuss (Gottingen, DE)

- 16:30 **GRK2 and GRK5 regulate cardiac hypertrophy: in vitro and in vivo studies.** 2917
 – D. Sorriento, G. Santulli, P. Campiglia, A. Campanile, A. Fusco, B. Trimarco, G. Iaccarino (Naples and Salerno, IT)
- 16:45 **Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy.** 2918
 – L. Duboscq-Bidot, P. Charron, V. Ruppert, L. Fauchier, A. Richter, T. Wichter, B. Maish, M. Komajda, R. Isnard, E. Villard (Paris and Tours, FR; Marburg and Munster, DE)
- 17:00 **Coupling of ErbB4 but not ErbB1/2 to intracellular activation of Akt-1 in the adult ventricle: implications for anti-ErbB cancer therapy.** 2919
 – K. Doggen, K. Lemmens, G.W. De Keulenaer (Antwerp, BE)
- 17:15 **Targeted deletion of BMP and Activin Bound Inhibitor (BAMBI) increases and accelerates left ventricular remodeling under pressure overload.** 2920
 – M. Llano, A.V. Villar, M. Cobo, M. Tramullas, R. Merino, D. Merino, R. Martin-Duran, J.F. Nistal, M.A. Hurlle (Santander, ES)
- 17:30 **Liver X receptors attenuate cardiomyocyte hypertrophy.** 2921
 – I. Kuipers, J. Li, H.H.W. Sillje, L. Van Genne, S. Oberdorf-Maass, A.H. Maass, D.J. Van Veldhuisen, W.H. Van Gilst, R.A. De Boer (Groningen, NL; Changsha, CN)
- 17:45 **Neuregulin/ErbB signaling in pregnancy-induced hypertrophy.** 2922
 – K. Lemmens, K. Doggen, G.W. De Keulenaer (Antwerp, BE)

RECENT RANDOMIZED TRIALS AND REGISTRIES IN CORONARY REVASCULARISATION

Abstracts

Chairperson(s): A. Kastrati (Munich, DE); U. Limbruno (Grosseto, IT)

- 14:00 **Six-month follow-up of RES-ELUTION NEVO-I, a randomized multi-center comparison of the nevo reservoir-based sirolimus-eluting stent with the TAXUS liberte paclitaxel-eluting stent.** 2923
 – J. Fajadet, A. Abizaid, J. Ormiston, J. Schofer, L. Thuesen, L. Mauri, J. Popma, P. Fitzgerald, H.P. Stoll, C. Spaulding (Toulouse and Paris, FR; Sao Paolo, BR; Auckland, NZ; Hamburg, DE; Aarhus, DK; Boston and Palo Alto, US; Waterloo, BE)
- 14:15 **A randomized comparison of genous stent versus chromium-cobalt stent for treatment of ST-elevation myocardial infarction. A 6-month clinical, angiographic and IVUS follow-up. GENIUS-STEMI trial.** 2924
 – P. Cervinka, P.C. Cervinka, M.B. Bystron, R.S. Spacek, M.K. Kvasnak (Usti and Labem, CZ)
- 14:30 **A randomized comparison of sirolimus- versus paclitaxel-eluting stent for treatment of bifurcation lesions by single stent and kissing ballooning: results of SINGLE KISS trial.** 2925
 – K. Nasu, Y. Oikawa, E. Tsuchikane, T. Aizawa, T. Suzuki (Toyohashi and Tokyo, JP)
- 14:45 **Thrombosis in real practice with second generation drug-eluting stents. Results from the ESTROFA-2 spanish registry.** 2926
 – J.M. De La Torre Hernandez, F. Gimeno, J.A. Diarte, R. Lopez Palop, A. Perez De Prado, F. Rivero, J. Sanchis, M. Larman, J. Elizaga, F. Hernandez (Santander, Valladolid, Zaragoza, Alicante, Leon, Madrid, Valencia and San Sebastian, ES)
- 15:00 **Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomized trials.** 2927
 – F. Zhang, L. Dong, J. Ge (Shanghai, CN)
- 15:15 **Unprotected left main stenosis: multicenter randomized trial between CABG and PCI with sirolimus eluting stent.** 2928
 – E. Boudriot, G.S. Schuler, H.T. Thiele, T.W. Walther, C.L. Liebetrau, P.B. Boeckstegers, B.R. Reichart, H.M. Mudra, F.-J.N. Neumann, F.-W.M. Mohr (Leipzig, Bad Nauheim, Munich and Bad Krozingen, DE)

15:30 **Coffee break (Exhibits, Moderated Posters, How-to Tutorials Read with the Experts, Meet the Trialist & Hands-on Tutorials)**

DRUG ELUTING STENT RESTENOSIS: AN EMERGING CHALLENGE

Abstracts

Chairperson(s): S. Windecker (Berne, CH); T.-H. Koh (Singapore, SG)

- 16:30 **Angiographic measures of restenosis following drug-eluting stent implantation have a bimodal pattern of distribution.** 2929
 – R. Byrne, S. Eberle, A. Kastrati, A. Dibra, G. Ndrepepa, R. Iijima, J. Mehilli, A. Schoemig (Munich, DE)
- 16:45 **Optical coherence tomography patterns of stent restenosis.** 2930
 – N. Gonzalo Lopez, P.W. Serruys, T. Okamura, H.M. Van Beusekom, H.M. Garcia-Garcia, G. Van Soest, W.J. Van Der Giessen, E. Regar (Rotterdam, NL)
- 17:00 **Recurrent restenosis after drug-eluting-stents implantation in a cohort of 5595 lesions.** 2931
 – J. Mehilli, A. Kastrati, S. Schulz, R.A. Byrne, O. Bruskina, K. Tiroch, A. Birkmeier, J. Pache, J. Dirschinger, A. Schomig (Munich, DE)
- 17:15 **Stent fracture detected by multislice computed tomography after 'full metal jacket' using drug-eluting stents as cause of in-stent restenosis.** 2932 (W)
 – M. Kimura, T. Ito, O. Matsuda, N. Tanaka, K. Nasu, Y. Kinoshita, M. Ehara, E. Tsuchikane, Y. Asakura, T. Suzuki (Toyohashi, JP)
- 17:30 **Nonuniform stent strut distribution is not associated with angiographic restenosis or long-term clinical outcomes either in TAXUS or in bare metal stents. Integrated TAXUS IV, V and VI analysis.** 2933
 – R. Pracon, M.P. Opolski, G.S. Mintz, N.J. Weissman, L. Mandinov, J. Pregowski, M. Kruk, H. Wang, K.D. Dawkins, G.W. Stone (Washington, New York and Natick, US; Warsaw, PL)
- 17:45 **Quantitative coronary angiography (qca) matched comparison between randomized multicentre cutting balloon angioplasty (cba) with bms (reduce iii) and rapamycin-eluting stent evaluation rotterdam study.** 2934
 – Y. Ozaki, P.A. Lemos, T. Yamaguchi, T. Suzuki, M. Nakamura, T.F. Ismail, M. Kitayama, H. Nishikawa, O. Kato, P.W. Serruys (Toyoake, Tokyo, Toyohashi, Kanazawa and Meïwa, JP; Sao Paulo, BR; London, GB; Rotterdam, NL)

POSTER SESSION 4

Posters must be set up between 13:30 and 14:00, removed between 18:00 and 18:30 and be on display between 14:00 and 18:00. The presenter should be present throughout the coffee break (15:30 and 16:30) in order to discuss the poster.

**MODERATED POSTER 1
POPULATIONS AT RISK AFTER MYOCARDIAL INFARCTION: GENDER, AGE AND LIFESTYLE**

Chairperson(s): E. Swahn (Linköping, SE); J.C.A. Morais (Leiria, PT)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 15:30 and 16:30.

- 15:30 **Risk profile, quality of care and mortality and in women with acute myocardial infarction.** P2935
– F. Schiele, R. Chopard, J. Dutheil, V. Descotes-Genon, N. Meneveau, M.F. Seronde, J.P. Bassand (Besançon, FR)
- 15:35 **Female gender in STEMI: influence on mortality and reperfusion, results from the belgian STEMI registry.** P2936
– S. Gevaert, A. De Meester, M. Renard, P. Evrard, C. Beauloye, P. Coussement, P.H. Dubois, H. De Raedt, M. Claeys (Ghent, Jolimont, Brussels, Mont-Godinne, Brugge, Charleroi, Aalst and Antwerp, BE)
- 15:40 **Worldwide gender bias in angiographic obstructive acute coronary syndromes?** P2937
– O. Manfrini, J.L. Navarro Estrada, K. Nikus, A.S. Hall, R. Bugiardini (Bologna, IT; Buenos Aires, AR; Tampere, FI; Leeds, GB)
- 15:45 **Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians; trends and outcomes from a nine-year single center experience.** P2938
– B.E.P.M. Claessen, A.E. Engstrom, W.J. Kikkert, M.M. Vis, J. Baan, M.M. Meuwissen, R.J. De Winter, J.G.P. Tijssen, J.J. Piek, J.P.S. Henriques (Amsterdam, NL)
- 15:50 **Predictors of mortality in octogenarian patients with acute myocardial infarction.** P2939
– A.T. Timoteo, R. Ramos, A. Toste, A. Lousinha, J.A. Oliveira, M.L. Ferreira, R.C. Ferreira (Lisbon, PT)
- 15:55 **Thrombolysis versus primary angioplasty in older patients with ST-segment elevation myocardial infarction. Final results of the TRIANA randomized trial.** P2940 (W)
– H. Bueno, J.J. Alonso, A. Betriu, A. Cequier, E.J. Garcia, M. Heras, J.L. Lopez-Sendon, C. Macaya, R. Hernandez-Antolin (Madrid, Fuenlabrada, Barcelona and L'hospitalet De Llobregat, ES)
- 16:00 **Impact of obesity in the results after primary angioplasty in patients with ST-segment elevation acute myocardial infarction.** P2941
– A.T. Timoteo, R. Ramos, A. Toste, J.A. Oliveira, L. Patricio, R.C. Ferreira (Lisbon, PT)
- 16:05 **Lower rate of invasive revascularisation after coronary angiography, following acute coronary syndrome, the longer distance you live from an invasive centres.** P2942
– A. Hvelplund, S. Galatius, M. Madsen, J.N. Rasmussen, S. Rasmussen, J.K. Madsen, S.Z. Abildstrom (Copenhagen, Hellerup and Glostrup, DK)
- 16:10 **Discussion.** P2943



**MODERATED POSTER 2
NEW CHALLENGES IN EXERCISE TRAINING**

Chairperson(s): H. Saner (Berne, CH); P. Giannuzzi (Veruno, IT)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 15:30 and 16:30.

- 15:30 **diastolic dysfunction in chronic systolic heart failure and aging - effects of endurance training.** P2944
 – M. Sandri, S. Gielen, N. Mangner, R. Hoellriegel, S. Erbs, A. Linke, S. Moebius-Winkler, V. Adams, R. Hambrecht, G. Schuler (Leipzig, DE)
- 15:35 **Aerobic interval training versus strength training as a treatment for the metabolic syndrome.** P2945
 – D. Stensvold, E.A. Skaug, U. Wisloff, S.A. Sloer Dahl (Trondheim, NO)
- 15:40 **Metabolically guided exercise training in patients with diabetes mellitus type 2 and coronary heart disease is able to control postprandial hyperglycemia.** P2946
 – B. Schwaab, F. Kafsack, E. Markmann, N. Zwick, M. Schuett (Bernried, Timmendorfer Strand and Lubeck, DE)
- 15:45 **Benefits of chronic exercise training on aerobic capacity and NT-proBNP plasma levels in patients with Ventricular Assist Devices.** P2947
 – I.D. Laoutaris, A. Dritsas, S. Adamopoulos, A. Manginas, A. Gouziouta, M. Koulopoulou, P. Sfirakis, V. Voudris, D.V. Cokkinos, P.A. Alivizatos (Athens, GR)
- 15:50 **Cardiopulmonary test as a measure of rehabilitation in a patient supported by a Cardiowest total artificial heart (TAH).** P2948
 – F. Bellotto, P. Agostoni, L. Compostella, G. Torregrossa, T. Setzu, A. Gambino, A. Maddalozzo, G. Feltrin, G. Gerosa (Padua, Milan and Cortina D'Ampezzo, IT)
- 15:55 **Four recommendations to maintain physical fitness of patients with chronic heart failure after cardiac rehabilitation: a prospective randomized study.** P2949
 – P.J.M. Beckers, N.M. Possemiers, K. Wuyts, C.J. Vrints, V.M. Conraads (Edegem, BE)
- 16:00 **Exercise training increases adiponectin levels in patients with stable coronary artery disease.** P2950
 – S. Moebius-Winkler, V. Adams, C. Walther, S. Erbs, A. Linke, M. Von Roeder, R. Hambrecht, G. Schuler (Leipzig and Bremen, DE)
- 16:05 **Sustained benefit after one year of regular physical exercise training on hemodynamics and exercise capacity in patients with end-stage chronic heart failure (NHYA IIIb).** P2951
 – R. Hoellriegel, S. Erbs, A. Linke, E. Beck, M. Sandri, N. Mangner, S. Moebius-Winkler, V. Adams, R. Hambrecht, G. Schuler (Leipzig and Bremen, DE)
- 16:10 **Discussion.** P2952

THE KIDNEY AND CORONARY ARTERY DISEASE

- Prevention of cardiovascular complication after renal transplantation.** P2953
 – E. Rossi, M.P. Salerno, E. Zichici, E. Favi, G. Spagnoletti, F. Citterio (Rome, IT)
- Decreased renal function associated with incident adverse cardiovascular outcomes in patients with acute coronary syndromes.** P2954
 – D. Pereg, M. Benderly, S. Behar, M. Mossrei (Kfar Saba and Tel Hashomer, IL)
- Effectiveness and safety of drug eluting stents in patients with chronic renal failure.** P2955
 – K. Toutouzas, C.H. Patsa, E. Tsiamis, C. Tsioufis, M. Vavuranakis, A. Synetos, D. Tousoulis, A. Spanos, E. Stefanadi, C.H. Stefanadis (Athens, GR)
- Impact of high-dose N-ACC versus placebo on contrast-induced nephropathy and myocardial perfusion injury in patients with ST-elevation myocardial infarction undergoing primary PCI.** P2956
 – H. Thiele, I. Eitel, L. Hildebrand, C. Schirdewahn, V. Adams, G. Fuernau, M. Gutberlet, G. Schuler (Leipzig, DE)
- The impact of kidney transplantation on the incidence of cardiovascular events is affected by the presence of cardiovascular disease.** P2957
 – L.H.W. Gowdak, F.J. De Paula, R.L. Arantes, A.L.V. De Oliveira, L.A.M. Cesar, L.E. Ianhez, E.M. Krieger, J.J.G. De Lima (Sao Paulo, BR)
- Synergistic effects of asymmetric dimethylarginine accumulation and endothelial progenitor cells deficiency on renal function decline during a 2-year follow-up in stable angina.** P2958
 – A. Surdacki, E. Marewicz, E. Wieczorek-Surdacka, G. Szastak, T. Rakowski, E. Wieteska, J. Pryjma, D. Dudek, J.S. Dubiel (Krakow, PL)
- Renal effects of intravenous lipoxigenase inhibitor Quercetin in patients with acute myocardial infarction: prospective randomized study.** P2959
 – S. Kozhukhov, A. Parkhomenko (Kiev, UA)
- Contrast-induced nephropathy after an acute coronary syndrome.** P2960
 – A. Gaspar, S. Nabais, S. Ribeiro, S. Rocha, P. Azevedo, M. Pereira, A. Brandao, A. Correia (Braga, PT)
- Evaluation of Cockcroft-Gault and modification of diet in renal disease equations in post-ACS patients.** P2961
 – M. Lafitte, L. Barandon, Y. Pucheu, M. Riedel, T. Couffinhil (Pessac, FR)
- Intermittent claudication, history of cerebrovascular accident and renal failure each has prognostic value similar to the history of coronary artery disease in patients with acute coronary syndromes.** P2962
 – M. Zairis, P. Smilakos, C. Ritsatos, G. Tsiaousis, P. Margetis, Z. Katidis, I. Sarris, D. Beldekos, S. Handanis, S.G. Foussas (Piraeus, GR)
- The impact of renal function on long-term prognosis in patients with impaired glucose tolerance and acute myocardial infarction.** P2963
 – J. Kowalczyk, A. Sedkowska, A. Swiatkowski, T. Zielinska, O. Kowalski, J. Stabryla-Deska, B. Sredniawa, K. Strojek, L. Polonski, Z. Kalarus (Zabrze, PL)
- Prognostic significance of acute kidney injury after reperfused ST-elevation myocardial infarction: synergistic acceleration of renal dysfunction and left ventricular remodeling.** P2964
 – A. Anzai, T. Anzai, K. Naito, H. Kaneko, Y. Jo, Y. Nagatomo, Y. Maekawa, A. Kawamura, T. Yoshikawa, S. Ogawa (Tokyo, JP)

THE WIDE WORLD OF CORONARY ARTERY DISEASE

- Cardiac troponin I at 24 or 48 Hours predicts infarct size in patients with STEMI as determined by cardiac magnetic resonance imaging. A FIRE-substudy.** P2965
 – J. Hallen, J. Schwitter, P. Buser, P. Petzelbauer, B. Geudelin, D. Atar (Oslo, NO; Zurich and Basel, CH; Vienna, AT)
- Asymptomatic troponin T release after non-cardiovascular surgery is associated with poor long-term outcome.** P2966
 – O. Schouten, M. Dunkelgrun, T.A. Winkel, M. Voute, R.T. Van Domburg, H.J.M. Verhagen, J.J. Bax, S.E. Hoeks, W.J. Flu, D. Poldermans (Rotterdam and Leiden, NL)

- Differences in clinical presentation and 6-month outcomes in different age classes of elderly patients (75-80, 81-85, and >85 years). Data from prospective, nationwide, French PAPI registry.** P2967
 – J. Lipiecki, P. Dupouy, O. Wittenberg, E. Teiger, M. Hanssen, M. Slama (Clermont Ferrand, Antony, Marseille, Creteil, Haguenau and Clamart, FR)
- Outcome of acute coronary syndrome octogenarian patients in Israel.** P2968
 – M. Shechter, A. Roth, S. Atar, V. Boyko, S. Behar, S. Matetzky (Tel Hashomer, Tel Aviv and Nahariya, IL)
- The value of calprotectin as a prognostic marker of cardiovascular risk in acute chest pain.** P2969
 – T. Brugger-Andersen, V. Ponitz, F. Kontrny, H. Staines, H. Grundt, D.W.T. Nilsen (Stavanger and Oslo, NO; Balmullo, GB)
- Effects of subclinical hypothyroidism on cardiac and vascular morphological and functional changes.** P2970
 – D. Nikolic, D.K. Kalimanovska, V.M. Mitov, A.A. Aleksic (Zajecar and Belgrade, RS)
- Morbidity profile and treatment status of patients nonadherent to a Disease Management Programme (DMP): Results from the DMP Coronary Artery Disease (CAD) northrhine.** P2971
 – I. Schwang, R. Griebenow, B. Hagen, L. Altenhofen (Cologne, DE)
- Timing and energy of the extracorporeal cardiac shock wave treatment have profound influence on the outcome of therapy in ischemic heart disease.** P2972
 – F. Di Meglio, D. Nurzynska, C. Castaldo, R. Miraglia, V. Romano, C. Bancone, E. Marlinghaus, S. Russo, C. Vosa, S. Montagnani (Naples, IT; Kreuzlingen, CH)
- Predicting prognosis post acute coronary syndromes: can platelets do it?** P2973
 – F. Saraiva, R. Baptista, E. Jorge, R. Teixeira, P. Mendes, S. Monteiro, F. Goncalves, P. Monteiro, M. Freitas, L.A. Providencia (Coimbra, PT)
- Diastolic function: another way to predict outcome in acute coronary syndromes.** P2974
 – R. Teixeira, C. Lourenco, E. Jorge, R. Baptista, F. Saraiva, P. Mendes, F. Goncalves, P. Monteiro, M. Freitas, L. Providencia (Coimbra, PT)
- Genetic variant rs4355801 A>G is associated with both angiographically determined coronary atherosclerosis and reduced bone mineral density.** P2975
 – C.H. Saely, S. Beer, A. Muendlein, A. Vonbank, P. Rein, J. Breuss, B. Gaensbacher, H. Drexel (Feldkirch, AT; Triesen, LI)
- Aortic root calcification (ARC) can predict coronary artery disease (CAD) in albanian population.** P2976
 – N. Xhabija, F. Sula, S. Meco, E. Petrela, B. Horjeti (Tirana, AL)
- Prognosis at one-year of acute coronary syndrome in HIV-infected patients.** P2977
 – F. Boccarda, M. Mary-Krause, E. Teiger, S. Lang, P. Lim, K. Whabi, F. Beygui, G. Steg, D. Costagliola, A. Cohen (Paris and Creteil, FR)
- Efficacy of two long-term intervention strategies to promote long-term adherence to lifestyle changes and to reduce cardiovascular events in patients with coronary artery disease.** P2978
 – M. Vona, L. Chapuis, T. Iannino, E. Ferrari, L.K. Von Segesser (Glion Sur Montreux and Lausanne, CH)
- Superior long-term outcome after primary PCI compared to early thrombolysis in acute ST-segment elevation myocardial infarction.** P2979
 – M. Aasa, M. Dellborg, J. Herlitz, L. Svensson, L. Grip (Stockholm and Gothenburg, SE)
- Outcome of primary angioplasty during ‘off-hours’ is not worst than during ‘routine office hours’: experience at a high-volume interventional center.** P2980
 – E. Barge-Caballero, J.M. Vazquez-Rodriguez, R. Estevez-Loureiro, A. Rodriguez-Vilela, J. Salgado-Fernandez, G. Aldama-Lopez, R. Calvino-Santos, P. Pinon-Esteban, N. Vazquez-Gonzalez, A. Castro-Beiras (A Coruna, ES)
- The R in V1 in non-anterior wall infarction indicates lateral rather than posterior involvement. Results from ECG/MRI correlations.** P2981
 – K. Van Der Weg, S.C.A.M. Bekkers, B. Winkens, M.E. Lemmert, S.M. Schalla, G. Snoep, H.J.G.M. Crijns, J. Waltenberger, A.P.M. Gorgels (Maastricht, NL)

- Relation of N-terminal pro-B-type natriuretic peptide levels and their prognostic impact in acute STEMI patients treated with PCI to obesity status.** P2982
 – S.N. Hong, M.H. Jeong, Y.K. Ahn, S.C. Chae, Y.J. Kim, M.C. Cho, I.W. Seong, C.J. Kim, K.B. Seung, S.J. Park (Gwangju, Daegu, Cheongju, Daejeon and Seoul, KR)
- Endothelin-1: a useful prognostic marker after acute myocardial infarction.** P2983
 – X. Freixa, A. Doltra, J.T. Ortiz, S. Argiro, E. Guasch, M. Heras, M. Jimenez, A. Betriu, M. Masotti (Barcelona, ES)
- Increased rho kinases (ROCKs) activity in patients with acute coronary syndrome.** P2984
 – C.M. Yu, M. Dong, R.J. Li, M. Zhang, Q.H. Zhang, J.K. Liao (Hong Kong, CN; Boston, US)
- Low hs-CRP and von Willebrand factor levels and high brachial artery flow-mediated dilation correlates with the spontaneous reperfusion in STEMI patients.** P2985
 – I. Urazovskaya, D. Skrypnik, E. Vasilieva, A. Shpektor (Moscow, RU)
- High sensitivity C-reactive protein kinetic and prognosis in patients with ST-elevation acute myocardial infarction.** P2986
 – S.S. Makrygiannis, M. Zairis, G. Tsiaousis, C. Vogiatzidis, P. Smilakos, Z. Katidis, C. Garefalakis, P. Batika, E. Adamopoulou, S.G. Foussas (Piraeus, GR)
- Matrix metalloproteinase-2 and oxidative stress in patients with STEMI treated by primary PCI.** P2987
 – J. Parenica, M. Goldbergova-Pavkova, P. Kala, M. Poloczek, J. Manousek, Z. Cermakova, O. Toman, J. Tomandl, D. Tomcikova, J. Spinar (Brno, CZ)
- Early statin treatment normalizes MMP-9 and MMP-2 activity and is associated with fewer thrombotic complications and left ventricular remodeling in acute Q-wave myocardial infarction patients.** P2988
 – O. Koval, A. Ivanov, G. Dzyak, P. Kaplan, A. Skoromnaya, O. Mararenko (Dnipropetrovsk, UA)
- Cavotricuspid isthmus dependent flutter is associated with increased incidence of occult coronary artery disease.** P2989
 – J.P. De Bono, V.M. Stoll, A. Joshi, K. Rajappan, Y. Bashir, T.R. Betts (Oxford, GB)
- Is there an influence of advanced age on the results of percutaneous coronary interventions (PCI) in patients with ST-elevation myocardial infarction (STEMI)? Results from the ALKK PCI registry.** P2990
 – S. Tielke, H. Mudra, M. Hochadel, U. Zeymer, H. Darius, S. Kerber, K.E. Hauptmann, J. Senges, R. Zahn (Ludwigshafen am Rhein, Munich, Berlin, Bad Neustadt and Trier, DE)
- Comparison of prognostic value of epicardial blood flow and early ST-segment resolution in patient with primary angioplasty in acute myocardial infarction.** P2991
 – K. Ben Hamda, M. Hassine, W. Jomaa, S. Hamdi, M.A. Majdoub, F. Moatamri, H. Thawaba, K. Mzoughi, F. Betbout, F. Maatouk (Monastir, TN)
- A novel hospital discharge risk score system for the assessment of clinical outcomes in patients with acute myocardial infarction.** P2992
 – H.K. Kim, M.H. Jeong, Y.K. Ahn, Y.J. Kim, S.C. Chae, C.J. Kim, T.J. Hong, S.W. Rha, J.H. Bae, I.W. Seong (Gwangju, Daegu, Seoul, Busan and Daejeon, KR)
- Utility of biomarker scoring system using multimaker approach as risk stratification modality in patient with Non-ST Elevation Myocardial Infarction (NSTEMI).** P2993
 – J.S. Ko, M.H. Jeong, Y.G. Ahn, J.G. Cho, J.C. Park, J.C. Kang (Gwangju, KR)
- Cardiac Outcomes through Digital Evaluation (CODE) STEMI project.** P2994
 – R.A. Ducas, D.S. Jassal, R.K. Philipp, S.A. Hodge, E.R. Weldon, C.M.J. Schmidt, R.A. Grierson, J.W. Tam (Winnipeg, CA)

DIABETES, OBESITY AND HYPERLIPIDAEMIA

- Impact of diabetes mellitus on disease progression in non-stented coronary segments.** P2995
 – R. Byrne, R. Iijima, J. Mehilli, S. Schulz, A. Schoemig, A. Kastrati (Munich, DE)
- In-hospital metabolic changes and their consequences on short and long term outcome in patients with acute myocardial infarction.** P2996
 – R. Dragu, M. Kapeliovich, H. Hammerman (Haifa, IL)

Prevalence of newly detected abnormal glucose regulation in routine catheterisation laboratory patients with known or suspected coronary artery disease. P2997

– R. Doerr, S.G. Spitzer, J. Stumpf, W. Otter, D. Tschoepe, L. Heinemann, W. Hunger-Dathe, B. Kulzer, T. Lohmann, O. Schnell (Dresden, Unterschleissheim, Bad Oeynhausen, Neuss, Jena, Bad Mergentheim and Munich, DE)

Low HDL cholesterol. An independent risk factor of long term mortality in patients with acute coronary syndromes: results of the MITRAplus registry. P2998

– F. Towae, C. Juenger, U. Zeymer, R. Zahn, J. Senges, A.K. Gitt (Ludwigshafen am Rhein, DE)

Among patients with acute myocardial infarction, does time from symptom onset influence the impact of hyperglycemia as a risk factor? P2999

– J.C. Nicolau, R.R. Giraldez, C.V. Serrano, F.F. Lima, M. Franken, F. Ganem, R.C. Moraes, K.D. Rosa, C.C.F. Fernandes, L.M. Baracioli (Sao Paulo, BR)

Admission glycaemia in non-diabetic acute coronary syndrome patients: a marker of acute stress or of chronic glucose metabolism impairment? P3000

– P.F. Monteiro, S. Monteiro, E. Jorge, R. Baptista, P. Mendes, R. Teixeira, N. Antonio, F. Goncalves, M. Freitas, L.A. Providencia (Coimbra, PT)

Multidisciplinary approach for diabetic patients with ischemic heart disease. P3001

– S. Nodari, A. Manerba, G. Milesi, C. Maiandi, A. Vaccari, M. Triggiani, G. Caretta, S. Frattini, M. Metra, L. Dei Cas (Brescia, IT)

Abdominal obesity and outcomes after acute coronary syndromes. P3002

– S. Nabais, S. Rocha, A. Gaspar, S. Ribeiro, J. Costa, P. Azevedo, M. Alvares Pereira, A. Correia (Braga, PT)

Copeptin predicts and explains the association between IGFBP-1 and cardiovascular events in patients with type 2 diabetes and myocardial infarction. P3003

– L.G. Mellbin, K. Brismar, L. Ryden, N.G. Morgenthaler, J. Ohrvik, I.B. Botusan, S.B. Catrina (Stockholm, SE; Berlin, DE)

Familial combined hyperlipidemia in very young myocardial infarction survivors (below or equal 40 years of age). P3004

– G. Goliashch, H. Blessberger, D. Azar, O. Wagner, K. Huber, K. Widhalm, G. Sodeck, G. Maurer, M. Schillinger, F. Wiesbauer (Vienna, AT)

Is the impact of hyperglycemia as a risk factor homogeneous across different presentations of acute coronary syndromes? P3005

– J.C. Nicolau, M. Franken, F.G. Lima, L.M. Baracioli, C.V. Serrano Jr, R.R. Giraldez, F. Ganem, R.T. Ladeira, M.D. Andrade, R.C. Moraes (Sao Paulo, BR)

Hyperglycemia treatment in the setting of acute coronary syndromes: the outcome of the Dutch nationwide questionnaire. P3006

– V.A. Umans, M. De Mulder, J.H. Cornel (Alkmaar, NL)

Serum Apolipoprotein J profile after myocardial infarction. P3007

– J. Cubedo, T. Padro, X. Garcia-Moll, L. Badimon (Barcelona, ES)

Prognostic utility of lipoprotein(a) in patients with stable coronary artery disease. P3008

– M. O'Donoghue, D. Morrow, E. Braunwald, S. Sloan, M. Domanski, M. Sabatine (Boston and Bethesda, US)

CARDIAC COMPUTED TOMOGRAPHY: CORONARIES

Small coronary calcifications are not detectable by 64-slice computed tomography. P3009

– A.G. Van Der Giessen, F.J.H. Gijzen, J.J. Wentzel, T. Walsum, W.J. Niessen, F.N. Van De Vosse, P.J. De Feyter, A.F.W. Van Der Steen (Rotterdam and Eindhoven, NL)

Can coronary Computed Tomography Angiography (CTA) contribute to the risk stratification and subsequent decision making in patients with Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)? P3010

– H. Harigaya, S. Motoyama, M. Sarai, T. Hara, K. Hattori, M. Ishikawa, M. Okumura, S.C. Kan, H. Naruse, Y. Ozaki (Toyoake, JP; Irvine, US)

Multi-slice computed tomography coronary angiography assessment of plaque burden and plaque composition for risk stratification in coronary artery disease. P3011

– J.M. Van Werkhoven, J.D. Schuijff, O. Gaemperli, J.W. Jukema, E. Boersma, G. Pundziute, A.J. Scholte, E.E. Van Der Wall, P.A. Kaufmann, J.J. Bax (Leiden and Rotterdam, NL; Zurich, CH)

- Gender differences in atherosclerosis burden determined by cardiac 64 slice CT in a patient cohort of patients with chest pain.** P3012
 – M. Winkens, E.M. Laufer, I. Joosen, M. Versteyleen, T. Leiner, J. Wildberger, J. Narula, L. Hofstra (Maastricht, NL)
- Plaque thickness determines whether non-calcified plaques are detected by dual-source computed tomography angiography.** P3013
 – A.G. Van Der Giessen, M.H. Toepker, P.M. Donnelly, F. Bamberg, T. Irlbeck, C. Schlett, C. Raffel, F.J.H. Gijssen, J.J. Wentzel, U. Hoffmann (Rotterdam, NL; Boston, US)
- Distance-weighted evaluation of coronary artery calcifications is more predictive of cardiovascular events compared to the agatston score and volume score.** P3014
 – I. Marvasti, Q. Zhen, G. Vasquez, S. Rinehart, S. Voros (Atlanta, US)
- Clinical significance of the coronary plaque with increased intraplaque CT density and its histopathological characteristics.** P3015
 – T. Yonetsu, T. Kakuta, T. Lee, K. Takayama, T. Iwamoto, N. Kawaguchi, H. Fujiwara (Tsuchiura, JP)
- Evaluation of coronary atherosclerosis by 64-slice CT in patients with acute myocardial infarction without significant coronary stenosis.** P3016
 – A. Aldrovandi, D. Arduini, F. Ugo, A. Menozzi, F. Cademartiri, D. Ardissino (Parma, IT)
- Coronary artery calcification and Framingham risk score to predict coronary events in subjects under primary prevention care.** P3017
 – J. Shemesh, Y. Buber, N. Koren-Morag, A. Tenenbaum, S. Segev, E. Konen, E. Schwammenthal, M. Motro (Tel-Aviv, IL)
- Novel dedicated approach for automatic quantification of the degree of coronary artery stenosis on 64-slice multi-slice computed tomography: a comparison with quantitative coronary angiography.** P3018
 – M.M. Boogers, J.D. Schuijf, J.M. Van Werkhoven, P.H. Kitslaar, M. Frenay, J. Dijkstra, A. De Roos, J.W. Jukema, J.H.C. Reiber, J.J. Bax (Leiden, NL)
- Preinterventional coronary computed tomography significantly enhances success rate in PCI of complex chronic total occlusions.** P3019
 – A. Rolf, G.S. Werner, J. Rixe, M. Werle, H. Moellmann, H. Nef, C. Gundermann, K.H. Tischer, C. Hamm, T. Dill (Bad Nauheim and Darmstadt, DE)
- The use of 64-row multidetector CT in the investigation of patients with suspected coronary artery disease, initial 2 1/2 year single centre experience.** P3020
 – K.N. Asrress, G. Baldock-Apps, A. Bajpai, J. Pitts, K. Dickinson, J.A. Giles, D.M. Walker, E.T. McWilliams (Hastings, GB)
- Diagnostic accuracy of multidetector computer tomography to detect in-stent restenosis as defined by invasive angiography in devices smaller than 3 millimetre diameter.** P3021
 – E.P. Gurfinkel, M. Cerda, G. Ganum, F. Landeta, G. Caponi, E. Duronto (Buenos Aires, AR)
- The accuracy of CT coronary angiography has been systematically underestimated by standard trial methodology.** P3022
 – J. Otton, A. Hayen, M. Feneley (Sydney, AU)
- Incremental value of 64-slice computed tomography in patients with known or suspected CAD after inconclusive stress test.** P3023
 – N. Carrabba, F. Cademartiri, M. Acquafresca, R. Valenti, M. Moroni, S. Pradella, L. Nicolaci, G. Parodi, G.F. Gensini, D. Antoniucci (Florence and Parma, IT)
- Epicardial adipose tissue relation to coronary artery calcification is independent from abdominal visceral fat: prospective multislice computed tomography study.** P3024
 – N. Bettencourt De Sousa, D. Leite, J. Rocha, M. Carvalho, F. Sampaio, M. Teixeira, L. Simoes, V. Gama (Villa Nova de Gaia, PT)
- A platform for quantitative and dynamic calcium signal study in small rodent heart in vivo using Manganese Enhanced MR(MnEMR) T1 mapping without breath control.** P3025
 – Y.-X. Ye, X. Helluy, T. Basse-Luesebrink, V. Kocoski, A. Schlipp, P.M. Jakob, K.-H. Hiller, W.R. Bauer (Wurzburg, DE)

NOVEL TECHNIQUES: COMPUTED TOMOGRAPHY AND CARDIOVASCULAR MAGNETIC RESONANCE

- MRI-related heating at commercial cardiac pacemaker leads in vivo.** P3026
 – P. Nordbeck, O. Ritter, M. Warmuth, H.H. Quick, M.E. Ladd, K.H. Hiller, P.M. Jakob, W.R. Bauer (Wurzburg and Essen, DE)
- Direct comparison of 32-element magnetic resonance imaging at 3.0 T and 64-slice computed tomography for detection of coronary artery stenosis.** P3027
 – A. Hamdan, P. Asbach, H. Kilian, R. Gebker, I. Paetsch, C. Jahnke, A. Huppertz, E. Fleck (Berlin, DE)
- Multislice multiecho T2* cardiac magnetic resonance can detect heterogeneous myocardial iron distribution in thalassemia patients.** P3028
 – A. Pepe, V. Positano, M.F. Santarelli, A. Meloni, B. Favilli, D. De Marchi, P. Keilberg, V. Caruso, L. Landini, M. Lombardi (Pisa and Catania, IT)
- Magnetic resonance-guided aortic balloon valvuloplasty under rapid right ventricular pacing with MR compatible pacemaker lead in swine.** P3029
 – M. Neizel, N. Kraemer, F. Boenner, M. Kelm, R.W. Guenther, G.A. Krombach, H.P. Kuehl (Aachen, DE)
- New simplified method for quantification of left and right atrial volumes by multimodality tissue tracking (MTT) MRI.** P3030
 – T. Helle-Valle, A. Redheuil, W.-C. Yu, J.A.C. Lima (Baltimore, US)
- A cardiac magnetic resonance study: the effect of correction for through-plane motion in patients with tetralogy of fallot.** P3031
 – D.H.F. Gommans, J.W. Op Den Akker, M.J. Van Der Vlugt (Nijmegen, NL)
- Non-invasive quantification of myocardial fibrosis using in-vivo high-resolution MRI in diabetic mice and correlation with arrhythmias.** P3032
 – S.S. Bun, F. Kober, A. Jacquier, J. Kalifa, L. Espinosa, F. Kopp, M.F. Bonzi, J.C. Deharo, P.J. Cozzone, M. Bernard (Marseille, FR)
- CT coronary angiography with prospective ECG-triggering: body physique and heart rate variability determine the occurrence of stair-step artefacts.** P3033
 – L. Husmann, B.A. Herzog, R. Buechel, N. Burkhard, I. Valenta, O. Gaemperli, C.A. Wyss, U. Landmesser, P.A. Kaufmann (Zurich, CH)
- Comparison between visual score and 3D quantitative analysis of coronary angiography MDCT. How to overcome subjectivity.** P3034
 – D. Tavella, R. Malago, F. Beltrame, R. Pozzi Mucelli, P. Benussi (Verona, IT)
- Feasibility of a single-heart beat scan protocol in dual-source cardiac CT angiography.** P3035
 – B. Bischoff, F. Hein, T. Meyer, M. Hadamitzky, S. Martinoff, J. Hausleiter (Munich, DE)
- Coronary artery spatial distribution of vulnerable plaques in non-culprit segments by computed tomography angiography in patients with acute myocardial infarction.** P3036
 – A. Sato, D. Akiyama, H. Watabe, Y. Seo, T. Ishizu, N. Murakoshi, S. Watanabe, K. Aonuma (Tsukuba, JP)
- Low-dose CT coronary angiography matches regular-dose in image quality.** P3037
 – A.P. Bayol, J.A. Vallejos, R.E. Peloso, M.A. Agüero, R. Obregon, A.C. Zarza, M.A. Collante Bohle, D.H. Sandoval, P.A. Pozzer, J.I. Parras (Corrientes, AR)
- Progressive decline in the dual source cardiac CT radiation dose with time: a two years single center experience.** P3038
 – P.J. Sousa, P. De Araujo Goncalves, H. Marques, R. Dourado, A. Gaspar, F. Pereira Machado, J. Roquete (Lisbon, PT)
- Oral Ivabradine: an alternative to endovenous beta-blockade in the context of CT coronary angiography (CTCA). Heart rate reduction, image quality and motion artifacts.** P3039
 – L. Perez De Isla, J. Zamorano, G. Pizarro, P. Marcos-Alberca, C. Fernandez-Golfín, C. Almeria, J.L. Rodrigo, D. Herrera, A. Aubele, C. Macaya (Madrid, ES)
- Coronary-CT is not indicated in patients with agatston calcium score above 400.** P3040
 – A. Diederichsen, H. Petersen, L.O. Jensen, P. Thayssen, O. Gerne, N.C.F. Sandgaard, P.F. Hoiland-Carlson, H. Mickley (Odense, DK)
- ECG-gated MDCT of the patent ductus arteriosus in adult cases. Imaging findings and impact on management.** P3041
 – K. Takase, S. Matsumoto, S. Yoshida, Y. Morita, H. Saito, S. Takahashi (Sendai, JP)

MONITORING AND ANALYSIS

- A textile monitoring system for polysomnography at high altitude.** P3042
 – M. Di Rienzo, C. Lombardi, P. Meriggi, P. Mazzoleni, F. Rizzo, G. Parati (Milan, IT)
- Detection of stable atrial fibrillation sources from standard 12-lead ECG.** P3043
 – C. Duchene, M. Lemay, J.M. Vesin (Lausanne, CH)
- Nonlinear dynamic analysis of short-term R-R interval time series in patients with Sarcoidosis.** P3044
 – T.G. Papaioannou, E. Gialafos, A. Rapti, C. Aggeli, D. Soulis, M. Vavuranakis, G. Siasos, C. Kostopoulos, D. Tousoulis, C. Stefanadis (Athens, GR)
- Prediction of atrial fibrillation recurrence: non-linear and time domain analysis of the f- and P-waves.** P3045
 – K. Fugedi, S. Khor, N. Balogh, M. Khor, B. Kail, I. Kovacs (Budapest, HU)
- Electrocardiographic patterns of early repolarization attributable to increased transient outward current in the subepicardial region. A simulation study.** P3046
 – A.D. Corlan, B. Amuzescu, I. Milicin, L. De Ambroggi (Bucharest, RO; San Donato Milanese, IT)
- The detection of new-onset atrial fibrillation in vascular surgery patients with an implantable continuous electrocardiography monitoring device.** P3047
 – T.A. Winkel, D.R. Hampton, W.-J. Flu, A. Pietersma, O. Schouten, J.P.C.M. Oomen, H.J.M. Verhagen, D. Poldermans (Rotterdam, Maastricht and Purmerend, NL)
- Measures of heart rate variability from the Polar S810 and HRV analysis software 1.1: a validity and reliability study in chronic heart failure.** P3048
 – D. Nunan, D. Jakovljevic, G. Donovan, G. Sandercock, R. Grocott-Mason, S. Mcdonagh, D. Brodie (Chalfont St Giles, Colchester and London, GB)
- Digital phonocardiography as a screening tool in school aged children.** P3049
 – I. Germanakis, F. Parthenakis, R. Perakaki, PE. Vardas, M. Kalmanti (Heraklion, GR)
- Implementation of simulator based training for paediatric echocardiography.** P3050
 – M. Weidenbach, V. Razek, R. Wagner, F. Wild, T. Berlage, J. Janousek (Leipzig and St. Augustin, DE)
- Expert system to predict in-hospital mortality after ST elevation myocardial infarction.** P3051
 – E. Garcia Moran, C. Tapia, C. Hernandez Luis, M. Sandin, I. Amat, E. Zatarain, F. Gimeno, R. Andion, I. Gonzalez, J.A. San Roman (Valladolid, ES)
- Investigation on additional parameters for thoracic arc aneurysm rupture risk estimation by probabilistic finite element approach.** P3052
 – S. Celi, S. Berti, M. Mariani, F. Di Puccio, P. Forte (Massa and Pisa, IT)
- Electronic pathways in cardiology.** P3053
 – V.A. Umans, E.G. Zwaan, G. Kimman, A. Wals (Alkmaar, NL)
- Efficacy of self optimizing neural network (SONN) for predicting long-term outcomes in patients with STEMI treated with primary percutaneous coronary intervention.** P3054
 – J. Forsy, A. Popa, P. Fulmanski, A.M. Nowakowski, J.D. Kasprzak (Lodz, PL)
- Are there objective methods for choosing the best compression algorithm for coronary angiograms?** P3055
 – K. Kronberg, R. Kussebi, A. Franz, R. Motz, A. Elsaesser (Oldenburg, DE)
- A technical approach for registration of coronary venous anatomy to the site of latest mechanical contraction using cardiac CT and MRI.** P3056
 – C. Knackstedt, G. Muehlenbruch, K. Mischke, G. Schummers, A. Mahnken, R. Guenther, M. Kelm, P. Schauerte (Aachen and Unterschleissheim, DE)

STEM CELLS IN SITU

- Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease.** P3057
 – T. Fujimaki, K. Kato, S. Tanaka, T. Kawamiya, K. Yajima, T. Hibino, K. Yokoi, T. Murohara, G. Kimura, Y. Yamada (Tajimi, Nagoya and Tsu, JP)
- Sporadic arrhythmic right ventricular cardiomyopathy due to a de novo mutation.** P3058
 – E. Gandjbakhch, V. Fressart, G. Bertaux, L. Faivre, R. Frank, G. Fontaine, E. Villard, C. Coirault, B. Hainque, P. Charron (Paris and Dijon, FR)

- Stem cell therapy in pulmonary hypertension-induced right heart failure reduces right ventricular hypertrophy, dysfunction and remodeling by inhibiting pulmonary arteriolar medial hypertrophy.** P3059
 – S. Umar, P. Steendijk, G. Wagenaar, C. Schutte, W. Bax, D. Pijnappels, D. Atsma, M. Schali, E. Van Der Wall, A. Van Der Laarse (Leiden, NL)
- Use of heterologous non-matched Cardiac Stem Cells (CSCs) without immunosuppression as an effective regenerating agent in a porcine model of acute myocardial infarction.** P3060
 – G.M. Ellison, D. Torella, C. Trigueros, A. Gonzalez, C. Waring, C. Perez-Martinez, A. Perez, C. Indolfi, F. Fernandez, B. Nadal-Ginard (Liverpool, GB; Catanzaro, IT; San Sebastian, Leon and Madrid, ES)
- Epicardium-derived cells and CD117-positive cells in the adult human heart: common origin through epithelial-mesenchymal transition.** P3061
 – F. Di Meglio, D. Nurzyska, C. Castaldo, V. Romano, R. Miraglia, N. Amatruda, C. Bancone, V. Ruzsolillo, G. Langella, S. Montagnani (Naples, IT)
- GLP-1 CellBeads enhance myocardial angiogenesis and improve LV function.** P3062
 – K. Farrell, M. Hawthorne, C. Wallrapp, P. Geigle, A.L. Lewis, P.W. Stratford, N. Malik, C.M. Holt (Manchester and Surrey, GB; Alzenau, DE)
- Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model.** P3063
 – A. Schuh, A. Sasse, E.A. Liehn, M. Kelm, C. Weber, M.W. Merx (Aachen, DE)
- The influence of intracoronary autologous mononuclear bone marrow cell transplantation.** P3064
 – E. Trzos, M. Krzeminska-Pakula, T. Rechinski, M. Bugala, J.D. Kasprzak, M. Plewka, J.Z. Peruga, M. Kurpesa (Lodz, PL)
- Doxorubicin causes depletion of cardiac primitive cell pool that may add to the mechanisms of doxorubicin-mediated delayed cardiotoxicity.** P3065
 – D. Nurzyska, F. Di Meglio, C. Castaldo, V. Romano, R. Miraglia, L. Marina, E. Piegari, A. De Angelis, C. Bancone, S. Montagnani (Naples, IT)
- Time-course of the electrophysiological maturation and integration of transplanted cardiomyocytes.** P3066
 – M. Halbach, B. Krausgrill, T. Hannes, F. Pillekamp, M. Reppel, J. Hescheler, J. Muller-Ehmsen (Cologne, DE)
- Phenotypic analysis of adult human cardiac progenitor cells characterized by high aldehyde dehydrogenase activity and cardiosphere-forming ability.** P3067
 – A. Spicher, M.-E. Roehrich, P. Vogt, G. Pedrazzini, T. Moccetti, G. Vassalli (Lausanne and Lugano, CH)
- Circulating Oct-4+SSEA-4+ very small embryonic-like cells and improvement of LVEF in patients with acute myocardial infarction.** P3068
 – W. Wojakowski, J. Ciosek, M. Kucia, E. Paczkowska, M. Kazmierski, P. Buszman, A. Ochala, B. Machalinski, M.Z. Ratajczak, M. Tendera (Katowice and Szczecin, PL; Louisville, US)
- Stem cell combination therapy for the treatment of severe limb ischaemia.** P3069
 – G. Lasala, J. Silva, J. Minguell (Covington, US)
- Characterisation of a post-natal cardiac progenitor cell population that spontaneously forms beating cardiospheres with no need for differentiation media nor for co-culture with cardiomyocytes.** P3070
 – M.-E. Roehrich, A. Spicher, P. Vogt, G. Pedrazzini, T. Moccetti, G. Vassalli (Lausanne and Lugano, CH)
- Characterisation, isolation and expansion of human Islet-1 stem cells and their progeny from progenitor stage to spontaneously beating cardiomyocytes.** P3071
 – K.H. Grinnemo, R. Genead, C. Danielsson, M. Simonsson, E. Wardell, M. Corbascio, M. Westgren, E. Sundstrom, C. Sylven (Stockholm, SE)
- Mid-term cell loss of mouse embryonic stem cell derived cardiomyocytes after intramyocardial injection into cryo-injured hearts is similarly high, but occurs earlier than in sham-operated mouse hearts.** P3072
 – B. Krausgrill, M. Halbach, S.P. Soemantri, T.G. Plenge, K. Schenk, N. Lange, J. Hescheler, T. Saric, J. Mueller-Ehmsen (Cologne, DE)

- Left atrium of adult porcine heart as a source of progenitor cells.** P3073
 – L. Ye, L.P. Su, K.K. Poh, K.H.H. Haider (Singapore, SG; Cincinnati, US)
- Activin A or inhibition of BMP-2/4 by a specific inhibitor combined with Wnt-3a enhances the differentiation into cardiac myocytes in mouse embryonic stem cells.** P3074
 – S. Ueno (Tochigi, JP)
- Beta-catenin regulates cardiac resident precursor cells.** P3075
 – M.P. Zafiriou, C. Noack, A. Renger, R. Dietz, L. Zelaryan, M.W. Bergmann (Berlin and Hamburg, DE)
- Regenerative potential of adult human cardiac primitive cells is influenced by chronic pathological conditions: a phenotypic and genetic study.** P3076
 – F. Di Meglio, C. Castaldo, D. Nurzynska, R. Miraglia, V. Romano, C. Bancone, G. Langella, C. Vosa, S. Montagnani (Naples, IT)
- Endothelin1-induced postnatal rat cardiac stem cells with transfected pAdCGI-HCN2 and co-expressed beta-KCNE2 for functional assembly of self-organizing pulsatile myocardial tubes.** P3077
 – A.N. Kharlamov, J.L. Gabinsky (Yekaterinburg, RU)
- Kruppel-like factor 15 (KLF15) represses beta-catenin-dependent gene transcription in cardiomyocytes.** P3078
 – C. Noack, A. Renger, M.P. Zafiriou, R. Dietz, L. Zelaryan, M.W. Bergmann (Berlin and Hamburg, DE)
- Enhanced in vivo endothelialisation of allogenic decellularized heart valves by surface coating using autologous fibrin.** P3079
 – P. Akhyari, H. Kamiya, P. Mambou, M. Barth, H. Ziegler, S. Schilp, I. Berger, W.W. Franke, M. Karck, A. Lichtenberg (Jena, Heidelberg and Kassel, DE)
- Human cardiac stem cells are present in a severely damaged, ischemic myocardium.** P3080
 – M.O. Zembala, P. Wilczek, T. Cichon, R. Smolarczyk, R. Przybylski, K. Filipiak, A. Sokal, S. Szala, M. Zembala (Zabrze and Gliwice, PL)
- Association of polymorphisms of zinc metalloproteinases with clinical response to stem cell therapy.** P3081
 – R. Panovsky, A. Vasku, J. Meluzin, S. Janousek, J. Mayer, M. Kaminek, V. Kincl, L. Groch, M. Navratil (Brno and Olomouc, CZ)
- STEM CELLS IN TRANS**
- Loss of CD26 function promotes stabilization of SDF-1 protein yielding enhanced stem cell homing and attenuation of ischemic cardiomyopathy after treatment with G-CSF.** P3082
 – M.-M. Zaruba, H.D. Theiss, U. Mehl, M. Vallaster, R. David, S. Brunner, B. Huber, G. Assmann, J. Mueller-Hoecker, W.M. Franz (Munich, DE)
- Regulation of cardiac angiogenesis in pressure overload by endothelial progenitor cells from the bone marrow.** P3083
 – P. Mueller, P. Jagoda, A. Kazakov, A. Semenov, M. Boehm, U. Laufs (Homburg, DE)
- Intracoronary delivery of endothelial progenitor cells transfected with endothelial nitric oxide synthase in a porcine model of myocardial infarction.** P3084
 – J. Graham, M.R. Ward, K.A. Connelly, R. Vijayaraghavan, G.A. Wright, D.J. Stewart, A.J. Dick (Toronto and Ottawa, CA)
- STRO-1 immunoselection enhances the biological properties and cardiovascular paracrine effects of bone marrow mesenchymal stromal cells.** P3085
 – P.J. Psaltis, F. See, S. Paton, T.P. Martens, S. Itescu, S.G. Worthley, S. Gronthos, A.C.W. Zannettino (Adelaide, AU; New York, US)
- A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD).** P3086
 – S. Seth, B. Bhargava, R. Narang, S. Mohanty, R. Ray, G. Gulati, B. Airan, P. Venugopal (New Delhi, IN)
- Expression and subcellular localization of f-channels in early human development using hESC-derived cardiomyocytes.** P3087
 – A.G. Bosman, L. Sartiani, V. Spinelli, M. Del Lungo, E. Cerbai, M.E. Jaconi (Geneva, CH; Florence, IT)

- Comparison of cardiac regenerative capacity of human mesenchymal stem cells from different sources.** P3088
 – N. Ma, R. Gaebel, D. Furlani, W. Li, K. Bieback, K. Luetzow, A. Lendlein, R.K. Li, G. Steinhoff (Rostock, Mannheim and Teltow, DE; Toronto, CA)
- Improvement of flow-mediated dilatation in patients with acute myocardial infarction treated with intracoronary infusion of CD34⁺CXCR4⁺ cells.** P3089
 – M. Kazmierski, W. Wojakowski, A. Michalewska-Wludarczyk, J. Ciosek, W. Rychlik, E. Hrycek, M. Tendera (Katowice, PL)
- Circulating CD34⁺/VEGFR2 cells derived from endothelial colony-forming cells are associated with infarct size reduction.** P3090
 – N. Meneveau, F. Deschaseaux, V. Descotes Genon, F. Schiele, P. Tiberghien, J.P. Bassand, S. Davani (Besançon, FR)
- Which type of stem cells to choose for endocardial injections in ischemic heart failure patients: bone marrow or peripheral blood?** P3091
 – E. Pokushalov, A. Romanov, S. Artemenko, P. Larionov, O. Poveshenko, I. Terehov, E. Kliver, A. Cherniavskiy (Novosibirsk, RU)
- Human c/kit⁺ amniotic fluid derived stem cells: first step in vitro and in vivo before cardiomyoplasty.** P3092
 – G. Walther, J. Gekas, D. Skuk, E. Larose, O. Costerousse, E. Bujold, O. Bertrand (Quebec, CA)
- Impaired Function of Bone Marrow Derived Mesenchymal Stem Cells from Type II Diabetic Rat.** P3093
 – Y.S. Kim, Y. Ahn, J.S. Kwon, M.H. Jeong, J.G. Cho, J.C. Park, J.C. Kang (Gwangju, KR)
- From SWISS-AMI to CARDIASTIM - translation of a clinical, progenitor-cell based protocol into GMP.** P3094
 – D. Surder, T. Moccetti, G. Astori, G. Soldati, J. Schwitter, P. Erne, A. Moschovitis, S. Windecker, T.F. Luescher, R. Corti (Lugano, Zurich, Lucerne and Berne, CH)
- Early passage mesenchymal stem cells could display abnormalous genotype, karyotype and metabolism.** P3095
 – D. Furlani, W. Li, L. Wang, R. Li, A. Lendlein, G. Steinhoff, N. Ma (Rostock and Teltow, DE; Toronto, CA)
- Junctional adhesion molecule-A is expressed on human CD34⁺ cells and promotes adhesion to immobilized platelets and differentiation to endothelial progenitor cells.** P3096
 – K. Stellos, H. Langer, S. Gnerlich, V. Panagiota, E. Ninci, I. Mueller, B. Bigalke, A. Bueltmann, S. Lindemann, M. Gawaz (Tubingen, DE)
- Efficiency of intramyocardial injections of autologous bone marrow mononuclear stem cells in patients with ischemic heart failure: long-term results.** P3097
 – A. Romanov, E. Pokushalov, S. Artemenko, P. Larionov, I. Terehov, E. Kliver, O. Efanova, A. Cherniavskiy (Novosibirsk, RU)
- Intracoronary infusion of mononuclear cells from the bone marrow or peripheral blood on the recovery of microvascular function in acute myocardial infarction patients: HEBE Doppler substudy.** P3098
 – A. Hirsch, J.D.E. Haec, R. Nijveldt, A.M. Van Der Laan, J.G.P. Tijssen, K.M.J. Marques, F. Zijlstra, A.C. Van Rossum, J.J. Piek (Amsterdam and Groningen, NL)
- Hypoxia accelerates and enhances cardiomyogenesis in mesenchymal stem cells: an environmental cue for a cardiac challenge.** P3099
 – A.A. Ramkisoensing, D.A. Pijnappels, J. Swildens, C.I. Schutte, A. Van Der Laarse, A.A.F. De Vries, M.J. Schalij, D.E. Atsma (Leiden, NL)
- Sildenafil enhances endothelial progenitor cell protection against pulmonary hypertension in rats.** P3100
 – H.K. Yip, C.K. Sun, C.M. Yuen, S. Chua, L.T. Chang, F.Y. Lee, M. Fu (Kaohsiung Hsien, Kaohsiung Hsien and Pingtung, TW)
- Intracoronary infusion of mononuclear cells potentially prevents post-infarct ventricular remodeling in patients with an initial dilated left ventricle: a HEBE substudy.** P3101
 – A.M. Van Der Laan, P.A. Van Der Vleuten, A. Hirsch, R. Nijveldt, W.J. Van Der Giessen, B.J. Biemond, J.G.P. Tijssen, A.C. Van Rossum, F. Zijlstra, J.J. Piek (Amsterdam, Groningen and Rotterdam, NL)

Subpopulations of endothelial progenitor cells-isolation, culture, adhesion and migration. P3102

– K. Walenta, C. Rischar, M. Boehm, E.B. Friedrich (Homburg, DE)

MECHANISMS OF VASCULAR DISEASE

Systematic evaluation of CAD in hemodialysis patients: from screening to evaluation of the artery structure. P3103

– A.M. Varela, E. Taniguchi, J.R. Faria Neto, R. Pecoits-Filho (Curitiba, BR)

Heterogeneity in abdominal aortic aneurysm wall composition. P3104

– R. Hurks, A. Vink, I.E. Hofer, J.P.P.M. De Vries, C.A. Seldenrijk, F.L. Moll, G. Pasterkamp (Utrecht and Nieuwegein, NL)

Predicting cardiovascular events and mortality following abdominal aortic aneurysm surgery. P3105

– R. Hurks, I.E. Hofer, J.P.P.M. De Vries, S.M.W. Van De Weg, M. Kerver, D.P.V. De Kleijn, F.L. Moll, G. Pasterkamp (Utrecht and Nieuwegein, NL)

Association of increased carotid intima-media thickness and arterial stiffness with enhanced monocyte expression of adiponectin receptors in patients with coronary artery disease. P3106

– I. Ikonomidis, A. Kollias, J. Lekakis, I. Palios, P. Tsiotra, E. Maratou, K. Fountoulaki, G. Dimitriadis, S.A. Raptis, D.T. Kremastinos (Athens, GR)

Hemodynamic influences on abdominal aortic aneurysm wall composition. P3107

– R. Hurks, I.E. Hofer, J.A. Van Herwaarden, A. Vink, J.P.P.M. De Vries, G. Pasterkamp, F.L. Moll (Utrecht and Nieuwegein, NL)

Bone marrow-derived dendritic cell-like cells accumulate low-shear stress region in mice. P3108

– M. Tsuzuki (Nagoya, JP)

Central aortic pulse wave analysis among offspring of patients with high cardiovascular risk and symptomatic coronary artery disease. P3109

– A. Rapae, M.A. Nor Hanim, T.K. Ong, C.K. Ang, H.B. Liew, S.A.R.S. Alwi, S.K. Chua, K.L. Yew, B.C. Chang, K.H. Sim (Kuching, MY)

Influencing the anticontractile properties of adipose tissue: the effects of aldosterone, its antagonists and hypoxia. P3110

– C. Agabiti-Rosei, S.B. Withers, A. Greenstein, R. Aslam, K. Khavandi, R.A. Malik, A.M. Heagerty (Manchester, GB)

Human circulating monocyte subpopulations significantly differ in their functional properties. P3111

– F.S. Czepluch, S. Olieslagers, R. Van Hulten, S.A. Voo, J. Waltenberger (Maastricht, NL)

Role of Akt/mTOR/P70S6k and TGF-beta1 pathways on left ventricle remodelling after myocardial infarction. P3112

– G. Vilahur, B. Onate, B. Ibanez, J.J. Badimon, L. Badimon (Barcelona, ES; New York, US)

EFFECT OF PRIMARY AND SECONDARY PREVENTION

Cycling and sports are inversely associated with non-fatal and fatal cardiovascular diseases. P3113

– M.P. Hoevenaer-Blom, G.C.W. Wendel-Vos, A.M.W. Spijkerman, D. Kromhout, W.M.M. Verschuren (Bilthoven and Wageningen, NL)

Reported lifestyle habits and lifestyle changes in high risk patients from 12 European regions: The EUROASPIRE III survey in general practice. P3114

– C.S. Jennings, K. Kotseva, P. Amouyel, G. Debacker, D. Debacker, U. Keil, Z. Reiner, D. Wood (London, GB; Lille, FR; Ghent, BE; Munster, DE; Zagreb, HR)

Screening for asymptomatic peripheral artery disease: first results of the Evaluation of ankle/bRachial index in hungarian hypertensiVes (ERV) screening program. P3115

– K. Farkas, Z. Jarai, E. Kolossvary, A. Ludanyi, I. Kiss (Budapest, HU)

Risk factor control and treatment for patients with known CHD coronary heart disease 2005-2006. P3116

– D. Vulic, S. Loncar, M. Krneta, R. Skrbic, A. Lazarevic, B. Lee, N.D. Wong (Banja Luka, BA; Irvine, US)

- Predictors of risk factors management in patients after percutaneous coronary intervention-single center experience.** P3117
 – M. Licina, V. Giga, B. Beleslin, A. Djordjevic-Dikic, J. Stepanovic, I. Grozdic, I. Stankovic, M. Ostojic (Belgrade, RS)
- Prevention of ischaemic events in patients with peripheral arterial disease according to the European guidelines on cardiovascular disease prevention in clinical practice.** P3118
 – A. Blinc, M. Kozak, M. Sabovic, M. Bozic, M. Stegnar, P. Poredos, A. Kravos, B. Barbic Zagar, M. Pohar Perme, J. Stare (Ljubljana, Maribor and Novo Mesto, SI)
- Use of national intervention coronary registry data as evaluation tools for cardiovascular prevention strategies and treatment in developing countries.** P3119
 – G. Saade, A. Sarkis, G. Ghanem, J. Haddad, S. Dada, C. Abdallah, G. Kiwan, M. Tabbal, W. Chalak, F. Farhat (Beirut, LB)
- Classical risk factors in secondary prevention results from the atherogene study.** P3120
 – C.R. Sinning, S. Blankenberg, R. Schnabel, E. Lubos, P.S. Wild, T. Keller, T. Zeller, K.J. Lackner, T. Muenzel, C. Bickel (Mainz and Koblenz, DE)
- Case method assisted implementation of guidelines decreases mortality, a ten-year follow up of a randomized controlled study.** P3121
 – A. Kiessling, P. Henriksson (Stockholm, SE)
- The benefits of statin therapy in patients without cardiovascular disease: meta-analysis of randomized controlled trials.** P3122
 – J.J. Brughts, T. Yetgin, S.E. Hoeks, A.M. Gotto, J. Shepherd, R.H. Knopp, H. Nakamura, P. Ridker, R. Van Domburg, J.W. Deckers (Rotterdam, NL; New York, Washington and Boston, US; Glasgow, GB; Tokyo, JP)
- Individualized stepped care prevention based on voluntary risk profiling; a promising approach to battle the chronic disease burden.** P3123
 – B.E. Colkesen, B.S. Ferket, M.R. Hoppener, J.J. Mathijssen, R.J.G. Peters, C.K. Van Kalken, R.A. Kraaijenhagen (Amsterdam, NL)
- Cardiovascular screening of potentially sinister cardiac disorders in young apparently healthy individuals: the Northern Ireland experience.** P3124
 – N. Chandra, C. Edwards, M. Papadakis, J. Rawlins, S. Sharma (London, GB)
- Beta-blocker doses in coronary heart disease patients treated in UK primary care.** P3125
 – E. Setakis, G. Kassianos, S. Cockle, T.P. Van Staa, C. Morley (London, Bracknell, Slough and Bradford, GB)
- Determinants of physical inactivity among men and women from Greece; a 5-year follow-up of the ATTICA Study.** P3126
 – C. Chrysohoou, D. Panagiotakos, C. Pitsavos, J. Skoumas, J. Lentzas, A. Zeibekis, L. Papadimitriou, C. Masoura, I. Papaioannou, C. Stefanadis (Athens, GR)
- Long term results of optimal medical therapy with or without cardiac rehabilitation after an acute coronary syndrome.** P3127
 – M. Lafitte, X. Pillois, T. Couffinhal (Pessac, FR)
- Influenza vaccination as a secondary prevention for coronary artery disease. A subgroup analysis of the FLUCAD study.** P3128
 – A. Ciszewski, Z.T. Bilinska, M. Kruk, C. Kepka, L.B. Brydak, M. Romanowska, E. Ksiezycka, W. Piotrowski, A. Witkowski, W. Ruzyllo (Warsaw, PL)
- A multidisciplinary prevention program improves the outcome in non-diabetic patients undergoing percutaneous coronary intervention.** P3129
 – J.M. Vegas Valle, J.M. De La Hera, J.M. Garcia-Ruiz, E. Henandez-Martin, J. Bayon, F. Torres, E. Delgado, P. Avanzas, I. Lozano (Valladolid and Oviedo, ES)
- Antibiotic use and risk of death in patients with myocardial infarction- a nationwide study.** P3130
 – S. Skott Andersen, M.L. Hansen, M.L. Norgaard, F. Folke, E.L. Fosbol, P. Weeke, G.H. Gislason, L. Kober, C. Torp Pedersen (Copenhagen, DK)
- Predictors of change of dietary habits in cohort of 12,513 patients at high risk of cardiovascular risk followed by 860 Italian general Practitioners: preliminary analysis of the risk & prevention trial.** P3131
 – M.G. Silletta, R. Marchioli, F. Avanzini, P. Longoni, I. Marzona, R. Pioggiarella, M.C. Roncaglioni, M. Scarano, G. Tognoni, M. Tombesi (Santa Maria Imbaro, Milan and Monza, IT)

- Racial disparities in survival in patients with pulmonary hypertension.** P3132
 – S.A. Hart, A. Wang, J.K. Harrison, T. Bashore, R.A. Krasuski (Cleveland and Durham, US)
- REGIONAL/ETHNIC DIFFERENCES**
- Cuba singularity: different environmental and coronary heart disease mortality but similar life expectancy at birth than Spain.** P3133
 – A. Morales, R. Duenas, B. Martinez, A. Rodriguez, G.A. Perez, M. Grau, R. Elosua, J. Marrugat, R. Ramos, M. Reyes (Santa Clara, CU; Barcelona, ES)
- Heavy alcohol intake coincides with impaired arterial elasticity in hypertensive immigrants of Eastern European countries.** P3134
 – V. Katsi, I. Skiadas, E. Androulakis, G. Moustakas, G. Souretis, P. Theodoropoulos, C. Stefanadis, I. Kallikazaros (Athens, GR)
- A comparison of all coronary angiographies performed in 2008 in two European countries.** P3135
 – T. Gudnason, B. Lagerqvist, K. Eyjolfsson, T. Nilsson, T.F. Jonasson, R. Danielsen, G.S. Gudnadottir, G. Thorgeirsson, K. Andersen, S. James (Reykjavik, IS; Uppsala, SE)
- Prevalence of lipid disorders in statin treated patients from Sweden, Norway and Denmark: Results from the Dyslipidemia International Study (DYSIS).** P3136
 – K. Korsgaard Thomsen, P. Lundman, S. Salling, G. Journath, T. Pedersen (Esbjerg and Glostrup, DK; Stockholm and Sollentuna, SE; Oslo, NO)
- Arterial compliance and angiotensin converting enzyme gene I/D polymorphism with acute high altitude reaction.** P3137
 – N.L. Sun, L.Y. Wang, Y. Xi (Beijing, CN)
- Why better risk factors profile but more cardiovascular mortality in Romania compared with Poland?** P3138
 – M. Doborobantu, P. Bandosz, E. Badila, T. Zdrojewski, S. Ghiorghe (Bucharest, RO; Gdansk, PL)
- Abdominal obesity, hypertension and cardiovascular disease in Poland compared to North-West Europe Region: insights from IDEA study.** P3139
 – M. Chrostowska, A. Szyndler, R. Szczech, J. Wolf, P. Paczwa, K. Narkiewicz (Gdansk and Warsaw, PL)
- Quality of care and outcomes of acute coronary syndromes in aboriginal Australians: Data from the CASPA study.** P3140
 – A. Brown, S. Stewart, W. Beever, T. Weeramanthri, B. Currie (Melbourne and Darwin, AU)
- Cardiovascular risk profiles and outcomes of Chinese living in mainland China, Hong Kong/Singapore/Taiwan, Western Europe, and North America: the REACH OCEAN substudy.** P3141
 – J.F. Chiu, A.B. Bell, R.H. Herman, M.D. Hill, J.A. Stewart, E.A. Cohen, C.S. Liao, S.C. Smith, P.G. Steg, D.L. Bhatt (Edmonton, Toronto, Calgary and Laval, CA; Taipei, TW; Chapel Hill and Boston, US; Paris, FR)
- Despite the high incidence of IHD in Asians mortality post PCI for NSTEMI is the same as Caucasians.** P3142
 – D. Jones, K.S. Rathod, E. Wicks, N. Qureshi, A. Kapur, P.G. Mills, C. Knight, M.T. Rothman, A.D. Timmis, A. Wragg (London, GB)
- 20 years of experience in invasive treatment of acute myocardial infarction with 24-hours on-site cathlab service.** P3143
 – M. Gasior, Z. Kalarus, M. Gierlotka, A. Lekston, T. Was, P. Chodor, R. Wojnar, M. Swierad, M. Zembala, L. Polonski (Zabrze, PL)
- A comparison of all percutaneous coronary interventions, performed in 2008 in two European countries.** P3144
 – T. Gudnason, S. James, K. Eyjolfsson, S. Scheving, T. Gudjonsson, G. Karlsson, A.F. Sigurdsson, K. Andersen, G. Thorgeirsson, B. Lagerqvist (Reykjavik, IS; Uppsala, SE)
- The Maori population of New Zealand carry a high burden of coronary heart disease.** P3145
 – S. Mann, M. Tobias, L.-C. Yeh, C. Wright, W.C. Chan, T. Riddell, R. Jackson (Wellington and Auckland, NZ)

Correlates of microalbuminuria in Greek adolescents: Preliminary insights from the Lyceum Leontio Albuminuria (3L) study. P3146

– K. Dimitriadis, C. Tsioufis, D. Syrseloudis, C. Thomopoulos, D. Chatzis, A. Gennadi, E. Taxiarchou, D. Tsiachris, I. Kallikazaros, C. Stefanadis (Athens, GR)

Increased burden of high blood pressure and related risk factors among participants of World Heart Day in Cameroon. P3147

– D. Lemogoum, N. Hamadou, J.J. Pik, J. Dieuboue, W. Ngatchou, A. Nana, M. Leeman, J.P. Degaute, P.H. Van De Borne (Brussels, BE; Maroua and Douala, CM; Clermont Oise, FR)

Can one drug fit all? - urban Chinese population has high prevalence of CAD and stroke with unique pattern of risk factors - a study of CCMR. P3148

– D.Y. Hu, J.M. Yu, Y.H. Sun, F. Jian, H. Liu, J.H. Wang, F. Wang, H.L. Wang, D.Y. Zhang (Beijing and Shanghai, CN)

Population-based study of pediatric sudden death in Taiwan 2000-6. P3149

– M.H. Wu, H.C. Chen, J.K. Wang, S.C. Huang, S.K. Huang (Taipei, TW)

Prevalence and risk factors for stroke in the primary health care. Insights of the VALSIM study. P3150

– N. Cortez-Dias, S. Martins, A. Belo, M. Fiuzza (Lisbon, PT)

PSYCHO-SOCIAL FACTORS

The influence of stress at work on the risk of developing of cardiovascular diseases in general population 25-64 years old in Russia (program WHO MONICA-psychosocial). P3151

– V. Gafarov, E. Gromova, I. Gagulin, Y. Kabanov, A. Gafarova (Novosibirsk, RU)

10- years influence of stress in the family on the risk of developing of cardiovascular diseases in general population men 25-64 years old in Russia (program WHO MONICA-psychosocial). P3152

– V. Gafarov, E. Gromova, I. Gagulin, Y. Kabanov, A. Gafarova (Novosibirsk, RU)

Relationship between circulating endothelial progenitor cells, vascular dysfunction and depression status in diabetes mellitus subjects. P3153

– H. Chen, J. Qiuwaxi, C.Y. Wong, S.W. Li, H.T. Chan, S. Tam, C.P. Lau, H.F. Tse (Beijing and Hong Kong, CN)

Depressive symptoms and outcomes in patients with heart failure: data from the COACH. P3154

– I. Lesman-Leegte, D.J. Van Veldhuisen, H. Hillege, D. Moser, R. Sanderman, T. Jaarsma (Groningen, NL; Lexington, US)

Association of depressive and anxiety symptoms with heart rate variability and C-reactive protein in clinically non-depressed patients with acute coronary syndrome. P3155

– J.A. Hanash, B.H. Hanasen, M. Birket-Smith, O.W. Nielsen, A. Rasmussen, A. Sajadieh, J.F. Hansen (Copenhagen, DK)

Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. P3156

– C. Pizzi, S. Mancini, L. Angeloni, F. Fontana, G.M. Costa (Bologna, Modena and Bergamo, IT)

Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: A one-year follow-up study. P3157

– M. Nikolaou, J.T. Parissis, D. Farmakis, D. Birmpa, V. Bistola, T. Katsoulas, G. Filippatos, D. Kremastinos (Athens, GR)

Five-year follow-up of quality of life in randomized patients to receive coronary bypass surgery, percutaneous coronary intervention or medical treatment: the medicine angioplasty or surgery study. P3158

– M.E. Takiuti, P. Girardi, C.R.S.R. Nogueira, T. Nakano, E.G. Lima, R.D. Vieira, C.L. Garzillo, N. Lopes, W.A. Hueb, J.A.F. Ramires (Sao Paulo, BR)

Improvement in walking performance affects long-term quality of life in non-vascular peripheral artery patients. P3159

– I.I. De Liefde, S.E. Hoeks, K.G. Smolderen, J. Klein, J.J. Bax, H.J.M. Verhagen, R.T. Van Domburg, D. Poldermans (Rotterdam, Tilburg and Leiden, NL)

Strong association between subclinical atherosclerosis and type of occupation in 3711 high risk European individuals. P3160

– F. Veglia, C.C. Tedesco, K. Nyyssönen, D. Baldassarre, M. Amato, E. Tremoli (Milan, IT; Kuopio, FI)

Do negative psychosocial risk factors influence the person's behaviour to more unhealthy? The results of National multicenter health survey (WOBASZ). P3161

– J. Piwonski, A. Piwonska, W. Drygas, T. Zdrojewski, J. Gluszek, A. Pajak, K. Kozakiewicz (Warsaw, Lodz, Gdansk, Poznan, Krakow and Katowice, PL)

Brief depression screening with the PHQ-2 predicts poor prognosis following percutaneous coronary intervention with drug-eluting stenting. P3162

– T. Schmidt Pedersen, J. Denollet, P. De Jonge, C. Simsek, P. Serruys, R. Van Domburg (Tilburg, Groningen and Rotterdam, NL)

The impact of elevated serum levels of glucose and inflammatory biomarkers on the long term mortality in non-diabetics with acute coronary syndromes. P3163

– S.S. Makrygiannis, M. Zairis, C. Vogiatzidis, C. Ritsatos, S. Karvounaris, A. Benopoulos, C. Garefalakis, N. Patsourakos, C. Katsaros, S.G. Foussas (Piraeus, GR)

Type D personality and reduced benefit following exercise therapy in peripheral arterial disease. P3164

– K.G.E. Smolderen, L.M. Kruidenier, J. Denollet, S.P. Nicolai, P.W. Vriens, J.A.W. Teijink (Tilburg and Heerlen, NL)

Type D personality predicts clinical events after myocardial infarction, above and beyond disease severity and depression. P3165

– E.J. Martens, F. Mols, M. Burg, J. Denollet (Tilburg, NL; New Haven, US)

Psycho-social factors and outcome of very young adults following acute myocardial infarction, a single center experience. P3166

– M. Hammoud, D. Sharif, U. Rosenschein (Haifa, IL)

Quality of life and depressive symptoms in an outpatient population with heart failure. P3167

– B. Gonzalez, L. Cano, R. Cabanes, F. Pons, C. Diez, A. Urrutia, S. Altimir, R. Coll, T. Pascual, J. Lupon (Badalona, ES)

It is just a game: lack of association between watching football matches and risk of acute cardiovascular events. P3168

– F. Barone Adesi, L. Vizzini, F. Merletti, L. Richiardi (Turin, IT)

Poor patient-rated health status predicts 1-year prognosis in patients treated with percutaneous coronary intervention with drug-eluting stenting. P3169

– S. Schmidt Pedersen, H. Versteeg, J. Denollet, P. Serruys, R. Van Domburg (Tilburg and Rotterdam, NL)

Comprehensive cardiac rehabilitation improves self-estimated health and patient satisfaction - important factors in future risk factor and life style management. P3170

– A.M.B. Soja, A.D.O. Zwisler, N. Nissen, S. Rasmussen, T.M. Melchior, E. Hommel, J. Fischer Hansen, M. Madsen (Copenhagen, Roskilde and Gentofte, DK)

Divergent effects of laughter and mental stress on peripheral/central blood pressures and blood markers. P3171

– P. Xaplanteris, C. Vlachopoulos, C. Vassiliadou, D. Kardara, I. Dima, K. Baou, C. Stefanadis (Athens, GR)

Different psychological features of Takotsubo cardiomyopathy and acute myocardial infarction. P3172

– A.C. Compare, P. Silva, D. Gregori, R. Proietti, E. Grossi, R. Bigi (Milan and Padua, IT)

PROCEDURAL COMPLICATIONS OF PERCUTANEOUS CARDIAC INTERVENTIONS - PART I

Relationship between myocardial blush grades and microvascular damage assessed by cardiac magnetic resonance after primary angioplasty. P3173

– M. Perazzolo Marra, F. Corbetti, L. Cacciavillani, A.B. Ramondo, G. Tarantini, M. Napodano, C. Basso, A. Marzari, F. Maddalena, S. Illiceto (Padua, IT)

Distal embolisation in complex percutaneous coronary interventions: A CMR and inflammatory biomarkers study. P3174

– D. Locca, C.H. Bucchiarelli-Ducci, G. Ferrante, A. La Manna, N. Keenan, A. Grasso, P. Barlis, J.C. Kaski, D.J. Pennell, C. Di Mario (Lausanne, CH; London, GB)

- High dose atorvastatin reload pre PCI increases circulating levels of endothelial progenitor cells. The ARMYDA EPC study.** P3175
 – R. De Caterina, R. Madonna, L. Gatto, E. Ricottini, A. Tatasciore, G. Patti, G. Di Sciascio (Chieti and Rome, IT)
- IVUS insights into coronary rupture during PCI.** P3176
 – A.S.P. Sharp, R.T. Gerber, A. Latib, M. Bande, C. Godino, M. Ferraro, A. Colombo (Milan, IT)
- Impact of isolated troponin elevations after PCI on two-year mortality.** P3177
 – P. Sbarzaglia, S. Savonitto, R. Violini, G. Arraiz, Z. Olivari, S. Notaristefano, S. De Servi, G. Steffenino, D. Ardissino, C. Cavallini (Perugia, Milan, Rome, Treviso, Legnano, Cuneo and Parma, IT)
- Background. Cardiac Magnetic Resonance Imaging (CMR) can identify myocardial damage due to embolization after percutaneous coronary interventions (PCI). Late Gadolinium Enhancement (LGE) can non-invas.** P3178
 – D. Locca, G. Ferrante, C.H. Bucchiarelli-Ducci, A. La Manna, F. Delfuria, A. Grasso, P. Barlis, S.K. Prasad, D.J. Pennell, C. Di Mario (Lausanne, CH; London, GB)
- Altered fibrin clot structure and function are associated with in-stent thrombosis.** P3179
 – J. Zalewski, A. Undas, M. Krochin, Z. Siudak, M. Sadowski, J. Pregowski, M. Janion, A. Witkowski, D. Dudek, K. Zmudka (Krakow, Kielce and Warsaw, PL)
- The impact of age on the results of percutaneous coronary intervention (PCI) in patients with stable angina. Results from the ALKK PCI registry.** P3180
 – S. Kim, M. Hochadel, U. Zeymer, H. Darius, S. Kerber, K.E. Hauptmann, J. Senges, U. Sechtem, H. Mudra, R. Zahn (Ludwigshafen am Rhein, Berlin, Bad Neustadt/Saale, Trier, Stuttgart and Munich, DE)
- Trends, predictors and outcomes of stroke related to percutaneous coronary intervention: a fifteen year single center experience.** P3181 (W)
 – S. Hoffman, C.S. Rihal, R. Bashir, R.J. Lennon, A.A. Rabinstein, R.D. Simari, D.R. Homes Jr, R. Gulati (Rochester and Philadelphia, US)
- Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction.** P3182
 – M. Ergelen, H. Uyarel, D. Osmonov, E. Ayhan, E. Akkaya, O. Ozer, M. Bozbay, A. Turer, C. Turkan, E. Yildirim (Istanbul, Balikesir and Gaziantep, TR)
- Impact of preoperative multidetector computed tomography in percutaneous coronary intervention of chronic total occlusion.** P3183
 – K. Ueno, A. Kawamura, Y. Jo, K. Hayashida, S. Yuasa, Y. Maekawa, T. Anzai, M. Jinzaki, S. Kuribayashi, S. Ogawa (Tokyo, JP)
- Furosemide-induced diuresis with matched hydration compared to standard hydration for contrast-induced nephropathy prevention: preliminary results of the MYTHOS trial.** P3184
 – G. Marenzi, C. Ferrari, E. Assanelli, I. Marana, G. Lauri, J. Campodonico, G. Teruzzi, D. Trabattoni, A.L. Bartorelli (Milan, IT)
- Is rescue PCI related to worse outcome?** P3185
 – C. Hernandez, C. Tapia, R. Andion, J.M. Vegas, F. Gimeno, I. Gonzalez, I. Amat, H. Gutierrez, M. Sandin, J.A. San Roman (Valladolid, ES)
- Radial anomalies in the transradial access in percutaneous coronary intervention: characteristics and results of 7 years experience.** P3186
 – A. Rodriguez Vilela, J. Salgado Fernandez, G. Aldama Lopez, R. Estevez Loureiro, E. Barge Caballero, J.M. Vazquez Rodriguez, R. Calvino Santos, N. Vazquez Gonzalez, A. Castro Beiras (A Coruna, ES)
- Factors predicting neurological complications following percutaneous coronary angiography and interventions in a large series of transfemoral and transradial approach.** P3187
 – H. Tizon Marcos, G.R. Barbeau, C.M. Nguyen, B. Noel, R.H. Bagur, J.R. Rodes-Cabau, E. Larose, S. Rinfret, R.H. Delarochelliere (Quebec, CA)
- Impact of preinterventional plaque composition and eccentricity on the late acquired stent apposition after sirolimus-eluting stent implantation: an intravascular ultrasound radiofrequency analysis.** P3188
 – T. Sato, T. Kameyama, T. Noto, H. Inoue (Toyama, JP)

- Usefulness of urinary neutrophil gelatinase associated lipocalin to urinary creatinine ratio for monitoring of n-acetyl cysteine efficacy in contrast induced nephropathy.** P3189
 – C. Demponeras, N. Kafkas, K. Makris, A. Nikolaou, K. Triantafyllou, G. Mertzanos, S. Potamitis, I. Drakopoulos, D. Babalis (Athens, GR)
- Comparison influence oral versus intravenous hydration on renal function in diabetic patients before and after coronary angiography and angioplasty.** P3190
 – W. Wrobel, W. Sinkiewicz, M. Gordon, M. Zielinski (Bydgoszcz and Chojnice, PL)
- Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.** P3191
 – L. Testa, P. Agostoni, G.G.L. Biondi Zoccai, R.A. Latini, M.L. Laudisa, S. Pizzocri, S. Lanotte, N. Brambilla, A.P. Banning, F. Bedogni (Milan and Turin, IT; Utrecht, NL)
- Safety of balloon occlusion in angiographically normal coronary arteries.** P3192
 – S. Gloekler, P. Meier, T. Traupe, S.F. De Marchi, C. Seiler (Berne, CH; Ann Arbor, US)

PROCEDURAL COMPLICATIONS OF PERCUTANEOUS CARDIAC INTERVENTIONS – PART II

- Prevention of contrast-induced nephropathy in patients undergoing coronary angiography: comparison of two strategies.** P3193
 – S. Rocha Costa, M. Torres, P. Azevedo, J. Costa, R. Rodrigues, S. Nabais, A. Gaspar, S. Ribeiro, A. Salgado, A. Correia (Braga and Oporto, PT)
- Management and outcomes of coronary artery perforation during percutaneous coronary intervention- eight years of institutional experience.** P3194
 – A. Shimony, D. Zahger, R. Ilia, H. Gilutz, A. Shalev, C. Cafri (Beer Sheva, IL)
- Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction: Incidence, a simple risk score, and prognosis.** P3195
 – H. Uyarel, M. Ergelen, E. Ayhan, E. Akkaya, M. Gul, D. Demirci, T. Isik, G. Cicek, D.E. Demirci, R. Ozturk (Balikesir and Istanbul, TR)
- Combined treatment with ascorbic acid and N-acetylcysteine prevents contrast-induced nephropathy in patients with acute coronary syndrome undergoing coronary intervention.** P3196
 – M. Grygier, M. Janus, A. Araszkiwicz, J. Kowal, T. Mularek-Kubzdzela, M. Lesiak, M. Popiel, A. Olasinska, W. Seniuk, S. Grajek (Poznan, PL)
- Fate of jailed side branch during stent deployment -comparison between paclitaxel- and sirolimus -eluting stent-.** P3197
 – M. Yamawaki, T. Muramatsu, R. Tsukahara, Y. Ito, T. Sakai, H. Ishimori, K. Sasao, M. Nakano, K. Hirano, M. Araki (Yokohama, JP)
- Serial follow-up of coronary artery aneurysm after drug-eluting stent implantation at 6 months and 2 years.** P3198
 – W.-J. Kim, Y.-H. Kim, D.-W. Park, S.-W. Lee, S.-C. Yun, C.-W. Lee, M.-K. Hong, S.-W. Park, S.-J. Park (Seoul, KR)
- Impact of coronary plaque characteristics on distal embolization during elective PCI - tissue characterization using integrated backscatter intravascular ultrasound (IB-IVUS) -.** P3199
 – Y. Muraoka, S. Sonoda, M. Okazaki, Y. Otsuji (Kitakyushu, JP)
- Women undergoing coronary angiography have increased risk of bleeding compared to men.** P3200
 – S. Simek, P. Widimsky, Z. Motovska, P. Kala, R. Pudil, H. Skalicka, P. Kuchynka, R. Petr, F. Holm, M. Aschermann (Prague, Brno and Hradec Kralove, CZ)
- Multivessel PCI in stable angina, is there an avoidable cost to the myocardium?** P3201
 – A.S.P. Sharp, R.T. Gerber, A. Ielasi, M. Ferraro, A. Colombo (Milan, IT)
- Factors influencing the use of femoral route by default radial operators in coronary angioplasty may contribute to increased access site bleeding complication.** P3202
 – I. Mahmood, M.M. Uddin, T.D. Kinnaird, R.A. Anderson (Cardiff, GB)

INTERVENTION: PRE-CLINICAL STUDIES

Modification of contrast medium-induced renal tubular cell apoptosis via endoplasmic reticulum stress response. P3203

– C.K. Chiang, C.T. Wu, M.L. Sheu, S.H. Liu (Taipei, TW)

Assessment of a new biodegradable drug eluting stent for the inhibition of neovascularisation and neointimal hyperplasia: an experimental study with Optical Coherence Tomography. P3204

– K. Toutouzas, A. Synetos, A. Karanasos, E. Tsiamis, E. Stefanadi, N. Kipshidze, C. Stefanadis (Athens, GR; New York, US)

Early endothelialization in Paclitaxel eluting stents is similar to other drug-eluting and bare metal stents but shows transient endothelial dysfunction. P3205

– O. Sorop, M. Van Den Heuvel, Y. Onuma, A.H.J. Danser, D.J. Duncker, W.J. Van Der Giessen, H.M.M. Van Beusekom (Rotterdam, NL)

Inhibition of coronary neointimal hyperplasia in swine using a novel zotarolimus-eluting balloon catheter. P3206

– B. Cremers, J. Toner, L.B. Schwartz, R. Von Oepen, U. Speck, N. Kaufels, D. Mahnkopf, M. Boehm, B. Scheller (Homburg, Berlin and Rottmersleben, DE; Abbott Park, US)

A new DES with antiinflammatory and antiproliferative activity reduces in-stent restenosis. Experimental studies in the pig coronary model. P3207

– L. Casani, O. Juan, A. Serra, L. Duocastella, M. Molina, J. Garcia-Rafanell, L. Badimon (Barcelona, ES)

Serum hs-CRP levels predict plaque rupture identified by optical coherence tomography, in acute coronary syndromes or stable angina. P3208

– K. Bouki, M. Katsafados, D. Chatzopoulos, S. Psychari, H. Gika, E. Kapsali, H. Sakali, K. Paravolidakis, G. Liakos, T. Apostolou (Pireaus, GR)

Endothelial progenitor cell (EPC) capture in stented porcine coronary arteries increases endothelialization but does not affect intimal thickening. P3209

– H.M.M. Van Beusekom, G. Ertas, O. Sorop, I. Peters-Krabbendam, W.J. Van Der Giessen (Rotterdam and Utrecht, NL; Kocaeli, TR)

Only specific coronary drug-eluting stents interfere with distal microvascular function. P3210

– M. Van Den Heuvel, O. Sorop, W.W. Batenburg, S.C. Krabbendam, H.M.M. Van Beusekom, D.J. Duncker, A.H.J. Danser, W.J. Van Der Giessen (Rotterdam, NL)

The balance between polymer degradation and drug concentration determines the neointimal response to stents eluting Tacrolimus from a biodegradable polymer coating up to 1 year post stenting. P3211

– H.M.M. Van Beusekom, O. Sorop, J. Wentzel, D.J. Duncker, W.J. Van Der Giessen (Rotterdam and Utrecht, NL)

Beneficial gene profile after local rosiglitazone treatment of in-stent-restenosis in a porcine coronary model. P3212

– K. Pels, S.I. Utchil, D. Boesel, J. Klinowski, C. Loddenkemper, H.P. Schultheiss, C. Dang-Heine (Berlin, DE)

PROCEDURAL COMPLICATIONS OF PERCUTANEOUS CARDIAC INTERVENTIONS – PART III. COMPLICATIONS

Impact of heparin dosage on bleeding in primary PCI for ST-elevation myocardial infarction. P3213

– R.S. Hermanides, J.P. Ottervanger, J.H.E. Dambrink, M.J. De Boer, J.C.A. Hoorntje, A.T.M. Gosseliink, H. Suryapranata, A.W.J. Van 't Hof (Zwolle, NL)

Determinants of bleeding in ST-elevation myocardial infarction patients treated with triple antiplatelet therapy - a subanalysis of the ONTIME II study. P3214

– R.S. Hermanides, J.P. Ottervanger, T. Dill, G. Van Houwelingen, J.M. Ten Berg, C. Hamm, A.W.J. Van 't Hof (Zwolle, Enschede and Nieuwegein, NL; Bad Nauheim, DE)

Do not miss the presence of deep echo attenuation without calcification on intravascular ultrasound. P3215

– N. Mitsuba, H. Teragawa, K. Nishioka, S. Mikami, Y. Fujii, N. Fujimura, T. Okada, F. Tadehara, Y. Kihara (Hiroshima, JP)

- Can we estimate safe doses of contrast media during PCI without risk of contrast media induced nephropathy.** P3216
 – H.J. Yoon, H.T. Kim, I.C. Kim, H.S. Park, Y.K. Cho, H. Kim, C.W. Nam, S.H. Hur, Y.N. Kim, K.B. Kim (Daegu, KR)
- Clinical outcomes and predictors of adverse events of patients presenting with documented stent thrombosis.** P3217
 – D. Zavalloni, L. Porcu, V. Torri, M.L. Rossi, G.L. Gasparini, M. Scatturin, D. Soregaroli, E. Corrada, V. Lisignoli, P. Presbitero (Rozzano and Milan, IT)
- Clinical experience of catalyst ii wire vascular access management device in diagnostic and interventional percutaneous procedures with the same day discharge (The BOOMERANG same day discharge trial).** P3218
 – R.S. Kiesz, B.K. Wiernek, S.L. Wiernek, G.V. Nazarewicz, J.L. Martin, P.E. Buszman (San Antonio, US; Katowice, PL)
- Effect of two-day atorvastatin pre-treatment on the incidence of peri-procedural myocardial infarction following elective percutaneous coronary intervention.** P3219
 – J. Veselka, D. Zemanek, P. Hajek, M. Maly, R. Adlova, L. Martinkovicova, D. Tesar (Prague, CZ)
- Intravenous glutathione prevents contrast-induced nephropathy by reducing renal oxidative stress after coronary angiography: a new use of an old drug.** P3220
 – T. Saitoh, H. Satoh, M. Saotome, T. Urushida, H. Katoh, H. Hayashi (Hamamatsu, JP)
- Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI.** P3221
 – S. Worasuwannarak, S. Pornratanarangi (Bangkok, TH)
- Is contrast-induced nephropathy an independent predictor of long-term mortality in patients who undergo primary PCI?** P3222
 – G. Crimi, V. Rancati, G.M. De Ferrari, A. Repetto, M. Lettino, B. Marinoni, F. Russo, A. Potenza, S. Pica, L. Oltrona Visconti (Pavia, IT)
- Long term results after switch from abciximab to eptifibatid during percutaneous coronary interventions.** P3223
 – M. Koutouzis, B. Lagerqvist, P. Albertsson, G. Matejka, L. Grip (Gothenburg and Uppsala, SE)
- The 5352 A allele of the pro-inflammatory Caspase-1 gene predicts late acquired stent malapposition in STEMI patients treated with sirolimus stents.** P3224
 – S.C. Bergheanu, D. Pons, B.L. Van Der Hoeven, S.S. Liem, B. Siegerink, M.J. Schaliij, J.G. Van Der Born, J.W. Jukema (Leiden, NL)
- The impact of elevated body mass index versus metabolic abnormalities on mortality following percutaneous coronary intervention.** P3225
 – L. Razzouk, P. Muntner, A.S. Kini, M.C. Kim, P.M. Moreno, S.K. Sharma, M.E. Farkouh (New York, US)
- Radiation doses to patients in interventional cardiology.** P3226
 – A. Benini, F. Pedersen, S. Helqvist, J. Kastrup, H. Kelbaek, K. Saunamaki, E. Jorgensen (Copenhagen, DK)
- Positive influence in survival of operator defined strategies during percutaneous coronary intervention.** P3227
 – R. Teles, L. Raposo, M. Almeida, P. Goncalves, F. Pereira-Machado, P. Sousa, J. Brito, R. Cale, J. Abecasis, A. Silva (Carnaxide, PT)
- Differential impact of bleeding complications on in-hospital outcome at the time of PCI.** P3228
 – D. Faes, J. Jamart, P. Chenu, V. Dangoisse, A. Guedes, L. Gabriel, M. Gerard, B. Marchandise, P.H. Colles, E. Schroeder (Yvoir, BE)
- Intra-procedural continuous venous venous hemofiltration in preventing contrast induced nephropathy in patients with very low creatinine clearance undergoing coronary intervention.** P3229
 – L. Politi, F. Sgura, R. Rossi, D. Monopoli, F. Rollini, S. Perrone, G.M. Sangiorgi, M.G. Modena (Modena, IT)
- The role of renal function at discharge in patients with acute myocardial infarction and contrast-induced nephropathy after invasive treatment.** P3230
 – J. Kowalczyk, R. Lenarczyk, A. Sedkowska, M. Mazurek, P. Pruszkowska-Skrzep, A. Wozniak, T. Kukulski, J. Gumprecht, L. Polonski, Z. Kalarus (Zabrze, PL)

Ratio of Urinary Neutrophil Gelatinase Associated Lipocalin to urinary creatinine as predictor of contrast induced nephropathy after coronary angiography. P3231
 – N. Kafkas, C. Demponeras, K. Makris, A. Nikolaou, K. Triantafyllou, G. Mertzanos, S. Potamitis, I. Drakopoulos, D. Babalis (Athens, GR)

Hypoglycemia predicts peri-procedural myocardial damage in patients undergoing elective percutaneous coronary revascularisation. P3232
 – A. Nusca, G. Patti, F. Marino, A. Abbate, A. D'Ambrosio, F. Mangiacapra, G. Di Sciascio (Rome, IT; Richmond, US)

GENETIC ASPECTS OF CARDIOMYOPATHIES

Mutations in Desmocollin-2: is A897KfsX3 pathogenic for arrhythmogenic right ventricular cardiomyopathy? P3233
 – M. De Bortoli, G. Beffagna, B. Bauce, A. Lorenzon, G. Smaniotta, C. Basso, G. Thiene, G.A. Danieli, A. Nava, A. Rampazzo (Padua, IT)

Severe familial left ventricular noncompaction cardiomyopathy due to a novel troponin T (TNNT2) mutation. P3234
 – P. Ehlermann, M. Luedde, D. Weichenhan, R. Will, A. Mueller, S. Rupp, H. Steen, B. Kern, H.A. Katus, N. Frey (Heidelberg, Kiel and Giessen, DE)

Systolic dysfunction in hypertrophic cardiomyopathy caused by Arg723Gly mutation in the beta-myosin gene. P3235
 – F. Navarro-Lopez, A. Francino, J.C. Pare (Barcelona, ES)

Hereditary transthyretin-related amyloidosis with exclusive cardiac phenotype. P3236
 – P. Ciliberti, C.C. Quarta, L. Riva, S. Longhi, G. Galati, C. Villani, F. Salvi, M. Lorenzini, A. Branzi, C. Rapezzi (Bologna, IT)

Endothelial nitric oxide synthase polymorphisms interact with glucose homeostasis and inflammatory profile to cause coronary microvascular dysfunction in dilated cardiomyopathy. P3237
 – M. Coceani, M.G. Colombo, T. Sampietro, D. Adlerstein, M.G. Andreassi, C. Carpeggiani, A. L'Abbate, D. Neglia (Pisa, Massa and Vercelli, IT)

Myocardial atrophy onset is a postnatal event initiated by cardiomyocyte necrosis in desmoglein-2 transgenic mice with arrhythmic cardiomyopathy. P3238
 – K. Pilichou, C. Basso, C.A. Remme, S. Rizzo, M.E. Campian, B. Bauce, A.A.M. Wilde, A.F.M. Moorman, G. Thiene, C.R. Bezzina (Padua, IT; Amsterdam, NL)

99Tc-DPD scintigraphy can detect early myocardial amyloid deposition in transthyretin-related familial amyloid polineuropathy. P3239
 – L. Riva, C.C. Quarta, S. Longhi, P.L. Guidalotti, P. Ciliberti, G. Galati, E. Biagini, C. Pettinato, A. Branzi, C. Rapezzi (Bologna, IT)

NEBL encoding the cardiac Z-disc protein nebulin as a novel disease gene for cardiomyopathies. P3240
 – P. Tomasov, A. Perrot, D. Zemanek, S. Homolova, M. Sedlakova, J. Lossie, R. Dietz, M.G. Posch, C. Ozcelik, J. Veselka (Prague, CZ; Berlin, DE)

Diagnostic mutation analysis in hypertrophic cardiomyopathy by DNA resequencing array. P3241
 – S. Fokstuen, A. Munoz, P. Melacini, A. Perrot, X. Jeanrenaud, M. Farr, U. Sigwart, R. Lerch, S.E. Antonarakis, J.L. Blouin (Geneva and Lausanne, CH; Padua, IT; Berlin and Bad-Oeynhausen, DE)

Validation of revised task force criteria for the diagnosis of arrhythmogenic right ventricular cardiomyopathy in families with dominant mutations. P3242
 – A. Tsatsopoulou, A. Anastasakis, L. Antoniadis, G. Chlouverakis, P. Syrris, A. Asimaki, C. Eutychiou, C. Stefanadis, W.J. McKenna, N. Protonotarios (Naxos, Athens and Heraklion, GR; Nicosia, CY; London, GB)

Familial noncompaction cardiomyopathy: genetic and cardiologic features in adults and children. P3243
 – Y.M. Hoedemaekers, K. Caliskan, M. Michels, I. Frohn-Mulder, J. Van Der Smagt, J.E. Phefferkorn, F.J. Ten Cate, D. Dooijes, D.F. Majoer-Krakauer (Rotterdam and Utrecht, NL)

- Outcome of genetic screening of sarcomere protein genes in isolated left ventricular noncompaction.** P3244
 – S. Klaassen, S. Probst, E. Oechslin, B. Gerull, F. Berger, L. Thierfelder, R. Jenni (Berlin, DE; Toronto, CA; Zurich, CH)
- Myosin mutations in familial hypertrophic cardiomyopathy: primary functional defects and development of contractile dysfunction.** P3245
 – T. Kraft, S. Dunda, S. Tripathi, E. Becker, A. Perrot, C. Oezcelik, W.J. McKenna, F. Navarro-Lopez, A. Francino, B. Brenner (Hannover and Berlin, DE; London, GB; Barcelona, ES)
- The growth hormone inducible transmembrane gene is a novel genetic modifier of left ventricular hypertrophy in families with hypertrophic cardiomyopathy.** P3246
 – M. Parker, C. Kinneer, B. Keavney, H. Watkins, B.M. Mayosi, J. Moolman-Smook (Cape Town, ZA; Newcastle-upon-Tyne and Oxford, GB)
- Complex sarcomeric genetic status is not an important modifier of disease severity in MYBPC3 associated hypertrophic cardiomyopathy.** P3247
 – M. Van Tienhoven, Y.M. Hoedemaekers, M. Michels, F.J. Ten Cate, D.F. Majoor-Krakauer, D.J.J. Halley, D. Dooijes (Rotterdam, NL)
- Analysis of sarcomeric gene proteins in a child cohort enlarges the genetic spectrum of hypertrophic cardiomyopathy.** P3248
 – G. Frisso, G. Limongelli, G. Pacileo, A. Del Giudice, L. Forgione, P. Calabro', M. Iacomino, L.M. Di Fonzo, R. Calabro', F. Salvatore (Naples, IT)
- Fabry Mice (Knock-Out) have infiltrative cardiomyopathy with atrial arrhythmia and dilated ascending aorta.** P3249
 – B. Escoubet, D.G. Warnock, A. Nguyen Dinh Cat, V. Griol-Charhbil, M. Beck, C. Kampmann, F. Jaisser (Paris, FR; Birmingham, US; Mainz, DE)
- Screening of the four genes most commonly involved in hypertrophic cardiomyopathy.** P3250
 – G. Smaniotto, P. Melacini, C. Calore, V. Pescatore, A. Lorenzon, S. Iliceto, G.A. Danielli (Padua, IT)
- Cytokine gene polymorphisms are associated with disease severity and prognosis in patients with idiopathic dilated cardiomyopathy.** P3251
 – S. Adamopoulos, F. Kolokathis, A.G. Gkouziouta, P. Georgiadou, A. Chaidaroglou, G. Karavolias, D. Degiannis, V. Voudris, D.T.H. Kremastinos (Athens, GR)
- Connexin expression patterns in the pathophysiology of arrhythmogenic right ventricular cardiomyopathy.** P3252
 – M. Paul, G. Weiss, P. Milberg, E. Schulze-Bahr, V. Arps, M. Kaestel, J. Wiekowski, C.G. Wollmann, G. Breithardt, T. Wichter (Munster, DE)
- Phenotypic characterization of hypertrophic cardiomyopathy associated with K600fs mutation in cardiac myosin-binding protein C gene.** P3253
 – M.F. Ortiz, M. Hermida-Prieto, R. Barriales-Villa, X. Fernandez, M.I. Rodriguez-Garcia, L. Cazon, L. Nunez, E. Veira, A. Castro-Beiras, L. Monserrat (A Coruna, ES)
- The +49A/G polymorphism in exon 1 of the cytotoxic T lymphocyte-associated protein 4 (CTLA4) gene is associated with dilated cardiomyopathy.** P3254
 – V. Ruppert, T. Meyer, C. Struwe, A. Perrot, M.G. Posch, C. Oezcelik, A. Richter, B. Maisch, S. Pankuweit (Marburg and Berlin, DE)
- Genetic screening in patients with cardiomyopathy in the west of Scotland.** P3255
 – I.N. Findlay, V. Murday (Glasgow, GB)
- Lamin A/C mutations in patients with dilated cardiomyopathy and conduction disease, ventricular dysrhythmia or family history of sudden death.** P3256
 – P. Ehlermann, K. Georgiev, B. Ivandic, R. Zeller, R. Pribe, C. Zugck, A. Rempis, E. Gruenig, D. Weichenhan, H.A. Katus (Heidelberg and Bad Krozingen, DE)
- Striking ethnic differences in the prevalence of apical hypertrophic cardiomyopathy.** P3257
 – L.A. McGill, S.P. Page, F. Choudhry, J. Orpin, P.G. Mills, S.A. Mohiddin (London, GB)

DISEASE MECHANISM AND OUTCOME IN CARDIOMYOPATHIES

- Incidence, clinical characteristics and outcome of patients with tako tsubo syndrome.** P3258
 – D. Primetshofer, A. Rusudan, H. Kratzer, J. Reisinger, P. Siostrzonek (Linz, AT)

- Anthracyclin-induced cardiomyopathy: long-term follow-up of 106 patients.** P3259
 – C. Lestuzzi, E. Viel, L. Massa, L. Tartuferi, G. Sinagra, A. Lleshi, F. Martellotta, G.M. Miolo, D. Lombardi, N. Meneguzzo (Aviano and Trieste, IT)
- Morpho-functional correlates of the electroanatomic abnormalities in arrhythmogenic right ventricular cardiomyopathy.** P3260
 – P. Santangeli, M. Pieroni, F. Marzo, A. Dello Russo, G. Pelargonio, M. Casella, A. Camporeale, N. Vitulano, F. Bellocchi, F. Crea (Rome, IT)
- Comparison of electroanatomic voltage mapping and contrast-enhanced magnetic resonance imaging for delineation of fibrofatty scar in arrhythmogenic right ventricular cardiomyopathy/dysplasia.** P3261
 – M. Perazzolo Marra, B. Bauce, F. Corbetti, L. Cacciavillani, G. Buja, L. Leoni, A. Nava, C. Basso, S. Illiceto, D. Corrado (Padua, IT)
- Correlation between SCD risk factors and appropriate ICD shocks in HCM patients - 13-years-single centre experience.** P3262
 – P. Syska, M. Lewandowski, A. Przybylski, K. Gepner, A. Maciag, M. Pytkowski, I. Kowalik, R. Maczynska-Mazuruk, L. Chojnowska, H. Szwed (Warsaw, PL)
- Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term type I diabetes.** P3263
 – O. Lorenzo, S. Ares-Carrasco, B. Picatoste, E. Camafeita, J.A. Lopez, J. Egido, J. Tunon Fernandez (Madrid, ES)
- Apparent and persistent healing in spite of severe presentation in idiopathic dilated cardiomyopathy: long-term analysis of a subgroup of patients.** P3264
 – S. Pyxaras, M. Merlo, G. Barbati, G. Sabbadini, G. Lardieri, B. Pinamonti, A. Di Lenarda, G. Sinagra (Trieste, IT)
- High incidence of left ventricular involvement in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy determined by tissue deformation imaging.** P3265
 – A.J. Teske, W. Noordzij, M.G. Cox, B.W. De Boeck, M. Burgmans, B.K. Velthuis, P.A. Doevendans, R.N. Hauer, M.J. Cramer (Utrecht, NL)
- Endothelial dysfunction in hypertrophic cardiomyopathy is related to more severe disease.** P3266
 – F. Cambroner, F. Ruiz-Espejo, J.A. Vilchez, A. Garcia-Honrubia, V. Roldan, D. Hernandez-Romero, G. De La Morena, V. Climent, M. Valdes, F. Marin Ortuno (Murcia and Alicante, ES)
- Blood pressure changes associated with eNOS gene polymorphism at engine-drivers with stress cardiomyopathy.** P3267
 – E. Kovaleva, M. Bogdanova, E. Zemtsovsky, V. Larionova (St.-Petersburg, RU)
- Early detection of left ventricular diastolic abnormalities in asymptomatic well-chelated b-thalassaemia major patients with excellent systolic function.** P3268
 – D. Mytas, L. Kosma, I. Kyriazis, E. Athanasopoulou, P. Stougiannos, L. Pappas, I. Dendrinou, M. Bader, K. Farmaki, V. Pyrgakis (Corinth, GR)
- Marfan's cardiomyopathy: a novel entity from a well-known disease?** P3269
 – F. Alpendurada, A. Kiotsekoglou, J. Wong, W. Banya, R. Mohiaddin (London, GB)
- Myocardial fibrosis by late-enhancement magnetic resonance is related to ventricular arrhythmias in dilated cardiomyopathy.** P3270
 – A.M.G. Almeida, J.S. Marques, L.M. Sargento, C. David, N. Cortez-Dias, D. Brito, M.J. Correia, M.G. Lopes (Lisbon, PT)
- Low accessibility of human cardiomyocytes with advanced Fabry disease to enzyme replacement therapy.** P3271
 – A. Frustaci, E. Morgante, D. Antuzzi, R. Verardo, M.A. Russo, C. Chimenti (Rome, IT)
- Deleterious impact of anemia on survival in patients with idiopathic dilated cardiomyopathy.** P3272
 – A. Aleksova, M. Merlo, G. Barbati, S. Brigido, G. Sabbadini, F. Silvestri, A. Di Lenarda, G. Sinagra (Trieste, IT)
- Electrophysiological and molecular remodeling in septal myocytes from fHCM patients.** P3273
 – R. Coppini, F. Stillitano, S. Suffredini, L. Sartiani, J. Olivotto, F. Cecchi, A. Mugelli, E. Cerbai (Florence, IT)

- Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.** P3274
 – R. Maczynska-Mazuruk, M. Klopowski, K. Kukula, B. Kusmierczyk, M. Polanska, M. Dabrowski, L.A. Malek, L. Kalinczuk, L.S. Chojnowska, W. Ruzylo (Warsaw, PL)
- Presence of myocardial scar is strongly associated with abnormal regional myocardial blood flow in hypertrophic cardiomyopathy.** P3275
 – H. Nakajima, K. Onishi, T. Kurita, M. Ishida, M. Nagata, K. Kitagawa, K. Dohi, M. Nakamura, H. Sakuma, M. Ito (Tsu, JP)
- High prevalence of cardiac involvement in type 2 myotonic dystrophy.** P3276
 – K. Wahbi, C. Meune, H.M. Becane, A. Lazarus, P. Laforet, G. Bassez, H. Radvanyi-Hoffman, B. Eymard, D. Duboc (Paris and Boulogne, FR)
- Circadian and seasonal variation in the onset of tako-tsubo cardiomyopathy - results of the German Tako-tsubo registry.** P3277
 – A. Athanasiadis, B. Schneider, J. Schwab, W. Pistner, W. Von Scheidt, S. Kerber, U. Gottwald, U. Sechtem (Stuttgart, Lubeck, Nuremberg, Aschaffenburg, Augsburg, Bad Neustadt and Celle, DE)
- Chagas cardiomyopathy patients with preserved ventricular function and sustained ventricular tachycardia present regional myocardial sympathetic denervation and increased sympathetic activity.** P3278
 – C.H. Miranda, E. Arfeli, A.B. Figueiredo, A.O. Pintya, B.C. Maciel, J.A. Marin-Neto, M.V. Simoes (Ribeirao Preto, BR)
- Survival and clinical outcome of 154 patients one year after diagnosis of dilated cardiomyopathy.** P3279
 – A. Richter, B. Schwalb, S. Pankuweit, R. Funck, A. Ramadanovic, B. Maisch (Marburg, DE)
- Left ventricular outflow tract obstruction in patient with hypertrophic cardiomyopathy: increase in gradient after dynamic exercise.** P3280
 – A. Palinkas, R. Sepp, E. Nagy, L. Halmaj, A. Rigopoulos, H. Seggewiss, V. Nagy, T. Forster, M. Csanady (Hodmezovasarhely and Szeged, HU; Athens, GR; Schweinfurt, DE)
- Magnetic resonance stress perfusion imaging in patients with left ventricular hypertrophy commonly detects perfusion defects and does not identify coronary disease.** P3281
 – S.P. Page, L.A. McGill, T.R. Burchell, C. Davies, A. Mathur, P.G. Mills, M.A. Westwood, S.A. Mohiddin (London, GB)
- Implantable cardioverter defibrillator (ICD) treatment and cardiac death after percutaneous transluminal septal myocardial ablation (PT SMA) in hypertrophic obstructive cardiomyopathy (HOCM).** P3282
 – M. Jensen, O. Havndrup, S. Helqvist, H. Kelbaek, E. Joergensen, C. Hassager, L. Koeber, H. Bundgaard (Copenhagen and Roskilde, DK)
- Sublingual isosorbide dinitrate for detection of obstruction in hypertrophic cardiomyopathy.** P3283
 – D. Zemanek, P. Tomasov, S. Homolova, K. Linhartova, J. Veselka (Prague, CZ)
- Incidence of adequate ICD interventions for primary prophylaxis of sudden cardiac death in patients with hypertrophic cardiomyopathies.** P3284
 – C. Prinz, J. Vogt, B.G. Muntean, J. Heintze, D. Hering, D. Horstkotte, L. Faber (Bad Oeynhausen, DE)
- Impact of myocardial iron loading on right ventricular function.** P3285
 – F. Alpendurada, M. Deac, J.P. Carpenter, P. Kirk, G.C. Smith, D.J. Pennell (London, GB)
- Dilated cardiomyopathy: prevalence of familial, inflammatory and viral forms.** P3286
 – S. Pankuweit, A. Richter, V. Ruppert, B. Maisch (Marburg, DE)
- Interobserver variability in the detection of myocardial parvovirus B19 genomes.** P3287
 – U. Lotze, R. Egerer, R. Zell, O. Scheck, H. Sigusch, C. Ehrhardt, A. Heim, R. Kandolf, P. Wutzler, H.R. Figulla (Naumburg, Jena, Zwickau, Hannover and Tubingen, DE)
- Early cardiac manifestations of Fabry Disease (FD) in male and female children.** P3288
 – C. Kampmann, C. Whybra, G. Kalkum, B. Escoubet, A.N. Dinh Cat, V. Griol-Charhbili, F. Jaisser, D. Warnock, M. Beck (Mainz, DE; Paris, FR; Birmingham, US)

VENTRICULAR ARRHYTHMIAS: DIAGNOSIS AND TREATMENT

- Incidence and characteristics of spontaneous ventricular tachyarrhythmias in 778 patients with coronary artery disease and idiopathic dilated cardiomyopathy and implantable defibrillator.** P3289
 – J. Kuschyk, F. Streitner, N. Schoene, S. Ammar, C. Veltmann, R. Schimpf, C. Wolpert, C. Dietrich, E. Mahl, M. Borggreffe (Mannheim, DE)
- Relationship between abnormalities of ventricular repolarisation and occurrence of malignant arrhythmias in Takotsubo Cardiomyopathy.** P3290
 – D. Haghi, I. Wiltstein, K. Hamm, A. Baranchuck, Y. Akashi, H. Nef, P. Hilpert, L. Bonello, C. Wolpert, M. Borggreffe (Mannheim and Bad Nauheim, DE; Boltmore, US; Kingston, CA; Kawasaki, JP; Marseille, FR)
- Endocardial electrograms in epicardially ablated ventricular tachycardias.** P3291
 – T. Boussy, A. Berruezo, J. Ortiz, E. Guasch, D. Perez, D. Andreu, E. Silva, T. De Caralt, L. Mont, J. Brugada (Barcelona, ES)
- Usefulness of contrast enhanced-cardiac magnetic resonance to identify the epicardial origin of ventricular tachycardias.** P3292
 – A. Berruezo, J.T. Ortiz, E. Guasch, P. Perez, T. Boussy, T.M. De Caralt, A. Olaya, A. Cuesta, L. Mont, J. Brugada (Barcelona, ES)
- Incidence and recurrence of electrical storm in patients with a cardioverter-defibrillator implanted for primary or secondary prevention.** P3293
 – F. Streitner, N. Schoene, E. Mahl, C. Dietrich, C. Veltmann, S. Ammar, C. Wolpert, M. Borggreffe, J. Kuschyk (University Hospital Mannheim, DE)
- Torsade de Pointes arrhythmias in the chronic AV-block block dog are not determined by changes in conduction nor dominated by reentrant mechanisms.** P3294
 – M. Boulaksil, J.G. Jungschleger, G. Antoons, R. Wilders, J.D. Beekman, J.G. Maessen, F.F. Van Der Hulst, H.V.M. Van Rijen, J.M. De Bakker, M.A. Vos (Utrecht, Maastricht and Amsterdam, NL; Leuven, BE)
- Effect of ranolazine on ventricular tachycardia in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention.** P3295
 – E. Karwatowska-Prokopczuk, W. Wang, E. Layug, L. Belardinelli (Palo Alto, US)
- Primary prevention ICD implantation in patients with ischemic heart disease: A narrow QRS-T angle predicts arrhythmia free survival.** P3296
 – R.W.C. Scherptong, C.J.W. Borleffs, S.C. Man, G.H. Van Welsenes, J.J. Bax, L. Van Erven, C.A. Swenne, M.J. Schalij (Leiden, NL)
- The synergic effect of amiodarone and beta-blockers on antitachycardia pacing effectiveness reduces the need of shocks to terminate ventricular tachycardias.** P3297
 – J. Jimenez-Candil, J. Hernandez, M. Ruiz Olgado, J. Morinigo, A. Martin, C. Ledesma, C. Martin-Luengo (Salamanca, ES)
- Do post-infarct ventricular arrhythmias predict prognosis in patients with or without heart failure in the modern treatment era?** P3298 (W)
 – R. Sankaranarayanan, M.A. James, H. Gonna, S. Burtchaell, R. Holloway (Blackpool, Taunton and Worthing, GB)
- Left bundle-branch block reentrant ventricular tachycardias. Elucidation of the mechanism based on activation time to the right ventricular apex.** P3299
 – R. Cozar, R. Peinado, J.L. Merino, S. Moreno, A. Perez, E. Diaz, D. Filgueira, L. Pena, J.L. Lopez Sendon, J.A. Sobrino (Madrid, ES)
- Beneficial Effects of successful ablation on LV and RV function in patients with frequent PVC and preserved ejection fraction.** P3300
 – A.P. Wijnmaalen, V. Delgado, M.J. Schalij, E.R. Holman, J.J. Bax, K. Zeppenfeld (Leiden, NL)
- Impact of the shortness of the repetitive response intervals for the initiation of the polymorphic VT/VF in idiopathic outflow tract tachycardia.** P3301
 – M. Igarashi, H. Tada, D. Akiyama, K. Kurosaki, Y. Sekiguchi, T. Arimoto, H. Yamasaki, K. Kuga, A. Nogami, K. Aonuma (Tsukuba and Yokohama, JP)

- Comparison of electroanatomical voltage map and contrast enhanced-cardiac magnetic resonance in determining the true endocardial scar area in post myocardial infarction ventricular tachycardia.** P3302
 – T. Boussy, A. Berrueto, J. Ortiz, D. Perez, E. Guasch, E. Silva, D. Andreu, P. Perea, L. Mont, J. Brugada (Barcelona, ES)
- A vasodilating agent without cardioactive effect can inhibit the early afterdepolarization-related ventricular tachyarrhythmias in rabbits.** P3303
 – S. Yamagishi, K. Tsutsui, N. Yamagishi, N. Hayami, T. Kunishima, Y. Murakawa (Kawasaki, JP)
- Electrical Storm in patients with an Implantable Cardioverter-Defibrillator.** P3304
 – G. Leibundgut, S. Osswald, C. Sticherling, M. Kuehne, B. Schaer (Basel, CH)
- Evaluation of ventricular radiofrequency ablation lesions with contrast enhanced-cardiac magnetic resonance.** P3305
 – T. Boussy, A. Berrueto, J. Ortiz, E. Guasch, D. Perez, E. Silva, D. Andreu, T. De Caralt, L. Mont, J. Brugada (Barcelona, ES)
- Left ventricular mechanical dispersion predicts ventricular arrhythmia in patients after myocardial infarction.** P3306
 – K.H. Haugaa, M.K. Smedsrud, E. Kongsgaard, O.A. Smiseth, J.P. Amlie, T. Edvardsen (Oslo, NO)
- Cheyne-Stokes respiration indicates an increased risk for the manifestation of malignant arrhythmias in patients with heart failure.** P3307
 – T. Bitter, C. Prinz, C. Langer, D. Horstkotte, O. Oldenburg (Bad Oeynhausen, DE)
- Utility of modified moving average analysis of T-wave alternans with exercise test to predict ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy.** P3308
 – J. Zou, X. Hou, S. Xue, D. Xu, K. Cao (Nanjing, CN)
- Determinants of long term success of radiofrequency catheter ablation of postinfarction ventricular tachycardia.** P3309
 – L. Geller, S.Z. Szilagyi, A. Magyar, E. Vegh, M. Srej, E. Zima, L. Molnar, T. Tahin, B. Merkely (Budapest, HU)
- Influence of diabetes on time of onset of life-threatening cardiac arrhythmias in a population-based study.** P3310
 – A. Bardai, M.T. Blom, J. Berdowski, H.L. Tan (Amsterdam, NL)
- Baseline QTc duration predicts changes in QTc duration during Haloperidol use in an in-hospital population.** P3311
 – M.T. Blom, A. Bardai, M. Nieuwland, S.E.J.A. De Rooij, H.L. Tan (Amsterdam, NL)
- Anti-arrhythmic efficacy of Verapamil and Flunarizine against dofetilide induced Torsade de Pointes arrhythmias is based upon a shared and a different mode of action.** P3312
 – A. Oros, M.J. Houtman, P. Neco, A.M. Gomez, S. Rajamani, N.J. Attevelt, L. Belardinelli, S. Richard, G. Antoons, M.A. Vos (Utrecht, NL; Montpellier, FR; Palo Alto, US)
- Purkinje fibre injury and electrical remodeling in non-ischemic cardiomyopathy: Implications for sudden cardiac death.** P3313
 – P.J. Psaltis, A. Carbone, D. Lau, T. Jantzen, K. Williams, P. Sanders, S. Gronthos, A.C.W. Zannettino, S.G. Worthley (Adelaide, AU)
- Association of paroxysmal supraventricular and ventricular tachycardia. Clinical significance.** P3314
 – B. Brembilla-Perrot, J.M. Sellal, P.Y. Zinzius, M. Valla, N. Benzaghoul, Y. Lefrancois, D. Beurrier, A. Abdelaal, S. State, J. Cedano (Vandoeuvre les Nancy, FR)
- Cardiac resynchronization therapy-defibrillator utilization rates in 234 elderly patients at a single center.** P3315
 – T.A. Charlton, E.E. Johnson, M.A. Coppess, F.A. McGrew, B. Hamilton, S.B. Charlton, J.J. Sims (Memphis and Moundsview, US)
- Clinical and electrocardiographic identification of cavotricuspid isthmus dependent right sided atrial flutter presenting without typical patterns on surface electrocardiogram.** P3316
 – M. Ray, N. Hoang, A. Narula, R. Misra, S. Siddique (Allentown, US)

SUPRAVENTRICULAR ARRHYTHMIAS: FROM MECHANISMS TO TREATMENT

- Magnetocardiography can identify abnormal atrial electrical activities during sinus rhythm in patients with paroxysmal atrial fibrillation.** P3317
 – H. Sato, H. Takaki, W. Shimizu, S. Kamakura, M. Sugimachi (Suita, JP)
- Heart rate variability and occurrence of atypical atrial flutter after circumferential ablation for atrial fibrillation.** P3318
 – A. Ardashev, A. Shavarov, Y. Belenkov (Moscow, RU)
- Evaluation of atrial refractoriness early after radiofrequency catheter ablation of accessory pathway in Wolff-Parkinson-White syndrome.** P3319
 – K. Cagli, S. Topaloglu, D. Aras, N. Sen, I. Akpınar, A. Durak, H. Kisacik (Ankara, TR)
- Asymptomatic ventricular preexcitation mimicking dilated cardiomyopathy: the location of the pathway is predictive of this association.** P3320
 – N. Sreeram, F. Udink Ten Cate, M. Kruessell, M. Emmel (Cologne, DE)
- Atrial flutter ablation after pulmonary veins isolation: the coronary sinus atrial activation pattern is useful for circuit localization.** P3321
 – P. Adragao, D. Cavaco, P. Carmo, K. Santos, F. Morgado, R. Bernardo, D. Cabrita, A. Silva (Lisbon and Carnaxide, PT)
- Mortality of patients with lone atrial fibrillation is similar to mortality in general population.** P3322
 – T. Potpara, M. Grujic, B. Vujisic-Tesic, M. Ostojic, M. Polovina (Belgrade, RS)
- Increase in the prevalence of atrial fibrillation compared to aging in the general population: its kinetics and risk factors.** P3323
 – T. Tomizawa, M. Otaka, M. Kanashiki, H. Watanabe, I. Yamaguchi (Mito, JP)
- Impact of use of robotic catheter navigation on fluoroscopy exposure during atrial fibrillation ablation procedures.** P3324
 – A. Kamal, R. Cihak, P. Peichl, D. Wichterle, J. Kautzner (Prague, CZ)
- Effect of angiotensin-receptor-blockers on dynamics of left atrial size after pulmonary vein isolation in patients with atrial fibrillation and hypertension.** P3325
 – A. Berkowitsch, T. Neumann, M. Kuniss, S. Zaltsberg, S. Janin, M. Wojcik, C. Hamm, H.F. Pitschner (Bad Nauheim, DE)
- Predictive value of atrial electromechanical coupling time for paroxysmal atrial fibrillation.** P3326
 – H. Karapınar, Z. Kaya, S. Pala, Y. Karavelioglu, T. Dasli, D. Sirma, O.B. Esen, M. Akcakoyun, A.M. Esen, C. Kirma (Van and Istanbul, TR)
- Risk factors for atrial fibrillation in elderly subjects without cardiovascular disease.** P3327
 – D. Zachariah, P.R. Kalra, P.R. Roberts, R.N. Foley (Portsmouth and Southampton, GB; Minneapolis, US)
- Effect of obesity on P wave duration and dispersion in a Chinese population.** P3328
 – T. Liu, Z. Fu, P. Korantzopoulos, X. Zhang, S. Wang, G. Li (Tianjin, CN; Ioannina, GR)
- Echocardiographic predictors of the transformation of primary paroxysmal atrial fibrillation into permanent form.** P3329
 – L.G. Tunyan, S.V. Grigoryan (Yerevan, AM)
- Short-term kinetics of NT-proBNP in recent-onset atrial fibrillation.** P3330
 – S. Dettreos, G. Giannopoulos, A. Theodorakis, C. Toli, C. Kossyvakis, M. Driva, A. Kaoukis, I. Rentoukas, I. Mantas, E. Matsakas (Athens, Mesologgi and Halkida, GR)
- Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.** P3331
 – D. Poli, E. Antonucci, E. Grifoni, R. Marcucci, L. Mannini, R. Abbate, G.F. Gensini, D. Prisco (Florence, IT)
- Is it always possible to follow the guidelines for the treatment of atrial fibrillation? Different realities between Switzerland and Cameroon.** P3332
 – M. Zimmermann, M. N'tep, A. Meiltz, L. Conti, N. Tran, S. Kingue (Meyrin-Geneva, CH; Yaounde, CM)
- Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly.** P3333
 – A. Tveit, S.R. Ulimoen, S. Enger, H. Arnesen, I. Seljeflot (Rud and Oslo, NO)

- Preoperative atrial mechanical dysfunction may predict postoperative atrial fibrillation after coronary artery bypass graft operation: a tissue Doppler and velocity vector imaging study.** P3334
 – Y. Tayyareci, O. Yildirimturk, A. Tugcu, V. Aytekin, F. Behramoglu, K. Memic, I.C.C. Demiroglu, S. Aytekin (Istanbul, TR)
- Noninvasive mechanoanatomical mapping to detect atrial fibrillation substrates.** P3335
 – M. Amnuepol, O. See, T. Ngarmukos, S. Apiyasawat, P. Chandanamattha, S. Yamwong, T. Tangcharoen, C. Charoenpanichkit (Bangkok, TH)
- Impact of catheter ablation of atrial fibrillation on quality of life: preliminary results from the EVABLAF study.** P3336
 – G. Moubarak, P. Jais, P. Mabo, E. Aliot, J.S. Hermida, D. Lacroix, E. Vicaut, F. Extramiana, A. Leenhardt (Paris, Pessac, Rennes, Vandoeuvre les Nancy, Amiens and Lille, FR)
- Efficacy of the circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.** P3337
 – N. Calvo, L. Mont, D. Tamborero, A. Berruero, D. Andreu, B. Vidal, M. Sitges, G. Viola, E. Guasch, J. Brugada (Barcelona, ES)
- Polyunsaturated fatty acids, inflammatory markers and the incidence of postoperative atrial fibrillation.** P3338
 – R. Heidarsdottir, D.O. Arnar, O.S. Indridason, B. Torfason, R. Palsson, V. Edvardsson, G. Gottskalksson, G.V. Skuladottir (Reykjavik, IS)
- Relationship of circulating endothelial progenitor cells to the recurrence of atrial fibrillation after successful conversion and maintenance of sinus rhythm.** P3339
 – C.W. Siu, T. Watson, W.H. Lai, Y.K. Lee, Y.H. Chan, K.M. Ng, C.P. Lau, G.Y.H. Lip, H.F. Tse (Hong Kong, HK; Birmingham, GB)
- Radiofrequency ablation of coronary sinus dependent atrial flutters guided by mid-diastolic atrial potentials.** P3340
 – A. De Sisti, J. Tonet, W. Amara (Poissy and Paris, FR)
- Direction-dependent conduction abnormalities: implications for the development of atrial arrhythmias in humans.** P3341
 – C.X. Wong, M.K. Stiles, B. John, A.G. Brooks, P. Kuklik, D.H. Lau, H. Dimitri, G. Sharma, G.D. Young, P. Sanders (Adelaide, AU)
- Difference in ventriculoatrial intervals during entrainment and tachycardia: a simpler method for distinguishing supraventricular tachycardias with long ventriculoatrial intervals.** P3342
 – E. Gonzalez Torrecilla, J. Almendral, F.J. Garcia-Fernandez, A. Arenal, F. Atienza, L.F. Atea, D. Calvo, C. Hadid, M. Pachon, F. Fernandez-Aviles (Madrid and Burgos, ES)
- Cavotricuspid isthmus ablation using the maximum voltage guided technique: acute success and mid-term follow-up results.** P3343
 – C.L. Foldesi, A. Kardos, P. Abraham, A. Mihalcz, Z. Som, J. Borbola, J. Vanyi, T. Szili-Torok (Budapest, HU; Rotterdam, NL)
- Successful treatment of inappropriate sinus tachycardia with ivabradine.** P3344
 – J. Borbola (Budapest, HU)
- HEART FAILURE: VENTRICULAR FUNCTION**
- Mechanotransduction-related signalling via focal adhesion kinase is preserved in pressure overload hypertrophy but absent in congestive cardiomyopathy.** P3345
 – L. Delrue, M. Vanderheyden, M. Goethals, F. Casselman, S. Verstreken, J. Bartunek (Aalst, BE)
- Impaired left ventricular twist and untwist in heart failure and normal ejection fraction is associated with reduced ventricular suction.** P3346
 – Y.T. Tan, F. Wenzelburger, E. Lee, G. Heatlie, K. Patel, F. Leyva, M. Frenneaux, J.E. Sanderson (Birmingham and Stoke-On-Trent, GB)
- The induction of mild hypothermia preserves myocardial contractility after ventricular fibrillation/resuscitation in pigs.** P3347
 – H. Post, M. Schwarzl, S. Huber, H. Maechler, P. Steendijk, M. Truschnig-Wilders, B. Pieske (Graz, AT; Leiden, NL)

- Increased baseline diastolic volume and filling pressure blunt the response to cardiac resynchronization therapy.** P3348
 – E. Carluccio, P. Biagioli, G. Alunni, V. Leonelli, F. Ascani, A. Murrone, P. Pantano, G. Ambrosio (Perugia, IT)
- Advanced heart failure due to chronic volume overload in rats is characterized by profound downregulation of myocardial fatty acid metabolism.** P3349
 – J. Benes, P. Skaroupkova, L. Kazdova, D. Sedmera, F. Papousek, H. Strnad, M. Kolar, V. Melenovsky (Prague, CZ)
- Myocardial performance index determined by Doppler Tissue Imaging in patients with congestive heart failure identifies patients with poor prognosis.** P3350
 – M. Alam, J. Olson, B.A. Samad (Stockholm, SE)
- Importance of haemodilution in haemoglobin concentrations in outpatients with chronic heart failure. Results of IMPACT-RECO Program III.** P3351
 – M. Galinier, N. Demil, P. Assyag, P. De Groote, R. Isnard, A. Ducardonnet, G. Jondeau, J.F. Thebaut, M. Komajda (Toulouse, Rueil Malmaison, Paris, Lille and Sarcelles, FR)
- Coupling of systolic and diastolic function and regional synchrony in normal, hypertrophic, and failing myocardium quantified by speckle-tracking echocardiography.** P3352
 – K. Dohi, K. Onishi, T. Takamura, E. Sugiura, H. Nakajima, K. Ichikawa, M. Tanabe, M. Miyahara, M. Nakamura, M. Ito (Tsu, JP)
- Epirubicin late cardiotoxicity 5 years after chemotherapy for breast cancer: Usefulness of 2D strain analysis.** P3353
 – H. Samet, A. Trinh, C. Cohen, S. Louboutin, P. Bareiss, G. Roul (Strasbourg, FR)
- Longitudinal, but not global systolic dysfunction is a mechanism of acute hypertensive pulmonary edema.** P3354
 – A.D. Margulescu, R.C. Sisu, M. Florescu, M. Cinteza, D. Vinereanu (Bucharest, RO)
- Echocardiographic parameters as a non-invasive means of volume response to asymptomatic, diuretic-induced volume changes in stable left ventricular systolic dysfunction.** P3355
 – M.J. Ng Kam Chuen, G.Y.H. Lip, R.J. Macfadyen (Birmingham, GB)
- Comparison of echocardiographic parameters between systolic and diastolic dysfunction in elderly patients with heart failure.** P3356
 – R. Handschin, K. Goetschalckx, B. Julius, P. Hilti, S. Kiencke, A. Bernheim, P. Buser, M. Pfisterer, H.P. Brunner-La Rocca, P. Rickenbacher (Bruderholz, Basel, Bulach and Langenthal, CH)
- Anthracycline-induced subclinical right ventricular dysfunction in adults.** P3357
 – M.A. Ustaoglu, D. Duman, M. Gucun, V. Konya, F. Dane, M. Gumus (Istanbul, TR)
- Systolic and diastolic beneficial adaptation to an acute hemodynamic overload is impaired during myocardial ischemia: benefits of early reperfusion and ischemic preconditioning.** P3358
 – R. Ladeiras-Lopes, J. Ferreira-Martins, M. Pintalhao, A.L. Pires, R. Ferreira, R. Fontes Carvalho, P. Castro-Chaves, A. Leite-Moreira (Porto, PT)
- Increased central venous pressure is a strong predictor of worsening renal function in patients with cardiovascular disease.** P3359
 – K. Damman, A.A. Voors, G. Navis, D.J. Van Veldhuisen, H.L. Hillege (Groningen, NL)
- Heterogeneous cardiac response to high dose dobutamine magnetic resonance stress test in patient with left ventricular dysfunction.** P3360
 – G.D. Aquaro, V. Lionetti, C. Passino, P.G. Masci, V. Valenti, E. Strata, M. Emdin, M. Lombardi, A. Pingitore (Pisa, Rome and Florence, IT)
- A novel correlation of gamma-glutamyltransferase with elevated left ventricular filling pressure in coronary artery disease patients with preserved left ventricular systolic function.** P3361 (W)
 – S.M. Kang, J. Oh, N.-K. Hong, H.Y. Won, Y. Jang, N. Chung (Seoul, KR)
- Randomised trial of carvedilol and metoprolol on left ventricular dyssynchrony in patients with dilated cardiomyopathy.** P3362
 – M.G. Kaya, B. Sarli, O. Gunebakmaz, M. Yarlioglu, T. Inanc, A. Dogan, A. Oguzhan, R. Topsakal (Kayseri, TR)

Impact of time resolution of the full-volume data set in assessing left ventricular dyssynchrony using real-time three-dimensional echocardiography. P3363

– L. Badano, D. Muraru, R. Onut, D. Ermacora, M.T. Grillo, E. Zakja, P. Gianfagna, P.M. Fioretti (Udine, IT)

Inert gas rebreathing: the effect of pulmonary shunt flow correction on the accuracy of cardiac output measurements in clinical practice. P3364

– F. Trinkmann, T. Papavassiliu, F. Kraus, H. Leweling, S.O. Schoenberg, M. Borggreffe, J.J. Kaden, J. Saur (Mannheim, DE)

HEART FAILURE MODELS AND MECHANISMS

The transcription factor Eya 4 is a new player in heart failure. P3365

– T. Williams, N. Burkard, C. Gebhard, M. Czolbe, F. Panther, J. Schonberger, O. Ritter (Wurzburg, DE)

IBP, a novel inhibitor of the calcineurin/NF-AT cascade. P3366

– C. Gebhardt, F. Panther, N. Burkard, M. Czolbe, O. Ritter (Wurzburg, DE)

Interleukin-1Trap, a novel interleukin-1 antagonist, inhibits apoptosis and ameliorates cardiac remodeling in experimental acute myocardial infarction. P3367

– A. Abbate, A. Varma, F.N. Salloum, I.M. Seropian, N.N. Hoke, B.W. Van Tassel (Richmond, US)

Incident AF is a strong independent predictor of mortality and heart failure development in the elderly. P3368

– D. Zachariah, P.R. Kalra, P.R. Roberts, R.N. Foley (Portsmouth and Southampton, GB; Minneapolis, US)

Routine in-hospital care and prognosis of elderly patients with heart failure. P3369

– P. Le Corvoisier, B. Renaud, I. Mahe, J.F. Bergmann, D. Mottier, P. Maison, S. Letulle, J.L. Dubois-Rande, E. Paillaud, O. Montagne (Creteil, Paris and Brest, FR)

Interleukin-6-Deficient mice resist development of experimental autoimmune cardiomyopathy provoked by beta1-adrenergic receptor. P3370

– L.-P. Ma, G. Premaratne, E. Bollano, C. Lindholm, M. Fu (Shanghai, CN; Gothenburg, SE)

G-CSF induces reverse remodeling processes of hypertrophied hearts. P3371

– H. Moellmann, H. Nef, S. Voss, C. Troidl, M. Rauch, S. Szardien, S. Kostin, M. Weber, C. Hamm, A. Elsaesser (Bad Nauheim and Oldenburg, DE)

Cardiac STAT3 plays an important role in the protection against beta-adrenergic stress-related development of heart failure. P3372

– P. Fischer, B. Stapel, M. Hoch, S. Erschow, H. Drexler, D. Hilfiker-Kleiner (Hannover, DE)

Mutations in the intermediate filament protein desmin severely compromise nanomechanical filament and network properties. P3373

– H. Baer, M. Schopferer, S. Sharma, N. Muecke, L. Kreplak, N. Willenbacher, H. Herrmann (Heidelberg and Karlsruhe, DE; Halifax, CA)

Jun nh2-terminal kinase2 is involved in angiotensin ii-induced oxidative stress and cardiac dysfunction via toll-like receptor 4. P3374

– S. Matsuda, S. Umemoto, H. Yoshino, T. Nakashima, S. Ito, H. Aoki, K. Yoshimura, T. Murata, M. Matsuzaki (Ube, Shimonoseki and Kurume, JP)

Suppression of left ventricular lipin 1 mRNA and corresponding phosphatidate phosphohydrolase 1 activity in experimental type 2 diabetic cardiomyopathy. P3375

– C. Burgdorf, L. Haensel, M. Heidbreder, O. Joehren, F. Schuette, H. Schunkert, T. Kurz (Lubeck, DE)

BNP gene transfer improves cardiac function after myocardial infarction and in hypertensive heart failure. P3376

– A.M. Moilanen, J. Rysa, E. Mustonen, A. Manninen, J. Aro, R. Serpi, H. Leskinen, H. Tokola, O. Vuolteenaho, H. Ruskoaho (Oulu, FI)

carvedilol infusion before reperfusion improves left ventricular hemodynamic parameters at early stage in experimental model of acute myocardial infarction via inhibition of MCP-1 and MMP-2 activity. P3377

– G. Cimmino, B. Ibanez, S. Prat, R. Hutter, C. Giannarelli, J. Sanz, M.J. Garcia, V. Fuster, J.J. Badimon (New York, US)

- Sustained PKC β inhibition restores both proteasome activity and protein quality control in two different heart failure models.** P3378
 – J.C.B. Ferreira, P.C. Brum, D. Mochly-Rosen (Sao Paulo, BR; Stanford, US)
- Mechanism of inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor- β 1 in cultured cardiac fibroblast.** P3379
 – K.G. Shyu, B.W. Wang (Taipei, TW)
- Sarcoplasmic reticulum calcium leak accelerates development of heart failure.** P3380
 – X.H.T. Wehrens, J. Respress, S. Sarma, C. Reynolds, D.G. Skapura, R.J. Van Oort (Houston, US)
- Influence of cardiac shape on left ventricular twist.** P3381
 – B.M. Van Dalen, F. Kauer, W.B. Vletter, O.I.I. Soliman, H.B. Van Der Zwaan, F.J. Ten Cate, M.L. Geleijnse (Rotterdam, NL)
- Beneficial effects of ivabradine on cardiac remodelling in the diabetic hypertensive heart are mediated through modulation of connective tissue growth factor.** P3382
 – E. Velkoska, R.G. Dean, K. Spencer, L.M. Burrell (Melbourne, AU)
- Effects of diabetes mellitus, pressure overload and their association on myocardial structure and function.** P3383
 – I. Falcao-Pires, N. Goncalves, C. Moura, K. Kupreishvili, I. Lamego, H.W.N. Niessens, J.C. Areias, A.F. Leite-Moreira (Porto, PT; Amsterdam, NL)
- Spontaneous activation of hypertrophic pathways in the heart of a novel human relevant mouse model of diabetes.** P3384
 – S. Gibbons, Z. Hegab, M. Zi, S. Prehar, D. Oceandy, M. Goldsworthy, E. Cartwright, R. Cox, M. Mamas, L. Neyses (Manchester and Oxford, GB)
- Major cardiopulmonary defects of Caveolin-1 disrupted mice are caused by a dysfunctional endothelium.** P3385
 – C. Wunderlich, A. Schmeisser, M. Kasper, M. Forkmann, N. Steinbronn, A. Brandt, R.H. Strasser (Dresden, DE)
- Increased NADPH-oxidase activity and alterations in antioxidant enzymes in the right and left ventricle from human failing heart.** P3386
 – E. Borchi, V. Bargelli, F. Stillitano, C. Giordano, G. D'Amati, E. Cerbai, C. Nediani (Florence and Rome, IT)
- Heart failure and nucleocytoplasmic transport.** P3387
 – R. Cortes, E. Rosello-Lleti, M. Rivera Otero, L. Martinez-Dolz, A. Salvador, M. Portoles (Valencia, ES)
- Cardiac hypertrophy with ventricular preexcitation and glycogen accumulation in transgenic mice with activated polyamine catabolism.** P3388
 – M.J. Merentie, E. Pirinen, M. Hedman, J. Lipponen, A. Virkamaki, J. Kuusisto, S. Yla-Herttua, M. Laakso (Kuopio and Helsinki, FI)
- Left ventricular torsion decreases after alcohol septal ablation in hypertrophic obstructive cardiomyopathy patients.** P3389
 – W. Brouwer, F.D.B. Tammer, I.K. Russel, T. Germans, M.J.W. Gotte, A.C. Van Rossum (Amsterdam, NL)
- Exercise training delays cardiac dysfunction, inhibits autophagy and improves the fatty acid uptake on post-infarction left ventricular remodelling in the rabbit.** P3390
 – C.Y. Chen, B.C. Lee, H.C. Hsu, M.F. Chen (Taipei, TW)
- Depressed contractile function, SERCA-activity and reduced T-tubule density in myocytes isolated from the free left ventricular wall from patients with post-infarction heart failure.** P3391
 – M. Hoydal, I. Kirkeby-Garstad, A. Karevold, R. Haaverstad, A. Wahba, O.J. Kemi, O. Ellingsen, G.L. Smith, U. Wisloff (Trondheim, NO; Glasgow, GB)
- Brain natriuretic peptide protects cardiac and skeletal muscle mitochondrial respiratory chain against Doxorubicin -induced deleterious effects through mitochondrial K-ATP channel opening.** P3392
 – A.P. Di Marco, J. Bouitbir, J. Zoll, S. Talha, A.L. Lang, I. Enache, V. Goldbar, F. Piquard, B. Geny (Strasbourg, FR)
- Increased rho kinases (ROCKs) activity in patients with heart failure.** P3393
 – C.M. Yu, M. Dong, R.J. Li, M. Zhang, Q.H. Zhang, J.K. Liao (Hong Kong, CN; Boston, US)

- YB-1 prevents ventricular cardiomyocytes from TGFbeta induced apoptosis.** P3394
 – B. Meyering, S. Partsch, J. Heger, H.M. Piper, G. Euler (Giessen and Dusseldorf, DE)
- Increased sensitivity to ischemia in an early diabetic cardiomyopathy: the role of calcium handling.** P3395
 – N. Rolim, C. Ingul, H. Hansen, T. Stolen, M. Hoydal, A.B. Johnsen, U. Wisloff (Trondheim, NO)
- Molecular mechanism of desminopathy: analysing the interaction of desmin and its disease variants with aB-crystallin.** P3396
 – S. Sharma, N. Muecke, H.A. Katus, R. Quinlan, H. Herrmann, H. Baer (Heidelberg, DE; Durham, GB)

PATHOPHYSIOLOGY OF HYPERTENSION

- Apelin haplotypes and serum levels in essential hypertension with metabolic disorders.** P3397
 – W. Li, Y. Zhang, P. Gao, D. Zhu (Shanghai, CN)
- Are the connexin40 -44G>A and +71A>G polymorphisms correlated to hypertension?** P3398
 – A. Pfenniger, B. Foglia, F. Mach, R.W. James, B.R. Kwak (Geneva, CH)
- Free leptin is associated with masked hypertension in non-obese subjects: a cross-sectional study.** P3399
 – C. Thomopoulos, O. Papazachou, A. Bratsas, S. Massias, A. Komnou, E. Michalopoulou, D.P. Papadopoulos, T.H. Makris (Athens, GR)
- Resistin levels as a link between adipose tissue and cardiorenal dysfunction in non-diabetic essential hypertensive subjects.** P3400
 – M. Selima, C. Tsioufis, K. Dimitriadis, A. Gennadi, A. Miliou, E. Stefanadi, S. Sideris, V. Tzarnou, E. Andrikou, C. Stefanadis (Athens, GR)
- ACE gene polymorphism is associated with the adipokine phenotype in essential hypertension: the adipose tissue products revisited from within.** P3401
 – O. Papazachou, D.P. Papadopoulos, C. Thomopoulos, S. Massias, A. Bratsas, A. Komnou, C. Tsoukala, T.H. Makris (Athens, GR)
- Acromegaly is characterized by insulin resistance and sympathetic inhibition: direct microneurographic evidences.** P3402
 – G. Seravalle, L. Lonati, M. Scacchi, C. Carzaniga, R. Attanasio, M. Montini, R. Cozzi, F. Tzarnou, G. Grassi, G. Mancia (Milan, Bergamo and Monza, IT)
- Sex-specific hemodynamic and non-hemodynamic predictors of aortic root size in hypertensive subjects with left ventricular hypertrophy.** P3403
 – W. Nadruz Junior, F.A. Souza, J.A. Cipolli, J.R. Matos-Souza, M.C.S. Ferreira-Sae, J.A. Pio-Magalhaes, K.G. Franchini (Campinas, BR)
- Association of clinical blood pressure phenotypes with adiponectin and resistin plasma levels: a cross-sectional study.** P3404
 – C. Thomopoulos, D.P. Papadopoulos, O. Papazachou, A. Bratsas, S. Massias, E. Michalopoulou, M. Daskalaki, V. Votteas, T.H. Makris (Athens, GR)
- The p22phox -640A/G polymorphism of NADPH oxidase adversely affects endothelin levels but not peripheral and central pressures in healthy, young, normotensive individuals.** P3405
 – P. Xaplanteris, C. Vlachopoulos, C. Vassiliadou, I. Dima, K. Baou, D. Kardara, N. Ioakeimidis, C. Stefanadis (Athens, GR)
- In mild-to-moderate renal failure sympathetic activation precedes methylarginines accumulation.** P3406
 – G. Seravalle, F. Arenare, F. Quarti Trevano, C. Mineo, S. Buzzi, C. Zoccali, F. Mallamaci, G. Grassi, G. Mancia (Milan, Monza and Reggio Calabria, IT)
- Overweight-related hypertension is not mediated by low plasma levels of adiponectin.** P3407
 – C. Asferg, R. Moegelvang, A. Flyvbjerg, J. Frystyk, J.S. Jensen, J.L. Marott, M. Appleyard, G.B. Jensen, J. Jeppesen (Glostrup, Gentofte, Aarhus, Copenhagen and Hvidovre, DK)
- Uncovering the role of circulating soluble receptor for advanced glycation end products in hypertension: relationships with albuminuria.** P3408
 – C. Tsioufis, K. Dimitriadis, D. Syrseloudis, C. Thomopoulos, A. Mazaraki, P. Tolis, S. Sideris, E. Stefanadi, I. Kallikazaros, C. Stefanadis (Athens, GR)

The VKORC1 (-1639) G>A promoter polymorphism is associated with elevated systemic arterial blood pressure. P3409

– A. Panzenboeck, S. Zehetmayer, P. Bauer, G. Endler, V. Leibetseder, T.R. Bader, C. Mannhalter, I.M. Lang (Vienna, AT)

Upgrading the role of uric acid in essential hypertension: cross-sectional relationships with subclinical inflammation, endothelial dysfunction and arterial stiffening. P3410

– C. Tsioufis, K. Dimitriadis, D. Tsiachris, D. Syrseloudis, A. Miliou, V. Tzamouri, I. Andrikou, A. Mazaraki, D. Tousoulis, C. Stefanadis (Athens, GR)

Gamma-glutamyltransferase and incident hypertension: a three year follow-up study. P3411

– J.K. Huh, B.J. Kim (Seoul, KR)

Neural and structural remodeling of arteries in SHR during blood pressure increasing. P3412

– Y. Xi, N.L. Sun, D.F. Su (Beijing and Shanghai, CN)

Activation of liver X receptor attenuates activation of the renal and cardiac renin-angiotensin system. P3413

– I. Kuipers, L. Van Genne, F. Kuipers, D.J. Van Veldhuisen, W.H. Van Gilst, R.A. De Boer (Groningen, NL)

Acute administration of vitamin C blunts sympathetic activation in hypertensive patients. P3414

– R.M. Bruno, E. Daghini, L. Ghiadoni, I. Sudano, A. Magagna, C. Passino, M. Varanini, M. Emdin, A. Salvetti, S. Taddei (Pisa, IT; Zurich, CH)

The influence of adipocytokines on blood pressure in middle age women in relation to menopause status. P3415

– A. Olszanecka, A. Posnik-Urbanska, D. Czarnecka, D. Fedak, K. Kawecka-Jaszcz (Krakow, PL)

The Importance of anatomical examination of adrenal vein using thin-slice contrast-enhanced computed tomography on success rate of adrenal vein sampling. P3416

– K. Nishioka, H. Teragawa, Y. Fujii, K. Oki, S. Mikami, N. Mitsuba, N. Fujimura, T. Ishida, Y. Higashi, Y. Kihara (Hiroshima, JP)

**HEART AND MIND DECISION IN THE TREATMENT OF
HYPERTENSION: EPROSARTAN**

Satellite

Chairperson(s): L. Tokgozoglu (Ankara, TR); V.S. Ram (Dallas, US)

Satellite Symposium organised by Solvay Pharmaceuticals GmbH

- | | | |
|-------|---|------|
| 18:30 | Introduction.
– L. Tokgozoglu (Ankara, TR) | 3417 |
| 18:35 | Cerebrovascular protection and antihypertensive therapy.
– L. Tokgozoglu (Ankara, TR) | 3418 |
| 19:00 | Prevention of cerebrovascular events in hypertension: new hopes and new prospects - The MOSES trial (Morbidity and Mortality After Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention).
– V.S. Ram (Dallas, US) | 3419 |
| 19:25 | Eprosartan and cognitive decline: Insight into the OSCAR study (Observational Study on Cognitive function and SBP Reduction).
– A. Pathak (Toulouse, FR) | 3420 |
| 19:50 | Conclusion.
– V.S. Ram (Dallas, US) | 3421 |

**C-CURE: FROM 1ST TO 2ND GENERATION CARDIAC
REGENERATIVE THERAPIES**

Satellite

Chairperson(s): S. Dimmeler (Frankfurt, DE); M. Tendera (Katowice, PL)

Satellite Symposium organised by Cardio3 BioSciences

- | | | |
|-------|---|-------------|
| 18:30 | Introduction and session objectives. | 3422 |
| | – S. Dimmeler, M. Tendera (Frankfurt, DE; Katowice, PL) | |
| 18:35 | Stem cell therapies: lessons from clinical experience. | 3423 |
| | – H. Drexler (Hannover, DE) | |
| 18:51 | Scientific evidence in stem cell research. | 3424 |
| | – C. Verfaillie (Leuven, BE) | |
| 19:07 | Stem cell platforms fo cardiac repair. | 3425 |
| | – A. Terzic (Rochester, US) | |
| 19:23 | The C-Cure trial: state-of-the-art clinical program for advanced regenerative therapies. | 3426 |
| | – J. Bartunek (Aalst, BE) | |
| 19:39 | Autologous or allogenic approaches to stem cell therapies. | 3427 |
| | – D. Charron (Paris, FR) | |
| 19:55 | Regenerative medicine for practicing cardiologists: conclusions and take home messages. | 3428 |
| | – S. Dimmeler, M. Tendera (Frankfurt, DE; Katowice, PL) | |

**MANAGEMENT OF CARDIOVASCULAR DISEASES: DEFINING
CURRENT CHALLENGES AND FUTURE OPTIONS**

Satellite

Chairperson(s): R. Willenheimer (Malmö, SE); J.L. Lopez-Sendon (Madrid, ES)

Satellite Symposium organised by Merck Serono, a division of Merck KGaA

- | | | |
|-------|--|------|
| 18:30 | Introduction.
– R. Willenheimer (Malmö, SE) | 3429 |
| 18:35 | Anticipating the future in antihypertensive treatment: beta-blockade dead or alive?
– G. Bakris (Chicago, US) | 3430 |
| 18:55 | Management of coronary artery disease: contemporary approaches and future expectations.
– J.L. Lopez-Sendon (Madrid, ES) | 3431 |
| 19:15 | Targeting cardioprotection in noncardiac surgery: beta-blockade for improved outcomes?
– D. Poldermans (Rotterdam, NL) | 3432 |
| 19:35 | Chronic heart failure: current challenges and future opportunities.
– R. Willenheimer (Malmö, SE) | 3433 |
| 19:55 | Closing remarks.
– J.L. Lopez-Sendon (Madrid, ES) | 3434 |

**THROMBOSIS MANAGEMENT IN CARDIOLOGY:
THE RELEVANCE OF DIRECT FACTOR XA INHIBITION**

Satellite

Chairperson(s): J.-P. Bassand (Besançon, FR); K.A.A. Fox (Edinburgh, GB)
Satellite Symposium organised by Bayer Schering Pharma AG

- | | | |
|-------|---|------|
| 18:30 | Welcome and introduction.
– J.-P. Bassand (Besançon, FR) | 3435 |
| 18:40 | Growing evidence for the effectiveness of Factor Xa inhibition.
– C. Esmon (Oklahoma City, US) | 3436 |
| 18:55 | Factor Xa inhibition and the prevention of venous thromboembolism.
– A.G.G. Turpie (Hamilton, CA) | 3437 |
| 19:10 | Anticoagulant issues in routine clinical care of patients with atrial fibrillation: lessons from registries.
– J.-P. Bassand (Besançon, FR) | 3438 |
| 19:25 | Prospects for improving thrombosis management strategies in cardiology.
– F.W.A. Verheugt (Nijmegen, NL) | 3439 |
| 19:40 | Panel and audience discussion. | 3440 |
| 19:55 | Summary and close.
– K.A.A. Fox (Edinburgh, GB) | 3441 |

ECHOCARDIOGRAPHY IN HEART FAILURE

Satellite

Chairperson(s): A. Evangelista Masip (Barcelona, ES); J.U. Voigt (Leuven, BE)
Satellite Symposium organised by GE Healthcare

- | | | |
|-------|--|-------------|
| 18:30 | Role of echocardiography in heart failure.
– G.R. Sutherland (London, GB) | 3442 |
| 18:53 | Diastolic dysfunction in heart failure.
– G.A. Derumeaux (Bron, FR) | 3443 |
| 19:15 | Improving workflow and accuracy with 4D stress-eco.
– L. Badano (Udine, IT) | 3444 |
| 19:37 | Cardiac resynchronisation therapy for heart failure - Measuring mechanical timing with echo.
– P. Sogaard (Hellerup, DK) | 3445 |

**STROKE PREVENTION IN ATRIAL FIBRILLATION:
LATE-BREAKING INSIGHTS FROM THE RE-LY TRIAL**

Satellite

Chairperson(s): S. Yusuf (Hamilton, CA); G.Y.H. Lip (Birmingham, GB)
Satellite Symposium organised by Boehringer Ingelheim GmbH

- | | | |
|-------|--|------|
| 18:30 | Chairman's introduction.
– G.Y.H. Lip (Birmingham, GB) | 3446 |
| 18:35 | Direct thrombin inhibition: a new approach to anticoagulation.
– J. Weitz (Hamilton, CA) | 3447 |
| 18:45 | RE-LY trial design and demographics.
– M.D. Ezekowitz (Wynnewood, US) | 3448 |
| 18:55 | Efficacy of dabigatran etexilate for prevention of stroke in atrial fibrillation.
– L.C. Wallentin (Uppsala, SE) | 3449 |
| 19:10 | Safety of dabigatran etexilate for prevention of stroke in atrial fibrillation.
– S.J. Connolly (Hamilton, CA) | 3450 |
| 19:20 | Impact of RE-LY and its relevance to current clinical practice.
– J. Halperin (New York, US) | 3451 |
| 19:35 | Panel discussion. | 3452 |
| 19:55 | Key learning points and close of meeting.
– S. Yusuf (Hamilton, CA) | 3453 |

A NEW CONCEPT IN STROKE PREVENTION

Satellite

Chairperson(s): K.M. Fox (London, GB); M. Hennerici (Mannheim, DE)
Satellite Symposium organised by Servier

18:30	Introduction. – M. Hennerici (Mannheim, DE)	3454
18:35	Epidemiology. – P.M. Rothwell (Oxford, GB)	3455
18:55	Antithrombotic agents in stroke prevention. – J.L. Mas (Paris, FR)	3456
19:15	Thromboxane and prostaglandin endoperoxide receptor antagonist: a new concept in atherothrombosis and stroke prevention. – J.J. Badimon (New York, US)	3457
19:35	The PERFORM study: rationale and design. – M. Hennerici (Mannheim, DE)	3458
19:55	Conclusion. – K.M. Fox (London, GB)	3459

**REDEFINING THE THERAPEUTIC GOALS OF ATRIAL
FIBRILLATION: THE TIME IS NOW!**

Satellite

Chairperson(s): S.H. Hohnloser (Frankfurt, DE); T. Meinertz (Hamburg, DE)

Satellite Symposium organised by sanofi-aventis

- | | | |
|-------|---|-------------|
| 18:30 | Introduction. | 3460 |
| | – S.H. Hohnloser (Frankfurt, DE) | |
| 18:35 | Atrial fibrillation: a key determinant in the cardiovascular risk continuum. | 3461 |
| | – J.S. Alpert (Tucson, US) | |
| 18:55 | Preventing atrial fibrillation recurrences or improving cardiovascular outcomes: two perspectives. | 3462 |
| | – T. Meinertz (Hamburg, DE) | |
| | • Preventing atrial fibrillation recurrences is what matters. | 3463 |
| | – N. Marrouche (Salt Lake City, US) | |
| | • Improving cardiovascular outcomes is what matters. | 3464 |
| | – P.G. Steg (Paris, FR) | |
| 19:15 | Beyond rate versus rhythm: why do we treat atrial fibrillation? | 3465 |
| | – P. Dorian (Toronto, CA) | |
| 19:35 | Changing the face of atrial fibrillation management in 2009 and beyond! | 3466 |
| | – E. Aliot (Vandoeuvre-les-Nancy, FR) | |
| 19:55 | Take home messages. | 3467 |
| | – S.H. Hohnloser (Frankfurt, DE) | |

**THE NOVEL AGENT TO SUPPORT SYMPTOMATIC STABLE
ANGINA PATIENTS IN MAINTAINING THEIR QUALITY OF LIFE**

Satellite

Chairperson(s): A.J. Camm (London, GB); C.W. Hamm (Bad Nauheim, DE)

Satellite Symposium organised by Menarini International

- | | | |
|-------|--|------|
| 18:30 | Introduction.
– A.J. Camm (London, GB) | 3468 |
| 18:35 | Understanding the pathophysiology of ischemic chronic disease: stable angina, the tip of the iceberg.
– L. Tavazzi (Pavia, IT) | 3469 |
| 18:55 | Previous clinical conditions and comorbidities: need to optimize therapy.
– M. Komajda (Paris, FR) | 3470 |
| 19:15 | New mechanism of action: from late INa to O2 balance.
– A. Mugelli (Florence, IT) | 3471 |
| 19:35 | From pharmacology to clinical practice.
– A.J. Camm (London, GB) | 3472 |
| 19:55 | Conclusion.
– C.W. Hamm (Bad Nauheim, DE) | 3473 |

LIVING WITH PULMONARY ARTERIAL HYPERTENSION (PAH) – CHALLENGES AND OPTIONS – Satellite

Chairperson(s): N. Galie (Bologna, IT); M.A. Gomez Sanchez (Madrid, ES)

Satellite Symposium organised by GlaxoSmithKline

- 18:30 **Welcome and introduction.** 3474
– N. Galie, M.A. Gomez Sanchez (Bologna, IT; Madrid, ES)
- 18:35 **What are the challenges of treating today's PAH patients?** 3475
– A. Torbicki (Warsaw, PL)
- 18:50 **Evidence for improved survival with PAH therapies.** 3476
– S. Gibbs (London, GB)
- 19:05 **Long-term treatment with ambrisentan: functional class II (FCII) and connective tissue disease (CTD).** 3477
– J.L. Vachiery (Brussels, BE)
- 19:20 **Treat to goal: implications of new guidelines.** 3478
– O. Sitbon (Clamart, FR)
- 19:35 **Panel discussion.** 3479
– N. Galie, S. Gibbs, M.A. Gomez Sanchez, O. Sitbon, A. Torbicki, J.L. Vachiery (Bologna, IT; London, GB; Madrid, ES; Clamart, FR; Warsaw, PL; Brussels, BE)
- 19:55 **Summary & close.** 3480
– N. Galie, M.A. Gomez Sanchez (Bologna, IT; Pozuelo De Alarcon, ES)

PLAQUE VULNERABILITY AND THE SPECTRUM OF CORONARY HEART DISEASE RISK: DIFFERENCES BETWEEN ACUTE AND CHRONIC DISEASE. **Satellite**

Chairperson(s): W. Koenig (Ulm, DE); P. Libby (Boston, US)
Satellite Symposium organised by GlaxoSmithKline

- | | | |
|-------|--|-------------|
| 18:30 | Welcome and introductions.
– W. Koenig (Ulm, DE) | 3481 |
| 18:35 | Residual risk in acute and chronic heart disease.
– P.W.F. Wilson (Atlanta, US) | 3482 |
| 18:55 | Potential mechanisms of plaque destabilisation and atherothrombosis.
– P. Libby (Boston, US) | 3483 |
| 19:15 | Insights on characterising advanced atherosclerotic lesions in vivo.
– H.M. Garcia Garcia (Rotterdam, NL) | 3484 |
| 19:35 | Cardiovascular disease risk markers in acute and chronic disease: theoretical and practical applications.
– F. Crea (Rome, IT) | 3485 |
| 19:55 | Closing remarks.
– W. Koenig (Ulm, DE) | 3486 |

OPTIMAL USE OF DUAL ANTIPLATELET THERAPY

Satellite

Chairperson(s): D. Ardissino (Parma, IT); G. Montalescot (Paris, FR)

Satellite Symposium organised by Daiichi Sankyo and Ely Lilly and Company

- | | | |
|-------|--|-------------|
| 18:30 | Introduction.
– D. Ardissino (Parma, IT) | 3487 |
| 18:35 | In unstable angina / Non-ST-Elevation Myocardial Infarction patients.
– F. Fernandez-Aviles (Madrid, ES) | 3488 |
| 18:55 | In acute coronary syndrome / percutaneous coronary intervention patients with a high bleeding risk.
– F.J. Neumann (Bad Krozingen, DE) | 3489 |
| 19:15 | In diabetic acute coronary syndrome / percutaneous coronary intervention patients.
– D.J. Angiolillo (Jacksonville, US) | 3490 |
| 19:35 | In ST-Elevation Myocardial Infarction patients treated with percutaneous coronary intervention.
– G. Montalescot (Paris, FR) | 3491 |
| 19:55 | Concluding remarks.
– D. Ardissino (Parma, IT) | 3492 |

**THE RESPONSIBLE GATEKEEPER: IS REFERRAL FOR
PERCUTANEOUS CORONARY INTERVENTION APPROPRIATE
AFTER SYNTAX OR COURAGE OR IN WOMEN?**

Satellite

Chairperson(s): M.C. Morice (Massy, FR); R. De Caterina (Chieti, IT)
Satellite Symposium organised by Abbott Vascular

- | | | |
|-------|---|-------------|
| 18:30 | Introduction. | 3493 |
| 18:35 | Debate 1: after SYNTAX, patients with multi-vessel disease should ideally be referred for surgery.
– P.W. Serruys, J.L. Pomar Moya-Prats (Rotterdam, NL; Barcelona, ES) | 3494 |
| 19:00 | Debate 2: Yentl syndrome is dead: women are no longer a special case.
– R. Virmani, E. Swahn, S. Windecker (Gaithersburg, US; Linköping, SE; Berne, CH) | 3495 |
| 19:25 | Debate 3: the COURAGE and BARI 2D results should be extrapolated to Europe.
– B. De Bruyne, W. Boden (Aalst, BE; New York, US) | 3496 |
| 19:50 | Conclusion. | 3497 |

EXPLORING CARDIO-RENAL PROTECTION THROUGH DIRECT RENIN INHIBITION – AN INNOVATIVE APPROACH TO CARDIOVASCULAR RISK MANAGEMENT **Satellite**

Chairperson(s): M. Pfeffer (Boston, US); J.L. Zamorano Gomez (Madrid, ES)
Satellite Symposium organised by Novartis Pharma AG

- 18:30 **Welcome and introduction.** **3498**
– J.L. Zamorano Gomez (Madrid, ES)
- 18:35 **Renin-angiotensin-aldosterone system therapy - The hub of hypertension and cardio-renal disease management?** **3499**
– G. Mancia (Monza, IT)
- 18:55 **Debate: Combining renin-angiotensin-aldosterone system inhibitors - Still a valid strategy?** **3500**
– J.R. Gonzalez-Juanatey (Santiago de Compostela, ES), G.T. McInnes (Glasgow, GB)
- 19:15 **Intermediate clinical endpoints of disease progression in high-risk patients - New evidence.** **3501**
– J.J.V. McMurray (Glasgow, GB)
- 19:35 **How do we advance cardio-renal protection beyond angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers?** **3502**
– M. Pfeffer (Boston, US)
- 19:55 **Summary and close.** **3503**
– M. Pfeffer (Boston, US)

**DIAGNOSING AND TREATING CHRONIC THROMBOEMBOLIC
PULMONARY HYPERTENSION (CTEPH) NOW AND IN FUTURE**

Satellite

Chairperson(s): H.A. Ghofrani (Giessen, DE); P. Corris (Newcastle-upon-Tyne, GB)

Satellite Symposium organised by Bayer Schering Pharma AG

- | | | |
|-------|--|------|
| 18:30 | Welcome and introduction.
– H.A. Ghofrani, P. Corris (Giessen, DE; Newcastle-upon-Tyne, GB) | 3504 |
| 18:35 | Pathophysiological mechanisms of different forms of pulmonary hypertension.
– M. Humbert (Clamart, FR) | 3505 |
| 18:55 | State of the art diagnosis for treatment decision.
– J. Pepke-Zaba (Cambridge, GB) | 3506 |
| 19:15 | Treatment of CTEPH - Surgical and post-operative concepts.
– E. Mayer (Mainz, DE) | 3507 |
| 19:35 | Riociguat - An upcoming therapeutic tool for CTEPH?
– N. Kim (La Jolla, US) | 3508 |
| 19:55 | Discussion and closing comments.
– H.A. Ghofrani, P. Corris (Giessen, DE; Newcastle-upon-Tyne, GB) | 3509 |

OPTIMISING THE ANTITHROMBOTIC RISK-BENEFIT PROFILE FOR PERCUTANEOUS CORONARY INTERVENTION (PCI) **Satellite**

Chairperson(s): C.A. Nienaber (Rostock, DE); R. Mehran (New York, US)

Satellite Symposium organised by The Medicines Company

- | | | |
|-------|---|------|
| 18:30 | Opening remarks.
– C.A. Nienaber (Rostock, DE) | 3510 |
| 18:35 | ESC guidelines - Improving ischaemic and haemorrhagic outcomes during PCI.
– S.D. Kristensen (Aarhus, DK) | 3511 |
| 18:50 | Determinants of post-PCI mortality - What are the attributable events?
– R. Mehran (New York, US) | 3512 |
| 19:05 | Tailoring anticoagulant and antiplatelet management for the catheter lab.
– C. Di Mario (London, GB) | 3513 |
| 19:20 | From clinical trials to clinical practice - Implementing the new evidence base.
– D.J. Blackman (Leeds, GB) | 3514 |
| 19:35 | Moderated round-table discussion. | 3515 |
| 19:50 | Concluding remarks.
– C.A. Nienaber (Rostock, DE) | 3516 |